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1.1 G protein-coupled receptors 
 
G protein-coupled receptors (GPCRs) form the largest superfamily of proteins in 
the human body. About 1 % of the human genome encodes for over a 1000 
GPCRs 1. GPCRs are located at the cell surface and are expressed ubiquitously. 
GPCRs regulate many diverse intracellular responses and therefore are involved 
in all kinds of diseases, making them interesting therapeutic targets 2. The name 
GPCRs originates from the first step in the signal transduction, which requires the 
direct activation of a hetero-trimeric G protein. However, this name is somewhat 
misleading as G-proteins are also able to couple to other proteins besides GPCRs 
and GPCRs are able to signal without G-proteins 3. Therefore, GPCRs are 
sometimes referred to as heptahelical, serpentine or 7-transmembrane (TM) 
receptors. The name 7-TM originates from the fact that GPCRs are 
transmembrane proteins, which cross the membrane seven times. Each individual 
TM domain is an α-helix connected to the next TM domain via alternating 
intracellular or extracellular loops, starting with an extracellular amino-terminal tail 
and ending with an intracellular carboxyl-terminal tail (Figure 1.1). 
 
 
Figure 1.1: Computer model of a G protein- coupled receptor monomer or dimer interacting with one 
hetero-trimeric g-protein, based on the crystal structure of rhodopsin. Figure adapted from 4 
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The superfamily of GPCRs can be activated by a plethora of different stimuli, 
including protein hormones, lipids, peptides, biogenic amines and nucleotides 5,6 
but also stimuli such as tastes, odors and light 5. The bundle of 7 TM domains 
forms a cavity that is big enough to fit small ligands, such as the biogenic amines 
whereas larger ligands, like peptides and hormones generally interact and bind to 
the N-terminal tail and/or extracellular loops 7. 
Numerous GPCRs are involved in a wide variety of diseases, including asthma, 
hypertension, Parkinson’s disease, cancer, and HIV infection 8,9. The presence of 
GPCRs at the cell surface makes these receptors very accessible for therapeutic 
drugs. Currently about 50% of all marketed drugs are targeted at GPCRs, with 
sales for individual drugs reaching up to several billions of US dollars per year 2. 
Although belonging to one superfamily, GPCRs are diverse and can be subdivided 
into smaller families on basis of sequence homology and/or pharmacological 
characteristics. In general GPCRs are divided into three major subfamilies; the 
subfamily of rhodopsin receptor-like GPCRs (family A), secretin receptor-like 
GPCRs (family B) and the metabotropic neurotransmitter receptor-like GPCRs 
(family C). The yeast pheromone (family D), the cAMP receptors (family E) and the 
frizzled/smoothened family make up three minor subfamilies 5,10.  Family A GPCRs 
form the largest of the three major subfamilies and include, among others, the 
aminergic receptors (histaminergic, serotonergic, muscarinergic, dopaminergic and 
adrenergic receptors), peptide, (rhod)opsin as well as the large subfamily of 
olfactory receptors. 
Family B consists of approximately 25 GPCRs 10. These GPCRs are recognized 
by a range of neuropeptides and peptide hormones, like glucagon, calcitonin and 
secretin. One of the hallmark features of family B GPCRs is the large extracellular 
amino terminal tail containing numerous cysteines, which probably forms a 
network of disulfide bridges. Unlike family A GPCRs, no DRY motif, which is 
involved in the activation of family A GPCRs, is present in family B receptors 5. 
Hallmark features for family C receptors include a short and highly conserved 
intracellular loop 3 (IL3), a relatively long carboxyl terminal tail and an 
exceptionally long amino terminal tail, which is shaped like a Venus-fly trap to 
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facilitate ligand binding. Family C receptors include the metabotropic glutamate, γ-
aminobutyric acid (GABA), calcium and taste receptors. The human genome 
project has revealed the existence and position of all GPCRs. However for several 
GPCRs their respective cognate ligand is unknown. These GPCRs are known as 
orphan GPCRs. Excluding the olfactory GPCRs, approximately 300 full open 
reading frames (ORFs) have been identified to encode putative GPCRs. Out of 
these 300, about 100 are considered orphan receptors 11. Much effort is invested 
in attempts to de-orphanize these receptors and trying to link these GPCRs to 
possible diseases. In addition to these orphan receptors, many genes encoding 
GPCRs can be alternatively spliced, adding to the complexity and magnitude of 
this superfamily 12. 
 
G protein coupling 
 
As mentioned before GPCRs primarily transduce their signals through coupling 
and activation of intracellular hetero-trimeric G-proteins. These G-proteins consist 
of three subunits; the Gα, Gβ and Gγ subunits. The Gα subunit harbours an 
intrinsic GTPase activity able to hydrolyze GTP to GDP. The Gβ and Gγ subunits 
form dimeric Gβγ-subunit that associate and dissociate from the Gα subunit 
depending on whether the Gα subunit is bound to GDP or GTP, respectively. In its 
resting state the Gα subunit is bound to GDP and is associated to a hetero-dimeric 
Gβγ-subunit. While bound to the Gα subunit the Gβγ-subunit inhibits the 
spontaneous release of GDP from the Gα subunit 13,14. Upon agonist-binding to the 
receptor, the activated receptor subsequently activates the intracellular hetero-
trimeric G protein by causing an increase in the rate of GDP-GTP exchange on the 
Gα subunit. Upon activation the now GTP-bound Gα subunit dissociates from the 
Gβγ-subunit, and both the Gα- and Gβγ-subunit subsequently activate their 
respective effectors. Hydrolysis of GTP to GDP by the intrinsic GTPase returns the 
Gα subunit to its inactive, GDP-bound state, followed by re-association with a Gβγ-
subunit. 3. 
Currently 20 α subunits, 6 β subunits and 12 γ subunits have been identified, 
however, only four main classes of hetero-trimeric G-proteins can be 
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distinguished: Gαs, Gαi, Gαq, Gα12 15. The Gαs- and Gαi-proteins stimulate or inhibit 
the activity of adenlyl cyclase, to result in an increase or decrease in cAMP 
formation, respectively. The cAMP subsequently can activate protein kinase A 
(PKA). Gαq-proteins activate phospholipase C, which lead to the hydrolysis of 
phosphatidylinositol biphosphate (PIP2), resulting in the formation of diacyl glycerol 
(DAG) and inositol triphosphate (InsP3), subsequently leading to activation of 
protein kinase C (PKC) and increases in intracellular Ca2+-ions 16,17. Gα12/Gα13-
proteins can regulate the small G-protein RhoA 16 (Figure 1.2).  
 
Figure 1.2: Overview of G-protein coupling and signaling pathways mediated through GPCR activation. 
GPCRs can be stimulated by a wide assortment of ligands like biogenic amines, ions, lipids and 
hormones. Activated GPCRs can transfer the extracellular stimulus into intracellular signals through 
binding to a variety of G proteins (Gαi, Gαq, Gαs and Gα12), which can activate intracellular and nuclear 
effectors. Figure adapted from 17. 
 
Originally receptors were thought to interact with only one type of heterotrimeric G-
protein. However, it is now appreciated that depending on cellular and external 
conditions GPCRs can promiscuously interact and signal via multiple pathways 18. 
Furthermore, recently ligands were discovered that act as agonist in sytems 
devoid of constitutive activity, but become inverse agonists in constitutivly active 
systems, these ligands are known as protean ligands 18. 
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In addition, GPCRs can also activate small monomeric G-proteins like Ras 19. The 
Gβγ-dimer can separately activate several different signaling pathways, such as 
adenylyl cyclases, PLC-β, a multitude of kinases as well as ion channels 17,20 
(Figure 1.3). Moreover, GPCRs can signal independently of G-proteins. This 
signaling is mediated through by interacting with β-arrestins and G-protein kinases 
(GRK), and can result in activation of cytoplasmic effectors such as Src, Ras and 
ERK, ultimately playing roles in chemotaxis and apoptosis 21,22. In conclusion, 
through the years increasing knowledge on GPCR signal transduction has led to a 
better understanding of GPCR signaling but has also revealed more of the actual 
complexity of GPCR signaling. 
 
Figure 1.3: Overview of the current GRK- and β-arrestin-mediated signaling functions and biological 
activities. Upon agonist stimulation of a GPCR, β-arrestins and GRKs are recruited and activated. They 
subsequently activate or inhibit various signaling pathways. Additionally, β-arrestin 1 can translocate to 
the nucleus and regulate the expression of various genes through reorganization of chromatin. Adapted 
from 22 
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Constitutive activity of GPCRs 
 
In 1989 Costa and Herz reported for the first time on the ligand independent 
intrinsic basal activity of GPCRs 23. This observation was followed by the discovery 
that single point mutations were able to increase this apparent constitutive activity 
of GPCRs 24. The concept of constitutive activity has now been firmly established 
and has been shown to occur for over 60 GPCRs 25. The discovery of constitutive 
active GPCR was accompanied by the finding that certain ligands formerly known 
as antagonists were actually able to inhibit the constitutive receptor activity. In 
contrast to agonist, these ligands posses a negative intrinsic activity and are now 
known as inverse agonists 23. Constitutive active GPCRs may be the cause of 
several diseases, such as male precocious puberty, dwarfism, Kaposi’s sarcoma 
and congenital night blindness 25. The detection of constitutive activity also had 
implications for the ternary model describing receptor activation. 
The two state model portrayed only the binding of an agonist (A) to the receptor 
(R), causing the activation of the formed complex (AR). The ternary model also 
took the G-protein (G) coupling into account, which would couple to the activated 
AR complex (AR*), forming the ternary AR*G complex. Constitutive activity 
demanded an extension of this ternary model, allowing for receptors to be 
activated and bind G proteins in the absence of agonists. An even more complex, 
but thermodynamically more complete model is the cubic ternary model 26-28 
(Figure 1.4). This model also allows for the formation of a non-signaling complex 
between the inactive receptor and the G-protein. Monczor and co-workers found 
evidence to support the cubic ternary complex, using the H2 inverse agonist 
tiotidine 29. The discovery that GPCRs can form oligomeric structures 30, chapter 
5), which exhibit different affinities for certain G-proteins 31, will undoubtedly result 
in models with even higher levels of complexity. An example of such a model has 
been described by Durroux 32. 
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Figure 1.4: Models describing GPCR systems. The traditional model merely describes the binding of 
an agonist (A) to the receptor (R) and subsequent activation of this complex (AR). The ternary complex 
introduces the G-protein (G) as a third partner, that can interact with the activated agonist-receptor 
complex (AR*). The ternary complex was extended after the discovery of ligand-independent activation 
of the receptor 23, allowing for the formation of R*G. The cubic ternary complex makes up a 
thermodynamically more complete model. Figure adapted from 27 
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GPCRs structure 
 
The development of therapeutic drugs acting on GPCRs is largely based on two 
different strategies. For a newly identified target large libraries are tested in a high 
throughput screening (HTS) approach. These libraries frequently consist of a 
selection of known drugs, a large diversity of scaffolds, and sometimes also a 
selection of natural occurring compounds. A more rational approach to drug design 
can be employed when detailed information on the target, especially data obtained 
by mutational of the ligand-binding pocket, is known. Rational based drug design 
may benefit a great deal from the elucidation of the high resolution structures of 
GPCRs. So far the crystallization of GPCRs other than rhodopsin 33, have not 
yielded high resolution structural data. However, using the rhodopsin structure as 
template, homology models of these GPCRs can be created, which are useful for 
rational drug design on these GPCRs 34.  
Although all GPCRs share the same topology of a 7TM receptor, they do not 
necessarily share high sequence homology. However, within the large subfamily of 
family A GPCRs there are several amino acid residues that seem to be important 
for either the structural integrity or signal transduction and are conserved among 
these family A GPCRs 35. These amino acids are: an asparagine (Asn/N) in TM1, 
an aspartate (Asp/D) in TM2, an arginine (Arg/R) in TM3, a tryptophan (Trp/W) in 
TM4, and proline residues (Pro/P) in TM5, TM6 and TM7. The arginine in TM3 is 
part of a larger conserved motif (D/E-R-Y) called the DRY motif. This motif is 
supposedly involved in keeping the receptor in its inactive conformation 36. On top 
of TM3 a conserved cysteine (Cys/C) is located. This cysteine forms a disulphide 
bridge with a cysteine located in extracellular loop 2. The proline in TM6 is part of 
the larger FxxCWxP motif, whereas the proline in TM7 is part of the conserved 
NPxxY motif. Whereas GPCRs of family A consist of 7 alpha helices spanning the 
plasma membrane, the C-terminal tail also contains a region, following TM7 that 
can form an eight alpha helix (Figure 1.5) 35. 
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Figure 1.5: Schematic representation of a GPCR depicting highly conserved amino acids and motifs 
within GPCRs belonging to family A. The most conserved amino acid within each transmembrane 
domain has been giving the number 50, according to the Ballesteros Weinstein numbering 37.  
 
Recently the study of H1 receptor activation revealed that Asn 7.45 (according to 
Ballesteros Weinstein numbering 37) may play a crucial role in transferring the 
conformational rearrangement of the receptor upon agonist binding, to receptor 
activation. In the case of the H1 receptor Asn 7.45 appears to function as link 
between the ligand binding pocket (formed by Ser 3.36, Trp 6.48 and Phe 6.52) 
and conformational transition of Asn 7.49, part of the NPxxY motif, which leads to 
GPCR activation. The amino acids in this proposed mechanism are well conserved 
amino-acids (~70%), within the family A GPCRs, suggesting that the observed 
activation mechanism may apply to other rhodopsin-like GPCRs as well 38.  
 
GPCR oligomerization 
 
Initially GPCRs were thought to exist as monomeric entities that interact in a 1:1 
ratio with hetero-trimeric G-proteins. Increasingly more evidence suggesting that 
GPCRs may exist as well as function as dimeric or even higher oligomeric 
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structures have emerged30,39. Especially the development of biophysical assays to 
study receptor oligomerization, including techniques making use of resonance 
energy transfer, largely contributed to this shift in believe40. For some GPCRs, like 
the GABAB and taste receptors oligomerization is even a prerequisite for their 
function 41-46. A couple of studies showed that dimeric receptors interact in a 2:1 
ratio with the cognate G-protein i.e. one dimer binding only one G protein 47,48. A 
more comprehensive overview on GPCR oligomerization is provided in chapter 5. 
 
GPCR desensitization and internalization 
 
To regulate the responsiveness of the cell to multiple stimulation of GPCRs over 
time, many receptors are desensitized after ligand binding and GPCR activation 49. 
There are two variants of desensitization: heterologous and homologous 
desensitization. The former, also known as agonist, non-specific desensitization, 
involves protein kinases A (PKA) and C (PKC), while the latter, which is also 
known as agonist-specific desensitization involves G protein-coupled receptor 
kinases (GRKs) and the two non-visual arrestins (β-arrestin 2 and arrestin 3) 49.  
For heterologous desensitization, GPCRs are phosphorylated by second 
messenger–dependent kinases (PKA and PKC) 50-52. However, PKA and PKC can 
also indirectly affect GPCR desensitization by phosphorylation of GRK2 53,54. After 
agonist binding to the receptor GRK is translocated to the membrane where it is 
co-localized with the receptor. The GRK can contact several GPCRs, but can only 
phosphorylate the receptor that is in the appropriate conformational state, i.e. R*. 
Phosphorylation of receptors by GRKs alone does not lead to high levels of 
desensitization. However, this phosphorylation increases the affinity of the 
arrestins to bind to the GPCR. The arrestin binding to the receptor prevents the 
heterotrimeric G protein binding to the receptor and  results in maximal receptor 
desensitization of the receptor 55,56 GRK phosphorylation usually occurs at 
serine/threonine clusters. Several research groups have shown that mutating the 
serines and threonines in these clusters to alanines abolish phosphorylation and 
inhibit internalization 57-59  
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After desensitization the receptor is sequestered and removed from the 
membrane. One of the mechanisms for translocation of the receptor to intracellular 
compartments makes use of clathrin coated vesicles. While sequestered the 
receptor can be dephosphorylated followed by recycling of the receptor to the 
membrane (resensitization). If not recycled the endosome will fuse with a 
lysosome and the receptor is degraded (Figure 1.6) 60. Although most receptors 
are only internalized following ligand (agonist) binding some receptors can be 
found to internalize constitutively 61. It has been shown that GPCRs that do not 
undergo agonist activated internalization, through hetero-oligomerization, can 
exert a dominant negative effect on GPCRs that internalize after ligand activation, 
retaining these GPCRs at the cell surface 62,63. It has also been shown that GPCR 
hetero-dimerization can cause GPCRs to be co-internalized with another GPCR 
which is internalized after agonist binding 64,65. 
 
Figure 1.6: Trafficking of GPCRs. Activation of a GPCR by an agonist leads to the dissociation of α and 
βγ subunits. The free βγ dimers recruit G-protein receptor kinases (GRK) to the receptor, where they 
specifically phosphorylate agonist-occupied receptors. This, in turn, leads to the recruitment of β-
arrestin to the receptor and targets the receptor–β-arrestin complexes to clathrin-coated pits. The 
receptor is internalized into acidic endosomes and then either dephosphorylated and recycled to the 
cell surface or degraded. Figure adapted from 10. 
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1.2 Histamine and histamine receptors 
 
Histamine 
The biogenic amine histamine (2-(imidazol-4-yl)ethylamine, Figure 1.7) is an 
endogenous substance first described in 1910 66. Histamine is synthesized by 
decarboxylation of the amino-acid L-histidine by the enzyme L-histidine 
decarboxylase (HDC). However, histamine can also be taken upfrom certain 
foods, such as soy products, fish and fermented vegetables 67. Histamine is stored 
in the body mainly in cytoplasmic granules within mast cells, basophils and 
enterochromaffin cells but is also present in the central nervous system (CNS). In 
the brain histamine is synthesized and stored in neurons in the tuberomammillary 
nucleus of the posterior hypothalamus. Also certain cells (e.g. macrophages, 
dendritic cells and T cells) have been identified that can release readily 
synthesized histamine (neo-synthesized histamine), without prior storage 68.  
In response to various imunnological and non-immunological stimuli histamine can 
be release in large amounts from the ctyoplasmic granules. Upon release, 
histamine can be metabolized through two pathways 69: histamine can either be 
methylated at the Nτ imidazole by histamine-N-methyltransferase or be oxidized by 
diamine oxidase to form imidazole acetaldehyde. The actions of histamine are 
mediated through histamine receptors of which currently four have been identified 
and cloned, namely the histamine H1, H2, H3 and H4 receptor. Several histamine 
binding proteins exist, including  cytochrome P450, which can bind histamine but 
also other imidazole containing histaminergic ligands, such as thioperamide and 
clobenpropit 70,71. 
 
Figure 1.7 Chemical structure of histamine 
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The histamine H1 receptor 
 
Gene structure and expression 
The existence of a histaminergic receptor as mediator of histamine induced effects 
has been appreciated for almost a century. Although not completely aware of the 
target many ligands have been developed that counteracted the effect of 
histamine. The first so called “anti-histamine” was synthesized in 1936 72 and 
demonstrated effectiveness in protection against histamine-induced 
bronchospasm 72. However, the histamine H1 receptor (H1R) was firstly introduced 
by Ash and Schild in 1966 73, and was defined further after the discovery of the 
histamine H2R by Black and co-workers in 1972 74. The gene encoding the human 
H1R was eventually cloned in 1993 75,76. The gene encoding the hH1R is located on 
chromosome 3 band 3p14-p21 77, or 3p25 76,78. The intronless gene encodes a 487 
amino acid polypeptide. Correctly folded H1 protein crosses the plasma-membrane 
seven times and contains also other hallmark motifs, such as the conserved 
disulphide bridge between extracellular loop 2 and 3, attributed to GPCRs. The 
H1R consists of a remarkable long third intracellular loop, and relatively small C-
amino terminal tail. While the N-amino terminal tail holds potential N-glycosylation 
sites, the C-terminal tail lacks cysteine residues, thus lacking possible 
palmitoylation sites. The H1R has an apparent molecular weight of ∼55 kDa 79. The 
existence of several single nucleotide polymorphisms of the H1R, which may be 
linked to certain diseases have been reported (80, 
http://www.ncbi.nlm.nih.gov/projects/SNP/). The H1R is expressed ubiquitously and 
can be found to exert its effects in e.g. lung smooth muscle cells, vascular 
endothelium, the gastro-intestinal tract, the heart and the central nervous system 
(CNS), including the cerebellum, neocortex, hippocampus, thalamus and nucleus 
accumbens 79. The presence of the H1R in the brain explains why the first 
generation of anti-histamines cause sedation as primary side effect. By reducing 
the ability of anti-histamines to pass the blood brain barrier, the second generation 
of anti-histamines does not exhibit this side effect anymore. 
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H1R mediated signalling 
Histamine H1R signalling is regulated predominantly by coupling to Gq/11-proteins 
81. Stimulation of the H1R results in activation of phospholipase C, which 
hydrolyses phosphatidyl 4, 5-biphosphate (PIP2) generating diacylglycol (DAG) 
and inositol (1,4,5) triphosphate (InsP3) in the process. Activation of InsP3 
receptors in the endoplasmatic reticulum (ER) by InsP3 regulates the subsequent 
release of Ca2+ 82. The released DAG can activate protein kinase C (PKC), which 
in turn can phosphorylate other proteins, including the H1R resulting in  
desensitization of the receptor 83,84. Activation of the H1R can also activate nuclear 
factor κB (NFκB). This transcription factor can regulate the transcription of several 
genes supposed to be involved in inflammation 85. The H1R can signal in a ligand-
independent manner as well. This constitutive activity of the H1R was first reported 
by Bakker and co-workers 86. While NFκB in ligand activated H1R can occur via 
both the Gq/11- and Gβγ-subunits, the constitutively activated H1R can activate 
NFκB only via the Gβγ-subunits 85. In addition H1R activation has been shown to 
activate several other signalling pathways including activation of nitric oxide (NO) 
synthase 87, activation of phospholipase A2 and subsequent arachidonic acid 
release 88-90, stimulation of phopholipase D (PLD) 91. Finally the H1R was found to 
couple to PTX sensitive Gi-proteins 92. 
 
Specific ligands for the H1R 
 
The development of specific agonists for the H1R has been complicated, as 
changes of the ethylamine side chain of histamine, the endogenous ligand, are not 
well tolerated 93. However, modifications at the 2-position of the imidazole ring of 
histamine are acceptable and have resulted in the development of relatively 
selective H1R agonists, such as 2-methylhistamine 93 and 2-(3-
trifluormethyl)phenylhistamine 94. Other options in which the imidazole ring has 
been replaced by a non-imidazole moiety have resulted in H1R agonists, such as 
2-pyridylethylamine and 2-thiazolylethylamine 95.  
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Currently the most potent and selective H1R agonist are the so called 
histaprodifens. These ligands combine the histamine moiety with a diphenylalkyl 
substituent at the 2-position 96. Remarkably this diphenylalkyl substituent is 
typically used for H1R antagonists.  Apparently maintaining the histamine moiety 
retains H1R agonism, whilst the additional “antagonist” substituent results a better 
fit and subsequent higher affinity. Another potent yet non-selective H1R agonist is 
8R-lisuride 97. This ergot alkoloid is structurally very different from the typical H1R 
agonists, but is known to bind dopaminergic and serotinergic receptors as well 98. 
The scaffold of 8R-lisuride however, might serve as lead for the development of 
more selective H1R agonists. 
Fortunately, design of the pharmaceutically more interesting H1R antagonist has 
been less complicated. In general these anti-histamines contain the ethylamine 
moiety linked to two aromatic rings as e.g. in mepyramine. However, fusion of the 
aromatic rings to form tricyclic ligands, such as doxepine and clozapine, is also 
tolerated. As mentioned before, many of these classical H1R anti-histamines cause 
sedative side effects, and also can antagonize muscarinic and serotinergic 
receptors 99.  This has led to the development of new H1R antagonists practically 
devoid of these unwanted side effects. Several of these second generation anti-
histamines have become very successful therapeutics in the treatment of allergic 
symptoms 100. Drugs like cetirizine (Zyrtec®), ketotifen (Zaditor®), Loratidine 
(Claritin ®) and fexofenadine (Allegra ®) have become billion dollar selling 
blockbusters 79.  
The finding of H1R constitutive signalling has not only caused a reclassification of 
H1R antagonists to inverse agonists 85, it has also led to the development of 
several neutral antagonist for the H1R, such as histabudifen and histapendifen 101. 
 
Physiological roles of the H1R 
Most of the physiological effects caused by an allergic reaction can be attributed to 
the H1R. Constriction of the airway results from contraction of smooth muscle cells 
in the lung due to H1R activation. Red, swollen skin and eyes are caused by H1R 
mediated contraction of endothelial cells and subsequent increases in vascular 
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permeability 79. Activation of H1R in the brain can induce sedation. While this effect 
is often unwanted, in the United States anti-flu medicines, containing a mixture of 
therapeutic drugs, are sold. Often the tablets are divided in day and night tablets, 
where the night tablets contain first generation anti-histamines, thus inducing sleep 
as part of the therapeutic effect. Although normally overshadowed by the 
stimulatory effects of the H2R, in human myocardium H1R activation is associated 
with inhibitory effect on heart rate 102. 
 
 
Figure 1.8:  Chemical structure of several H1R ligands 
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The histamine H2 receptor 
 
Gene structure and expression 
The existence of a second histamine receptor was initially proposed by Ash and 
Schild, based on the inability of “anti-histamines” to block histamine-mediated 
gastric acid secretion 73. It took another six years before the idea of this H2R 
became generally accepted. In 1972 Black and co-workers synthesized the first 
selective H2R antagonist burimamide, which could block histamine effects in 
stomach and heart, but were not antagonized by the classical anti-histamines 74. 
Almost two entire decades later the gene encoding the human H2R was cloned in 
1991 103, even preceding the cloning of the human H1R by two years. Similar to the 
H1R the H2R is intronless. The H2R gene is located on chromosome 5q35.2 and 
encodes a 359 amino acid protein. So far only few single nucleotide 
polymorphisms have been identified in the H2R gene. These SNPs could not be 
associated with either atopic asthma or schizophrenia 104,105. The H2R is C-
terminally palmitoylated 106 and potentially N-glycosylated based on the presence 
of N-glycosylation sites in the N-terminal tail of the H2R. Whereas palmitoylaytion 
might be required for surface expression 106, the C-terminal tail is also important in 
H2R signalling, desensitization and internalization 59. The existence of putative H2R 
oligomers was proposed based on higher molecular weight species on Western 
blots 107,108. The human H2R is expressed ubiquitously, and can be found both in 
the CNS and peripheral tissue, including gastric parietal cells, vascular smooth 
muscle cells and neutrophils 79.  
 
H2R mediated signalling 
In contrast to the H1R, the H2R is primarily linked to activation of adenylyl cyclase 
via Gs-proteins. This Gs-coupling was established through observation of 
enhanced GTP azidoanilide- labelling of Gs-like proteins in H2R expressing Sf9 
cells 81. The GS-mediated increase in cAMP and subsequent activation of protein 
kinase A (PKA) can result in cell division, cell differentiation, ion transport and ion 
channel function 71. Besides being coupled to Gs-proteins, support for H2R 
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mediated Gq-signalling has emerged. The H2R has been suggested to activate c-
fos, c-jun 71, phospholipase C 109,110 and increase Ca2+ concentrations 109,111 as 
well as inhibit arachidonic acid release 112. However, in CHO cells stably 
expressing the H2R no Gq-coupling could be identified 88. Therefore, this putative 
Gq/11-coupling could be cell-type specific. Similar to the H1R the H2R can be 
activated in a ligand-independent manner 113. This constitutive activity of the H2R 
has led to reclassification of many H2R antagonists to inverse agonists 114. 
 
Specific ligands for the H2R 
One of the few selective H2R agonists is amthamine (2-amino-5-(2-aminoethyl)-4-
methylthiazole), which exhibits slight higher potency than histamine, but combined 
with reasonable selectivity. Recently, amthamine as well as other H2R agonists, 
including 4-methylhistamine, dimaprit and impromidine were shown to have higher 
affinity for the H4R than for the H2R 115. Compared to H2R agonists many more 
selective H2R antagonists are available. Ligands like ranitidine, famotidine and 
tiotidine are potent antagonists/inverse agonists for the H2R. The discovery of the 
H3R and H4R has revealed that some classical H2R antagonists such as 
burimamide are less selective as initially believed 115. 
 
Physiological roles of the H2R 
The H2R is involved in the release of gastric acid. Several H2R antagonists, 
cimetidine being the first, have been used successfully in treatment of gastric 
ulcers. Several of these therapeutic H2R antagonist have become blockbuster drug 
e.g. Zantac® (ranitidine) and Pepcid® (famotidine) 116. However, the use of these 
H2R antagonist in treatment of peptic ulcers has been largely replaced by the more 
effective proton pump inhibitors, such as Losec® (omeprazol) 117. H2R are also 
involved in the regulation of cytokine and chemokine production and differentiation 
and maturation of a variety of cells in cardiac tissue, smooth muscle, and cells of 
the immune system 118. Activation of the H2R can induce vascular and smooth 
muscle relaxation as well 119. Elevated H1R and H2R mRNA levels have been 
detected in patients suffering from irritable bowel syndrome 120. Together with the 
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H4R, activation of the H2R results in histamine-induced release of interleukin-16 
from CD8+ T cells linking these receptors to play a role in asthma 118. The potential 
role for the H2R in allergic asthma was further supported by the finding of H2R 
mediated reductions in tumor necrosis factor α in rat peritoneal mast cells 121. 
 
Figure 1.9:  Chemical structure of several H2R ligands 
 
 
The histamine H3 receptor 
 
Gene structure and expression 
In 1983 Arrang et al discovered a third member of the histamine receptor family 
122. However, it would take sixteen more years before the gene encoding the 
human histamine H3 receptor (H3R) was cloned 123. The H3R gene is located on 
chromosome 20q13.32-20q13.33 124, and unlike the previously cloned genes for 
the H1- and H2-receptors consists of at least two 125 and perhaps three introns 126. 
The presence of intronic regions allows for the H3R to be alternativly spliced. So 
far twenty different human H3R isoforms have been identified 124,127. The majority 
of alternative spliced H3R have an alternative length of intracellular loop 3 126,127. In 
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general the H3(445)R with a length of 445 amino acids is considered the full-length 
or wild-type H3R. Besides alternative spliced H3Rs, the existence of single 
nucleotide polymorphisms (SNPs) contributes to H3R heterogeneity. At least three 
SNPs in the coding region of the H3R are reported, the most important being the 
A280V H3R, which might be linked to Shy-Drager syndrome 124. The H3R shares 
low homology with the H1R (22%) and H2R (21.4%). This is in the same order as 
the homology between the H3R and other members of the aminergic subfamily of 
GPCRs (20-27%) 123. 
The H3R appears to be expressed almost exclusively in the central nervous 
system (CNS). However, H3Rs can also be detected in other tissues 128,129. The 
H3R is present both on histaminergic neurons (auto-receptors), as well as on non-
histaminergic receptors (hetero-receptors). This means that activation of H3R can 
inhibit the release of histamine as well as other neurotransmitters, such as 
dopamine, acetylcholine, serotonin, norephinephrine and γ-amino butyric acid 130.  
 
H3R mediated signalling 
The involvement of Gi/o-proteins in H3R signalling was initially demonstrated by 
inhibition of H3R-mediated [35S]GTPγS binding with pertussis toxin 131.  After the 
cloning of the H3R these findings were encouraged through heterologous 
expression. Unlike the H1- and H2-receptors the H3R couples to Gi/o-proteins, thus 
inhibiting the production of cAMP via adenyly cyclase 123. A decrease of cAMP 
results in a reduction in protein kinase A (PKA) activation and subsequent 
phosphorylation of cAMP responsive element binding proteins (CREB). As these 
CREB proteins can modulate gene transcription, H3R activation has a negative 
influence on the expression of other proteins. H3R activation has also be 
demonstrated to involve activation of mitogen-activated protein kinase (MAPK), 
phosphatidyl 3-kinase (PI3K), phospholipase A2 (PLA2), inhibition of the Na+/H+  
exchanger and lowering of intracellular Ca2+ concentrations 132-136 . Besides being 
activated by ligands the H3R can also be constitutively activated. While this is not 
uncommon for GPCRs, the constitutive activity has been shown not only in vitro 
but also in vivo 132,137. 
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Specific ligands for the H3R 
Most likely, due to the low homology of the H3R with the H1- and H2-receptors, 
most H3R agonists, including the classical H3R agonists R-α-methylhistamine and 
Nα-methylhistamine exhibit low affinity (∼10000 fold) for the H1R and the H2R. 
However, the recent discovery of the H4R made apparent that some of the more 
selective H3R agonists, such as immepip also share high affinity binding for the 
H4R. 
Recently, successful efforts have been made to produce selective H3R agonists, 
including immethridine 138 and the N-methylated immepip analogue methimmepip 
139. The latter displays a 2000-fold selectivity over the H4R 139. Many potent and 
selective H3R antagonists have been developed. However, most imidazole-
containing H3R antagonists, including thioperamide, proxyfan and GT2331 exhibit 
good affinity towards the H4R, as well. In order to design more selective H3R 
antagonists several non-imidazole-containing H3R antagonists have been 
developed. Among others, Abbott Laboratories (ABT-239 and A349821) and 
Johnson & Johnson pharmaceutics (JNJ 520785) have been successful in 
producing several potent selective H3R anatagonists 140-142. Noteworthy are also 
the H3R inverse agonist clobenpropit, which behaves as partial agonist on the H4R 
115, and proxyfan which is a so called protean agonist i.e. depending on the cell 
physiology proxyfan can exert H3R responses ranging from full agonist to full 
inverse agonist 115. 
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Figure 1.10:  Chemical structure of several H3R ligands 
 
Potential physiological roles of the H3R 
The dual role of H3R as both hetero- and auto-receptor has led to the development 
of both antagonists as well as agonists as potential drugs. It has been suggested 
that inhibition of histamine release from histaminergic neurons, through activation 
of the H3R could induce sleep, and thus be used for treatment of insomnia 143. 
Agonists of the H3R might be used for antinociceptive purposes 144. H3R 
antagonists might be of therapeutical use in commercially interesting diseases. 
H3R antagonists have been demonstrated to be effective in reducing food intake of 
rodents 145. As hetero-receptor the H3R is involved in modulation of 
neurotransmitter release. In particular the modulated release of acetylcholine 
makes the H3R an interesting target in treatment of neuropsychiatric diseases, 
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such as Alzheimer’s disease, Parkinsons’s disease and attention-deficit 
hyperactivity disorder (ADHD). 
 
The histamine H4 receptor 
 
Long before the cloning of the histamine H4 receptor, evidence of a histamine 
receptor present in eosinophils was found.  In 1975 Clark and co-workers found 
that a relatively low dose of histamine (in the range of 0.3-1.25 μM) caused 
migration of eosinophils 146. The effect of histamine could not be blocked by H1- 
(mepyramine) or H2- (metiamide) receptor antagonists 146. Histamine and Rα-
methyl-histamine can induce calcium mobilization in eosinophils and the effect of 
these ligands could be blocked by thioperamide, burimamide and impromidine 147. 
However, the potency of Rα-methyl-histamine is lower than of histamine, which is 
inconsistent for H3 mediated effects. 147. 
 
H4R gene structure 
With the clarification of the human genome, the search for other members of the 
histamine family by homology (BLAST) search was performed by several groups 
simultaneously leading to the discovery and cloning of a fourth histamine receptor 
148-153. This H4 receptor was located on chromosome 18q11.2 (Figure 1.11). The 
gene for the histamine H4 receptor spans over 20.6 kbp. Similar to the H3 receptor, 
the H4R gene consists of three exons and two introns (Figure 1.12). Like for the 
H3R this has allowed for the occurrence of alternatively spliced H4R isoforms 
(chapter 4). Transcription of the gene results in mRNA with a length of 3.7 kb. The 
open reading frame consists of 1173 bp or 390 amino acids. So far single 
nucleotide polymorphisms have been reported but either in the introns or 3’ 
untranslated region (3’ UTR) (See NCBI website). The 5’ flanking region contains 
several bindings motives (e.g. interferon stimulated response element; ISRE, 
nuclear factor κB; NF-κB, nuclear factor to interleukin 6; NF-IL6, interferon 
regulatory factor; IRF) for the binding of transcription factors 154. After the cloning 
of the human H4R, genes corresponding to the H4R were identified and cloned 
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from mouse, rat, guinea pig, pig and monkey. The homology between the human 
and the rodent and pig H4 are relatively low (65-72%). However, the monkey H4R 
and human H4R show higher homology (92%). This explains why the 
pharmacological profile of the human H4Rs is similar to that of the monkey H4R but 
is quite different from that of the rodent H4R   155-157 
 
Figure 1.11:  Location of the locus of the H4R gene on chromosome 18 
 
 
Figure 1.12:  Genomic structure of the H4R.Exon sequence in upper case and intron sequence in lower 
case. The sizes of exons are labeled by the numbers according to the coding sequence. The sizes of 
introns are estimated base on the genomic sequence. Figure adapted from 151 
 
H4R protein structure 
The amino acid sequence, independently determined by the groups that cloned 
the H4 receptor, is identical to each other with one exception. In the original cloning 
paper of Oda et al, three amino acids were reported, that were inconsistent with 
the sequence reported by the other groups namely the amino acids at position 138 
(A138V), 206 (H206R), 253 (Q253R). However, at the moment the sequence in 
NCBI that refers to sequence of Oda et al is the same as the sequence of the 
others, suggesting that the differences were most likely caused by sequencing 
errors. The H4R protein contains two asparagines in the N-terminus (Asn5 and 
Asn9), which could function as possible glycosylation sites. Additionally the H4R 
protein contains a disulphide bridge between the Cys87 (extracellular loop 2) and 
Cys264 (EL 3) and a possible palmitoylation site in the C-terminus (Cys374). The 
receptor also contains several other hallmark features of (aminergic) G protein 
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coupled receptors: a conserved aspartates in TM2 and TM3, a DRY motif in TM3, 
conserved tryptophane residues in TM4 and TM6, a conserved proline in TM5 and 
a NPxxY motif in TM7. Using Western blot analysis Nguyen et al already showed 
hints of a unglycosylated (44 kDa), glycosylated (85 kDa) and putative oligomeric 
(>250 kDa) forms of the H4 receptor 149. 
In 2002 Shin and co-workers tried to identify the binding pocket of histamine to the 
H4 receptor (Figure 1.13). They mutated several residues earlier found to be 
important for binding of histamine to the other members of histamine receptor 
family. They suggest that Asp94 (3.32) and Glu182 are critical for histamine binding 
as mutations of either of these residues to alanine completely eliminated histamine 
binding. The Asp94 might serve as counter-anion to the cationic amino group of 
histamine, whereas the Glu182 could interact with histamine by forming an ion-pair 
with the Nτ nitrogen atom. They also reported on the importance of residues Asn147 
(4.57) and Ser320 (6.20) in receptor activation 158. 
 
Figure 1.13:  A molecular model of the binding pocket of the H4R. Asp94 (3.32) in TM3 is expected to 
form an ion pair to the cationic amino group of histamine. Thr178 (5.42) and Ser179 (5.43) in TM5 could 
form a hydrogen bond to the imidazole Nπ nitrogen. Glu182 (5.46) in TM5 could form an ion pair to the 
protonated imidazole Nτnitrogen. Asn147 (4.57) in TM4 and Ser320 (6.52) in TM6 point toward the central 
histamine-binding cavity. Figure adapted from 158 
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The H4 receptor shares highest homology with the histamine H3 receptor; ~37% 
overall and ~58% for the transmembrane domains, whereas the homology with the 
H1 and H2 receptors is lower than 25% 149. (Figure 1.14).  
 
Figure 1.14: Phylogenetic tree demonstrating homology between members of the aminergic receptors 
belonging to the superfamily A GPCRs. Figure adapted from 159. 
 
H4R protein expression 
Northern blot and quantative PCR analysis showed that the H4 receptor is 
predominatly expressed in hematopoietic cells, particularly eosinophils, mast cells, 
basophils and T cells. Presence of the histamine H4 receptor in the brain is 
contradictive and therefore still inconclusive. Zhu and co-workers found traces of 
H4 receptor in in situ hybridization studies in mouse brain 151, whereas also RNase 
protection assays performed on human brain tissue provided evidence for the 
existence for H4 mRNA in brain 148. However, Northern analysis performed by 
other groups reported the absence of H4 receptor in the brain 149,150,152. Since the 
transcription of the H4 receptor gene is regulated by IL-10 and IL-13 150 it is 
possible that the H4 receptor was absent under the conditions used for the 
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Northern blot assay. Although the H4- and H3- receptor apparently exhibit 
completely different expression patterns, they have been shown to be co-localized 
in nerve cells of human nasal mucosa 160.  
 
H4R mediated signaling 
Similar to the H3 receptor, stimulation of the H4 receptor causes an inhibition in 
forskolin induced cAMP production 148,151-153. This effect can be abolished by pre-
treatment with pertussis toxin (PTX) suggesting that the receptor is coupled to the 
Gαi/o G-proteins. The H4 receptor has also been shown to activate mitogen 
activated protein kinase (MAPK) in HEK 293 cells upon histamine stimulation, but 
not in monocyte-derived dendritic cells 161. The activation of MAPK in HEK293 is 
Gi/o mediated as the effect is blocked by PTX 150.  In transfected cells calcium 
mobilization could only be induced if the H4 receptor was co-expressed with 
promiscuous (Gα15 and Gα16) or chimeric G proteins, such as Gαq15, Gαqi1/2, Gαqi3, 
148,150-152. Activation of the H4R may also cause modulation of the cytokine induced 
JAK/STAT (Janus Kinase/Signal Transducer and Activator of Transcription) 
pathway in atopic and non-atopic lymphocytes 162,163. Histamine activation of H4R 
in non-atopic lymphocytes reduced the formation and phosphorylation of STAT1α 
162,163, whereas in atopic lymphocytes blockade of the H4R with JNJ 7777120 
resulted in a increase in STAT6 phosphorylation 163. Constitutive activity was 
shown using a [35S]GTPγS assay 150 and a CRE-β-galactosidase reporter gene 
assay 148. In these assays thioperamide acts as inverse agonist 148,150. 
Histamine activation of the H4 receptor was shown to induce chemotaxis and 
calcium mobilization from intracellular stores in murine mast cells. Both effects can 
be blocked by incubation with selective H4 receptor antagonists (thioperamide and 
JNJ 7777120), PTX treatment and by inhibiting phospholipase C, using the PLC 
inhibitor U-73122 164. Activation of the H4 receptor leads to the release of Gα and 
Gβγ subunits. Most likely the Gβγ subunits activate phospholipase C, leading to 
production of DAG and InsP3. InsP3, possibly through interaction with an InsP3 
receptor, releases calcium from intracellular storage vesicles (Figure 1.15). 
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Figure 1.15: Overview of H4R mediated signaling pathways. The H4R is a Gαi-coupled receptor 
inhibiting the production of cAMP via inhibiton of adenylyl cyclase (AC). The reduction in cAMP will lead 
to a reduction in PKA activation and subsequent phosphorylation of the transcription factor CREB. The 
decreases PKA causes an increase in mitogen activated protein kinase (MAPK). The Gβγ subunit 
activates phospholipase C, which in turn hydrolyze phosphatidylinositol 4,5-biphosphate to 
diacylglycerol (DAG) and inositol-1,4,5,-triphosphate (InsP3) releasing calcium from intracellular storage 
vesicles. Acitvation of H4R has also causes inhibition of the cytokine induced JAK/STAT (Janus 
Kinase/Signal Transducer and Activator of Transcription) pathway. CR, chemokine receptor. 
 
In human eosinophils, which do not express the H3R 165,166, activation of the H4R 
can induce shape changes. The effect was attributed to the H4R since the H4R 
agonist/H3R antagonist clobenpropit as well as clozapine induced the cytoskeletal 
change 167. Additionally, histamine and clobenpropit were also able to induce actin 
polymerization 167. Histamine causes upregulation of the cell adhesion molecule 
CD11b/CD18 (Mac-1) and CD54 (ICAM-1) 165,167. Upregulation of adhesion 
molecules on the cell surface is essential for cell spreading and the passage of 
(white) blood cells in the process of cell migration 165. In eosinophils histamine and 
clozapine were able to cause an increase in intracellular calcium.  All these effects 
could be blocked by thioperamide 165,167. Histamine is able to induce chemotaxis of 
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human eosinophils 165,168. However,  earlier findings of Buckland et al, did not 
observe any significant histamine induced chemotaxis in eosinophils 167. 
Remarkably O’Reilly et al, showed histamine induced chemotaxis in eosinophils 
could be inhibited by thioperamide, but also by the H4R agonist clobenpropit 168. 
Nakayama et al found significant chemotaxis after treatment with CCL16/LEC, 
which could be blocked by thioperamide 166. Pretreatment of eosinophils with IL-5 
led to a 4-fold increase in the chemotactic response of histamine 168. Preincubation 
with histamine has been reported to enhance the chemotaxtic potential of several 
chemokines including CCL7/MCP-3, CCL11/eotaxin and CCL24/eotaxin-2 165,167.  
 
Specific ligands for the H4R 
Reports on the cloning of the H4R also provided a limited characterization of the 
H4R pharmacology using several typical histamine receptor ligands. The relatively 
high homology with the H3R explains that most ligands that bind to the H3R also 
have affinity for the H4R. In most cases the affinity is lower for the H4R than for the 
H3R. Histamine appears equipotent on the H4R and H3R whereas Nα-
methylhistamine and R(-)-α-methylhistamine are both >100 fold more potent at the 
H3R. Yet, immepip and imetit are only >10 fold  more potent at the H3R. On the 
other hand clozapine and dimaprit exhibit higher affinity for the H4 than for the H3R. 
Analysis of the binding data for several ligands on the H4R gave the following rank 
order imetit>clobenpropit>histamine> immepip>thioperamide>NAMHA 
>RAMHA>dimaprit>clozapine 148-153. Thioperamide an inverse agonist on the H3 
receptor also acts as inverse agonist on the H4R. Clobenpropit is a remarkable 
ligand as it behaves as inverse agonist on the H3R, but as partial agonist on the 
H4R. Therefore, in several early studies on H4R functionality, clobenpropit was 
used to prove that an effect is H4R and not H3R mediated. However, in more 
recent years several potent and selective H4R ligands have been identified 169,170 
making the use of clobenpropit for this purpose obsolete.  
So far few H4R selective ligands have been identified and it has been easier to 
produce H3 specific ligands. In the search for more selective H4 ligands, 
Hashimoto et al developed a series of chiral imidozole-containing ligands. The 
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most potent compound OUP-16 (Figure 1.16) is >40 fold more potent on the H4R 
than on the H3R 171. One of the first potent and selective H4R antagonists was 
synthesized d by Jablonowksi et al in 2003 169. The compound JNJ 7777120 
(Figure 1.16) showed >1000 fold selectivity over the other histamine receptors 
169,172. Screening of benzimidazole analogs of JNJ 7777120 resulted in another 
selective H4R antagonist, VUF6002 (Figure 1.16), with comparable affinity to JNJ 
7777120 173. The same compound was also picked up in a screening by Johnson 
and Johnson (JNJ 10191584), as high affinity H4R antagonist (pA2 = 7.7), and 
showed no cross reactivity to a panel of over 50 receptors, transported and ion 
channels 174. 
 
 
Figure 1.16:  Chemical structure of several H4R ligands 
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In search of potent selective agonists for the H4R, a series of dibenzodiazepine 
derivatives was screened 175. Optimization of the tricyclic clozapine (Figure 1.16) 
lead to (E)-7-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine. The 
ligand is a potent full agonist (pKi = 7.6, pEC50 = 7.7), and is selective over the H2R 
and H3R (>300 fold), but not the H1R 175. However, the screen provided useful 
information on the ligand binding pocket, which can be used in development of 
more potent and selective H4R ligands.  A remarkable finding came from the group 
of Yoshie, who reported that the chemokine CCL16/LEC was able to bind to and 
activate the H4 receptor. CCL16 was shown to bind to the H4 receptor with an 
affinity of 17 nM and induce calcium mobilization and chemotaxis of L1.2 cells 166. 
 
Potential physiological roles of the H4R 
The exclusive expression pattern of the H4R in cells belonging to the 
hematopoeitic lineage, such as eosinophils, and mast cells, already early on led to 
speculation for this receptor to be play a role in immune, inflammatory diseases 
148,150,151. The H4R, histamine is involved in mast cell migration both in vitro and in 
vivo 172. Mast cell migration may play a role in allergic rhinitis and allergy 176,177. To 
study inflammation zymosan is often used to experimentally induce acute 
inflammation 178. In a peritonitis model in mice blockage of the H4R with 
thioperamide or JNJ 7777120 showed a reduction in the accumulation of 
polymorphonuclear cells after zymosan injection, suggesting a role for the H4R in 
general inflammation 172,179. In the same test model Takeshita et al also found that 
histamine induces leukotriene B4 release 179. Leukotriene B4 (LTB4) is a potent 
chemotactic factor for neutrophils and has been postulated to play an important 
role in a variety of pathological conditions including rheumatoid arthritis (RA), 
psoriasis, and inflammatory bowel disease 180. By acting on the H4R histamine 
stimulation was able to mimic the zymosan induced neutrophil release from murine 
bone marrow 178. The H4R was also shown to play a role in the early phase 
inflammatory responses in carrageenan-induced acute inflammation 181. The H4R 
is partly responsible for the release of interleukin-16 (IL-16) upon activation with 
histamine in CD8+ lymphocytes 118. IL-16 is a mediator found in lungs of asthma 
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patients following challenge 182,183. Additionally, the H4R also causes the release of 
several other cytokines 184. For example, blockade of the H4R in of CD4+ T cells 
stimulated using dendritic cells (expressing H4R) led to a decrease of in IL-4, IL-6 
and IL-7 184. Stimulation of H4R in monocyte-derived dendritic cells suppressed IL-
12 production, potentially through activation of the transcription factor AP-1 161. IL-
12 is a major Th1 driving cytokine. Therefore, a reduction of IL-12 may result in 
Th2-type immune responses 185, suggesting that the H4R may cause immune-
modulatory effects. The H4R was further linked to allergic responses by the finding 
that H4R knock out mice, or mice treated with the H4R antagonist JNJ 7777120, 
showed decreased allergic lung inflammation. In these disease models decreases 
in both  eosinophil and lymphocyte infiltration in the lung were observed 184. Based 
on the induction of scratching upon treatment of clobenpropit the H4R has been 
linked to be involved in itch in BalbC mice 186. Dunford et al, showed that histamine 
and 4-methylhistamine induced scratching in mice could be inhibited by treatment 
with the H4R antagonist JNJ 7777120 with higher potency then with H1R 
antagonists 187. This result suggests a potential role for H4R antagonists as 
therapeutic in chronic pruritic diseases that cannot be treated with H1R antagonists 
187.   
The H4R is abundantly present in synovial cells from patients suffering from 
rheumatoid arthritis. The amount of H4 receptor differed between patients, 
suggesting the possibility that there is a relation between the amount of H4 
receptor and the duration and severity of rheumatoid arthritis 188. Moreover, a 
possible involvement of the H4R in ulcerative colitis has been demonstrated 189. 
Measurable effects of acute colitis induced by trinitrobenzene in rat, such as 
elevation of tumour necrosis factor-α (TNF-α), and histologically assessed 
increase in neutrophil infiltration, mucosal and submucosal thickness could be 
inhibited by the selective H4R antagonists JNJ 10191584 (VUF6002) and  JNJ 
7777120 189. In colon cancer cells (Caco-2 and COX-2-positive HT29) histamine 
was shown to increase COX-2 expression/activity, cell proliferation, and VEGF 
production 190. Treatment with either H2- or H4- receptor antagonists averted these 
effects, suggesting that these receptors may play a role in tumor progression e.g. 
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proliferation and angiogenesis 190. Recently Maslinska and co-workers reported the 
presence of H4R protein on mammary epithelial cells of the human breast 191. 
Interestingly a strong presence of H4R protein in fibroadenoma (benign tumour) 
and carcinoma tubulare (malignant tumour) was detected, suggesting a possible 
role for the H4R in breast cancer 191.  
In order to use H4R antagonists in clinical trials they need to be evaluated for their 
pharmacokinetic and pharmacodynamic properties. The selective H4 antagonist 
JNJ 7777120 has already been tested for its pharmacokinetic profile in rodent and 
dogs. The compound has a biological half life of 1-2.5 hours and a bioavailability 
after oral administration of 22% (rats) and 100% (dogs) 172. In comparison JNJ 
10191584 (VUF6002) the benzimidazole analogue of JNJ 7777120 had a slightly 
shorter half life of 1 hour 174. 
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1.3 Scope and aim of the thesis 
In 2000 a fourth member of the histamine receptor family of GPCRs was 
discovered by several groups simultaneously 148-153. Although this H4R shares 
highest homology with the H3R there is little overlap in tissue distribution. Whereas 
the H3R is expressed mainly in the brain, the H4R is expressed in hematopoietic 
cells such as, white blood cells, mast cells and dendritic cells.  
At the time the Ph.D. project was initiated, still only little information was known 
about the H4R. In order to obtain a better insight in the pharmacology of this novel 
receptor, a large set of H1R, H2R and H3R ligands were screened on the H4R. The 
results of this screen are summarized in chapter 2. In all living organisms DNA is 
transcribed to so-called messenger RNA and subsequently translated into 
proteins. In many cases the mRNA undergoes a special treatment in which 
specific regions (introns) are removed from the mRNA, and the remaining regions 
(exons) are fused together before translation. This process is known as splicing. 
Whereas the genes encoding the H1R and H2R are intronless, both the genes 
encoding the H3R and H4R consist of several introns and exons. It is known that 
H3R mRNA can be alternatively spliced giving rise to different H3R isoforms. Some 
of these H3R splice variants can play a dominant negative role on the wild-type 
H3R. In chapter 4 the identification of and characterization of two splice variants of 
the H4R is described. Additionally, the effect of these H4R splice variants on the 
wild-type H4R was investigated. 
Unlike many other classes of proteins, GPCRs were thought for a long time to 
exist and function solely as monomeric entitities. However, during the last decade 
of the previous century progressively data emerged suggesting that GPCRs may 
exist as higher oligomeric complexes. The study of GPCR oligomerization has 
grown exponentially the last years and has resulted in the publication of hundreds 
of articles on this topic A large percentage of these papers concern GPCR 
belonging to the class of aminergic receptors, i.e. receptors that bind small 
endogenous biogenic amines, such as histamine, dopamine and adrenaline. In 
chapter 6, a review has been written summarizing the current state of research on 
oligomerization of aminergic receptors. 
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The study of oligomerization of the H4R played an important part of the Ph.D. 
project.  
With the aim of studying homo- and hetero-oligomerization of the H4R several 
biochemical and biophysical techniques were employed. The biophysical assays 
relied on the principal that one fluorescent conjugate can excite a second 
fluorescent moiety if in close proximity. The biochemical assays, benefited from 
the development of a specific H4R antibody. In chapter 3 the results concerning 
homo-oligomerization of the H4R and hetero-oligomerization between the H4R and 
H1R are described.  
The H4R is suggested to play a role in inflammation and is expressed in cells, 
which are known to also express several receptors belonging to the chemokine 
family. These chemokine receptors are acknowledged for their role in the immune 
system 192,193. Several viruses including several herpes viruses carry genes within 
their genome encoding GPCRs resembling chemokine receptors. The human 
cytomegalovirus is encoded by the chemokine receptor US28 and three other 
chemokine receptors. We found evidence that the H4R may form hetero-oligomers 
with the US28 receptor. Chapter 6 describes the study of the interaction between 
the H4R and US28 receptor and its potential functional implications. 
An additional objective in this Ph.D. project has been to study the molecular 
pharmacology of the H4R using biophysical approaches. The project focused on 
large scale production and purification of the H4R using various strategies e.g. 
baculovirus and semliki forest virus expression systems, with the goal of using the 
purified receptor in analysis of the protein structure. A potentially effective strategy 
to obtain structural information on a protein is to produce large purified quantities 
of the protein of interest. The purified protein can subsequently be studied at high 
resolution by employing techniques such as X-ray crystallography, and Nuclear 
Magnetic Resonance (NMR) and Mass Spectrometry (MS). Our efforts to produce 
large amounts of H4R protein are described in chapter 7. We have employed 
several strategies to over-express the H4R in different cell lines. These efforts 
include the use of viral overexpression systems, such as baculovirus and Semliki 
Forest virus as well as codon optimization of the H4R. 
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ABSTRACT 
 
The histamine H4 receptor (H4R) is involved in the chemotaxis of leukocytes and 
mast cells to sites of inflammation and is suggested to be a potential drug target for 
asthma and allergy. So far, selective H4R agonists have not been identified. In the 
present study we therefore evaluated the human H4R (hH4R) for its interaction with 
various known histaminergic ligands. Almost all of the tested H1R and H2R 
antagonists, including several important therapeutics, displaced less than 30% of 
specific [3H]histamine binding to the hH4R at concentrations up to 10 μM. Most of 
the tested H2R agonists and imidazole-based H3R ligands show micromolar to 
nanomolar-range hH4R affinity and these ligands exert different intrinsic hH4R 
activities, ranging from full agonists to inverse agonists. Interestingly, we identified 
4-methylhistamine as a high affinity H4R ligand (Ki = 50 nM) that has a >100-fold 
selectivity for the hH4R over the other histamine receptor subtypes. Moreover, 4-
methylhistamine potently activated the hH4R (pEC50 = 7.4 ± 0.1, α=1) and this 
response was competitively antagonized by the selective H4R antagonist JNJ 
7777120 (pA2 = 7.8). The identification of 4-methylhistamine as a potent H4R 
agonist is of major importance for future studies to unravel the physiological roles 
of the H4R. 
INTRODUCTION 
 
Histamine exerts many (patho-)physiological effects through its interaction with four 
histamine receptor subtypes that all belong to the family of G-protein coupled 
receptors (Hough, 2001). The histamine H1 receptor (H1R) and H2 receptor (H2R) 
had been pharmacologically identified long before their cDNAs were cloned (Gantz 
et al., 1991, Yamashita et al., 1991) and have been successful blockbuster targets 
for more than two decades. The cDNA encoding the histamine H3R was cloned 
more recently (Lovenberg et al., 1999), and bioinformatic analysis of human 
genome databases resulted in identification of the gene encoding the human H4R 
(hH4R) based on its sequence homology to the H3R gene (37%) (Oda et al., 2000; 
Liu et al., 2001a; Morse et al., 2001; Nguyen et al., 2001; Zhu et al., 2001). While 
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the hH3R is mainly present in the nervous system, the hH4R is distributed mainly in 
hematopoietic cells (Oda et al., 2000; Liu et al., 2001a; Morse et al., 2001; Zhu et 
al., 2001). The H4R shows a different pharmacological profile compared to the 
closely related H3R, although many H3R ligands also interact with the H4R. Like the 
H3R, the H4R couples to pertussis toxin-sensitive Gi/o-proteins and thereby inhibits 
forskolin-induced cAMP production (Oda et al., 2000; Liu et al., 2001a; Zhu et al., 
2001). In addition, the H4R also activates MAP kinase (Morse et al., 2001) and 
mobilizes calcium in eosinophils and mast cells (Buckland et al., 2003; Hofstra et 
al., 2003).  
 
The presence of the hH4R on leukocytes and mast cells suggests that this new 
histamine receptor plays an important role in the modulation of the immune system. 
This hypothesis is supported by the fact that IL-10 and IL-13 modulate hH4R 
expression (Morse et al., 2001) and that binding sites for cytokine-regulated 
transcription factors, like ISRE, IRF-1, NF-κB, and NF-IL6, are present upstream of 
the hH4R gene (Coge et al., 2002). Physiological roles of the hH4R include the 
control of IL-16 release by human CD8+ T cells (Gantner et al., 2002), chemotactic 
responses and cyctoskeletal changes of human eosinophils (O’Reilly et al., 2002; 
Buckland et al., 2003; Ling et al., 2004), chemotaxis and intracellular calcium 
mobilization in mast cells (Hofstra et al., 2003), and control of leukotriene B4 
production by mast cells that subsequently lead to neutrophil recruitment into 
peritoneum (Takeshita et al., 2003; Thurmond et al., 2004). These studies suggest 
that the hH4R is a potential drug target for immune system-related diseases. 
 
Until recently, potent and selective H4R ligands were not available. In the early 
studies, the H3R antagonist thioperamide was identified as an equally effective H4R 
antagonist (Oda et al., 2001). High-throughput screening and subsequent 
medicinal chemistry efforts recently identified the indolylpiperazine JNJ 7777120 
(Jablonowski et al., 2003; Thurmond et al., 2004) and the related benzimidazole 
analog VUF 6002 (Terzioglu et al., 2004) as selective and potent H4R antagonists. 
Studies directed towards selective H4R agonists have so far been less successful. 
Burimamide, clozapine, and clobenpropit are all known to act as H4R agonists, and 
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clozapine and clobenpropit have been proven useful for initial pharmacological 
studies (Gantner et al., 2002; Buckland et al., 2003; Bell et al., 2004; Ling et al., 
2004). However, their non-selectiveness for the H4R limits their use as H4R 
agonists. 
 
In our search for selective H4R agonists, many known histaminergic ligands of 
different structural classes, including several important therapeutics, were 
evaluated for their interaction with the hH4R. Our studies resulted in the 
identification of 4-methylhistamine, a presumed moderately active and selective 
H2R agonist (Durant et al., 1975), as a high affinity H4R agonist with a more than 
100-fold selectivity over the H1R, H2R, and H3R. 
 
RESULTS 
 
Pharmacological characteristion of the hH4R expressed in SK-N-MC cells 
Stable transfection of the human H4R (hH4R) cDNA in SK-N-MC cells resulted in 
the expression of functional hH4R proteins. The hH4R could be labeled with both 
agonist and antagonist radioligands. The H4R agonist [3H]histamine shows 
saturable binding to the expressed H4R with a minimal amount of non-specific 
binding (Figure 2.1A). Analysis of the [3H]histamine saturation binding yielded a Kd 
value of 11 ± 1.0 nM (n=6) and a Bmax value of 1.8 ± 0.4 pmol/mg protein. Recently, 
JNJ 7777120 was described as a selective H4R antagonist (Jablonowski et al., 
2003). In our hands, the non-imidazole JNJ 7777120 shows a 300-fold selectivity 
for the hH4R (pKi = 7.8 ± 0.1 against [3H]histamine) over the hH3R (pKi = 5.3 ± 0.1 
against [3H]Nα-methylhistamine), allowing the use of [3H]JNJ 7777120 to label the 
H4R (Thurmond et al., 2004). The H4R antagonist [3H]JNJ 7777120 exhibits a 
somewhat higher level of non-specific binding to hH4R expressing SK-N-MC cells, 
but also binds saturably and shows an equipotent affinity (Kd = 11 ± 3.6 nM, n=3) 
and results in a Bmax value of 1.7 ± 0.4 pmol /mg protein (Figure 2.1B). The binding 
of either 10 nM [3H]histamine (Figure 2.1C) or 10 nM [3H]JNJ 7777120 (data not 
shown) to the hH4R is fully displaced by histamine (pKi = 7.8 ± 0.1), the H3/4R 
antagonist thioperamide (pKi = 6.9 ± 0.1) and the H4R agonist/H3R antagonist 
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clobenpropit (pKi = 8.1 ± 0.1), in a good agreement with the results reported 
previously (Oda et al., 2000; Liu et al., 2001a; Morse et al., 2001).  
 
The SK-N-MC/hH4 cells used in this study co-express a CRE-controlled β-
galactosidase reporter gene and can therefore also be used for a functional 
analysis of H4R ligands. Stimulation of the hH4R with histamine resulted in the 
inhibition (58±3%, n = 16) of the forskolin-stimulated (1 µM) cAMP–mediated 
reporter gene transcription with a pEC50 value of 7.7 ± 0.1 (n = 16) (Figure 2.1D). 
Treatment of SK-N-MC/hH4 cells with the Gαi/o protein inhibitor pertussis toxin 
(100ng/ml for 16 hours) completely inhibited histamine induced responses, 
confirming the coupling of the H4R to Gαi/o proteins (Oda et al., 2000; Liu et al., 
2001a; Zhu et al., 2001). In our hands, histamine exerted the maximally observed 
level of inhibition in this assay, and is therefore referred to as a full agonist (intrinsic 
activity α=1). As reported before (Oda et al., 2000; Liu et al., 2001a; Morse et al., 
2001), clobenpropit acts as a potent partial H4R agonist with a pEC50 value of 7.7 ± 
0.1 (n = 3) and an intrinsic activity of 0.8 (Figure 2.1D). 
 
Treatment of SK-N-MC/hH4 cells with pertussis toxin (100ng/ml for 16 hours) 
resulted in an increase of 1 µM forskolin-stimulated CRE activity by 130 ± 3%, 
suggesting that the H4R shows a detectable level of constitutive acitivity in the SK-
N-MC/hH4 cells. In line with earlier observations on inverse agonism by 
thioperamide (Liu et al., 2001a; Morse et al., 2001), 1 µM forskolin-stimulated CRE 
activity was increased by thioperamide with a pEC50 value of 7.0 ± 0.1 (Figure 
2.1D). The inhibition of the constitutive activity of the H4R by thioperamide was of 
the same magnitude as observed after treatment with pertussis toxin and 
thioperamide is referred to as a full inverse H4R agonist (intrinsic activity α=-1).  
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Figure 2.1. The cell line SK-N-MC/hH4 stably expresses functional hH4R and CRE-control β-
galactosidase. The homogenate of SK-N-MC/hH4 shows a saturable binding to H4R agonist 
[3H]histamine (A) with a minimal amount of nonspecific binding and also to H4R antagonist [3H]JNJ 
7777120 (B) with a higher level of nonspecific binding. The binding of [3H]histamine to the hH4R is nicely 
inhibited by H3/4R ligands, displaying a one-binding binding site property (C). The full agonist histamine 
and partial agonist clobenpropit hH4R inhibits the 1 μM forskolin-induced cAMP formation, which is 
manifested as β-galactosidase activity, while the inverse agonist thioperamide dose-dependently blocks 
the hH4R constitutive activity (D). 
 
In SK-N-MC/hH4 cells the cAMP-driven β-galactosidase reporter-gene transcription 
can also be activated by endogenously expressed Gαs protein coupled β 
adrenergic receptors (Bahouth et al., 2001). The β2 adrenergic receptor agonist 
feneterol induced β-galactosidase activity to a similar extend to that of forskolin 
with a pEC50 value of 6.9 ± 0.1 (n = 6). H4R activation by histamine inhibited the 
100 nM feneterol-induced β-galactosidase activity for 39 ± 3 % with a pEC50 value 
of 7.4 ± 0.1 (n = 7). However, inverse agonistic activity of thioperamide, at the 
hH4R, could not be easily demonstrated with a feneterol-based assay system (data 
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not shown). The evaluation of the functional activity of all the various histaminergic 
ligands was therefore performed using forskolin (1 µM) stimulated SK-N-MC/hH4 
cells. 
All compounds were preliminarily tested as displacers of [3H]histamine binding to 
the hH4R expressed in SK-N-MC/hH4 cells at a concentration of 10 μM. 
Compounds inhibiting the specific binding of 10 nM [3H]histamine to the hH4R by 
≤30% are expected to have a Ki > 10 μM (based on the Cheng and Prusoff 
equation Ki = IC50/(1+[radioligand]/Kd)), and were excluded for further testing. 
Active compounds (displacement > 30%) were tested more extensively in both 
[3H]histamine displacement studies and the CRE-β-galactosidase based functional 
H4R assay.  
 
Most H1R ligands are devoid of H4R activity 
Histamine potently displaces [3H]histamine from the hH4R with a pKi value of 7.8 ± 
0.1 (Table 2.1), while H1R agonists with substituents at the 2 position of the 
imidazole ring show significantly lower affinities. Substitution of the imidazole ring 
with either a small methyl or large 3-bromophenyl substitutent is not tolerated and 
causes an almost 100-fold drop of affinity. Bulkier substituents at the 2-position 
(1,1-diphenylpropyl in histaprodifen) even result in a total loss of affinity for the 
hH4R (Table 2.1). Agonists, lacking the imidazole ring, like 2-(2-
thiazolyl)ethylamine (TEA), 2-pyridylethylamine (PEA) or 8R-lisuride (Bakker 2004), 
are also not active at the hH4R (Table 2.1). 
 
Following an initial report that the H4R can be labeled with [3H]-mepyramine 
(Nguyen et al., 2001), a large number of H1R antagonists (Table 2.1), including 
many clinically relevant drugs, were evaluated for their hH4R affinity as well. Almost 
all tested H1R antagonists, including mepyramine, showed pKi values <5 (Table 
2.1) and did not show functional activity at 1 and 10 μM at the hH4R (data not 
shown). Although structurally similar to some tricyclic H1R antagonists devoid of 
H4R affinity, clozapine binds with moderate potency to the hH4R (pKi 6.7 ± 0.1) and 
exerts full agonistic activity at the hH4R with a pEC50 value of 6.8 ± 0.1 (n = 5). N-
desmethyl clozapine, a clozapine metabolite, showed a slightly decreased affinity 
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(pKi 6.5 ± 0.1), while N-oxide clozapine, another clozapine metabolite, is totally 
devoid of hH4R affinity. Further, we evaluated clozapine analogs of therapeutic 
importance as well. Loxapine and amoxapine showed >10-fold lower affinity (pKi 
5.4 ± 0.1 and 5.3 ± 0.1, respectively), while octoclothepin did not show binding for 
the hH4R at all. 
 
Table 2.1. Activity of H1R ligands at the hH4R. The ligands were tested as described in Methods and 
Materials. Data shown are mean ± standard error of mean of at least 3 independent experiments 
H1R ligandd H1R activity pKia pEC50b αc 
Histamine agonist 7.8 ± 0.1 7.7 ± 0.1 1 
2-methylhistamine agonist 6.1 ± 0.1 5.9 ± 0.1 0.8 
2-(3-bromophenyl)histamine agonist 6.0 ± 0.1 5.9 ± 0.2 0.6 
Histaprodifen agonist <5 n.d. n.d. 
2-(2-thiazolyl)ethylamine (TEA) agonist <5 n.d. n.d. 
2-Pyridylethylamine (PEA) agonist <5 n.d. n.d. 
8R-lisuride agonist 5.3 ± 0.1 e - 
Azatidine antagonist <5 n.d. n.d. 
Cetirizine antagonist <5 n.d. n.d. 
Clozapine antagonist 6.7 ± 0.1 6.8 ± 0.1 1 
Amoxapine antagonist 5.3 ±0.1 6.7 ± 0.1 0.5 
Loxapine antagonist 5.4 ±0.1 6.2 ± 0.1 0.8 
Octoclothepin antagonist <5 n.d. n.d. 
Ebastine antagonist <5 n.d. n.d. 
Fexofenadine antagonist <5 n.d. n.d. 
Hydroxyzine antagonist <5 n.d. n.d. 
Loratidine antagonist <5 n.d. n.d. 
Mizolastine antagonist <5 n.d. n.d. 
Mepyramine antagonist <5 n.d. n.d. 
R(+)-terfenadine antagonist <5 n.d. n.d. 
a pKi values were determined with [3H]histamine displacement assay. 
b pEC50 values show the inhibition of 1 μM forskolin-induced CRE-β-galactosidase activity in SK-N-
MC/hH3 or SK-N-MC/hH4 cells. 
c α is intrinsic activity, 1 designated for full agonistic, 0 for neutral antagonist, and -1 for inverse agonistic 
activity. 
d The H1R antagonists Chlorpheniramine, Cyproheptadine, Desipramine, Dexchlorpheniramine, 
Diphenhydramine, Doxepine, Imipramine, Ketotifen, Mianserine, Octoclothepin, ORG-3770, 
Promethazine, S(-)-terfenadine, Tripelennamine, and Triprolidine also have pKi values < 5. 
e due to non H4R-mediated effects of 8R-lisuride, the pEC50 value was not determined. 
n.d. = not determined. 
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Some H2R ligands act as hH4R agonists 
 
Within the series of known H2R agonists that we have tested, only some ligands 
retain H4R activity. Replacement of the imidazol ring of histamine in the selective 
H2R agonists amthamine and amselamine (Leurs et al., 1994) results in a total loss 
of hH4R activity at concentrations up to 10 μM. Dimaprit, a H2R agonist/H3R 
antagonist lacking an imidazole group, binds the H4R with moderate affinity, 
showing a pKi value of 6.5 ± 0.1, and exerts partial H4R agonistic activity (Table 
2.2). Impromidine, which was reported to bind to both H2R and H3R, also binds 
potently to the hH4R with a pKi value of 7.6 ± 0.1 and acts as a partial H4R agonist 
(α = 0.5). Both the S and R enantiomers of the related sopromidine bind 
respectively >10 and >100 times less potently. In fact, the first reported H2R 
selective agonist 4-methylhistamine (Durant et al., 1975) is the only known H2R 
agonist that also acts as full agonist at the H4R (Table 2.2). 4-Methylhistamine 
binds two times less potent than histamine to the hH4R, exhibiting a pKi value of 7.3 
± 0.1 (n = 3). 
 
Most tested H2R antagonists, including cimetidine, mifentidine, aminopotentidine, 
ranitidine, famotidine, and tiotidine, only displaced < 30% of 10 nM [3H]histamine 
binding to the hH4R. Only the H2/3R ligand burimamide shows a good affinity for the 
hH4R pKi = 7.4 ± 0.1 (Table 2.2). Moreover, burimamide acted as a potent, albeit 
partial H4R agonist (pEC50 = 7.7 ± 0.1, α = 0.7). Previously, we reported on various 
burimamide analogs as H3R antagonists. In our search for H4R selective ligands 
various burimamide analogs were therefore investigated for their H4R activity.  
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Table 2.2. Activity of H2R ligands at the hH4R. The ligands were tested as described in Methods and 
Materials. Data shown are mean ± standard error of mean of at least 3 independent experiments 
H2R ligand H2R activity pKia pEC50
b αc 
4-Methylhistamine agonist 7.3 ± 0.1  7.4 ± 0.1 1 
Amthamine agonist 5.3 ± 0.1 - 0 
Amselamine agonist 5.6 ± 0.1 - 0 
Dimaprit agonist 6.5 ± 0.1 5.8 ± 0.2 0.8 
Impromidine agonist 7.6 ± 0.1 7.6 ± 0.1 0.5 
S(+)-sopromidine agonist 5.5 ± 0.1 - 0 
R(-)-sopromidine agonist 6.1 ± 0.1 - 0 
Aminopotentidine antagonist <5 n.d. n.d. 
Burimamide antagonist 7.4 ± 0.1 7.7 ± 0.1 0.7 
Cimetidine antagonist <5 n.d. n.d. 
Famotidine antagonist <5 n.d. n.d. 
Mifentidine antagonist <5 n.d. n.d. 
Ranitidine antagonist <5 n.d. n.d. 
Tiotidine antagonist <5 n.d. n.d. 
a pKi values were determined with [3H]histamine displacement assay. 
b pEC50 values show the inhibition of 1 μM forskolin-induced CRE-β-galactosidase activity in SK-N-
MC/hH3 or SK-N-MC/hH4 cells. 
c α is intrinsic activity, 1 designated for full agonistic, 0 for neutral antagonist, and -1 for inverse agonistic 
activity. 
d The H1R antagonists Chlorpheniramine, Cyproheptadine, Desipramine, Dexchlorpheniramine, 
Diphenhydramine, Doxepine, Imipramine, Ketotifen, Mianserine, Octoclothepin, ORG-3770, 
Promethazine, S(-)-terfenadine, Tripelennamine, and Triprolidine also have pKi values < 5. 
e due to non H4R-mediated effects of 8R-lisuride, the pEC50 value was not determined. 
n.d. = not determined. 
 
In this series of compounds, the presence of an isopropyl (VUF 4683 and VUF 
4616) or cyclohexyl (VUF 4617) moiety adjacent to the thiourea group is optimal 
the hH4R affinity (Table 2.3). Interestingly, this series of closely related compounds 
exerts partial agonistic, neutral antagonistic, and inverse agonistic activities at the 
hH4R (Table 2.3, Figure 2.2A). Substitution of the thiourea with aromatic 
substituents, like a benzyl group in VUF 4686, results in a loss of H4R agonistic 
activity. A total loss of agonistic H4R activity, but not affinity (pKi = 7.6 ± 0.1) is 
surprisingly observed for VUF 4614. As can be seen in Figure 2.2B, VUF 4614 was 
able to competitively block the H4 agonistic responses of histamine (Figure 2.2B), 
resulting in a pA2 value of 6.8. Finally, within this series we identified VUF 4742 as 
4-methylhistamine, a potent and selective H4R agonist 
 
 53
an hH4R inverse agonist (Figure 2.2). This burimamide analog bound with 
moderate affinity to the H4R (pKi = 6.9 ± 0.1, n = 4) and acted as a full inverse 
agonist with a pEC50 value of 7.2 ± 0.1 (n =5), in accordance with its binding 
affinity. 
 
Table 2.3. Activity of burimamide analogs at the hH4R. The ligands were tested as described in 
Methods and Materials. Data shown are mean ± standard error of mean of at least 3 independent 
experiments 
NH N
N
H
N
H
R
S
n
 
 
ligand n R pKi
a pEC50b αc 
burimamide 4 methyl 7.4 ± 0.1 6.8 ± 0.1 0.7 
VUF 4681 4 ethyl 7.6 ± 0.1 7.0 ± 0.1 0.8 
VUF 4682 4 n-propyl 8.0 ± 0.1 7.2 ± 0.1 0.8 
VUF 4683 4 isopropyl 8.1 ± 0.1 7.7 ± 0.1 0.8 
VUF 4686 4 benzyl 7.3 ± 0.1 7.1 ± 0.3 0.3 
VUF 4687 4 ethylbenzyl 7.2 ± 0.1 5.9 ± 0.3 0.3 
VUF 4614 5 ethyl 7.6 ± 0.1 - 0 
VUF 4616 5 isopropyl 7.9 ± 0.1 d n.d. 
VUF 4617 5 cyclohexyl 7.9 ± 0.1 d n.d. 
VUF 4742 5 4-chlorobenzyl 6.9 ± 0.1 7.2 ± 0.1 -1 
a pKi values were determined with [3H]histamine displacement assay. 
b pEC50 values show the inhibition of 1 μM forskolin-induced CRE-β-galactosidase activity in SK-N-
MC/hH3 or SK-N-MC/hH4 cells. 
c α is intrinsic activity, 1 designated for full agonistic, 0 for neutral antagonist, and -1 for inverse agonistic 
activity. 
d These compounds exerted a biphasic response: a slight decrease of forskolin stimulated β-
galactosidase activity at concentration up to 1 μM and an increase at concentration ≥ 10 μM. The latter 
effect is not mediated by the hH4R, as it cannot be blocked by H4R antagonist JNJ 7777120. 
n.d. = not determined. 
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Figure 2.2. Burimamide analogs exert different intrinsic activities at the hH4R. (A) Burimamide acts as a 
H4R partial agonist, which dose dependently inhibits 1 μM forskolin-induced cAMP in SK-N-MC/hH4 
cells, which is manifested as reporter β-galactosidase activity. Modifications of burimamide structure 
(Table 2.2) result in changes of ligand intrinsic activity, ranging from agonistic (VUF 4683, burimamide, 
VUF 4686) to neutral antagonist (VUF 4614) and inverse agonist (VUF 4742). (B) The neutral 
antagonist VUF 4614 competitively antagonizes histamine activity at the hH4R, resulting in a rightward 
shift of histamine dose-response curve. 
 
Evaluation of H3R ligands at the hH4R 
In view of the high sequence homology between the H3R and the H4R, it is not 
surprising that in the initial studies some H3R ligands were identified as H4R ligands 
as well. We therefore characterized in this study a large set of known H3R ligands 
for their interaction with the H4R. The histamine analogs Nα-methylhistamine, (R)-
α-methylhistamine, and (S)-α-methylhistamine show an almost 2 order lower 
affinity for the hH4R than for the hH3R. However, the hH4R retains some level of 
stereo-selectivity for (R)-α- (pKi = 6.6 ± 0.1) and (S)-α-methylhistamine (pKi = 5.4 ± 
0.1) (Table 2.4). Increasing the spacer-length between imidazole and amine group 
from 2 carbon atoms (histamine, pKi = 7.8 ± 0.1) to 3 carbon atoms 
(homohistamine, pKi = 7.5 ± 0.1) slightly decreases the affinity for the hH4R, while 
4 carbon atoms (imbutamine, pKi = 8.0 ± 0.1) results in a slightly higher hH4R 
affinity. A further increase of the spacer length proved to be detrimental for hH4R 
affinity. The highly potent H3R agonist impentamine shows only moderate affinity at 
the H4R (pKi = 6.6 ± 0.1) (Table 2.4). Interestingly, besides the affinity, 
impentamine also looses intrinsic activity for the hH4R (α = 0). Previously identified 
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H3R agonists, including immepip, imetit, and VUF 8328 (an imetit analog) (Wieland 
et al., 2001), also potently bind the H4R with pKi values of 7.7 ± 0.1, 8.2 ± 0.1, and 
8.0 ± 0.1, respectively. At the H4R these ligands also act as agonists, but exert 
somewhat lower intrinsic activity (α values of 0.9, 0.9, and 0.6, respectively) (Table 
2.4).  
 
Table 2.4. Activity of H4R ligands at the hH3R and the hH4R. The ligands were tested as described in 
Methods and Materials. Data shown are mean ± standard error of mean of at least 3 independent 
experiments 
 a pKi values were determined with [3H]histamine displacement assay. 
b pKi values were determined with [3H]Nα-methylhistamine displacement assay. 
c pEC50 values show the inhibition of 1 μM forskolin-induced CRE-β-galactosidase activity in SK-N-
MC/hH3 or SK-N-MC/hH4 cells. 
d α is intrinsic activity, 1 designated for full agonistic, 0 for neutral antagonist, and -1 for inverse agonistic 
activity. 
hH3R hH4R 
Ligand pKi
a pEC50c αd pKib pEC50c αd 
Histamine 8.0 ± 0.1 8.3 ± 0.1 1 7.8 ± 0.1 7.7 ± 0.1  1 
Nα-methylhistamine 8.4 ± 0.1 9.4 ± 0.1 1 6.5 ± 0.1 6.1 ± 0.1 1 
(R)-α-methylhistamine 8.2 ± 0.1 9.5 ± 0.1 1 6.6 ± 0.1 6.2 ± 0.1 1 
(S)-α-methylhistamine 7.2 ± 0.1 8.0 ± 0.1 1 5.4 ± 0.1 4.9 ± 0.1 1 
Homohistamine 7.3 ± 0.1 7.4 ± 0.2 0.9 7.5 ± 0.1 6.7 ± 0.1 0.8 
Imbutamine 8.4 ± 0.1 9.2 ± 0.1 1 8.0 ± 0.1 7.5 ± 0.1 0.8 
Impentamine 8.3 ± 0.1 8.4 ± 0.1 0.9 6.6 ± 0.1 - 0 
Immepip 9.3 ± 0.1 10.4 ± 0.1 1 7.7 ± 0.1  7.8 ± 0.1 0.9 
Methimmepip 9.0 ± 0.1 9.5 ± 0.2 0.8 5.7 ± 0.1 5.3 ± 0.2 0.5 
Immethridine 9.1 ± 0.1 9.8 ± 0.1 0.9 6.6 ± 0.1 6.0 ± 0.1 0.5 
Imetit 8.8 ± 0.1 9.9 ± 0.1 1 8.2 ± 0.1 7.9 ± 0.1 0.9 
VUF 8328 8.5 ± 0.1 9.3 ± 0.2 1 8.0 ± 0.1 7.9 ± 0.1 0.6 
Clobenpropit 8.6 ± 0.1 9.4 ± 0.1 -1 8.1 ± 0.1 7.7 ± 0.1 0.8 
Iodophenpropit 8.2 ± 0.1 8.5 ± 0.1 -1 7.9 ± 0.1 - 0 
Impromidine 6.8 ± 0.1 6.5 ± 0.3 -0.5 7.6 ± 0.1 7.6 ± 0.1 0.5 
Burimamide 7.9 ± 0.1  7.0 ± 0.1  0.5 7.4 ± 0.1 7.7 ± 0.1 0.7 
Thioperamide 7.3 ± 0.1 7.5 ± 0.1 -1 6.9 ± 0.1 7.0 ± 0.1 -1 
Proxyfan 7.9 ± 0.1 8.5 ± 0.1 1 7.3 ± 0.1 7.2 ± 0.1  0.5 
Iodoproxyfan 9.2 ± 0.1 10.3 ± 0.1 1 7.9 ± 0.1 7.9 ± 0.1 0.7 
JNJ 7777120 5.3 ± 0.1 6.0 ± 0.1 -0.7 7.8 ± 0.1 - 0 
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As reported previously (Kitbunnadaj et al., 2004), the recently identified H3R 
agonist immethridine (pKi = 9.1 ± 0.1) binds much less potently to the hH4R (pKi 6.6 
± 0.1) and is also not able to fully activate the H4R (Table 2.4).  
 
 
Figure 2.3. Iodophenpropit is an hH4R neutral antagonist. (A) SK-N-MC/hH4 cells, which stably express 
functional hH4R and CRE-control β-galactosidase, were treated with1 μM forskolin in the presence of 
various concentrations of histamine, thioperamide, clobenpropit, and iodophenpropit for 6 hours, 
whereafter β-galactosidase activity was determined spectrophptmetrically at 420 nm. Histamine and 
clobenpropit dose-dependently inhibit forskolin-induced β-galactosidase (agonistic activity) at the hH4R, 
while thioperamide causes increase of β-galactosidase, indicating a blockade of hH4R constitutive 
activity. Iodophenpropit does not change forskolin-induced β-galactosidase activity although it binds to 
the hH4R, indicating it is a neutral antagonist. (B) While clobenpropit is a partial agonist and 
iodophenpropit is a neutral antagonist at the H4R, they are both inverse agonists at the hH3R. (C) 
Iodophenpropit (IPP) antagonizes activity of histamine at the hH4R, resulting in a rightward shift of 
histamine dose-response curve. (D) Schild plot analysis of iodophenpropit antagonism against 
histamine results in a pA2 value of 8.0.  
 
In agreement with our findings with Nα-methylhistamine, the methylated immepip 
analog methimepip show a large selectivity for the hH3R (pKi = 9.0 ± 0.1) over the 
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hH4R (pKi = 5.7 ± 0.1), as reported previously (Kitbunnadaj et al., 2005). Also 
various H3R antagonists bind to the hH4R (Oda et al., 2000; Liu et al., 2001a; 
Morse et al., 2001; Zhu et al., 2001). In our hands the isothiourea-based H3R 
antagonists clobenpropit and iodophenpropit both potently bind to the hH4R (Table 
2.4). Yet, both ligands have very distinguishable intrinsic activities at the H4R. 
Clobenpropit, which acts as inverse agonist at the hH3R (Wieland et al., 2001) 
behaves as a potent partial agonist at the hH4R (Table 2.4 and Figure 2.3A and B). 
In contrast, iodophenpropit, which also acts as an inverse agonist at the hH3R 
(Wieland et al., 2001) behaves as a neutral antagonist at the hH4R with a pKi value 
of 7.9 ± 0.1 (n = 6) (Table 2.4 and Figure 2.3A and B). As expected, iodophenpropit 
competitively antagonized the action of histamine at the hH4R, yielding a linear 
Schild-plot and a pA2 value of 8.0 (Figure 2.3C and D), in accordance with its 
binding affinity. Besides clobenpropit, also the known H3R ligands proxyfan and the 
related iodoproxyfan show reasonable H4R affinity with pKi values of 7.3 ± 0.1 and 
7.9 ± 0.1 respectively. As observed for their action at the H3R, both compounds act 
as partial agonist at the H4R (Table 2.4). 
 
Evaluation of the potential use of [125I]iodophenpropit as H4R radioligand 
As reported in the previous section and in other studies, the H4R can be labeled 
with either [3H]histamine or the H4R antagonist [3H]JNJ 7777120 (Oda et al., 2000; 
Liu et al., 2001a; Morse et al., 2001; Nguyen et al., 2001; Zhu et al., 2001; 
Thurmond et al., 2004). Previously, we described [125I]iodophenproprit as a suitable 
high affinity H3R radioligand (Jansen et al., 1992). Considering, the relatively high 
affinity of iodophenpropit at the hH4R and its high sensitivity, we investigated the 
potential of this radioligand to label the H4R. Due to the H4R affinity of 
[125I]iodophenpropit saturation binding experiments were not feasible. We therefore 
used homologous [125I]iodophenpropit displacement analysis to determine a KD 
value of 34.4 ± 4.1 nM for [125I]iodophenpropit. The Bmax value obtained using 
homologous [125I]iodophenpropit-binding displacement experiments (3.8 ± 0.4 
pmol/mg protein) is approximately 2 times higher than those obtained with either 
[3H]histamine (1.8 ± 0.4 pmol/mg protein) and [3H]JNJ 7777120 (1.7 ± 0.4 pmol/mg 
protein). [125I]Iodophenpropit binding to membranes of SK-N-MC/hH4 cells was 
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nicely displaced by a variety of H3/4R ligands (Figure 2.4), despite a high level of 
non-specific binding of approximately 60% as determined with 10 μM imetit. 
However, iodophenpropit and the related clobenpropit also displaced the non-
specific binding, resulting in a multiple site binding profile. The pKi values of 
compounds for the hH4R obtained using [125I]iodophenpropit displacement studies 
correlate well with their corresponding values obtained using displacement of either 
[3H]histamine or [3H]JNJ 7777120 binding to the hH4R; only the pKi value of 
thioperamide obtained using [125I]iodophenpropit displacement studies appears to 
deviate somewhat form the pKi values obtained using either [3H]histamine or 
[3H]JNJ 7777120 displacement studies (Figure 2.4 and Table 2.5). 
 
Table 2.5. hH4R affinity for selected H4R ligands as determined with displacement of the binding of 
[3H]histamine, [3H]JNJ 7777120 or [125I]iodophenpropit. Data shown are mean ± standard error of mean 
of at least 3 independent experiments 
pKi value 
Compound 
[3H]histamine [3H]JNJ 7777120 [125I]iodophenpropit 
Histamine 7.8 ± 0.1 7.7 ± 0.1 7.6 ± 0.2 
4-Methylhistamine 7.3 ± 0.1 7.6 ± 0.1 not determined 
Immepip 7.7 ± 0.1 7.9 ± 0.1 7.7 ± 0.1 
Clozapine 6.7 ± 0.1 6.4 ± 0.1 6.5 ± 0.2 
Clobenpropit 8.1 ± 0.1 7.9 ± 0.1 7.8 ± 0.1 
Iodophenpropit 7.9 ± 0.1 7.7 ± 0.1 7.7 ± 0.1 
Thioperamide 6.9 ± 0.1 7.1 ± 0.1 7.4 ± 0.1 
JNJ 7777120 7.8 ± 0.1 7.8 ± 0.2 not determined 
Kd (nM) 20.9 ± 1.6 11.1 ± 3.6 34.4 ± 4.1a 
Bmax (pmol/mg protein) 1.8 ± 0.4 1.7 ± 0.4 3.8 ± 0.4 
a Determined by homologous displacement analysis, employing equation Kd = IC50 – [radioligand]. 
 
4-methylhistamine, a potent and selective H4R agonist 
 
 59
 
Figure 2.4. Analysis of ligand binding to the hH4R using [125I]iodophenpropit. (A) Homogenate of SK-N-
MC/hH4 cells were incubated with 0.1 nM [125I]iodophenpropit in the presence of different concentrations 
of H3/4 ligands and the nonspecific activity was determined with 1 μM imetit. The data, shown as % of 
specific binding, fit nicely into a one-site ligand- receptor model.  
 
4-methylhistamine as a selective H4R agonist 
Following our intial observation of the relative high affinity of 4-methylhistamine for 
the hH4R, this histamine analog was evaluated in more detail. 4-Methylhistamine 
does not only have high affinity for the hH4R (pKi = 7.3 ± 0.1, n = 3), but it also 
exhibits considerable selectivity for the hH4R over the other three human histamine 
receptors (Figure 2.5A). The human histamine H1, H2 and H3 receptors were tested 
for their interaction with 4-methylhistamine, using respectively 1 nM 
[3H]mepyramine (Kd = 1.6 nM), 0.5 nM [125I]iodoaminopotentidine (Kd = 0.5 nM) and 
1 nM [3H]Nα-methylhistamine (Kd = 2.9 nM) binding to homogenates of transfected 
cells. As can be seen in Figure 2.5A, 4-methylhistamine shows highest affinity for 
the hH4R and binds considerable less potently to the other histamine receptors, 
resulting in a >100-fold and >100,000-fold selectivity over the H3R and H2R, and 
H1R, respectively. 4-Methyl histamine does not only bind to the hH4R, but also has 
a high affinity, albeit reduced compared to the hH4R, for the mouse and rat H4R 
with Ki values of 73 and 55 nM, respectively (Figure 2.5B). Moreover, 4-
methylhistamine exerts full agonistic activity at the hH4R, resulting in a pEC50 value 
of 7.4 ± 0.1 (α = 1, n = 5). In contrast, 4-methylhistamine exhibits only moderate 
affinity for the hH3R (pKi = 5.2 ± 0.1, n = 4) and partial agonistic hH3R activity 
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(Figure 2.5C). The hH4R agonistic effects of 4-methylhistamine can be antagonized 
by the selective H4R antagonist JNJ 7777120 (Figure 2.5D). Schild-plot analysis of 
the JNJ 7777120 antagonism of the 4-methylhistamine-induced hH4R-mediated 
inhibition of forskolin-induced β-galactosidase activity yields a pA2 value of 7.8, 
which is in agreement with the hH4R affinity of JNJ 7777120 (Table 2.4) 
(Jablonowski et al., 2003; Thurmond et al., 2004). At the mouse and rat H4R, 4-
methylhistamine also acts as a full H4 agonist, although with reduced pEC50 values 
of respectively 5.8 ± 0.1 and 5.6 ± 0.1. 
 
Figure 2.5. 4-Methyl histamine is a potent and selective H4R full agonist. (A) 4-Methylhistamine 
displaces binding of 1 nM [3H]mepyramine (Kd = 1.6 nM), 0.5 nM [125I]iodoaminopotentidine (Kd = 0.5 
nM), 1 nM [3H]Nα-methylhistamine (Kd = 2.9 nM), and 10 nM [3H]histamine (Kd = 11 nM) to the human 
H1, H2, H3, and H4 receptor, respectively. The data is presented as % of specific binding, and the 
nonspecific binding of the radioligand was determined with 1 μM mianserine and 1 μM tiotidine for H1R 
and H2R binding, respectively, and 1 μM clobenpropit for both H3R and H4R binding. 4-Methyl histamine 
shows a >100-fold selectivity for the hH4R against the other histamine receptors. (B) 4-Methylhistamine 
exerts a full hH4R agonistic activity that is competitively antagonized by JNJ 7777120. (C) Schild plot 
analysis of antagonism of JNJ 7777120 against 4-methylhistamine-induced hH4R activity from 3 
independent experiments, results in a pA2 value of 7.8. 
 
Previously the H4R has been shown to be involved in the regulation of eosinophil 
and mast cell function (O’Reilly et al., 2002; Buckland et al., 2003; Hofstra et al., 
2003; Ling et al., 2004; Takeshita et al., 2004; Thurmond et al., 2004). Indeed, 4 
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methylhistamine also acted as H4R agonist at human eosinophils and induced a 
rapid change in eosinophil cell shape, as measured by the gated autofluorescence 
forward scatter assay (Ling et al., 2004). The H4R agonist 4-mehtylhistamine acted 
as a full agonist and dose dependently induced a change in forward scatter (Figure 
2.6A) with an EC50 value of 0.36 ± 0.09 μM, which was 3 fold less active compared 
to histamine. The effects of 4-methylhistamine on human eosinophils were not 
inhibited by H1R antagonist mepyramine or H2R antagonist ranitidine, but could be 
antagonized by the H4R antagonist JNJ 7777120 (Figure 2.6B). Finally, 4-
methylhistamine was tested as H4R agonist at mouse bone marrow derived mast 
cells (BMMC) as described before (Hofstra et al., 2003). Like histamine, 4-
methylhistamine dose-dependently induced migration of murine BMMCs with an 
EC50 value of 12 µM (Figure 2.6B), again a somewhat lower potency compared to 
histamine (Hofstra et al., 2003). 
 
Figure 2.6. Physiological effects of 4-methylhistamine on leukocyte cells in vitro. (A) 4-Methylhistamine 
increases human eosinophil shape change, (B) the effect of 4-methylhistamine on human eosinophil 
shape change is inhibited by H4R antagonist, but not by H1R or H2R antagonist, and (C) 4-
methylhistamine dose-dependently increase migration of murine bone marrow mast cells (BMMC).  
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DISCUSSION 
With the addition of the H4R to the histamine receptor family (Oda et al., 2000; Liu 
et al., 2001a; Morse et al., 2001; Nguyen et al., 2001; Zhu et al., 2001).), this 
potential new drug target has created a lot of excitement in the field. The 
predominant expression of the histamine H4R on hematopoietic cells (Oda et al., 
2000; Liu et al., 2001a; Morse et al., 2001; Zhu et al., 2001) and the H4R effects on 
e.g eosinophil and mast cell functions (Gantner et al., 2002; O’Reilly et al., 2002; 
Buckland et al., 2003; Hofstra et al., 2003; Ling et al., 2004; Takeshita et al., 2003; 
Thurmond et al., 2004) implies that this new histamine receptor subtype may play a 
role in various allergic and inflammatory conditions. So far, the search for of 
selective H4R ligands has resulted in the discovery of potent neutral H4R 
antagonists as JNJ 7777120 (Jablonowski et al., 2003; Thurmond et al., 2004) and 
VUF 6002 (Terzioglu et al., 2004), whereas potent and selective H4R agonists or 
inverse agonists have so far not been described. In search for new hH4R ligands, 
we therefore screened a library of known histaminergic ligands, using SK-N-MC 
cells stably expressing the hH4R. In this cell line the H4R binds [3H]histamine and 
[3H]JNJ 7777120 with high affinity (Figure 2.1A and 2.1B) and functionally inhibits 
forskolin-induced CRE-mediated responses through pertussis toxin-senstive Gi/o 
proteins (Figure 2.1D). In these cells the hH4R also exhibits constitutive activity, 
which is blocked by pertussis toxin or the non-selective inverse agonist 
thioperamide (Figure 2.1D). 
 
Considering the high sequence similarity with the H3R, it is not surprising that the 
H4R is targeted by various imidazole containing H3R ligands (Oda et al., 2000; Liu 
et al., 2001a; Morse et al., 2001; Zhu et al., 2001)). The standard H3R inverse 
agonist thioperamide (Arrang et al., 1983) also acts as an inverse agonist at the 
H4R. Moreover, in the present study we confirm that the presumed H3R agonists 
immepip, imetit, (R)-α-methylhistamine, and imbutamine also act as potent H4R 
agonists. Furthermore, the H4R is activated by the H2R/H3R antagonist burimamide 
and the H3R antagonists as clobenpropit and iodoproxyfan, indicating that for H4R 
agonism considerable structural diversity (piperidine, isothiourea, thiourea, ether) in 
the side chain is allowed, including aromatic substitutions, as indicated by the H4R 
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agonism displayed by clobenpropit. However, our detailed analysis of various H3R 
ligands indicates that H4R efficacy can be modulated by differential aromatic 
substitution of the side chain. In the burimamide series we observed that 
differential substitution of the thiourea group gives rise to H4R (partial) agonists, a 
neutral antagonist (VUF 4614, pKi = 7.6) and a full inverse agonist (VUF 4742, pKi 
= 6.9). Also, in the clobenpropit series, we observe that a slight change of the 
isothiourea substituent results in a modulation of H4R efficacy. The clobenpropit 
analog iodophenpropit (a phenyl substitutent instead of a benzyl group) retains 
high H4R affinity (pKi = 7.9), but has lost agonistic activity completely. In this study 
we identified iodophenpropit as a high affinity, neutral antagonist for the H4R. In 
view of the ~15 nM affinity of iodophenpropit for the hH4R, we evaluated 
[125I]iodophenpropit as a potential new H4R radioligand. The hH4R can be labeled 
to the same extent with both the agonist [3H]histamine and the neutral antagonist 
[3H]JNJ 7777120. Surprisingly, the Bmax value determined with [125I]iodophenpropit 
was twice as much as that determined with either [3H]histamine or [3H]JNJ 
7777120, suggesting that the three radioligands bind to hH4R subpopulations. The 
binding of the three radioligands to membranes of SK-N-MC/hH4 cells was 
displaced by a variety of H3/4R ligands and the pKi values obtained from these 
displacement studies show a high correlation. Despite being showed as a potential 
hH4R radioligand, [125I]iodophenpropit has to be used with caution, as in our hands 
a high level of non-specific binding limits its use. 
 
Based on our findings that also iodoproxyfan has a high affinity (pKi = 7.9) the 
observation of Corbel et al. (1997) of [125I]iodoproxyfan binding to a non-H3R 
binding site on the myeloid cell line FDCP-2 is of interest. The [125I]iodoproxyfan 
binding to a proposed histamine transporter might actually represent 
[125I]iodoproxyfan binding to the hH4R (Corbel et al., 1997). 
 
From our screening of many H1R ligands only the tricyclic clozapine shows 
reasonable H4R affinity, as reported before (Oda et al., 2000; Liu et al., 2001a; Zhu 
et al., 2001). Despite their structural similarity to clozapine, the tested H1R 
antagonists do not show any appreciable affinity for the hH4R. We can therefore 
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not confirm that mepyramine binds to the hH4R (Nguyen et al., 2001), either 
studied by displacement of [3H]histamine binding to the hH4R, by saturation 
[3H]mepyramine binding assays (data not shown), or by functional H4R assays. 
Clinically used H1R antagonists, such as cetirizine, ebastine, fexofenadine, and 
loratidine, demonstrate significant in vitro anti-inflammatory activity, which are not 
related to their H1R activity (Gefland et al., 2004). The data from our study do not 
support the involvement of the hH4R in the anti-inflammatory effects of these H1R 
antagonists. 
 
An important finding of this study is the discovery of 4-methylhistamine as a potent 
and selective hH4R agonist in both recombinant and endogenously expressing H4R 
systems. Whereas this compound is originally described as a relatively selective 
H2R agonist (Durant et al., 1975), our present data show that this histamine analog 
exhibits more than 100-fold selectivity over the recombinant H1R, H2R, and H3Rs. 
4-Methylhistamine not only acts as a full agonist at the recombinant hH4R, but also 
induces migration of mouse bone marrow derived mast cells and a shape change 
of human eosinophils. Both processes have recently been shown to be induced by 
histamine via interaction of the H4R (Hofstra et al., 2003; Ling et al., 2004). Similar 
to the observations with histamine (Hofstra et al., 2003; Ling et al., 2004), the 
potency of 4-methylhistamine on human eosinophils and the mouse mast cells is 
somewhat lower than in recombinant system. Although the mouse H4R shows a 
lower affinity for both histamine and 4-methylhistamine compared to the hH4R, the 
low potency at BMMC seems not merely an issue of species difference, but might 
also be related to a low H4R expression level. In fact, the H4R in BMMC is present 
at a very low density as it can not be detected by radioligand binding studies 
(Thurmond, unpublished observations). Moreover, the cellular environment might 
dictate the potency of an agonist, such as composition of G proteins and 
accessories proteins in the cells (Kenakin, 2004). 
 
In conclusion, from a large screening of many known histamine receptor ligands we 
have identified a variety of compounds with interesting H4R activities. Based upon 
our data, many imidazol-containing H3R ligands, including various H3R reference 
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compounds show potent H4R activities and should be treated with caution. More 
recently developed H3R agonists, like immethridine (Kitbunnadaj et al., 2004) or 
methimmepip (2005) or non-imidazole H3R antagonists, like JNJ 6379490 
(Daugherty, 2004) or A-349821 (Esbenshade et al., 2004), hardly act at the H4R 
and will therefore provide good tools to selectively target the H3R. In the series of 
tested H3R ligands, we have identified iodophenpropit as potent neutral H4R 
antagonist and the burimamide analog VUF 4742 as the second identified H4R 
inverse agonist. From the screening of H2R ligands we have identified 4-
methylhistamine as the first high affinity H4R agonist (Ki = 50 nM) that has a >100-
fold selectivity for the hH4R over the other histamine receptor subtypes. The 
identification of 4-methylhistamine as a potent H4R agonist will be of major 
importance for future studies to unravel the physiological roles of the H4R. 
MATERIALS AND METHODS 
Materials. Burimamide oxalate and burimamide analogs (Vollinga, 1995), clobenpropit dihydrochloride, 
dimaprit dihydrobromide, histaprodifen dimaleate, homohistamine dihydrobromide, imbutamine 
dihydrobromide, imetit dihydrobromide, impentamine dihydrobromide, immepip dihydrobromide, 
immethridine dihydrobromide, iodophenpropit dihydrobromide, JNJ 7777120, methimmepip 
dihydrobromide, 2-pyridylethylamine (PEA) dihydrochloride, 2-(2-thiazolyl)ethylamine (TEA), 
thioperamide fumarate, and VUF 8328 (S-[2-(4-imidazolyl)propyl]isothiourea dihydrobromide) were 
synthesized at the Department of Medicinal Chemistry, Vrije Universiteit Amsterdam. Ketotifen fumarate 
and 8R-lisuride were purchased from ICN Biomedicals Inc. (USA), amoxapine, d-chlorpheniramine 
maleate, clozapine, cimetidine, N-desmethyl clozapine, diphenhydramine hydrochloride, doxepin 
hydrochloride, forskolin, histamine dihydrochloride, imipramine hydrochloride, loxapine, mepyramine 
(pyrilamine maleate), (R)-α-methylhistamine dihydrochloride, (S)-α-methylhistamine dihydrochloride, Nα-
methylhistamine dihydrochloride, N-oxide clozapine, octoclothepin, pertussis toxin, polyethyleneimine 
(PEI), tripelennamine hydrochloride, and triprolidine hydrochloride were purchased from Sigma RBI 
(USA). 2-Nitrophenol-β-D-pyranoside (ONPG) and G418 were from Duchefa (The Netherlands), and 
[3H]Nα-methylhistamine (85 Ci/mmol), [3H]histamine (12.4 Ci/mmol), and [3H]mepyramine (23 Ci/mmol) 
from Perkin-Elmer Life Science, Inc. (USA). [125I]iodoaminopotentidine and [125I]iodophenpropit were 
labeled at the Department Nuclear Medicine and PET Research, Vrije Universiteit Medical Centre, 
Amsterdam, as described previously (Jansen et al., 1992), while [3H]JNJ 7777120 (84 Ci/mmol) was 
synthesized at Johnson & Johnson Pharmaceuticals, Inc., USA (Thurmond et al., 2004). Gifts of 
astemizole (Janssen Pharmaceutica NV, Belgium), cyproheptadine hydrochloride (MSD, The 
Netherlands), cetirizine hydrochloride (UCB Pharma, Belgium), ebastine (Almirall Prodesfarma, Spain), 
loratidine (Schering Plough, USA), mianserin hydrochloride and Org 3770 (Organon NV, The 
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Netherlands), mizolastine (Synthelabo, France), proxyfan dihydrochloride and iodoproxyfan 
dihydrochloride (Dr. J.A.M. Christiaans (Kovaleinen et al., 1999)), R(+)- and S(-)-terfenadine carboxylate 
(Sepracor, Inc., USA), 2-methylhistamine dihydrochloride, 4-methylhistamine dihydrochloride, and 
impromidine dihydrochloride (SmithKline, Beecham, UK), are greatly acknowledged. 
 
Cell culture. SK-N-MC cell lines, which stably express either the human H3R (SK-N-MC/hH3) or H4R 
(SK-N-MC/hH4) as well as a cAMP responsive element (CRE)-driven β-galactosidase reporter gene SK-
N-MC/hH3 or SK-N-MC/hH4 cells (Lovenberg et al. 1999; Liu et al., 2001a), were cultured in EMEM 
medium supplemented with 5% fetal calf serum, 0.1 mg/ml streptomycin, 100 u/ml penicillin, and 600 
μg/ml G418 at 37ºC in 5% CO2 and 95% humidity.  
 
Radioligand binding assays. The SK-N-MC/hH3 cell homogenates were incubated for 40 minutes at 
25°C with approximately 1 nM [3H]Nα-methylhistamine in 25 mM KPO4 buffer and 140 mM NaCl (pH 7.4 
at 25°C), with or without competing ligands, whereas the SK-N-MC/hH4 cell homogenates were 
incubated 1 hour at 37°C in 10 nM [3H]histamine and 50 mM Tris-HCl (pH 7.4 at 37°C), with or without 
competing ligands. Bound radioligands were collected on 0.3% polyethyleneimine pretreated Whatmann 
GF/C (and washed three times with 3 ml of ice-cold washing buffer (4°C) containing 25 mM Tris-HCl 
and 140 mM NaCl (pH 7.4 at 4°C) for the hH3R and 50 mM Tris-HCl (pH 7.4 at 4°C) for the hH4R. 
Binding analysis of 10 nM [3H]JNJ 7777120 and 0.1 nM [125I]iodophenpropit to the hH4R was performed 
with the same conditions as described for [3H]histamine. In saturation binding analysis, the nonspecific 
binding of [3H]histamine or [3H]JNJ 7777120 was determined with 1 μM clobenpropit. The binding 
analysis of [3H]mepyramine and [125I]iodoaminopotentidine binding to human H1R and human H2R, 
respectively, was performed according to Bakker et al. (2004). The binding data were analyzed with 
Prism 4.0 (Graphpad Software, Inc.) and data are presented as mean ± SEM. Mouse and rat H4R 
radioligand binding assays was performed according to Liu et al. (2001b). 
 
Colometric cyclic AMP Assay. A reporter CRE-β-galactosidase reporter gene assay was employed to 
determine (inverse) agonistic or antagonistic activity of either the hH3R or hH4R. Approximately 4 million 
cells/96-well plate of SK-N-MC/hH3 and SK-N-MC/hH4 cells were exposed for six hours to histaminergic 
ligands in serum-free EMEM medium containing 1 μM forskolin. Thereafter, the medium was discarded, 
the cells were lysed in 100 μl assay buffer (100 mM sodium phosphate buffer at pH 8.0, 4 mM ONPG, 
0.5% Triton X-100, 2 mM MgSO4, 0.1 mM MnCl2, 40 mM β-mercaptoethanol), incubated overnight at 
room temperature, and the β-galactosidase activity was determined at of 420 nm with a 
PowerwaveX340 plate reader (Bio-Tek Instruments, Inc., USA). 
 
Primary cell experiments. Cell culture of BALB/c mice-derived bone marrow mast cells (BMMC) and in 
vitro BMMC chemotaxis assay was performed as previously described (Hofstra et al., 2003). Purification 
of human polymorphonuclear leukocytes (PMNL) and the human eosinophil shape change assay were 
performed as previously described (Ling et al., 2004). 
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ABSTRACT 
 
In this study we report the homo- and hetero-oligomerization of the human 
histamine H4R (hH4R) by both biochemical (Western blot and immobilized metal 
affinity chromatography) and biophysical (BRET and tr-FRET) techniques. The H4R 
receptor is the most recent discovered member of the histamine family of G 
protein-coupled receptors. Using specific polyclonal antibodies raised against the 
C-terminal tail of the H4R we demonstrate the presence of H4R oligomers in HEK 
293 and COS-7 cells heterologously overexpressing H4Rs, as well as putative 
native H4R oligomers in human PHA blasts endogenously expressing H4Rs. 
Moreover, we show that H4R homo-oligomers are formed constitutively, are formed 
at low receptor densities (300 fmol/mg protein) and are present at the cell surface, 
as detected by tr-FRET. The formation of these oligomers is independent of N-
glycosylation and not modulated by H4R ligands, covering the full spectrum of 
agonists, neutral antagonists and inverse agonists. Whereas we show H4R homo-
oligomer formation at physiological expression levels, the detection of H1R-H4R 
hetero-oligomers was achieved only at higher H1R expression levels and are most 
likely not physiologically relevant. 
 
INTRODUCTION 
 
The human histamine H4R (hH4R), a prototypical member of the superfamily of G-
protein coupled receptors (GPCRs), has been identified recently through the use of 
bioinformatics by several groups simultaneously 148-152. The H4R couples to 
members of the Gi/o family of heterotrimeric G-proteins to mediate the inhibition of 
adenylyl cyclase. In addition, the receptor may activate phospholipase C and 
induce calcium mobilization 194. The H4R expression is almost exclusively restricted 
to hematopoietic cells and is suggested to mediate functions of the immune 
system. As such the H4R is a target for the development of anti-inflammatory drugs 
164,172,194. 
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The use of various biochemical and biophysical approaches has recently revealed 
that members of the GPCR family may exist as homo- as well as hetero-oligomers 
at the cell surface. When considering the hetero-trimeric G protein, which is about 
twice the size of the GPCR 195, it seems reasonable that GPCRs need to 
oligomerize to interact with the G protein as suggested for the leukotriene B4 
receptor 47. Currently, hetero-oligomerization has been shown to be pivotal for the 
GABABR1, which needs to associate with GABABR2 receptors in order to be 
transported to the cell membrane 42, and for the T1R taste receptors, which require 
hetero-oligomerization to form receptors that can recognize sweets 46 or amino-
acids 45. In other cases, hetero-oligomerization may change the ligand binding 
characteristics potentially giving rise to a new dimension in GPCR drug discovery 
196-198. 
We have previously reported the detection of homo-oligomers of the human 
histamine H1 receptor (H1R) by applying biochemical and tr-FRET experiments, as 
well as by the formation of H1R radioligand binding sites upon the co-expression of 
two ligand-binding deficient mutant H1Rs 199. The H1R is a well known target for the 
treatment of seasonal allergies, but has also been shown to mediate inflammatory 
responses in keratinocytes 200,201. The H1R is ubiquitously expressed, and is co-
expressed together with the H4R in leukocytes, including monocytes and T 
lymphocytes 150,202, suggesting that on these cells histamine may modulate 
inflammatory actions through the action on both H1Rs and H4Rs. We therefore 
investigated the potential homo-oligomerization of the H4R as well as the hetero-
oligomerization of the H1R with the H4R using heterologous expression systems. 
Herein, we report on the generation of specific antibodies raised against the H4R, 
the detection of homo-oligomers of the H4R, and the potential formation of H1R-
H4R hetero-oligomers by using biochemical as well as BRET and tr-FRET 
approaches. Using these methodologies, we show the human H4R to constitutively 
form homo-oligomers at the cell surface, and that the oligomerization is 
independent of ligand stimulation of the receptors. Furthermore, N-glycosylation of 
the H4R receptor is not a pre-requisite for oligomer formation. Whereas we can 
detect H4R homo-oligomers at physiologically relevant H4R expression levels and 
Chapter 3 
 
 70
in endogenously H4R expressing PHA blast cells, the detection of H1R-H4R hetero-
oligomers requires higher receptor expression levels. 
 
RESULTS 
 
Pharmacological characterization of the hH4R and hH1R  
expressed in COS-7 cells 
We have previously used COS-7 cells successfully for the heterologous expression 
of the hH1R as well as for the identification of H1R oligomers 199. To investigate the 
potential oligomerization of the human H4R (hH4R) we therefore expressed the 
hH4R heterologously in COS-7 cells. Transfection of these cells with cDNA coding 
for the hH4R resulted in the expression of a high affinity [3H]histamine binding site 
(Table 3.1). Subsequent displacement studies using [3H]histamine as a radioligand 
revealed these binding sites to display a characteristic H4R pharmacological profile 
(Table 3.1). The H1R and H4R constructs used in the tr-FRET, BRET and 
immobilization assays were also characterized by radioligand binding (saturation 
and displacement) assays. COS-7 cells were transiently transfected with cDNA 
encoding the HA-H4R, FLAG-H4R, H4R-Rluc, H4R-eYFP, c-myc-H4R-his, HA-H1R, 
H1R-Rluc, or the H1R-eYFP. [3H]histamine bound to the H4Rs according to a one 
site saturable model with Hill slopes of approximately 1 and dissociation constants 
(Kd) similar to the wild-type hH4R, although the Bmax value is affected by fusion of 
the Renilla luciferase enzyme (Table 3.1). Bound [3H]histamine could be displaced 
from all the N- and/or C-terminally tagged H4Rs by the agonist histamine and the 
inverse agonist thioperamide with affinity values (pKi) comparable to the wild-type 
(Table 3.1). Similarly the H1R radioligand [3H]mepyramine bound the various hH1R 
contructs according to a one site saturable binding model with Kd values similar to 
the wild-type hH1R (data not shown). The agonist histamine and H1R inverse 
agonist mepyramine were able to displace the radioligand with affinities equal to 
the wild-type H1R (data not shown). The aforementioned H4R constructs were 
functionally characterized using a CRE-luciferase-luciferase reporter gene assay. 
In these assays histamine behaved as a full H4R agonist and thioperamide as a full 
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inverse H4R agonist for each H4R-construct with pEC50 values comparable to those 
obtained for the wild-type H4R (Table 3.1). 
 
Table 3.1. Characterization of epitope-tagged and H4R fusion constructs. The KD values for histamine in 
nM, expression (Bmax) levels in pmol/mg protein, and the pKi values of histamine and thioperamide for 
the H4R constructs used in the experiments were determined by [3H]histamine saturation and 
displacement binding assays. The pEC50 values of histamine and thioperamide as determined using a 
CRE-luciferase reporter gene assay. The values are expressed as mean ± SEM of at least three 
separate experiments performed in triplicate. 
[3H]histamine pEC50 
pKi Receptor  
KD 
 
Bmax Histamine Thioperamide 
Histamine 
pEC50 
Thioperamide 
pIC50 
Wild-type H4R 19.9 ± 1.4 1.0 ± 1.4 7.6 ± 0.1 7.3 ± 0.1 8.8 ± 0.2 6.4 ± 0.3 
HA-H4R 23.2 ± 0.6 2.0 ± 0.5 7.4 ± 0.1 7.0 ± 0.1 8.9 ± 0.2 6.4 ± 0.2 
FLAG-H4R 26.3 ± 5.5 1.3 ± 0.3 7.6 ± 0.1 7.4 ± 0.1 9.0± 0.1 6.5 ± 0.4 
H4R-Rluc 30.8 ± 2.3 0.1 ± 0.02 7.6 ± 0.1 7.4 ± 0.1 9.0 ± 0.1 6.0 ± 0.3 
H4R-eYFP 57.4 ± 3.6 1.1 ± 0.3 7.2 ± 0.1 7.3 ± 0.2 8.6 ± 0.3 5.7 ± 0.1 
c-myc-H4R-his10 33.3 ± 2.0 2.6 ± 0.5 7.3 ± 0.1 7.6 ± 0.1 9.0± 0.1 6.3 ± 0.3 
 
Generation of hH4R specific antibodies 
To enable our biochemical approaches and to study H4R function in native tissue 
we raised a rabbit polyclonal anti-hH4 (374-390) receptor antibody, which 
represents the first published selective immunological probe for the hH4R. The 
antibody was generated against the last 17 amino acids of the C-terminal tail of the 
H4R (Figure 3.1A). The selectivity of the anti-hH4R antibody was confirmed by 
blockade with the C-terminal peptide of the H4R (Figure 3.1B, lane 3) and a lack of 
cross reactivity with the human H3R, the most related GPCR 194 (Figure 3.1B, lane 
1). In transfected HEK 293 cells, the antibody detects two major reactive species at 
Mr 34-36 kDa and 65-72 kDa (Figure 3.1B, lane 2). The lower bands most likely 
represent monomeric H4Rs. Occasionally an addition band (Mr approx. 45 kDa) 
was detected which is likely to be a proteolytic fragment. We suspect the Mr 34 kDa 
to be the unglycosylated product of the species at Mr 36 kDa. The higher molecular 
weight species, could either represent a heavily glycosylated form of the H4R or 
dimeric H4Rs.  
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Figure 3.1.  Characterization of specific polyclonal H4R antibodies. A, snake plot of the hH4R; the region 
of the C-terminal tail (374-390) against which the antibody was raised is marked in grey. HEK 293 cells 
expressing hH3(445)Rs or hH4Rs (B), and human PHA blasts (C) were probed by immunoblotting using 
the anti-H4 (374-390) antibody (0.5 µg /ml) either alone or pre-incubated for 16h at 4°C with 500 µg /ml 
(374-390) peptide. The major immunoreactive species labeled in the HEK 293 hH4R and the human 
PHA blasts were greatly suppressed by preincubation with the antigen peptide (B, lane 3 and C, lane 2, 
respectively), demonstrating the sequence selectivity of the antibody. Furthermore, no significant 
labeling of the hH3(445)R (B, lane 1) or in untransfected HEK293 cells (not shown) was detected. 
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Evidence that native H4R are robust dimers 
The H4R clearly plays a role as an immune modulator, with mRNA expression 
shown in e.g. human mast cells, neutrophils, eosinophils and T lymphocytes 118,150-
153,164. A single major diffuse immunoreactive species (approx. Mr 77 kDa) 
coincident with the putative recombinant dimeric hH4R species expressed in COS-
7 cells was detected in human PHA blasts (Figure 3.1C, lane 1). This species was 
abolished by preincubation with the (374-390) peptide, again demonstrating the 
peptide selectivity of the antibody. Interestingly, little or no protein monomers were 
detected in the native preparation, consistent with our previous data with the H3R 
203,204. Notably, these experiments were performed under reducing conditions, 
indicating the robust nature of the dimeric species in native tissue. An identical 
labeling pattern was detected with the anti-hH4 374-390 antibody probing human 
spleen lysates (not shown). The putative dimeric recombinant hH4R species 
expressed in HEK 293 cells was consistently smaller (approx. Mr 72 kDa which 
may reflect differential glycosylation in the two cell lines (Figure 3.3). Coincident 
protein species were detected by the anti-hH4 374-390 and the anti-epitope-tagged 
antibodies in the respective cell lines, further confirming that the hH4 receptor is 
being labeled by the anti-hH4 374-390 antibody (not shown). No signal was 
detected in either COS-7 or HEK 293 cell lines, further supporting the selectivity of 
the anti-hH4 374-390 antibody. These data identifies for the first time the H4R 
protein in human T lymphocytes. 
 
Immunoprecipitation of recombinantly expressed HA-H4Rs  
from HEK 293 cells 
To further characterize the selectivity of the H4R antibody an immunoprecipitation 
assay was performed. HA-H4Rs transiently expressed in HEK 293 cells (Figure 3.2, 
Lane 3-5) were immunoprecipitated using anti-HA antibodies (Figure 3.2, lane 4), 
or a non-immune Ig (Figure 3.2, lane 3). As negative control non transfected HEK 
293 cells (Figure 3.2, lane 1), and non transfected HEK293 cells 
immunoprecipitated with anti-HA antibodies (Figure 3.2, lane 2) were used. As 
positive control solubilized HEK 293 cells expressing HA-H4Rs (Figure 3.2, lane 5) 
was used. All samples were subjected to immunoblotting using the anti-H4R 
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antibodies. Immunoreactive species were only detected for the HEK 293 cells 
expressing the HA-H4R, which had been anti-HA immunoprecipitated (Figure 3.2, 
lane 4). The immunoreactive species represent the putative monomeric and 
dimeric H4R and are identical to the reactive species in the positive control (Figure 
3.2, lane 5). 
 
Figure 3.2.  The anti-H4R antibodies recognize anti-HA immunoprecipitated HA-H4Rs. HEK 293 cells 
alone (lane 1-2) or transfected with cDNA encoding the HA-H4R (lane 3-5) were subjected to 
immunoprecipitation with an anti-HA antibody (lane 2, 4) or a non-immune Ig (lane 3). The precipitates 
(lane 2-4) or solubilized cells (lane 1, 5) were immunoblotted using the anti-H4R antibody. 
 
Cross linking of H4Rs 
To further investigate the homo-oligomeric structure of the H4R, a crosslinking study 
was performed using N-terminally c-myc-tagged H4R expressed in COS-7 cells. 
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Upon application of increasing concentrations of the cell impermeable crosslinker 
BS3, a progressive reduction in the monomeric doublet species (Mr 34 kDa and 36 
kDa) was observed (Figure 3.3A). Concomitant the appearance of, initially, a diffuse 
species of Mr 77 kDa (putative glycosylated and unglycosylated dimers) and, then, 
higher molecular weight species (Mr > 175 kDa) at 0.25mM and 2mM BS3, 
respectively was noticed (Figure 3.3A). These data are highly consistent with hH4Rs 
expressed in HEK 293 cells (data not shown).  
 
Biochemical evidence that the hH4Rs is an N-glycosylated homo-dimer 
In the N-terminus of the hH4R Asn5 and Asn9 are potential sites for N-glycosylation 
(Figure 3.3B). To study whether the higher molecular weight species are the N-
glycosylated forms of the hH4R, we expressed H4Rs in the presence of the N-
glycosylation inhibitor tunicamycin. In the absence of tunicamycin, two major 
putative monomeric species, Mr 34 kDa and Mr 36 kDa, and a diffuse Mr 65-72 kDa 
species were detected as in Figures 3.1 (see also Figure 3.3C, lane 1). In the 
presence of 2 µg/ml tunicamycin, a complete loss of the Mr 36 kDa species and 
concomitant increase in intensity of the Mr 34 kDa species and an additional 
species at Mr 32 kDa was observed (Figure 3.3C, lane 2). Furthermore, the diffuse 
Mr 65-72 kDa species, detected in the absence of tunicamycin, was reduced to a 
single Mr 65 kDa species. Notably, an increase in tunicamycin concentration had no 
further effect upon either the Mr 34 kDa or Mr 65 kDa species (Figure 3.3C, lanes 3-
5). The Mr 32 kDa species observed upon tunicamycin treatment is likely to be a 
breakdown product of the glycosylated Mr 36 kDa species in untreated cells. These 
data strongly suggest, that the recombinant hH4R is N-glycosylated and forms 
dimers. This last process is independent of post-translational N-glycosylation. 
Notably, upon enzymic N-deglycosylation of PHA blasts, the Mr 77 kDA species 
was greatly reduced in intensity, and a new Mr 34 kDa species was detected, 
consistent with the monomeric hH4R (Figure 3.3D, lane 2). 
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Figure 3.3. Evidence for hH4R dimers and higher oligomers and glycosylation of the hH4R dimers. A, 
COS-7 cells transfected with cDNA encoding the hH4R were subjected to cross-linking using increasing 
concentrations of BS3 (0.12-2 mM). The resultant pellets were subjected to immunoblotting and probed 
with the anti-hH4 (374-390) antibody. Lane 1, COS-7 cells expressing hH4Rs as control; Lanes 2-5, 
COS-7 cells expressing hH4Rs treated with 0.12, 0.5, 1 and 2 mM BS3, respectively. The * species is 
likely to be a proteolytic fragment of the hH4R (observed in both host cells). B, Snakeplot of the N-
terminal tail and beginning of TM1 of the H4R; arrows are directed to possible N-glycosylation sites. C, 
HEK 293 cells transfected with the hH4R were grown in the absence and presence of 2, 4, 6 and 8 
µg/ml tunicamycin for 48h. The cells were harvested, homogenates prepared and subjected to 
immunoblotting. Immunoblots were probed with the anti-hH4 (374-390) receptor antibody. Lane 1, 
hH4Rs in absence of tunicamycin; Lanes 2-5, hH4Rs in presence of 2, 4, 6 and 8 µg/ml tunicamycin, 
respectively. D, PHA blasts were subjected to N-deglycosylation with PNGase F enzyme. Control PHA 
blasts were incubated in parallel with deglycosylation buffer alone. Samples were then subjected to 
immunoblotting, and immunoblots probed with the anti-hH4 (374-390) receptor antibody. Lane 1, control; 
Lane 2, in the presence of PNGase F. Enzymatic deglycosylation resulted in the reduction in intensity of 
the Mr 77 kDa species and appearance of the Mr 34 kDa putative monomer. 
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HA-H4Rs associate with c-myc-H4R-his10 
To further investigate if the H4Rs can associate with each other to form homo-
oligomers, membranes of COS-7 cells co-expressing N-terminally c-myc and C-
terminally his10 tagged hH4Rs (c-myc-H4R-his10) and N-terminally HA-tagged 
hH4Rs (HA-H4R) were solubilized and loaded on a Ni2+-resin column. The HA-
H4Rs, when co-expressed with the c-myc-H4R-his10, were retained on the Ni2+-
column and could be eluted with 250 mM imidazole as detected with anti-HA 
antibodies (Figure 3.4, lane 3). When cells individually expressing c-myc-H4R-his10 
and HA-H4Rs were mixed prior to solubilization, and subsequently loaded on the 
column, no HA-H4Rs were found to interact with the Ni2+-resin (data not shown). 
 
Figure 3.4.  Biochemical detection of homo-dimeric H4Rs. Cells co-expressing H4Rs with an N-terminal 
c-myc- and C-terminal His10-tag (c-myc-H4R-his10) and an N-terminally HA-tagged H4Rs (HA-H4R) 
receptors were solubilized and loaded onto a Ni2+-NTA column. Samples were taken of the solubilized 
receptors before loading onto the column (lane 1), of the unbound fraction (lane 2) and of the bound 
fraction, that was eluted using 250 mM imidazole (lane 3). Samples were resolved by SDS-PAGE and 
then immunoblotted using anti-HA antibodies 
 
BRET shows constitutive ligand-independent homo-oligomerization of hH4Rs 
The use of biophysical techniques has been of great value to the study of GPCR 
oligomerization. We have used BRET to study in further detail the homo-
oligomerization of the H4R. BRET was performed on COS-7 cells expressing either 
the H4R-Rluc or co-expressing the H4R-Rluc with the H4R-eYFP. After addition of 
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coelenterazine a robust BRET signal could be observed in the cells co-expressing 
the two H4Rs (Figure 3.5B). As a negative control, cells individually expressing 
either of the H4R constructs were mixed before adding coelenterazine (Figure 
3.5B). Previous studies have reported the ability of H1Rs to oligomerize 199,205 
Therefore cells in which the H1R-Rluc and the H1R-eYFP were co-expressed were 
taken as positive control. In these cells, a BRET signal was detected, that was 
approximately 2 fold lower than that observed for the H4Rs (Figure 3.5B).  
To investigate the effect of ligands on H4R oligomerization, cells co-expressing the 
H4R-Rluc with the H4R-eYFP were incubated with 10 μM of the agonist histamine, 
the neutral antagonist iodophenpropit 115 or the inverse agonist thioperamide for 15 
minutes before the actual BRET measurement. No significant change was 
observed in BRET signal between stimulated and non stimulated cells (Figure 
3.5C).  
Agonist-induced increase in oligomerization of somatostatin receptors occurs at 
physiological expression levels (160 fmol/mg protein) but not after overexpression 
206. We therefore also tested the effect of histamine stimulation on H4R 
oligomerization at different expression levels. While maintaining H4R-Rluc 
expression level constant (around 0.2 pmol/mg protein) we reduced the amount of 
expressed H4-eYFP. The concomitant reduction of the donor/acceptor ratio 
resulted in an expected drop in BRET signal. At total H4R expression levels, of 1.0, 
0.6 or 0.3 pmol/mg a significant BRET signal was observed. However, histamine 
did also not effect the H4R oligomerization at lower H4R expression levels (Figure 
3.5D). 
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Figure 3.5. Evaluation of homo-oligomerization of the H4R and homo-oligomerization of the H1R by 
BRET using the co-expression of Renilla luciferase (Rluc) and eYFP C-terminal receptor-fusion 
proteins. A, Schematic representation of BRET. After addition, coelenterazine is converted by the (Rluc) 
enzyme fused to the C-terminus of a receptor into light of a wavelength of 470 nm, which when in close 
proximity (<100Å) can excite the eYFP protein fused to the C-terminus of another receptor leading to 
the emission of light at a wavelength of 530 nm B, BRET ratios for the hH4R homo-oligomers compared 
with the hH1R homo-oligomers. Cells expressing the indicated receptor-fusion proteins were exposed to 
5 μM coelenterazine after which energy transfer was measured. Cells individually expressing either 
H4R-Rluc or H1R-Rluc were mixed prior to exposure to coelenterazine with cells individually expressing 
H4R-eYFP or H1R-eYFP, respectively (open bars). C, Effects of a 15 minutes stimulation of 10 μM 
histamine (Hist), iodophenpropit (IPP) or thioperamide (TP) on the BRET ratios for the hH4R homo-
oligomers. D, Effects of a 15 minute stimulation of 10 μM histamine (Hist) on H4Rs homo-oligomers. 
Cells were expressed with a constant amount of H4R-Rluc (~ 0.2 pmol/mg protein) and a decreasing 
amount of H4R-eYFP. Total H4R expression was 1.0, 0.6 and 0.3 (pmol/mg protein). Ratios are 
expressed as mean ± S.E.M. from at least three experiments each performed in triplicate. 
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tr-FRET shows presence of hH4R oligomers at cell surface. 
To study whether the H4Rs oligomers are actually present at the cell surface we 
performed tr-FRET assays on COS-7 cells co-expressing N-terminally FLAG 
tagged H4Rs (FLAG-H4R) and HA tagged H4Rs (HA-H4Rs). These cells were 
incubated with Europium (Eu3+) labeled anti-FLAG antibodies or a combination of 
the Eu3+ labeled anti-FLAG and allophycocyanin (APC) labeled anti-HA antibodies. 
As control, cells individually expressing the FLAG-H4Rs and the HA-H4Rs were 
mixed and exposed to the two antibodies. Only from the cells co-expressing the 
FLAG-H4Rs and HA-H4Rs a pronounced signal was observed (Figure 3.6B). This 
FRET signal can only be explained due to the resonance energy transfer from Eu3+ 
anti-FLAG antibodies bound to FLAG-H4Rs to APC anti-HA antibodies bound to 
HA-H4Rs. Since this resonance energy transfer can only take place within 100Å, 
the data indicates the formation of H4R oligomers at the cell surface of living cells. 
Stimulation of the COS-7 cells with 10 μM histamine or 10 μM thioperamide 
preceding tr-FRET measurement did not result in a significant change in signal 
(Figure 3.6B). The used antibodies did not have an influence on the ligand binding 
to the H4Rs as no significant difference was found in [3H]histamine binding in the 
absence or presence of the antibodies (data not shown).  
 
Lack of hetero-oligomerization between H4R and H1Rs. 
We have subsequently used tr-FRET to investigate whether hetero-oligomerization 
occurs between H4Rs and H1Rs. tr-FRET was performed on COS-7 cells co-
expressing the FLAG-H4Rs and N-terminally HA-tagged histamine H1Rs (HA-
H1Rs). As control, cells individually expressing the FLAG-H4Rs and the HA-H1Rs 
were mixed and exposed to the two antibodies. No significantly increased tr-FRET 
signal could be observed compared to the signal obtained from cells individually 
expressing the two receptors that were mixed prior to incubation with the 
antibodies (Figure 3.6C). The ratio and total amount of antibodies was maintained 
equal between experiments with H1R-H4Rs and H4R-H4Rs to ensure proper 
comparison. 
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Figure 3.6. Evaluation of homo-oligomerization of the H4R and hetero-oligomerization of the H4R with 
the H1R by tr-FRET using co-expression of differentially epitope-tagged receptors. A, Schematic 
representation of tr-FRET. Excitation at 337 nm of anti-FLAG Eu3+ antibody bound to the FLAG-epitope 
tagged receptor leads to emission of light at a wavelength of 620 nm, which when in close proximity 
(<100Å) can excite the anti-FLAG APC antibody bound to another FLAG-epitope tagged receptor 
leading to the emission of light at a wavelength of 665 nm B, tr-FRET using cells co-expressing FLAG-
tagged and HA-tagged H4Rs. Cells were incubated for 2 hours with the Eu3+-labelled anti-FLAG 
antibodies (open bar, Eu3+), or with both Eu3+-labelled anti-FLAG and APC-labelled anti-HA antibodies 
(filled bars, APC) in the presence or absence of 10 μM histamine (Hist) or 10 μM thioperamide (Thiop). 
C, tr-FRET using cells co-expressing FLAG-tagged H4Rs (FLAG-H4R) and either HA-tagged H4Rs (HA-
H4R) or HA-tagged H1Rs (HA-H1R). Cells were incubated for 2 hours with the Eu3+-labelled anti-FLAG 
antibodies (open bar, Eu3+), or with both Eu3+-labelled anti-FLAG and APC-labelled anti-HA antibodies 
(filled bars, APC). Data are normalized for the tr-FRET signal obtained from a mixture of cells that was 
obtained by mixing of cells that have been incubated with Eu3+-labelled anti-FLAG antibodies with cells 
that have been incubated with APC-labelled anti-FLAG antibodies. Data shown are from a 
representative experiment. 
 
Comparable results were obtained using Eu3+ anti-HA antibodies and APC anti-
FLAG antibodies (data not shown). Stimulation of co-transfected cells with 10 μM 
histamine did not lead to a change in FRET signal (data not shown).  
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Homo-oligomerization of H4Rs vs hetero-oligomerization of H4Rs and H1Rs. 
To further investigate hetero-oligomerization between H4Rs and H1Rs, BRET 
saturation curves were produced for both the H4R homo-oligomer and the H1R-H4R 
hetero-oligomer. Experiments were performed in which COS-7 cells were 
transfected with a fixed amount of H4-Rluc and increasing amounts of either H4R-
eYFP or H1R-eYFP cDNA. Expression levels were determined by radioligand 
binding. Expression of the H4R-Rluc was maintained around 0.2 pmol/mg protein 
while. Expression levels of H4R-Rluc were correlated with luminescence and 
expression levels for the eYFP fused H1R and H4R were correlated with 
fluorescence. 
 
 
Figure 3.7. Evaluation of receptor-expression dependency of the detection of H4R homo-oligomers and 
H1R-H4R hetero-oligomers using BRET. BRET saturation curves for the hH4R homo-oligomers (H4R-
Rluc + H4R-eYFP, solid line) compared with H1R-H4R hetero-oligomers (H4R-Rluc + H1R-eYFP, dotted 
line) at increasing expression levels of the eYFP tagged receptor. COS-7 cells were transfected with a 
fixed amount DNA encoding for the H4R-Rluc and increasing amounts of DNA encoding for the H4R-
eYFP or the H1R-eYFP. Plotted on the X-axis is the fluorescence obtained from the eYFP, which has 
been correlated to the expression of H4R-eYFP (z) and H1R-eYFP (Ο). Expression level of the H4R-
Rluc was maintained around 200 (fmol/mg protein) as determined from the luminescence, which has 
been correlated to the expression of the H4R-Rluc. 
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A lineair correlation was obtained for all three constructs. Expression for the H4R-
eYFP ranged from 0.3-2.5 pmol/mg protein, whereas expression levels of the H1R-
eYFP ranged from 0.5-16 pmol/mg protein. For the H4R homo-oligomers a steep 
increase in BRET signal is observed, showing detectable BRET when total H4R 
expression is 0.3 pmol/mg protein. For the H1R-H4R hetero-oligomers a more 
gradual increase in BRET signal is observed upon increased expression of the 
H1R-eYFP. A BRET signal is observed for the first time at expression levels of 1 
pmol/mg protein of the H1R-eYFP. The H4R-H4R homo-oligomer showed a two fold 
lower BRET50  (0.77 vs 1.6) and a 2.5 fold higher Bmax (0.1 vs 0.04) than the H1R-
H4R hetero-oligomer as determined from the BRET saturation curve.(Figure 3.7). 
 
DISCUSSION 
GPCR oligomerization has become a generally accepted phenomenon and has 
been reported to occur in all GPCR classes 207. Data obtained from atomic force 
microscopy 208, electron microscopy and western blot analysis 209 has provided 
compelling evidence that the light sensitive rhodopsin is predominately present as 
a dimer in the retinal disc membrane. For histamine receptors oligomerization has 
been convincingly shown for the hH1Rs 199,205, the hH2Rs 107 and H3Rs 204,210. In 
view of the emerging role of GPCR oligomerization in GPCR function and our 
interest in the H4R as new target for inflammatory conditions 194, we have 
investigated oligomerization of the human H4R by various means. Combining 
biophysical measurements like tr-FRET and BRET 39,211 with biochemical 
approaches, like Western blot analysis and histidine-tag based affinity 
chromatography, we provide compelling evidence for homo and hetero-oligomer 
formation of hH4Rs. 
To enable our biochemical approaches and to study H4R function in native tissues, 
we report in this study on the first polyclonal H4R antibody that can successfully be 
used for Western blot analysis. This new molecular tool is directed against the C-
terminal tail of the H4R and detected monomeric and potential dimeric H4R species 
after Western blot analysis of membranes from HEK 293 and COS-7 transfected 
cells. The selectivity of the new H4R antibody was confirmed by blockade with the 
C-terminal peptide, used to raise the antibody and the lack of cross reactivity 
Chapter 3 
 
 84
towards the highly related human hH3R. Furthermore, trough an 
immunoprecipitation study the H4R antibody was shown to detect the same HA-
H4Rs as detected by a commercially available anti-HA antibody 
Western blot analysis of the H4R expressed in tunicamycin treated cells, indicate 
that the H4R normally is N-glycosylated, most likely at Asn5 and/or Asn9 of the 
extracellular N-terminus of the H4R 149. However, inhibition of N-glycosolyation did 
not affect the presence of putative dimeric H4R species on the Western blot. To 
show that H4R proteins are in close proximity of each other, a requirement for 
oligomerization, a cross linking experiment, using BS3 was performed. With 
increasing concentrations of the crosslinker BS3, the bands representing the 
monomeric H4R disappeared. At the same time, bands representing oligomeric 
H4Rs became more apparent. These data indicate that the H4Rs are in close 
enough proximity for cross linking by BS3 and suggests that the 65-72 kDa species 
might represent dimerized H4R proteins. Finally, the polyclonal H4R antibody 
allowed us to study the presence of H4R proteins in human PHA blasts. High level 
H4R mRNA expression has been shown in various white blood cells, including T-
lymphocytes 150-153,164, but H4R protein expression has so far not been shown. 
Western blot analysis of membranes of PHA blasts with our polyclonal anti-H4R 
antibody, indeed revealed the presence of H4R protein in PHA blasts. Interestingly, 
the endogenously expressed H4R was only detected as high molecular weight 
species,. Enzymatic deglycosylation of the native H4R protein resulted in a partial 
reduction of the high molecular weight species ( 77 kDa) to monomeric H4Rs (34 
kDa) . These data in itself do not directly exclude a heavily glycosylated (ca.33 
kDa) H4R protein. However  the hH4Rs in human HEK293 cells is only moderately 
glycosylated (ca. 2 kDa) and the high molecular weight species coincide with the 
putative dimeric H4Rs when recombinantly expressed in COS-7 (77 kDa) and 
HEK293 cells (72 kDa). These data can be explained by assuming that in human 
PHA blasts the hH4R functions predominantly as a dimer. We hypothesize that N-
glycosylation is not a prerequisite for dimerization, but it helps to stabilize the H4R  
dimers. A similar stabilizing effect of glycosylation on receptor dimers has recently 
been shown for the human bradykinin B2 receptors 212. The putative H4R 
dimerization in native tissue clearly warrants further investigation. 
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As an alternative biochemical method, we employed an immobilized metal (Ni2+) 
affinity chromatography approach with a histidine-tagged H4R protein. To this end, 
we co-expressed c-myc-H4R-his10 and HA-H4Rs receptors to study oligomer 
formation via affinity column chomatography. In contrast to c-myc-H4R-his10 
receptors, HA-H4Rs are not robustly retained onto a Ni2+-NTA resin when 
expressed alone.  Yet, c-myc-H4R-his10 receptors immobilized onto Ni2+-NTA resin 
were shown also to retain co-expressed HA-H4Rs on the Ni2+-NTA column, as 
determined by HA-immunoreactivity detected after elution of histidine-tagged 
proteins with high imidazole concentrations. These findings indicate that c-myc-
H4R-his10 receptors physically interact with the co-expressed HA-H4Rs to form 
oligomers that can be retained on the Ni2+-NTA resin through the C-terminal his10 
tag. 
We continued our investigation of the oligomerization of the H4Rs in living cells 
using BRET and tr-FRET assays. Using the BRET assay, a clear signal could be 
detected when co-expressing H4R-Rluc with H4R-eYFP in non-stimulated cells, 
suggesting constitutive homo-oligomerization of H4Rs. Since the oligomers 
detected in the immobilization- and BRET-assay do not necessarily have to be 
present at the cell surface, we also studied H4R oligomerization on the cell 
membrane of living cells by tr-FRET. The tr-FRET approach uses antibodies, which 
do not permeate the cell membrane, and detects cell surface H4R oligomers 
present at the cell surface. Similar to the BRET assay, we detected a robust signal, 
indicating constitutive presence of H4R homo-oligomers at the cell surface.  
A number of studies have investigated the effect of agonists on receptor 
oligomerization. However, at present the effects of ligand-stimulation on GPCR 
oligomerization are not consistent. It has been found that agonists can promote or 
reduce GPCR oligomerization, or are without effect on GPCR oligomerization. 
39,207,213.  In the case of the H4R, we did not detect any significant difference in 
BRET signal if cells were treated with either the H4R agonist histamine, the neutral 
H4R antagonist iodophenpropit 115 or the inverse H4R agonist thioperamide 115,150, 
suggesting that H4R ligands do not modulate H4R homo-oligomerization. Similarly, 
no agonist or inverse agonist induced modulation of H4R oligomerization was 
detected in the tr-FRET assay. Previously, Patel et al. reported that agonist-
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induced oligomerization of somatostatin receptors was only detected at 
physiological expression levels, but not after over-expression 206. We therefore 
performed BRET experiments at various H4R expression levels. First of all, it is 
interesting to notice that already at an H4R expression level of approximately 300 
fmol/mg protein significant BRET signals can be observed. These data indicate that 
at physiological expression levels the H4R can indeed homo-oligomerize and 
corroborate our findings of H4R dimers, detected on PHA blasts with our anti-H4R 
antibody. Secondly, from the BRET experiments we might also conclude that also 
at low expression levels of the H4Rs homo-oligomerization is not affected by 
agonist stimulation. Nevertheless, one should be aware that results concerning 
ligand effects on dimerization obtained with these biophysical assays can be 
difficult to interpret, since agonist-induced changes in H4R conformation could 
potentially influence the energy transfer between the energy-acceptor and -donor 
214. 
The H4R has been linked to play a role in inflammation based on its expression 
pattern and recent findings, showing that the H4R induces chemotaxis of 
eosinophils 167,168 and mast cells 164, and stimulates the release of IL-16 from CD8+ 
T cells 118, and the release of leukotriene B4 in zymosan-challenged mice 179. 
Interestingly, the H1R is co-localized with the H4R in several white blood cells 150,202 
and also plays a prominent role in inflammatory conditions 200,201. Since both the 
H1Rs 199,205 and the H4R (this study) are able to form homo-oligomers, we were 
prompted to study whether the H4Rs can form hetero-oligomers with the H1Rs. In 
fact, previous work with hetero-oligomeric opioid receptors has revealed that 
GPCR hetero-oligomerization brings an additional layer of complexity to the class 
of GPCR proteins 30,197,198,215, but also offers opportunities to develop hetero-
oligomeric selective ligands (Waldhoer et al., 2005). Yet, using tr-FRET assays, we 
were unable to detect H1R-H4R hetero-oligomers, suggesting that such GPCR 
hetero-oligomers are not present at the cell surface. In contrast to the tr-FRET 
experiments, we were able to detect an expression-level dependent formation of 
H1R-H4R hetero-oligomers using BRET. Distinct from the detection of H4Rs homo-
oligomers, H1R-H4R hetero-oligomers were only detected at high expression levels, 
and we failed to detect hetero-oligomers at physiologically relevant conditions. 
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Results from BRET saturation studies demonstrate a higher propensity for the 
formation of H4R-H4R homo-oligomers over H1R-H4R hetero-oligomers. We 
presume that the signal observed with BRET at high expression levels possibly 
originates from intracellular H1R-H4R hetero-oligomers. Whereas some receptors, 
such as the 5-HT1A receptor appear to readily form heteromeric receptors 216, our 
present H4R data corroborate the idea that GPCR hetero-oligomerization is highly 
selective, as reported for instance for the adrenergic receptors 217,218 and the 
thyrotropin-releasing hormone receptors 219. Although hetero-oligomerization has 
been shown to occur even between receptors from different classes 220, the 
relatively low homology (23%) between H1R and H4Rs 152 is apparently too low to 
readily form hetero-oligomers.  
In conclusion, we have developed specific antibodies against the C-terminus of the 
H4R, which allowed the detection of endogously expressed H4R proteins. This anti-
hH4R antibody will be an important new molecular tool to study the localization and 
function of the H4R. Moreover, we determined by various methods that the H4R 
constitutively forms cell-surface homo-oligomers. Homo-dimeric H4Rs are not only 
found using heterologous expression systems, but are also present in PHA blasts 
and spleen lysates, endogenously expressing H4Rs. The formation of H4R 
oligomers is not dependent on N-glycosylation, nor affected by ligand stimulation 
but possibly destabilized by deglycosylation. While H1R-H4R hetero-oligomers 
could be detected using BRET upon receptor overexpression, these hetero-
oligomers are most likely not present at the cell surface. Moreover, H1R-H4R 
hetero-oligomers were not found at physiologically relevant expression levels. 
Future studies will have to reveal if the H4R can form hetero-oligomers with other 
GPCR family members or preferentially exists as homo-oligomer. 
MATERIALS AND METHODS 
Materials. Reagents for tr-FRET were from Cis bio international (Bagnols-sur-Cèze Cedex, France). 
Coelenterazine was purchased from Chemicon international (Temecula, CA, USA). Sheep anti-mouse 
IgG horseradish peroxidase (HRP) was from Amersham bioscience (Little Chalfont, Buckinghamshire, 
England). Bovin serum albumin, chloroquine diphosphate, DEAE-dextran (chloride form), histamine(2-
[4-imidazolyl]ethylamine hydrochloride), mepyramine (pyrilamine maleate), monoclonal mouse anti-
FLAG (DYKDDDDK), polyethyleneimine was purchased from Sigma (USA). Calf serum (Integro BV, 
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Dieren, The Netherlands). Cell culture media, penicillin, and streptomycin were obtained from Life 
technologies (Merelbeke, Belgium). Cell culture plastics were from Greiner Bio-one (Wemmel, Belgium). 
Tris was from AppliChem (Darmstadt, Germany). [3H]histamine (12.40 and 18.10 Ci/mmol) and 
[3H]mepyramine (23.00 Ci/mmol) were purchased from Perkin-Elmer Life Science, Inc. (USA). 
Oligonucleotides were purchased from Isogen Biocience (Maarsen, The Netherlands). PfuTurbo® DNA 
polymerase was purchased from Stratagene (La Jolla, CA). Restriction enzymes were from MBI 
Fermentas (St. Leon-Rot, Germany). Thioperamide, iodophenpropit, clobenpropit and JNJ 7777120 (1-
[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine), were synthesized at the Department of Medicinal 
Chemistry, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Gifts of mouse anti-hemagglutin 
(anti-HA) antibody (Dr. J. van Minnen), pcDNA3.1-eYFP vector (Dr. T. Schmidt), pRL-CMV vector (Dr. 
G. Milligan), pCR3.1-HA-H1R and pcDEF3-c-myc-H1R (Dr. S Hill), expression vector pcDEF3 (Dr. J 
Langer, 221), and mianserin (Organon NV) are greatly acknowledged. 
Wild type human H4R in pcDNA3.1 was purchased from Guthrie cDNA resource center (Sayre,PA). The 
vector was subcloned into the pcDEF3 using BamHI/XbaI sites.  
 
Construction of epitope-tagged proteins for tr-FRET. An N-terminally FLAG (DYKDDDDK) epitope 
tagged H4R was created by PCR. The coding sequence of the hH4 gene was amplified using the 
following sense oligonucleotide primer 5’-GGGAAGCTTGCCACCATGGACTACAAGGACGA 
CGATGACAAGGATCCAGATACTAATAGCAC-3’ and antisense primer 5’-GGAAGGCACGGGGG 
AGGGC-3’. The amplified gene was first cloned into the pCRII-Topo vector by TOPO TA cloning® 
(Invitrogen BV, Breda) and subsequently subcloned into the pcDEF3 expression vector using 
EcoRV/XbaI sites.  
An N-terminally hemagglutinin HA (YPYDVPDYA) epitope tagged H4R was created by PCR in two 
steps. The H4R gene was amplified by PCR with a 5’ SacII site and without start codon using the 
following sense 5’-ACCGCGGCCCCAGATACTAATAGCACAATC-3’and antisense primer 5’-
GGAAGGCACGGGGAGGGC-3’. The fragment was directly cloned to the pCRII-Topo vector. The gene 
was subsequently subcloned using SacII/XbaI sites into the pcDNA3.1-HA-rH3AR vector 204. The HA-H4 
gene was finally subcloned using BamHI/XbaI sites to pcDEF3. 
The HA-H1R gene was subcloned from the pCR3.1-HA-H1R into the pcDEF3 using Bsp1407I/SpeI 
restriction sites. 
 
Construction of fusion proteins for BRET. For the BRET assay H4Rs were c-terminally fused to 
either a Renilla luciferase (H4R-Rluc) or a yellow fluorescent protein (H4R-eYFP) in two steps. The 
coding sequence of the hH4R gene was amplified without its stopcodon using the following sense primer 
5’-TCGGATCCACCATGCCAGATACTAATAGC-3’ and antisense primer 5’-CCGCGGC 
CGCACTAGTAGAAGATACTGACCGAC-3’, harboring unique BamHI and NotI restriction sites, 
respectively. The gene was cloned directly into the pCRII-Topo vector and subsequently subcloned to a 
pcDEF3 vector using BamHI/NotI sites (pcDEF3-H4R (Del stop)).  
The coding sequence for the Rluc gene was amplified from the pRL-CMV vector lacking a startcodon 
and harboring a NotI restriction site using the following sense primer 5’-
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AGCGGCCGCGACTTCGAAAGTTTATGATCC-3' and antisense primer 5’-
TCTAGAATTATTGTTCATTTTTGAG-3’. The gene was directly cloned to the pCRII-Topo vector and 
subsequently subcloned in frame using NotI/XbaI sites into the pcDEF3-H4R (Del stop) vector.  
The coding sequence for the eYFP gene was amplified from the pcDNA3.1-eYFP vector lacking a 
startcodon and harboring a NotI restriction site using the following sense primer 5’-
CGCGGCCGCGGTGAGCAAGGGCGAGGAG-3' and antisense primer 5’-
GTCTAGATTACTTGTACAGCTCGTCCATG-3’. The gene was directly cloned to the pCRII-Topo vector 
and subsequently subcloned in frame using NotI/XbaI sites into the pcDEF3-H4R (Del stop) vector.  
A hH1R-eYFP fusion was generated by PCR using the following sense primer 5’- 
AAGAGAATTCTGCATATTCGCTCCATGGTGAGCAAGGGCG-3’ and antisense primer 5’-
TTCTCTAGATTACTTGTACAGCTCGTCC-3’, harboring unique EcoRI and XbaI restriction sites, using 
pcDNA3.1eYFP as template in. The PCR fragment was digested using EcoRI and XbaI and the purified 
fragment was subsequently ligated together with the fragment that was obtained by digestion of the 
pcDEF3-hH1R plasmid using EcoRI/XbaI sites. 
A hH1R-Rluc fusion was generated by PCR using the following sense primer 5’- 
AAGAGAATTCTGCATATTCGCTCCATGACTTCGAAAGTTTATGATCC-3’ and antisense primer 5’-
CGCTCTAGAATTATTGTTCATTTTTGAGAACTCGC-3’, harboring unique EcoRI and XbaI restriction 
sites, using. The PCR fragment was digested using EcoRI and XbaI and the purified fragment was 
subsequently ligated together with the fragment that was obtained by digestion of the pcDEF3-hH1R 
plasmid using EcoRI/XbaI sites. Each construct was fully sequenced before its expression and analysis. 
 
 Construction of His10-tagged proteins for immobilization. An N-terminally c-myc (EQKLISEEDL) 
and C-terminally His10- epitope tagged H4R was created as follows. First a c-myc epitope tagged H4R 
was created by PCR in two steps. The c-myc tag was amplified by PCR using a pcDEF3-c-myc-H1R 
vector as template with a 3’ NheI site using the following sense 5’-GGGTGGAGAC TGAAGTTAGGCC-
3’and antisense primer 5’-GTGCTAGCAGGTCCTCCTCGGAG-3’. The fragment was directly cloned to 
the pCRII-Topo vector (pCRII-topo-myc). The H4R gene was amplified without start codon and 
containing a 5’ NheI restriction site using the following sense 5’-CCGCTAGCCAGATACTAATAGCAC-3’ 
and antisense primer 5’-TCTTTAAGAAGATACTGACC-3’. The gene was directly cloned to the 
pcDNA3.1/ V5-His-Topo vector. The H4R gene was subsequently subcloned in frame using NheI/NotI 
into the pCRII-topo-c-myc vector (pCRII-topo-c-myc-H4R). The c-myc-H4R gene was subsequently 
subcloned into the pcDEF3 expression vector using the BamHI/XbaI sites. 
Second the gene of the wild type H4R was amplified by PCR without start and stop codon with a 
5’BamHI site and a 3’ SpeI site using the following sense 5’-CCGGATCCCCAGAT 
ACTAATAGCACAATCAA-3’and antisense primer 5’-CCGCGGCCGCACTAGTAGAAGATACT 
GACCGAC-3’ and directly cloned into the pCRII-Topo vector. The H4R gene was than subcloned in 
frame from the pCRII-topo-vector using BamHI/SpeI sites in the pSFV2genB vector. An N-terminally 
tagged FLAG and C-terminally tagged H4R-His10 gene was subcloned from the pSFV2genB-FLAG-H4R-
His10 behind the p10 promoter of the pFastbac_DUAL vector using NcoI/NheI restriction sites. 
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The H4R-His10 gene was amplified by PCR from the pFastbac_DUAL-FLAG-H4R-His10 vector without 
start codon and a 3’ XbaI site using the following sense 5’-CATCTAGATTAATTACCCACTGGGCCC-
3’and antisense primer 5’-GAGGATCC GCCAGATACTAATAGCACAATC-3’ and directly cloned into the 
pcDNA3.1/ V5-His-Topo vector by TOPO TA cloning and subsequently subcloned into the pcDEF3-c-
myc-H4R vector using BoxI/XbaI restriction sites. Each construct was fully sequenced before its 
expression and analysis. 
 
Cell culture and transfection of COS-7 cells. COS-7 African green monkey kidney cells were 
maintained at 37ºC humidified in 5% CO2/95% air atmosphere in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 5% (v/v) fetal calf serum, 50 IU/ml of penicillin and 50 μg/ml streptomycin 
and grown in 100 mm dishes. Cells were transiently transfected using the DEAE-dextran method as 
previously described 85. The total amount of DNA transfected was maintained constant by addition of 
pcDEF3. 
 
Cell culture and transfection of HEK 293 cells. HEK 293 cells were maintained at 37ºC humidified in 
5% CO2/95% air atmosphere in DMEM/F12 (Cambrex, UK) supplemented with 10% (v/v) fetal calf 
serum, 50 IU/ml of penicillin and 50 μg/ml streptomycin and grown in 100 mm dishes. HEK 293 cells 
were transfected with pcDEF3-H4R receptor essentially using the LipofectaminePlus method described in 
Shenton et al., 2005. Briefly for each cDNA, two microtubes were prepared: tube 1 contained 2µg cDNA, 
6µl of lipofectaminePLUS reagent (Invitrogen) and 150µl of Optimem-I media (Gibco); tube 2 contained 
5µl lipofectamine reagent (Invitrogen) and 150µl of Optimem-I media. The mixtures were incubated at 
room temperature for 15 minutes after which the contents of tube 2 were added to tube 1 followed by a 
further 15 minute incubation. In the meantime the HEK 293 cells at 50-80% confluence in 2ml petri 
dishes were washed three times with Optimem-I media. At the end of the second incubation period the 
contents of tube 1 were made up to 1.5ml with Optimem-I media and added to the washed HEK 293 
cells. The cells were incubated at 37oC for 6 hours. The transfection mixture was then removed and 
replaced with growth media. The cells were harvesed 48 hours post-transfection, and cell homogenates 
prepared for immunoblotting. 
 
[3H]histamine binding studies. Cells used for radioligand binding studies were harvested 48h post 
transfection and homogenized in ice cold H4R binding buffer (50 mM tris, pH 7.4). For saturation 
isotherms cell membrane homogenates were incubated at 37ºC for 60 minutes with 0-125 nM 
[3H]histamine in a total assay volume of 200 μl. Non-specific binding was determined by incubation in 
the presence of 10 μM JNJ 7777120. For competition binding assays the cell homogenates were 
incubated at 37ºC for 60 minutes with 0.1-10.000 nM ligand in the presence of ~15 nM [3H]histamine in 
a total volume of 200 μl. The incubations were stopped by rapid dilution with ice cold H4R binding buffer. 
The bound radioactivity was separated by filtration through Whatman GF/C filterplates that had been 
treated with 0.3% polyethyleneimine. Filters were washed four times with H4R binding buffer and 
radioactivity retained on the filters was measured by liquid scintillation counting. 
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[3H]mepyramine binding studies. Cells used for radioligand binding studies were harvested 48h post 
transfection and homogenized in ice cold H1R binding buffer (50 mM Na2/K-phosphate buffer, pH 7.4). 
For saturation isotherms cell membrane homogenates were incubated at room temperature for 30 
minutes with 0-25 nM [3H]mepyramine in a total assay volume of 200 μl. Non-specific binding was 
determined by incubation in the presence of 1 μM mianserin. For competition binding assays the cell 
homogenates were incubated at room temperature for 30 minutes with 0.1-10.000 nM in the presence 
of ~1.5 nM [3H]mepyramine in a total volume of 200 μl. The incubations were stopped by rapid dilution 
with ice cold H1R binding buffer. The bound radioactivity was separated by filtration through Whatman 
GF/C filterplates that had been treated with 0.3% polyethyleneimine. Filters were washed four times 
with H1R binding buffer and radioactivity retained on the filters was measured by liquid scintillation 
counting.  
 
Anti-H4R antibody generation. The unique peptide corresponding to the amino acids 
CIKKQPLPSQHSRSVSS of the human H4R subtype was conjugated to thyroglobulin by the Cys-
coupling method 222. The resultant conjugate was used to generate polyclonal antibodies in rabbits. 
Antibody production and affinity purification was performed as previously described 203.  
 
Production of human PHA blasts. Human peripheral blood mononuclear cells (PBMC) stimulated with 
phytohaemagglutinin (PHA blasts) were generated essentially as previously described 223. Briefly, 
heparinized human whole blood was obtained from healthy volunteers (with Local ethical approval), and 
PBMCs were separated using Lymphoprep (Axis-Shield Poc AS, Oslo, Norway) and centrifuged at 400 X 
g for 25 min. The PBMCs were isolated from the interfacial layer, washed twice in RPMI without L-
glutamine (Gibco™) and resuspended in RPMI complemented with 10% (v/v) Fetal Calf Serum, 1% (v/v) 
Penicillin, and Streptomycin, and 1% (v/v) L-Glutamine.. Cell density was adjusted accordingly to 1 x 106 
cells/ml with RPMI. 100μl PHA (‘Lectin’, Sigma, UK) was added to the cells to make PHA Blasts. These 
were grown in culture for 24h, harvested and a cell homogenate prepared in the presence of protease 
inhibitors (Protease Inhibitor Cocktail III, Calbiochem, UK). 
 
Immunoblotting. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was carried 
out using 6 % or 7.5 % polyacrylamide slab gels under reducing conditions. Samples of HEK 293 cells, 
COS-7 cells and PHA blasts (20-50 µg protein) were prepared using a chloroform/methanol method of 
protein precipitation, and immunoblotting was performed as previously described 203,204. Immunoblots 
were probed with anti-H4 374-390 antibody at a concentration of 0.5 µg /ml. 
Blots containing FLAG or c-myc tagged receptors were probed with primary antibodies, mouse anti-
FLAG (1.5 μg/ml) or mouse anti-c-myc (1 μg/ml), respectively. Horseradish peroxidase conjugated goat 
anti-mouse antibodies (1:2000-5000) were used as secondary antibodies. 
 
Immunoprecipitation HEK 293 cells were transfected with HA-H4 receptor, and solubilized with 1% 
Triton X100/0.15M NaCl for 30 min at 4°C. Immunoprecipitation was performed essentially as previously 
described 224. Solubilized HEK 293 cell extracts were incubated with 5 µg of rat anti-HA antibody (Roche 
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Diagnostics, Germany) or rat non-immune Ig (ADI, USA) at 4°C for 1 hour. 50 µl of pre-chilled washed 
Protein G agarose (Sigma, UK) slurry was added and incubated for 1 hour at 4°C on a rocking platform. 
Precipitation pellets were collected by centrifugation at 10,000xg for 30 seconds at 4°C, washed with 3 x 
PBS, resuspended in sample buffer, vortex-mixed and heated to 90-100°C for 3 minutes.  The sample 
was then re-centrifuged, and the supernatant subjected to immunoblotting. Control experiments were 
performed using untransfected HEK 293 cells.  
 
Cross-linking experiments. The cross-linking method used was essentially as described by Shenton et 
al. 204,210. Briefly, aliquots of COS-7 cells expressing c-myc-H4Rs were pelleted, the suspension buffer 
was removed and replaced with 150µl cross-linking buffer (150mM NaCl, 100mM Na-HEPES, 5mM 
EDTA pH7.5, 5mM DTT) to give a final protein concentration of approx. 0.5mg/ml. The cross-linker 
(bis(sulphosuccinimidyl) suberate sodium salt) was dissolved in 20mM HCl to give a 100mM stock 
solution. The tubes were incubated at room temperature with continual mixing for 12 minutes with 0.25, 
0.5, 1.0 and 2 mM crosslinker, centrifuged at 10,000rpm for 5mins, the cross-linking mixture removed 
and the resultant pellet prepared for immunoblotting.  
 
Tunicamycin experiments. HEK 293 cells expressing H4Rs were incubated with 2, 4, 6 and 8 µg/ml 
tunicamycin (stock dissolved in DMSO at 2 mg/ml) immediately after transfection and harvested 48 h 
post-transfection, homogenized and subjected to immunoblotting. 225. Cells grown in the absence of 
tunicamycin were incubated with the respective volume of DMSO.  
 
Deglycosylation of native H4 receptor. Human PHA blast cell suspensions were resuspended in 
deglycosylation buffer (50µM sodium phosphate pH6.0, containing 0.1% SDS, 0.1% β-mercaptoethanol 
and 20mM EDTA) and incubated with either water (control) or PNGase F enzyme (Sigma, UK) at a final 
enzyme concentration of 400iu/ml (test) for 16 hours at 37oC. The samples were then subjected to 
immunoblotting and probed with anti-H4 374-390 antibody at a concentration of 2µg/ml. The NMDAR1 
transfected into HEK 293 cells was used as a positive control essentially as described in 226 
 
Receptor immobilization. Membranes of COS-7 cells transiently expressing c-myc-H4R-His and 
FLAG-H4R or HA-H1R-His and FLAG-H4R receptors were homogenized, solubilized and subsequently 
immobilized on Ni-NTA columns (Invitrogen) as previously described 204. Immobilized receptors were 
eluted using 250 mM imidazole. Samples were prepared for immunoblotting subjected to 
chloroform/methanol extraction loaded on a 7.5 % SDS page gel and subsequently blotted on 
nitrocellulose paper (Amersham). 
 
BRET assay. Forty-eight hours post-transfection cells were detached with trypsin and washed twice 
with PBS. Approximately 50,000 cells per well were distributed in white bottom 96-wells microplates 
(Corning BV, Schiphol-Rijk). Coelenterazine was added to a final concentration of 5 μM and readings 
were collected immediately following this addition using a Victor2 allowing signal detection at 460 nm 
and 530 nm. 
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tr-FRET assay. tr-FRET assays were performed using Eu3+-labeled and allophyocyanin anti-FLAG and 
anti-HA antibodies as described by 204. Briefly, tr-FRET was assessed in 1 x 106 whole COS-7 cells 
transiently expressing the appropriate HA and FLAG tagged receptors. Cells were incubated in PBS 
containing 50% FCS (v/v), 0.8 nM of Eu3+-labelled antibody, and 8 nM of allophycocyanin-labelled 
antibody for two h at room temperature on a rotating wheel, after which the membranes were washed 
twice with PBS. The final pellet was resuspended in 50 μl PBS and transferred to a 384-microtiter plate. 
Energy transfer was measured by exciting the Eu3+ at 320 nm and monitoring the XL-665 
allophycocyanin emission for 500 μs at 665 nm using a Novostar (BMG Labtechnologies) configured for 
time-resolved fluorescence after a 100 μs delay. 
 
Analytical methods. Binding data were evaluated by a non-linear least squares curve fitting program 
using Graphpad Prism® (Graphpad Software Inc, San Diego, CA). Protein concentrations were 
determined according to Bradford 227, using BSA as standard. All data are represented as mean ± 
S.E.M. from at least three independent experiments in triplicate. Statistical significance was determined 
by a Students unpaired t-test (p<0.05 was considered statistically significant).
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ABSTRACT 
 
The histamine H4 receptor (H4R) is the latest identified member of the histamine 
receptor subfamily of G protein-coupled receptors with potential functional 
implications in inflammatory diseases and cancer. The H4R is primarily expressed 
in eosinophils and mast cells and shares highest homology with the H3R. The 
occurrence of at least twenty different hH3R isoforms led us to investigate the 
possible existence of H4R splice variants. Herein we report on the cloning of the 
first two alternatively spliced H4R isoforms from CD34+ cells from cord blood. 
These H4R splice variants are expressed in mast cells and eosinophils and are 
localized predominantly intracellular when expressed recombinantly in mammalian 
cells. We failed to detect any ligand binding, H4R-ligand induced signaling or 
constitutive activity for these H4R splice variants. However, when co-expressed 
with the full-length H4R (H4R(390)), the H4R splice variants have a dominant negative 
effect on the surface expression and function of the H4R(390). We detect H4R(390)-
H4R splice variant hetero-oligomers by employing both biochemical 
(immunoprecipitation, cell-surface labeling) and biophyisical (time-resolved FRET) 
techniques. Messenger RNAs encoding the H4R splice variants are detected in 
various cell types and are expressed at similar levels as the full-length H4R(390) 
mRNA in e.g. premonocytes.  We conclude that the herein described H4R splice 
variants have a dominant negative effect on H4R(390) functionality, being able to 
retain the H4R(390) intra-cellularly and to inactivate a population of H4R(390) 
presumably via hetero-oligomerization. 
. 
INTRODUCTION 
 
The human histamine H4 receptor (hH4R) is the fourth and most recently 
discovered member of the G-protein coupled receptor (GPCR) subfamily of 
histamine receptors 148-153. The H4R is predominantly expressed in hematopoietic 
cells and is suggested to play a role in inflammation 164,168 and allergy 184. 
Interestingly, recently connections of the H4R with rheumatoid arthritis 188, colon 
cancer 189,190 and breast cancer 191 have also been proposed. Consequently, the 
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H4R is currently seen as a potential new drug target 194 and is getting much 
attention from pharmaceutical industry.  
The hH4R gene has been cloned on the basis of its relatively high homology with 
the histamine H3 receptor (H3R) 148-153. The H4R gene shows the same genomic 
organization as the H3R gene, with the positions of two introns at identical sites as 
found for the H3R gene 125,151, potentially resulting in the existence of differentially 
spliced isoforms, as have been detected for both human and rat H3Rs 124,127. A 
large variety of genes encoding GPCRs have been found to be alternatively spliced 
12 and alternative splicing thereby introduces additional diversity to GPCR 
pharmacology. Natural occurring splice variants may have practically identical 
pharmacological properties as the full-length receptor 228, but can also have altered 
functionality or lack any functional responses 12,229,230. Moreover, the expression of 
full-length receptors and receptor isoforms can be differentially regulated as was 
recently demonstrated for e.g. the expression of the neurokinin-1 receptor and a C-
terminally truncated neurokinin-1 receptor isoform in undifferentiated and 
differentiated THP-1 cells 231. 
For the H3R a large number of alternatively spliced isoforms have been described 
124,127. Many human H3R isoforms with deletions in the third intracellular loop and 
potentially different signal transduction have been reported. However, also a 
variety of non-7TM isoforms are found in brain mRNA 124,127. Recently, we have 
shown that several natural occurring 6TM rH3R splice variants interfered with 
trafficking of the full-length rH3R to the cell membrane, hence reducing its signaling 
properties 204. Such dominant negative behavior of alternatively spliced isoforms 
has also been described for e.g. the α1A-adrenergic receptor 229, the dopamine D3nf 
receptor 230, an alternatively spliced rat vasopressin V2 receptor 232 and a naturally 
occurring splice variant of the calcitonin receptor lacking exon 13 233. 
In view of the great interest in the H4R as a pharmacological target and the large 
diversity of GPCR isoforms for the related H3R, the identification of H4R isoforms is 
of utmost importance for the future understanding of H4R pharmacology and target 
validation strategies. In the present study we report on the identification and 
pharmacological characterization of two new splice variants of the hH4R. Although 
translated and present at the cell surface, albeit to a lesser extent than the H4R(390), 
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these receptor isoforms are non-functional when individually expressed in 
recombinant mammalian cells. However, when co-expressed with the hH4R(390) the 
two H4R isoforms are able to decrease [3H]histamine binding to the hH4R(390) and 
histamine potency. Surface labeling experiments showed a reduction in H4R(390) 
surface expression when co-expressed with either of the H4R isoforms. The 
apparent mechanism underlying the dominant negative effect might be attributed to 
hetero-oligomerization between the hH4R(390) and the H4R splice variants as 
determined by biophysical and biochemical techniques. 
 
RESULTS 
 
Cloning of human H4R splice variants. 
Using mRNA isolated from mast cells, eosinophils, basophils and dendritic cells 
derived from CD34+ cord blood cells, we investigated the occurrence of hH4R 
isoforms. Our RT-PCR approach using specific primers (see Materials and 
Methods) identified two new H4R splice variants. The first splice variant encodes a 
protein consisting of 302 amino acids (H4R(302)), compared to 390 amino acids of 
the H4R(390) and was cloned from mRNA from eosinophils. Alternative splicing of 
mRNA encoding H4R(302) results in the deletion of exon 2. A previously unidentified 
exon/intron junction within exon 3 of the hH4R gene, however, allows for the use of 
an alternative splicing acceptor maintaining the gene in its original frame. 
Consequently, the H4R(302) isoform has a deletion of 88 amino acids between TMII 
and TMIV (Figure 4.1). The second splice variant was cloned independently from 
mRNA from both mast cells and eosinophils. Alternative splicing of mRNA 
encoding this H4R isoform also results in the removal of exon 2. However, in this 
case the H4R(390) splice acceptor site of exon 3 is recognized, causing a frame-shift 
and the introduction of an alternative stop codon. This results in a severely 
truncated H4R(67) receptor containing only the first 67 amino acids of the hH4R 
(Figure 4.1).   
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Figure 4.1. Sequence alignment of human H4R splice variants and genomic arrangement of the H4R 
gene. A Amino acid alignment of the hH4R with the two identified H4R splice variants. Indicated 
underneath the amino acids are seven transmembrane domains as proposed for the hH4R(390) (TM1 
through TM7). Two arrows indicate where intron 1 and intron 2 is splice out of the H4R(390) mRNA. The 
H4R(302) splice variant passes over exon 2 and recognizes an alternative acceptor site (arrow between 
TMIV and TMV) within exon 3. The H4R(67) splice variant also skips exon 2 but recognizes the typical 
acceptor site after intron 2, resulting in a frameshift and the introduction of an alternative, premature 
stop codon. B Overview of the exon/intron structure of the H4R gene on chromosome 18q11.2 
(Genbank accession number NM_021624 (GI:14251204)). The exon/intron junctions for the H4R(390), 
H4R(302) and H4R(67) are portrayed. Exon sequences are depicted in upper case, and intron sequences in 
lower case. 
 
Endogenous occurrence of H4R splice variants mRNA in human cells. 
Quantitative PCR (Q-PCR) was subsequently used to investigate the presence of 
mRNA encoding the genes of the hH4R(390) and the hH4R splice variants in several 
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cell types. To this end, mRNA of undifferentiated HL-60 cells (pre-monocytes) and 
HL-60 cells differentiated to produce eosinophils or granulocyts were collected and 
subjected to Q-PCR analysis. As control, a gene, encoding for ribosomal protein 
S11 was also amplified to correct obtained mRNA expression levels. RPS11 
mRNA expression is not affected by the various experimental conditions used, and 
Q-PCR efficiency of RPS11 is similar to that of the H4R(390) and the H4R splice 
variants (data not shown). Of all tested cells, eosinophils expressed the highest 
amounts of mRNA of the H4R isoforms (Table 4.1). In pre-monocytes the H4R(67) 
mRNA levels were almost 2-fold higher compared to the H4R(390) mRNA levels, 
whereas the H4R(320) expression was very low in this cell type. In the other tested 
cells, the mRNA levels of the H4R(390) were considerably higher compared to the 
levels of the 2 splice variants (Table 4.1). 
 
Table 4.1. Expression of H4R(390) and H4R isoforms messenger RNA in a variety of differentiated HL-60 
cells. HL-60 cells were cultured under various conditions (see Materials and Methods) to differentiate 
the cells to pre-monocytes (pH 7.4 or pH 8.0), granulocytes or eosinophils. The amount of mRNA 
encoding H4R(390), H4R(302) and H4R(67) were determined by Q-PCR. Messenger RNA expression values 
were normalized against the validated control gene encoding ribosomal protein S11 (RPS11).  
 Pre-monocytes Pre-monocytes 
(pH 8) 
Granulocytes Eosinophils 
H4R(390) 11.5 ± 10 4.7 ± 1.5 46.8 ± 23 179 ± 30 
H4R(302) <<1 <<1 <1 <1 
H4eR(67) <1 9.1 ± 5.9 <<1 29.0 ± 7.1 
Fold expression (relative to rps11, *10-6) 
 
Pharmacological characterization of newly identified H4R splice variants 
We have previously employed COS-7 cells successfully for the heterologous 
expression of the H4R as well as for the identification of H4R oligomers 234. To 
study their pharmacology we therefore also expressed the two H4R splice variants 
heterologously in COS-7 cells. The H4R agonist radioligand [3H]histamine and the 
H4R antagonist radioligand [3H]JNJ 7777120 bound to the H4R(390) according to a 
one site saturable model with dissociation constants (KD) of 23.9 ± 3.6 nM (n=3) 
and 11.1 ± 3.6 nM (n=3), respectively. The obtained Bmax-values for both 
radioligands are approximately 1 pmol/mg protein. However, transfection of COS-7 
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cells with cDNAs coding for the H4R splice variants did not result in the detection of 
significant specific radioligand binding using either [3H]histamine (Figure 4.2A) or 
[3H]JNJ 7777120 (Figure 4.2B).  
 
 
Figure 4.2.  The H4R splice variants are unable to bind the H4R agonist radioligand [3H]histamine nor 
the non-imidazole H4R neutral antagonist radioligand [3H]JNJ 7777120. Saturation isotherms were 
obtained for [3H]histamine (A) or [3H]JNJ 7777120 (B) by performing radioligand binding on membranes 
from transiently transfected COS-7 cells expressing either the H4R(390) (z), H4R(302) ({) or H4R(67) (Δ). A 
representative experiment is shown. 
 
To determine whether the H4R splice variants were constitutively active and/or able 
to signal via Gi/o-proteins, the cDNA encoding the H4R(390), H4R(302) or H4R(67) were 
heterologously transfected in HEK 293T cells together with a CRE-luciferase 
reporter gene. Histamine acts as a full agonist (pEC50 = 8.6 ± 0.1, n=5) on the 
H4R(390). Moreover thioperamide acts as a full inverse agonist (pEC50 = 6.7 ± 0.1, 
n=4), revealing the known constitutive activity of the H4R(390) (Figure 4.3A). No 
effect of either histamine or thioperamide could be observed for both the H4R(302) 
and the H4R(67) isoforms over a range of 0.1-10.000 nM (Figure 4.3C and 4.3E). 
Whereas pretreatment with 0.1 μg/ml pertussin toxin (PTX) abolishes the 
constitutive signaling of the H4R(390) (Figure 4.3B) in the CRE-reporter gene assay, 
no effect of PTX was observed for the H4R(302) and the H4R(67) isoforms compared 
to cells not treated with PTX (Figure 4.3D and 4.3F). 
Cloning of dominant negative H4R splice variants 
 
 101
 
Figure 4.3. Functional response of hH4R and H4R splice variants to agonist and inverse agonist 
stimulation in transiently transfected HEK 293T cells. Dose-response curves for the H4R agonist 
histamine (z) and H4R inverse agonist thioperamide ({) on the H4R(390) (A), the H4R(302) splice variant 
(C) and the truncated H4R splice variant H4R(67) (E) in a forskolin (1 μM) induced CRE-luciferase reporter 
gene assay. Inhibition of Gi-signalling and constitutive activity by pertussis toxin (PTX) pre-treatment of 
HEK 293T cells expressing the H4R(390) (B), the H4R(302) splice variant (D) and the truncated H4R splice 
variant H4R(67) (F) were grown for 16 hours in the absence (open bars) or presence (closed bars) of (0.1 
μg/ml) PTX. A representative experiment is shown. 
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H4R splice variants are translated and present predominantly intracellularly. 
The absence of radioligand binding and Gi/o-coupled signaling of the H4R splice 
variants could simply be due to the fact that receptor proteins are not expressed. In 
order to determine whether the H4R splice variants are translated into protein and 
to determine the localization of these splice variants an ELISA was performed with 
COS-7 cells expressing HA epitope-tagged the H4R(390) (HA-H4R(390)), FLAG 
epitope-tagged H4R(302) (FLAG-H4R(302)) or FLAG-H4R(67) (Figure 4.4A). The 
localization (cell surface or intracellular) of the receptors was determined by 
permeabilization of the cells using NP-40. Whereas the HA-H4R(390) is readily 
observed on the cell membrane, both H4R splice variants are located 
predominantly intracellularly, although a small fraction of each was clearly detected 
on the  cell membrane (Figure 4.4A).  
    
 
Figure 4.4. The H4R splice variants are expressed predominantly intracellular when recombinantly 
expressed in COS-7 cells. A, ELISA assays were performed on transiently transfected COS-7 cells 
individually expressing HA-H4Rs, FLAG-H4R(302) or FLAG-H4R(67). Receptor expression and localization 
were determined using anti-HA and anti-FLAG antibodies on intact (open bars) and permeabilized cells 
(closed bars). Data has been normalized against COS-7 cells transfected with empty vector. B, HEK 
293 cells were transfected with either FLAG-H4R(302) or FLAG-H4R(67) receptor isoforms. Intact cells were 
biotinylated for 15 min at 4ºC with 1mg/ml Sulfo-NHS-SS-Biotin, washed and homogenised. Biotinylated 
surface fraction was isolated by streptavidin chromatography, and analyzed by immunoblotting using 
anti-FLAG antibodies. Lanes 1 and 3: Intracellular fraction; Lanes 2 and 4: Surface fractions, where 
lanes 1 and 2 are FLAG- H4R(302) samples, and lanes 3 and 4 and FLAG- H4R(67) samples. 
Representative experiments are shown. 
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Surface labeling experiments provided additional evidence for the intracellular 
localization of the H4R splice variants (Figure 4.4B). HEK 293 cells expressing the 
FLAG-H4R(302) or the FLAG-H4R(67) were biotinylated to distinguish intracellularly 
localized H4R isoforms from receptors present at the cell surface. Similar to the 
ELISA results, the majority of the H4R isoforms can be detected intracellularly 
(Figure 4.4B). In both assays the presence of H4R splice variants at the cell surface 
is more evident for the FLAG-H4R(67) than for the FLAG-H4R(302) (Figure 4.4B). No 
anti-FLAG reactivity was observed in MOCK HEK 293 cells (data not shown). 
 
H4R splice variants are able to down-regulate H4R(390) binding. 
Natural occurring splice variants of e.g. the rH3R have a dominant negative effect 
on receptor cell-surface expression of the full-length rH3R 204. To investigate the 
effect of the H4R splice variants on the H4R pharmacology, [3H]histamine 
radioligand binding was performed on membranes of COS-7 cells co-expressing 
the H4R(390) together with either the H4R(302) or the H4R(67) splice variant. 
[3H]histamine bound to the COS-7 cells co-expressing the H4R(390) with the H4R 
splice variants according to a one site, saturable model with dissociation constants 
(KD) similar to the value obtained for the H4R(390) expressed individually in COS-7 
cells (Figure 4.5A, Table 4.2).  
 
Table 4.2. Characterization of the hH4R(390) expressed individually or co-expressed with either the 
H4R(302) or the H4R(67) splice variant in transiently transfected COS-7 cells. The KD values, the H4R 
expression (Bmax) and the pKi values of 4-methylhistamine (4-Me-HA), clozapine, JNJ 7777120 and 
thioperamide were determined by [3H]histamine saturation and displacement binding assays. COS-7 
cells were transfected in a 1:1 ratio with cDNA encoding the H4R(390) and the H4R splice variants. The 
values are expressed as mean ± SEM of at least three independent experiments. 
[3H]histamine 
pKi Receptor KD (nM) Bmax (%) 4-Me-HA Clozapine JNJ 7777120 Thioperamide 
H4R(390) 23.9 ± 2.8 100 7.1 ± 0.1 6.5 ± 0.1 7.7 ± 0.1 7.3 ± 0.1 
H4R(390) + H4R(302) 24.4 ± 2.0 45 ± 3 7.1 ± 0.1 6.5 ± 0.1 7.7 ± 0.1 7.2 ± 0.1 
H4R(390) + H4R(67) 20.2 ± 1.9 70 ± 5 7.1 ± 0.1 6.4 ± 0.1 7.7 ± 0.1 7.3 ± 0.1 
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Figure 4.5. Dominant negative effect of H4R splice variants on [3H]histamine binding to H4R(390). A 
Saturation of [3H]histamine to H4R receptors expressed individually (z) or co-expressed with the H4R 
splice variants H4R(302) () or H4R(67) ({) in COS-7 cells. B Dose dependent decrease of [3H]histamine 
binding to H4R(390) by increasing the amount of H4R(302) cDNA transfected transiently in COS-7 cells C 
Co-expression of H4R(390) with H1R in a 2:1 ratio has no negative influence on H4R(390) binding in COS-7 
cells D Displacement of [3H]histamine from H4R expressed individually (z) or co-expressed with the 
H4R splice variants H4R(302) () or H4R(67) ({) in COS-7 cells by the H4R antagonist JNJ 7777120 
(dotted line) or H4R agonist clozapine (solid line). E Co-expression of H4R(390) with H4R(302) or H4R(67) in 
HEK 293T cells decreases histamine potency in a CRE-luciferase reporter gene assay.   Representative 
experiments are shown. 
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However, the maximal amount of H4Rs labeled by [3H]histamine (Bmax) decreased 
upon co-transfection of individual cDNAs coding for the H4R(390) and the H4R splice 
variants in a 1:1 cDNA ratio compared to cells transfected only with cDNA 
encoding the H4R(390). A decrease in Bmax of 30 ± 5% (n=3) was observed when the 
H4R(390) was co-expressed with the H4R(67). An even larger decrease of 55 ± 3% 
(n=3) was observed when co-expressed with the H4R(302) (Figure 4.5A, Table 4.2). 
The decrease in Bmax is directly related to the ratio of H4R(390) and H4R(302) cDNA 
that was transfected. Transfecting more H4R(302) cDNA results in a concomitant 
decrease of the Bmax value for [3H]histamine (Figure 4.5B). This decrease was not 
a result of saturation of the translation system, as co-expression of H1R, which 
does not physically interact with the H4R 234 had no negative influence on H4R 
expression (Figure 4.5C). We also tested a set of typical H4R ligands for their 
affinity in cells expressing the H4R(390) alone or when co-expressed with the H4R(302) 
and H4R(67). No difference in Ki values for the selective H4R agonist 4-
methylhistamine, the H4R inverse agonist thioperamide, the non-imidazole H4R 
neutral antagonist JNJ 7777120 and the non-imidazole H4R agonist clozapine 
115,148 were observed (Figure 4.5C, Table 4.2). We further investigated the effect of 
co-expression of the H4R splice variants on the level of receptor signaling. We co-
transfected H4R(390) in a 1:1 cDNA ratio with either the H4R(302) or H4R(67) and a 
CRE-luciferase reporter gene (Figure 4.5E). Both the co-expression of H4R(302) and 
H4R(67) resulted in a significant (p<0.05) decrease in pEC50 of histamine (8.4 ± 0.1, 
n=4) compared to when H4R(390) is expressed alone (8.8 ± 0.1, n=6). 
 
Co-expression of the H4R(390) with the H4R splice variants results in reduced 
surface expression of the H4R(390). 
To determine the location of the H4R(390) upon co-expression with either of the two 
H4R isoforms a biotinylation-surface labeling assay was performed in combination 
with Western blot analysis using our previously described anti-H4R antibody 234 on 
HEK 293 cells either individually expressing the H4R(390) or co-expressing the 
H4R(390) with the H4R(302) or the H4R(67). In agreement with the ELISA results, the 
H4R(390) is expressed on the cell surface when expressed individually (Figure 4.6, 
lane 1). As reported previously 234, the H4R(390) is detected both as a monomer and 
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as a dimeric receptor. However, upon co-expression of the H4R(390) with the H4R(302) 
or H4R(67) a clear reduction in intensity in anti-H4R reactivity is observed in the cell 
surface fraction (Figure 4.6, lanes 4 and 7). This reduction in apparent H4R surface 
expression is clearly dependent on the amount of splice variant co-transfected with 
the H4R(390). Increasing the amount of H4R isoform 5-fold causes a stronger 
reduction in anti-H4R reactivity (Figure 4.6, lanes 5 and 8). This reduction was not 
observed when co-transfecting identical amounts of GFP (Figure 4.6, lane 2).  
 
Figure 4.6. Reduced surface expression of H4R(390) when co-expressed with H4R isoforms. HEK 293 
cells individually expressing H4R(390)  or co-expressing H4R(390)  with either GFP (control), H4R(302) or 
H4R(67) with cDNA ratios of 1:1 and 1:5, respectively. Intact cells were biotinylated for 15 min at 4ºC with 
1mg/ml Sulfo-NHS-SS-Biotin, washed and homogenised. Biotinylated surface fractions were isolated by 
streptavidin chromatography, and analyzed by immunoblotting. Surface fractions: lane 1: H4R(390) alone; 
lane 2: H4R(390)+ GFP (1:5 ratio) ; H4R(390) + H4R(302) (1:1 ratio); lane 3: H4R(390) alone; lane 4: H4R(390)+ 
GFP; lane 5: H4R(390) + H4R(302) (1:5 ratio); lane 6: H4R(390) alone; lane 7: H4R(390) + H4R(67) (1:1 ratio); lane 
8: H4R(390) + H4R(67) (1:5 ratio). All lanes were probed with anti-H4R receptor antibody. 
 
Hetero-oligomerization between H4R(390) and H4R splice variants. 
We hypothesized that hetero-oligomerization between the H4R(390) and the H4R 
splice variants might be responsible for intracellular retention of the H4R(390) and the 
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observed decrease in [3H]histamine binding to the co-expressed H4R(390). We 
therefore initially performed tr-FRET measurements to measure hetero-
oligomerization. For this purpose, COS-7 cells co-expressing N-terminally HA-
tagged histamine H4R(390) (HA-H4R(390)) and either FLAG-H4R(302) or FLAG-H4R(67) 
were incubated with Europium (Eu3+) labelled anti-HA antibodies or a combination 
of the Eu3+ labelled anti-HA and allophycocyanin (APC) labelled anti-FLAG 
antibodies.  
 
 
Figure 4.7. Evaluation of hetero-oligomerization between the HA-tagged H4R(390) and FLAG-tagged H4R 
splice variants H4R(302) and H4R(67) by tr-FRET using co-expression of differentially epitope-tagged 
receptors. Transiently transfected COS-7 cells co-expressing the HA-H4R and the FLAG-H4R(302) or 
FLAG-H4R(67) in a 0.2:1 or 1:1 cDNA ratio were incubated for 2 hours with the Eu3+-labelled anti-FLAG 
and APC-labelled anti-HA antibodies. As a controls tr-FRET was performed on COS-7 cells co-
expressing the FLAG-H4R and triple HA-tagged S1P1R or HA-H4(390)R. Data are normalized for the tr-
FRET signal obtained from a mixture of COS-7 cells that individually expressing the indicated 
constructs. Data shown are average of at least three experiments each performed in triplicate. 
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The resultant data were normalized against tr-FRET signals obtained from COS-7 
cells individually expressing the FLAG-tagged H4R splice variants and the HA-
H4R(390)s that were mixed and exposed to the two antibodies.  Upon co-expression 
of the HA-H4R(390) in a 0.2:1 cDNA ratio with the FLAG-H4R(302) or the FLAG-H4R(67) 
isoforms a significant tr-FRET signal could be observed compared to the tr-FRET 
signal obtained from a mixture of cells individually expressing the two receptors 
(Figure 4.7).  
Increasing the amount of HA-H4R(390) co-transfected with the H4R splice variant 5-
fold to a 1:1 cDNA ratio, resulted in an further increase in tr-FRET signal especially 
for the H4R(390)-H4R(67) hetero-oligomer (Figure 4.7). As a control, we used COS-7 
cells co-expressing the FLAG-H4R(390) and triple HA-tagged sphingosine-1-
phosphate (EDG1) receptor (3xHA-S1P1R). Although the S1P1R and the H4R(390) 
are co-localized in a variety of cell types 235 and the S1P1R is known to form homo- 
and hetero-oligomers 236, no hetero-oligomerization occurred between these two 
receptors in COS-7 cells (Figure 4.7). 
 
Additional support for hetero-oligomerization between H4R(390) and the two H4R 
splice variants arose from co-immunoprecipitation studies. HEK 293 cells co-
expressing either the H4R(390) with FLAG-H4R(390), FLAG-H4R(302) or FLAG-H4R(67) 
were solubilized and immunoprecipitated with anti-FLAG Sepharose beads and 
subsequently immunoblotted using the anti-H4R antibody. In all three cases the 
anti-H4R antibody was able to detect the H4R(390) (Figure 4.8, lane 2, 4 and 6). As 
the anti-H4R antibody recognizes the C-terminal tail of the H4R(390) the antibody can 
still react with the H4R(302) but not with the H4R(67). Western blot analysis on 
immunoprecipitated FLAG-H4R(302) clearly shows the presence of the full length 
H4R(390) as well as the shorter H4R(302). Additionally, a broad high molecular weight 
species can be distinguished, most likely consisting of homo-dimeric H4R(390) and 
FLAG-H4R(302) and hetero-dimeric H4R(390)-FLAG-H4R(302) (Figure 4.8, lane 4). 
Interestingly, no monomeric H4R(390) was detected in the immunoprecipitated 
FLAG-H4R(67) sample (Figure 4.8, lane 6). As control, transfected HEK 293 cells 
were immunoprecipitated with Sepharose beads. In these samples no detectable 
H4R was precipitated (Figure 4.8, lanes 1, 3 and 5).   
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Figure 4.8. Immunoprecipitation evidence for H4R(390) interaction with hH4R isoforms, H4R(302) and 
H4R(67). HEK 293 cells were co-transfected with equal amounts of H4R(390) and either FLAG-H4R(390), 
FLAG-H4R(302)or FLAG-H4R(67). Cells were harvested 40h post transfection, solubilised with 1% Triton-
X100 and subjected to immunoprecipitation with anti-FLAG sepharose or sepharose control beads for 
2h at 4ºC. Following washing, bound material was collected using SDS-PAGE sample buffer and 
analyzed by immunoblotting. Immunoblots were probed with anti-H4R antibody. Lane 1, 3 and 5 are 
control precipitations with sepharose beads; Lane 2, 4, and 6 are precipitations with anti-FLAG 
sepharose. Protein species identified were consistent with the dimeric and monomeric H4R(390) or 
H4R(302) species, respectively. The H4R(67) was not detected by this antibody. 
 
DISCUSSION 
The hH4R, the latest member of the histamine receptor family 148-153, is expressed 
abundantly on hematopoietic cells 148,150-152 and its role in eosinophil and mast cell 
functions 164,165,167 points to a potential role in various allergic and inflammatory 
conditions 164,184,194. Within the histamine receptor family the H4R shares highest 
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homology with the H3R, up to 58% within the transmembrane (TM) domains. 
Moreover, the organization of the gene encoding the H4R closely resembles that of 
the H3R gene, as both genes consist of three exons and two introns 125,151. In 
recent years, a large number of alternatively spliced isoforms have been 
discovered for the H3R 124,127. In our attempts to determine if alternative splice 
variants also exist for the H4R, we describe here for the first time two isoforms of 
the human H4R, which we cloned from cDNA from human CD34+ cord blood cells 
derived eosinophils and mast cells. The first splice variant, lacks part of TMII, TMIII 
and TMIV (H4R(302)), while the second splice variant is a heavily truncated H4R and 
contains only TMI and the first half of TMII (H4R(67)).  
Quantitative PCR showed that in different cell types mRNA encoding the H4R(390) 
the H4R splice variants are differentially expressed. The H4R splice variant mRNA 
was most abundant in eosinophils, which is in agreement with the fact that both 
isoforms were cloned from eosinophils. Interestingly, in pre-monocytes the 
expression of H4R(67) mRNA resembles that of the H4R(390). The lower abundance 
for mRNA of H4R splice variants in other cell types, could be due to reduced mRNA 
stability compared to the mRNA of the full-length receptor and appears to be 
common for other GPCR splice variants as well 237,238. Yet, it is possible that in 
different cells or under different (patho) physiological conditions the H4R splice 
variants are expressed more abundantly, resulting in the dominant negative effect 
seen in our recombinant cell systems. Evidence supporting this possibility has 
been reported recently for the H3R isoforms in the rat brain 204. Future studies 
should address these important questions. 
In March 2003 Merck registered a patent (WO 03/020907 A2) in which they 
describe the discovery of two splice variants of the hH4R, H4bR and H4cR, cloned 
from human spleen cDNA. While the alternative splicing of the H4R that leads to 
the formation of the H4bR and the H4R(67) is identical, the H4cR appears to result 
from alternatively splicing event after exon 2. The H4cR is the result of the 
recognition of an alternative acceptor site in exon 3, resulting in a 33 amino acid 
deletion near TMIV. Interestingly, the reported sequences of both the H4bR and 
H4cR contain additional amino acids, which we have not observed in the identified 
H4R(67) or H4R(302)  and can also not be explained based on the H4R genomic 
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sequence. According to the patent (WO 03/020907 A2), the H4bR and H4cR are 
able to bind [3H]histamine and to signal via several functional pathways, such as 
Ca2+-mobilization, inhibition of cAMP production and the activation of mitogen 
activated protein kinase (MAPK). In our search for H4R isoforms we did not detect 
the H4bR and H4cR in immature dendritic cells (DC), differentially activated DCs 
(LPS or TNFα/ILβ1), mast cells, eosinophils or basophils. Using PCR, we 
constructed both the putative H4bR and H4cR isoforms, but in contrast to the 
findings of Merck, we were not able to detect any specific [3H]histamine binding 
using these splice variants (data not shown).  
Both the H4R (302) and H4R (67) lack TMIII, which harbors the key aspartate residue, 
D94 (3.32), presumed to be crucial for histamine binding, as well as for the high 
affinity binding of other known orthosteric H4R ligands 34. As expected the two 
novel H4R splice variants were unable to bind the agonist radioligand [3H]histamine 
or the non-imidazole antagonist radioligand [3H]JNJ 7777120 172. Although the two 
isoforms apparently are unable to bind ligands with high affinity, it was still possible 
that the two receptor isoform could signal constitutively or at high histamine 
concentrations. Previous studies have shown that the H4R(390) is constitutively 
active and can be further activated by H4R agonists 115,148. However, whereas PTX 
treatment or the inverse agonist thioperamide inhibit the constitutive activity of the 
H4R(390), no effect of thioperamide or PTX treatment was observed for both new 
H4R isoforms. Moreover, also high concentrations of histamine were unable to 
modulate H4R signal transduction in cells expressing either one of the two H4R 
isoforms. These data indicate that neither the H4R(302) nor H4R(67) alone are able to 
(constitutively) activate the Gi/o-coupled signaling pathway by themselves.  
Since both the H4R(302) and H4R(67) isoforms are unable to signal and are expressed 
predominantly intracellular as determined by ELISA and Western blot experiments, 
we decided to explore the effects of these splice variants upon co-expression with 
the H4R(390). Dominant negative splice variants of GPCRs, influencing the 
functionality (e.g. signaling or trafficking) of the full-length receptor have been 
shown for a variety of GPCRs such as the histamine rH3R 204, the dopamine D3R 
230, the gonadotropin-releasing hormone receptor GnRH 239 and the growth 
hormone receptor GHR 240. In all these cases, the reported dominant negative 
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effect of the receptor isoforms was presumably due to hetero-oligomerization 
between the full-length receptor and the receptor isoform. Upon co-expression of 
the H4R(390) with the H4R(302) or the H4R(67) isoforms a clear decrease in Bmax for 
[3H]histamine was observed. However, the ligand binding properties of the 
remaining [3H]histamine binding sites were unaffected as the KD value for 
[3H]histamine as well as Ki values of other H4R ligands did not change when the 
H4R(390) is co-expressed with either of the H4R splice variants. As expected, the 
reduction in H4R expression induced by the H4R splice variants was paralleled by a 
decrease in the potency of histamine in the CRE-driven luciferase reporter gene 
assay. The apparent reduction in Bmax could be explained by reduced cell-surface 
expression of H4R(390). We have recently shown that three non-functional rH3R 
splice variants have a dominant negative effect on the cell-surface expression of 
full-length H3Rs, presumably by rH3 isoform hetero-dimerization 204. We have 
previously shown by various methods that also the H4R(390) can readily form homo-
oligomers 234. In the present study time-resolved FRET as well as co-
immunoprecipitation experiments revealed that the H4R(390) can also form cell-
surface hetero-oligomers with both the H4R(302) or the H4R(67) isoforms. Similar to 
the our previous reported on H4R homo-dimers, we find that the homo-dimers and 
hetero-dimers are (partially) insensitive to SDS and DTT, suggesting that these 
dimers may interact via strong hydrophobic interactions, as has been reported for 
e.g. the H3R receptor 204 and the µ-opioid receptor-α2A-adrenergic receptor hetero-
oligomer 241.  Co-expression of the H4R splice variants resulted in a clear reduction 
in the surface expression of the H4R(390) as determined in a surface labeling assay. 
The reduction in H4R binding and surface expression is not merely caused by 
saturation of the expression system, as both co-transfection of H1R and GFP did 
not have any negative influence on the expression of H4R. These findings 
resemble our previous findings with the rH3DEF isoforms, which trap all full-length 
rH3R intracellularly 204. However, the herein described H4R splice variants resemble 
more the D3nfR than the rH3R isoforms, which seem to be expressed exclusively 
intracellularly 204. As with H4R isoforms, the D3nfR is non-functional, expressed at 
the cell surface to some extent and reduces the binding of radioligand to the D3R 
through hetero-oligomerization 230.  
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Hetero-oligomerization between the H4R(390) and the H4R(67) appears to have a less 
pronounced effect on the cell surface location of the H4R(390) compared to the 
H4R(302) (reduction in Bmax 70% vs. 45% at similar cDNA ratios). However, tr-FRET 
assays show that the H4R(67) may form hetero-oligomers with the H4R(390) more 
readily. Moreover, co-immunoprecipitation data of the H4R(67) with the H4R(390) 
indicate the assembly of predominantly high molecular weight species. One might 
speculate that the small H4R(67) is able to form higher oligomeric complexes 
(trimers, tetramers) more readily than the larger  H4R(302) isoform with H4R(390), but 
has less cytoplasmic (ER) retention properties. More detailed studies (e.g. 
employing triple BRET/FRET assays using bimolecular fluorescence 
complementation 242 are required to further investigate this hypothesis. 
The observed hetero-oligomerization between the H4R(390) and either of the two 
H4R splice variants also offers insight into the domains involved in H4R 
oligomerization. In general, family A GPCRs are thought to oligomerize by 
interaction of TM domains, either via the formation of contact-dimers or by domain-
swapping 199,243. When focusing on aminergic receptors, several TM domains have 
been reported to be involved in the mechanism of oligomerization. For e.g. the 
dopamine D2 receptor, the involvement of TMIV in the oligomer interface has been 
clearly demonstrated 244. However, our data from the heavily truncated H4R(67) 
reveals that for the H4R TM IV is not crucial for the formation of H4R dimers, 
whereas TMI-II must be involved. This is similar to the α1B-adrenergic receptor for 
which TMI is important for homo-oligomerization 218,245. Since TMII of H4R(67) is 
partly truncated and has so far not been directly correlated with involvement in 
GPCR oligomerization, we propose TMI as an important domain involved in H4R 
oligomerization 
In summary, we have cloned and characterized two new splice variants of the 
human H4R from CD34+ cord blood derived eosinophils. Although both H4R splice 
variants are non-functional and mainly localized intracellularly, they can hetero-
oligomerize with the H4R(390), thereby reducing the ability of the H4R(390) to reach 
the cell surface and functionally bind histamine. As mRNA of these splice variants 
is differentially expressed in different cell types, we propose that under certain 
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conditions, these newly discovered H4R splice variants may have a role in the 
regulation of H4R(390) function. 
 
MATERIALS AND METHODS 
Materials. Reagents for tr-FRET were from Cis Bio International (Bagnols-sur-Cèze Cedex, France). 
Chloroquine diphosphate, DEAE-dextran (chloride form), histamine(2-[4-imidazolyl]ethylamine 
hydrochloride), 3,3’,5,5’tetramethyl benzidine (TMB) monoclonal mouse M2 anti-FLAG (DYKDDDDK), 
N,N-dimethylformamide, pertussis toxin, clozapine and polyethyleneimine was purchased from Sigma 
(St.Louis, MO). High affinity rat anti-HA (YPYDVPDYA) was from Roche Applied Science (Basel, 
Switzerland). Goat anti-mouse IgG (H+L) HRP was obtained from Bio-Rad (Hercules, USA), polyclonal 
rabbit anti-Rat IgG HRP was from Dakocytomation (Glostrup, Denmark). Calf serum was purchased 
from Integro BV (Dieren, The Netherlands). Polyethyleneimine (linear, MW~25.000) was from 
Polysciences Inc (Warrington, PA, USA). D-luciferin was from Duchefa (Haarlem, The Netherlands). 
Cell culture media, penicillin, streptomycin and TRIzol were obtained from Invitrogen (Breda, The 
Netherlands). Cell culture plastics were from Greiner Bio-one (Wemmel, Belgium). Tris was from 
AppliChem (Darmstadt, Germany). [3H]histamine (18.10 Ci/mmol) were purchased from Perkin-Elmer 
Life Science, Inc. (Boston, MA). Oligonucleotides were purchased from Isogen Bioscience (Maarsen, 
The Netherlands). PfuTurbo® DNA polymerase was purchased from Stratagene (La Jolla, USA). 
Restriction enzymes were from MBI Fermentas (St. Leon-Rot, Germany). The human H4R(390) cDNA in 
pcDNA3.1 was purchased from the Guthrie cDNA resource center (Sayre,PA). The hH4R was 
subcloned into the pcDEF3 using BamHI/XbaI sites. Thioperamide fumarate, clobenpropit 
dihydrochloride, 4-methylhistamine and JNJ 7777120, were synthesized at the Department of Medicinal 
Chemistry, Vrije Universiteit Amsterdam, Amsterdam. Gifts of expression vector pcDEF3 (Dr. J Langer) 
and [3H]JNJ 7777120 (Dr. R. Thurmond) are greatly acknowledged.  
 
Cloning and sequence analysis of the hH4(302)  and H4(67) splice variants cDNAs. 
In order to identify and isolate H4R splice variants, CD34+ cells were isolated from cord blood 
mononuclear cells and were cultured in 100 ng/ml stem cell factor (SCF) and 80 ng/ml interleukin 6 (IL6) 
for 8-10 weeks, in 5 ng/ml IL3 and 1 ng/ml transforming growth factor-β for 3-4 weeks or in 2 ng/ml IL3 
and 5 ng/ml IL5 for 4-5 weeks, to differentiate the CD34+ cells to mast cells, basophils or eosinophils, 
respectively 246-248.  Peripheral blood mononuclear cells were cultured in 100 ng/ml granulocyte-
macrophage colony-stimulating factor (GM-CSF) and 10 ng/ml IL4 to create immature dendritic cells, 
which were subsequently activated with either lipopolysaccharide (LPS) or a combination of tumor 
necrosis factor α and IL1β 150,249. Total RNA was isolated using the nucleo spin RNA II purification kit 
(Clontech Laboratories, Palo Alto, USA) and cDNA was obtained by random primed cDNA synthesis. A 
set of (nested) sense and anti-sense oligonucleotide primers, spanning the intron/exon junctions of the 
H4R gene sequence, were used in order to identify potential H4R splice variants. Use of the following 
sense primers 5’-TGTGATGCCAGATACTAATA-3’, 5’- ATGC CAGATACTAATAGCAC-3’, 5’-
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TCTTTGTGGGTGTGATCTCC-3’ and anti-sense primers 5’-TGTGATGGCAAGGATGTACC-3’, 5’-
TTAAGAAGATACTGACCGAC-3’, 5’-TCTTTAAGAAGATACTGACC-3’ resulted in the amplification of at 
least two different products. The generated PCR fragments were cloned in pCRII-TOPO (Invitrogen) 
and the cDNAs were sequenced on both DNA strands. The sequence of the identified hH4R(302) and 
hH4R(67)  have been deposited in the GenBank® database (accession number DQ835186 and 
DQ835187, respectively).The cloned cDNAs were transferred to a mammalian expression vector 
(pcDEF3), either untagged or tagged N-terminally with a FLAG-epitope (DYKDDDDK).  
 
Cell culture and transfection. COS-7 and HEK 293T cells were maintained at 37ºC humidified in 5% 
CO2/95% air atmosphere in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% (v/v) 
fetal calf serum, 50 IU/ml of penicillin and 50 μg/ml streptomycin and grown in 100 mm dishes. COS-7 
Cells were transiently transfected using the DEAE-dextran method as previously described 85. HEK 
293T cells were transfected using the polyethyleneimine (PEI) transfection method adapted from 
Durocher et al 250. Briefly, 5 μg DNA was diluted in 500 μl 0.9% NaCl, and 10 μl of a 1 mg/ml PEI (linear 
MW~25.000) was added. Following ten minutes of incubation the mixture was added to the HEK 293T 
cells. 24 hours after transfection, cells were transferred into 96 well plates. In all experiments the total 
amount of DNA transfected was maintained constant by addition of the empty expression vector 
pcDEF3. 
 
Culture and differentiation of HL-60 cells. HL-60 suspension cells were maintained at 37ºC 
humidified in 5% CO2/95% air atmosphere in RPMI 1640 + L-Glutamine supplemented with 10% (v/v) 
fetal bovine serum and antibiotics. Cells were differentiated to granulocytes and eosinophils. HL60 cells 
were incubated for 5 days with 0.65% (v/v) N, N-dimethylformamide to differentiate the cells to 
granulocytes. Eosinophilic differentiation was performed by culturing HL-60 cells in the presence of 0.5 
mM butyric acid for 48h. IL-5 was added to a concentration of 10 ng/ml, and the cells were further 
cultured for 72h 148. Total RNA was isolated using TRIzol according to manufacturer’s protocol. cDNA 
was synthesized using Iscript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The cDNA was 
subsequently used in Q-PCR 
 
Radioligand binding studies. Cells used for radioligand binding studies were harvested 48h post 
transfection and homogenized in ice cold hH4R binding buffer (50 mM Tris, pH 7.4). For saturation 
isotherms cell membrane homogenates were incubated at 37ºC for 60 minutes with 0-150 nM 
[3H]histamine or 0-30 nM [3H]JNJ 7777120 172 in a total assay volume of 200 μl. For competition binding 
assays the cell homogenates were incubated at 37ºC for 60 minutes with 0.1-10.000 nM ligand in the 
presence of ~15 nM [3H]histamine in a total volume of 200 μl. The incubations were stopped by rapid 
dilution with ice cold hH4R binding buffer. The bound radioactivity was separated by filtration through 
GF/C filterplates (Perkin Elmer) that had been treated with 0.3% PEI. Filters were washed four times 
with ice cold hH4R binding buffer and radioactivity retained on the filters was measured by liquid 
scintillation counting. 
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CRE-luciferase reporter gene assay. HEK 293T cells transiently co-transfected with 2.5 μg pTNLC-
121 and 5 μg pcDEF3-H4R,  pcDEF3-H4R(302), pcDEF3-H4R(67) were seeded in 96-well white-plates  in 
culture medium and after 42h incubated with histamine or thioperamide and 0.5 μM forskolin for 6h. 
After 48h, cells were assayed for luminescence by aspiration of the medium and the addition of 25 
μl/well luciferase assay reagent [0.83 mM ATP, 0.83 mM D-luciferin, 18.7 mM MgCl2, 0.78 μM 
Na2H2P2O7, 38.9 mM Tris, pH 7.8, 0.39% (v/v) glycerol, 0.03% (v/v) Triton X-100, and 2.6 μM 
dithiothreitol]. After 30 min, luminescence was measured for 3 s/well in a Victor2 1420 Multilabel Counter 
(PerkinElmer, Boston, USA). 
 
Enzyme linked immunosorbent assay (ELISA). 48h after transfection, receptor expression in COS-7 
cells was measured using an ELISA assay as previously described 251. To detect HA (hemagglutinin)-
epitope tagged receptors a rat anti-HA antibody was used as primary antibody, and a rabbit anti-rat–
horseradish peroxidase conjugate as secondary antibody. To detect FLAG-epitope tagged receptors a 
mouse anti-FLAG antibody was used as primary antibody and a goat anti-mouse–horseradish 
peroxidase conjugate as secondary antibody. The 3’, 3’, 5, 5’-tetramethylbenzidine liquid substrate 
system for ELISA was used as substrate and the optical density was measured at 450 nm using a 
Victor2 1420 Multilabel Counter. 
 
Quantitative PCR. The integrity and quality of isolated total RNA was determined by agarose 
gelelectrophoresis and concentration was determined spectrophotometerically. Next, 1μg of total RNA 
was DNase treated at 37ºC for 15 min (RQ1 DNase, Promega), and the reaction terminated at 60ºC for 
10 min. The treated RNA was directly subjected to 1st strand cDNA synthesis (Iscript, Bio-Rad) in 20 μl. 
The synthesized cDNA was diluted to 500 μl with distilled water and then used for Q-PCR (MyIQ, Bio-
Rad) in a 20 μl reaction (2x SYBR buffer 10 μl, 25 pM primers, and cDNA 5.0 μl). The reaction was 
stopped after the 40th PCR cycle was completed.  
Primers of H4R(390) and two splice variants H4R(302) and H4R(67) were designed using Beacon designer 
software (Bio-Rad). A sense primer was designed that recognizes both H4R(390) and the H4R splice 
variants 5’-TGCTAGGAAATGCTTTGGTC-3’. Isoform specificity was obtained by designing anti-sense 
primers that are only able to bind to the cDNA of either the H4R(390) 5’-GCGTGTGAGGGATGTACAAA-
3’, the H4R(302) 5’-TCCAAGACTCTGAAACCACAAA-3’ or the H4R(67) 5’-TCCAAGACTCTGAAACC 
ACAAA-3’. Specificity of primers was evaluated by checking dissociation curve and amplification slope. 
For data analysis, the nuclear ribosome protein 11 (rps11, NM001015) was used as reference to H4R 
expression. Expression level was analyzed based on 2-∆∆Ct value method 252.  
 
tr-FRET assay. tr-FRET assays were performed using a combination of both Eu3+-labeled and 
allophyocyanin-labeled anti-FLAG and anti-HA antibodies as described previously 234. Briefly, tr-FRET 
was assessed in 5 x 105 intact COS-7 cells, transiently expressing the appropriate HA and FLAG tagged 
receptors. Cells were incubated in PBS containing 50% FCS (v/v), 0.8 nM of Eu3+-labelled antibody, and 
8 nM of allophycocyanin-labelled antibody for two hours at room temperature, After two wash steps the 
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cells were resuspended in 50 μl PBS and transferred to a 384-microtiter plate. Energy transfer was 
measured by exciting the Eu3+ at 320 nm and monitoring the allophycocyanin emission for 500 μs at 665 
nm using a Novostar (BMG Labtechnologies, Offenberg, Germany) configured for tr-fluorescence after a 
100 μs delay. 
 
Immunoprecipitation of H4R isoforms. HEK 293 cells were transfected with H4R(390) with or without 
FLAG-H4R(302) or FLAG-H4R(67). Cell samples were solubilised with 1% Triton-X100 in 50 mM Tris-HCL 
pH 7.4 and incubated with 50 μl 50% (w/v) slurry of anti-FLAG Sepharose beads (Sigma, UK) for 2 hrs 
at 4ºC. Following incubation, beads were centrifuged at 9000rpm at 4ºC for  5 min. The supernatant was 
retained (unbound fraction) and the beads washed in 50 mM Tris-HCL pH7.4/Triton X100 and bound 
fraction isolated by elution in SDS PAGE Sample buffer/50mM DTT at  50ºC for 30 min. Supernatant 
following centrifugation at 9000 rpm was retained (bound fraction) for analysis.  
 
Surface biotinylation assay. HEK 293 cells were transfected with with clones encoding individual H4R 
isoforms or co-transfected with H4R(390) with variable amounts of green fluorecent protein (GFP, control), 
H4R(302) or H4R(67) isoforms (1:1 or 1:5). The medium was carefully removed 24-40 hours post 
transfection and cells were washed with ice-cold PBS/4 % (w/v) sucrose (3x1 ml per 35mm dish).  The 
cells were then incubated for 15 min at 4ºC with 1mg/ml Sulfo-NHS-SS-Biotin in ice-cold PBS/4 % (w/v) 
sucrose (0.5 ml/dish) with gentle shaking. Subsequently, cells were washed once with ice- cold PBS/4 
% (w/v) sucrose (1ml/dish), and incubated for 10 min at 4ºC with quenching buffer (192mM glycine, 4%  
(w/v) sucrose in 50mM Tris-HCl pH  
8.0 ) (0.5 ml/dish). Cells were scraped into PBS//4 % (w/v) sucrose and spun at 6000 rpm for 2 min. 
This wash procedure was repeated on a further occasion and the cells were homogenised in 1% (w/v) 
SDS in lysis buffer (50mM Tris-HCl, pH 8.0/ 2 mM EDTA/1% Triton-X100 The samples were then 
diluted five-fold in lysis buffer (without SDS), and incubated with 20 μl 50% (w/v) slurry of streptavidin 
beads for 2 hrs at 4ºC. Following incubation, beads were centrifuged at 9000rpm at 4ºC for  5 min. The 
supernatant (intracellular fraction) was retained and the beads washed in lysis buffer. The bound 
fraction was isolated by elution in SDS PAGE Sample buffer/50mM DTT at  50ºC for 30 min. 
Supernatants following centrifugation at 9000 rpm were retained (surface fraction) for analysis. 
 
Immunoblotting. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was carried 
out using 6 % or 7.5 % polyacrylamide slab gels under reducing conditions. Samples of HEK 293 cells 
(20-50 µg protein) were prepared using a chloroform/methanol method of protein precipitation, and 
immunoblotting was performed as previously described 203,204,234. Immunoblots were probed with anti-H4R 
374-390 antibody 234 at a concentration of 0.5 µg /ml. Blots containing FLAG- or HA-tagged receptors 
were probed with primary antibodies, mouse anti-FLAG (1.5 μg/ml) or rat anti-HA (1 μg/ml), respectively. 
Horseradish peroxidase conjugated goat anti-mouse or anti-rat antibodies (1:2000-5000) were used as 
secondary antibodies (Little Chalfont, Buckinghamshire, England). 
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Analytical methods. All radioligand binding data were evaluated by a non-linear least squares curve 
fitting program using Graphpad Prism® (Graphpad Software Inc, San Diego, CA). Protein concentrations 
were determined according to Bradford, using BSA as standard. All data are represented as mean ± 
S.E.M. from at least three independent experiments in triplicate. Statistical significance was determined 
by an ANOVA-tukey test (p<0.05 was considered statistically significant).  
Oligomerization of aminergic GPCRs 
 
 119
CHAPTER 5 
 
 
 
Mechanisms of aminergic receptor 
oligomerization – the 8 W’s: What, When, Where, 
Which, With Whom, hoW, and Why 
Van Rijn RM, Bakker RA, Leurs R 
Leiden/Amsterdam Center for Drug Research, Department of Medicinal Chemistry, 
Vrije Universiteit Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The 
Netherlands 
 
 
 
 
 
 
Chapter 5 
 
 120
ABSTRACT 
 
The oligomeric potential of G protein coupled receptors (GPCRs) has become 
generally accepted over the last years. Whereas for class C GPCRs, 
oligomerization has been shown to be pivotal for receptor function, receptor 
oligomerization of GPCRs belonging to other classes has thus far not been shown 
to be essential for receptor function. Whereas atomic force microscopy of native 
rhodopsin showed them to be arranged in rows of dimers it is still unclear if all 
GPCRs oligomerize in a similar fashion; whether the interaction points are the 
same, and what the fate is of oligomers upon ligand stimulation, desensitization or 
receptor internalization. While focusing primarily on GPCRs belonging to the class 
A subfamily of aminergic receptors, we provide a detailed summary of recently 
published data on GPCR oligomerization in order to answer some of the questions 
of when, where, how and why these receptors oligomerize. Finally, we try to 
identify gaps in current knowledge with suggestions for future investigations 
regarding oligomerization of aminergic receptors or GPCRs in general. 
 
What is receptor oligomerization? 
 
Originally G-protein-coupled receptors (GPCRs) were considered to function as 
monomers i.e. 7 trans-membrane proteins comprised of a single peptide chain. 
However, compelling evidence in recent years has shifted this believe to the 
current hypothesis where two or more GPCRs may associate to form oligomeric 
polypeptides. This shift began a couple of decades ago with observations of 
complex binding kinetics 253,254 and of higher molecular weight bands in both 
Western blots and photo-affinity labeling experiments, which provided indications 
for the existence of GPCR oligomers 255-257. More recent studies using biophysical 
approaches in living cells have generated more compelling evidence to support this 
new hypothesis.  
 
In fact, oligomerization of proteins is a very common phenomenon 258,259 and has 
been shown to occur between receptors within each of the three major classes of 
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mammalian GPCRs; class A (rhodopsin, olfactory, opioid, chemokine), class B 
(calcitonin, secretin, vasoactive intestinal peptide) and class C (GABA, 
metabotropic, calcium sensing, taste) 260. While for the class C family of GPCRs a 
certain consensus for oligomerization has been observed e.g. a carboxyl terminal 
coiled coil interaction 261 and disulfide bridges of the “venus flytrap” binding 
domains 262,263, oligomerization of members of class A family of GPCRs seem to 
follow less specific rules. A subfamily of the class A GPCRs are the aminergic 
receptors. Besides sharing the hallmarks of class A GPCRs e.g. aspartate residues 
within transmembrane (TM) domain  II and TM III, tryptophanes in TM IV and TM 
VI, a NPXXY motif in TM VII 35, a feature of aminergic receptors is that the ligand 
binding domain is localized within the TM domain 7. The focus of this review is to 
provide a detailed summary of research regarding oligomerization of GPCRs 
belonging to the subfamily of aminergic receptors with an emphasis on when, 
where and how these receptors form oligomers. Moreover, the partner specificity 
for hetero-oligomerization and the functional role of these oligomers will be 
discussed, as well as future prospects in the study of GPCR oligomerization. 
 
Methods for studying GPCR oligomerization. 
 
A diverse array of techniques has been employed to study GPCR oligomerization. 
Early indications for GPCR oligomerization came from Western blot and photo-
affinity labeling studies in which the presence of high molecular bands were 
detected in addition to bands corresponding to the expected weight of monomeric 
receptors 253,264. Maggio and co-workers pioneered the study of receptor oligomers 
utilizing an approach based on chimeric receptors 265,266. Co-immunoprecipitation 
emerged in the late 90’s as a valuable technique to study GPCR oligomerization 
267. Performing affinity chromatography prior to co-immunoprecipitation, allows the 
study of the interaction between three differentially tagged receptors 268. Although 
not commonly employed, the yeast two hybrid system can be a useful tool in 
studying the putative oligomer interface and discovering novel oligomeric partners 
269,270. 
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With the arrival of biophysical techniques such as fluorescence resonance energy 
transfer (FRET) and bioluminescence resonance energy transfer (BRET) a vast 
amount of evidence supporting GPCR oligomerization has been produced. In brief, 
both assays are based on the principle that resonance energy originating from a 
donor can excite a fluorescent acceptor if in close enough proximity, usual within 
100Ǻ. The difference between FRET and BRET lies with the donor used. While 
FRET employs a fluorescent probe, BRET donor energy is emitted by enzymatic 
conversion of a substrate (usually coelenterazine) into light/energy (for reviews on 
the advantages and disadvantages of BRET and FRET see 211,213,271). Frequently, 
different types of green fluorescent protein (GFP) are used e.g. for FRET CFP 
(cyan) and YFP (yellow), or for BRET renilla luciferase (Rluc) and YFP. However, 
also fluorescently labeled ligands can function as energy donor 272. Aminergic 
receptors predominantly bind small, non peptidergic ligands, which are more 
difficult to be conjugated with bulky fluorescent groups without affecting the ligands 
affinity and specificity too much. However, several fluorescent ligands have been 
developed 273,274, which would facilitate the use of such a FRET based assay for 
studying oligomerization of aminergic GPCRs.  
 
Over the years several adaptations to these RET assays have emerged (Figure 
5.1). The introduction of BRET2 provides improved signal resolution over BRET 275, 
whereas the introduction time-resolved FRET (tr-FRET) 276 facilitated the study of 
oligomers at the cell surface. An additional advantage of tr-FRET is that it only 
requires recombination of small N-terminal epitope tags plus the use of 
differentially labeled antibodies. The receptor is not required to be fused with large 
fluorescent proteins, which have a larger potential of changing receptor 
pharmacology compared to the epitope tags. Another adaptation to FRET is known 
as photobleaching FRET (pbFRET) or fluorescence recovery after photobleaching 
(FRAP). This technique allows for the study of lateral movement of receptors and 
receptor dimers on the cell surface by photobleaching a specific area of the cell 
surface and measure recovery of the fluorescent signal 277. Very recently, a new 
derivation of BRET, extended BRET (eBRET), has been described, which  makes 
use of a new derivative of the coelenterazine substrate named EnduRen™ 278. 
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Unlike coelenterazine or DeepBlueC™ (BRET2 substrate) this substrate is stable at 
37°C for prolonged periods of time, allowing for extended real-time BRET 
experiments 278. This method can potentially be used to follow a receptor homo-
dimer or hetero-dimer in time. A technique that can be very useful in the study of 
oligomerization between more than two different proteins is bimolecular 
fluorescence complementation 279, a technique that combines BRET with PCA 
(protein fragment complementation assay) 280. In this case YFP is split into two 
domains which can be linked to two different partners. Only if these two partners 
form hetero-oligomers a functional YFP is created that can function as acceptor in 
the BRET assay. In principal, the Renilla luciferase (Rluc) can also be split into two 
domains allowing for the study of four interacting partners 280. Another technique to 
measure interactions between multiple proteins is the three-fluorophore FRET. For 
this technique receptors are labeled with one of three different fluorophores. In a 
recent study the oligomerization state of the α1B-AR was investigated by fusing the 
receptors with eCFP, eYFP or dsRed 281. Resonance energy of eCFP is unable to 
directly excite dsRed, but eCFP can indirectly excite dsRed via excitation of eYFP, 
which resonance energy is capable of directly exciting dsRed 281. 
 
The use of atomic force microscopy was successfully employed to reveal 
rhodopsin formed rows of dimers 208, but so far no other GPCR dimers have been 
studied using this technique. In 2005, Hoffmann and co-workers described a 
FLAsH based FRET assay, in which they employed a small, membrane-permeant 
fluorescein derivative with two arsen-(III) substituents (Fluorescein arsenical hairpin 
binder; FLAsH). When bound to a specific tetracysteine region (CCXXCC) of a 
GPCR, the FLAsH molecule could then function as an acceptor, whereas a GPCR 
fused to cyan fluorescent protein (CFP) functioned as a donor 282. The described 
FLAsH based FRET was employed to study intramolecular changes during 
receptor activation 282. However, the introduction of additional fluorescent groups; 
CHoXAsH and ReAsH 283, may facilitate the study of GPCR oligomerization using a 
FRET assay that requires neither large fluorescent proteins nor large conjugated 
antibodies. Moreover, the FLAsH based FRET approach may be combined with the 
use of fluorescent ligands.  
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Figure 5.1.  Overview of several biophysical techniques that are used to study GPCR oligomerization. 
From left to right the depicted techniques are bioluminescence resonance energy transfer (BRET), time-
resolved fluorescence resonance energy transfer (tr-FRET), (three-fluorophore) FRET and bimolecular 
fluorescence complementation (BiFC). In all cases light from the donor can only excite the acceptor if 
the two are in close proximity (generally >100Å) of eachother. In BRET the donor light is produced by 
enzymatic oxidation of coelenterazine, while for tr-FRET and FRET the donor has to be excited by an 
external light source. Abbreviations: Rluc, Renilla luciferase; YFP, yellow fluorescent protein ; Eu3+, 
europium ; APC, allophycocyanin ; CFP, cyan fluorescent protein.  
 
 
When and Where are oligomers formed? 
 
It has been firmly established for the class C metabotropic GABAB receptors 41-44,284 
as well as for the class B calcitonin receptors 233 oligomerization already occurs 
within the endoplasmatic reticulum (ER), prior to transport of the receptors to the 
cell membrane.  In class A, a naturally occurring mutant of the CCR5 chemokine 
receptor is able to retain the wild-type CCR5 receptor intracellularly 269. Such 
dominant negative effects have been reported for other mutants of other receptor 
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and for receptor isoforms of aminergic GPCRs as well 204,285,286. In contrast, 
expression of receptors that by themselves are retained intracellularly can be 
chaperoned to the cell surface via oligomerization. 217,287. Hence, it appears class A 
hetero-oligomers are formed before or during translocation from ER/golgi to the 
plasma membrane. Indeed, measuring BRET or FRET signals in cell fractions 
collected from sucrose gradient, used to separate cell surface proteins from 
intracellular material, homo-oligomers could already be detected in light weight 
fractions (corresponding to ER/Golgi compartments) for the β2-AR 285, α1A-AR 218,288 
as well as hetero-oligomers between the D1R and D2R 289. Real-time FRET and 
pbFRET studies on the biogenesis of 5-HT2C-oligomerization convincingly revealed 
the presence of oligomers in the ER, and tracked them during transport to the Golgi 
and the plasma membrane 290. 
 
Which receptors oligomerize and With Whom? 
 
Only a fraction of the total population of GPCRs has been studied in regard to 
oligomerization 207. So far, with the single exception of the N-formyl peptide 
receptor 291, all GPCRs, including the majority of aminergic receptors that have 
been studied were able to form homo-oligomers (Table 5.1). However, aminergic 
GPCRs appear to be more selective with respect to hetero-oligomerization. Often 
receptors sharing high homology, are able to hetero-oligomerize e.g β2-AR-β3-AR 
62, α1B-AR-α1D-AR 217 5-HT1B-5HT1D 292. This is no rule of thumb; e.g. no interaction 
between α1D-AR and α1A-AR was detected 217,293. Probably, if two receptors share 
high homology, the homo-oligomerization interface is identical to the hetero-
oligomerization interface. But aminergic GPCRs hetero-oligomerization between 
different families of aminergic GPCRs (β2-AR-5-HT4D294), non-aminergic receptors 
belonging to class A (β2-AR-DOR65, D1R-A1R295, D2R-SSTR5272), ligand-gated 
channels; D1R-NMDA 296 and D5R-GABAA 297can also occur. It would be safe to 
state that in these cases the two partners do not have identical oligomerization 
interfaces. Thus different interfaces and interactions are required. Indeed, while the 
homo-oligomerization interface of the D2R has been shown to involve 
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transmembrane domain IV (TM IV) 244,298,299 hetero-oligomerization with the 
adenosine A2a receptor seems to involve an arginine-rich region in intracellular loop 
2 (IL2), which can interact with a positively charged phosphorylated serine or a 
double aspartate “DD” region of the A2a receptor 300. 
Still, one has to be careful when interpreting both homo- and hetero-oligomeric 
potential of receptors. In several cases hetero-oligomers between receptors can 
only be detected at very high, non-physiological expression levels 234,301. BRET 
saturation curves 301 are very useful to determine the relative propensity of 
receptors to form hetero-oligomers, i.e. to establish if detected hetero-oligomers 
are physiologically relevant. For this to be true the different receptors also need to 
be actually co-localized within the same tissue.  
 
Table 5.1. Overview of oligomerization of GPCRs belonging to the class A, subfamily of aminergic 
receptors. Represented are whether the receptors (histaminergic, adrenergic, dopaminergic, 
muscarinergic and serotonergic) have been reported to form homo- or hetero-oligomers. Also the 
specificy of hetero-oligomerization is depicted by listing receptors that have been reported not being 
able to form hetero-oligomers with the relevant receptor. Abbreviations: S1P1R, sphingosine 1 
phosphate receptor; M71, M71 olfactory receptor; AT, angiotensin; TRHR, thyrotropin receptor; CCR5, 
chemokine receptor; CCKR cholecystokinin receptor; V2R, vasopressin receptor; NE, no effect. 
Type Receptor Homo-
oligomerization 
Hetero-oligomerization Specificity 
H1R 199 α1b-AR 205,245 α1d-AR 217, H4R 234 
H2R 107  α1d-AR 217 
H3R  H3R 210 α1d-AR 217 
H
is
ta
m
in
e H4R 
234  H1R 234 
α1a-AR 218,288 α1bR 218 , DOR 288 M71 287, α1dR 217,293 
α1b-AR 205,218,245 α1aR 218 , α1dR 217,293,302, 
H1R 205,245, CCR5  
M71 287, CCR5 218 
α1d-AR  α1b-AR 217,293,302 , β2-AR 
217 
M71 287, α1a-AR, α2A-AR , α2B-
AR, α2C-AR, β1-AR, H1R, H2R, 
H3R, AT1, AT2, MOR, DOR, 
M1R, M2R, M3R, M4R, M5R, D1R, 
D2R, 5-HT1R 217 
α2A-AR 303 MOR 241, β1-AR 304 M71 287, α1d-AR 217 
α2B-AR 286  M71 287, α1d-AR 217,  
α2C-AR  305 M71 287, α1d-AR 217 
β1-AR 306, 301,307 β2-AR 301,306-309, α2AR 304 M71 287, α1d-AR 217 
β2-AR 214,285,301,306,307,31
0-316 
β1-AR 301,306-309, M71 287, 
α1d-AR 217, β3-AR 62, 
DOR 65, KOR 65 
TRHR 219 ,CCR5 214, CCKR 311 
MT1aR214, MT2R 310, GABAb-R2 
306, D2SR 317, KOR 275, DOR 
275,307,315, GABAb-R1 285 
A
dr
en
al
in
e 
β3-AR 62 β2-AR 62 M71 287, 
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Table 5.1. Overview of oligomerization of GPCRs belonging to the class A, subfamily of aminergic 
receptors. Represented are whether the receptors (histaminergic, adrenergic, dopaminergic, 
muscarinergic and serotonergic) have been reported to form homo- or hetero-oligomers. Also the 
specificy of hetero-oligomerization is depicted by listing receptors that have been reported not being 
able to form hetero-oligomers with the relevant receptor. Abbreviations: S1P1R, sphingosine 1 
phosphate receptor; M71, M71 olfactory receptor; AT, angiotensin; TRHR, thyrotropin receptor; CCR5, 
chemokine receptor; CCKR cholecystokinin receptor; V2R, vasopressin receptor; NE, no effect. 
Type Receptor Homo-
oligomerization 
Hetero-oligomerization Specificity 
D1R 299,318 A1R 295, NMDA receptor 
296, D2R 289,319,320 
α1d-AR 217, A2AR 321 
D2LR 244,298,299,322-325 SSTR5 272, D2SR 317,322, 
A2AR 300,321,326-328 , D3R 
329, D1R 289,319,320, 5-
HT1BR 323 
α1d-AR 217, A1R 295,330 , M4R 303 
D2SR 322 D2LR 322 β2-AR 317 
D3 299,331,332 D3nfR 230,331,332, A2AR 333, 
D2R 329 
 
D4R    D
op
am
in
e 
D5R    
M1R 334 M2R 334 α1d-AR 217, Smoothened 334 
M2R 253,268,334-337 M1R 334, M3R 265,334,338 DOR 337 ,KOR 337, MOR 337, 
α1d-AR 217, Smoothened 334 
M3R 334,338-340 α2C-AR 305,338,340, M1R 334 
M2R 265,334,338 
M1R 339 , M2R 339, V2R 339, α1d-
AR 217, Smoothened 334 
M4R 303 5-HT2cR 341 α1d-AR 217, D2R 303 
M
us
ca
rin
e 
M5R   α1d-AR 217 
5-HT1AR 216 5-HT1BR 216 , 5-HT1DR 216  
5-HT1BR 216,264,292,323,342 5-HT1AR 216, 5-HT1DR 
216,292,342, 5-HT2BR 343 
D2R 323 
5-HT1DR 216,292,299,342 5-HT1AR 216 5-HT1BR 
216,292,342 
 
5-HT2CR 48,341  CCR5 290 
5-HT4DR 294 β2-AR 294, 5-HT4GR 294  
5-HT4GR 294   
5-HT5R    
5-HT6R    S
er
ot
on
e 
5-HT7R    
 
HoW are oligomers formed? 
 
There are many different reports on which GPCR domain(s) are important for 
oligomerization. Several types can be recognized: C-terminal tail coiled-coil 
interaction (e.g. GABAB1 261), N-terminal disulphide bridging (e.g. mGluRs 262,263), 
and transmembrane (TM) domain interaction. The latter can be separated into 
either contact interactions (e.g. rhodopsin 344 and D2R 244) or domain swapping 
(e.g. H1R 199). The interactions are not limited to only one of these types. For both 
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the GABAB1 and calcitonin receptor disruption of one specified interaction does not 
completely abolish GPCR oligomerization 233,345. One provocative possibility is that 
TM domain interactions always play a role in the formation of oligomers.  
 
One of the early reports on GPCR oligomerization came from the group of Maggio. 
Using chimeric receptors M3/α2-AR and α2-AR/M3 in which TMI-TMV or TMVI and 
TMVII are interchanged, they were able to convincingly show GPCR 
oligomerization via domain swapping 305. A long IL3 loop, a feature that is lacking in 
family C GPCRs 5, in the mechanism of domain swapping was reported crucial 
265,266. Other evidence in favor of domain swapping came from the histamine H1 
receptor 199. Co-expression of two defective H1R mutants, one with a mutation in 
TM III and a second with a mutation in TM VI could be reconstituted into a 
functional receptor via domain swapping 199. However, similar attempts to rescue 
defective mutants of the α1B-AR 218 and the D2R 324 were ineffective, arguing 
against domain-swapping. Moreover, whereas Maggio and co-workers could not 
detect dimerization using a M3 receptor with a truncated IL3 loop 265,266, Zeng and 
co-workers showed oligomerization of a rat M3 receptor, with a truncated IL3 339, 
further undermining the domain swapping theory. 
 
Using evolutionary trace analysis, as well as computer model docking simulations 
and correlated mutational analysis Gouldson proposes an important role for TM V 
and VI in the oligomerization interface 346. Evolutionary trace analysis performed 
specifically on aminergic GPCRs predicted a potential role for TM IV and V for 
muscarinic and possibly 5-HT2 receptors, whereas for other members of the 
aminergic receptor family TM V and VI were important 347. This prediction fits the 
TM I-V TM VI-VII domain swapping strategy. Gouldson predicts a minor role for TM 
I and TM VII, which would fit the intermediate stage of the domain swapping 346,348-
350 (Figure 5.2). However, the TM I-V, TM VI, VII domain swapping model, as 
proposed by Gouldson, is only energetically favorable when bound to an agonist 
346. This is not in agreement with the previously reviewed data that oligomers are 
constitutively assembled in the ER. One may speculate that oligomers can shift 
between a contact-oligomer interface, when unbound or bound to an antagonist, 
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and a domain swapping interface when bound to an agonist. However, such a 
rearrangement would most likely be revealed in BRET assays. As was shown for 
e.g. the H4 receptor no change in BRET could be detected upon binding of an 
inverse agonist, neutral antagonist or agonist 234. These observations would argue 
against a situation in which dimers can switch between contact interaction and 
domain-swapped interaction upon ligand binding. 
 
Figure 5.2.  Schematic representation of GPCRs forming dimers via domain swapping. The flexible 
intracellular loop 3 allows for TM VI-VII to be interchanged between the two GPCRs, possibly via an 
intermediate in which TM I is interacting with TM VII.  Figure adapted from 348.   
 
One of the best examples of GPCR oligomerization occurring via contact between 
the TM domains comes from the rhodopsin receptor. Using atomic force 
microscopy (AFM) rhodopsin was shown to have contacts between TM IV and V 
351. Rhodopsin dimers form rows as a result of contacts between the cytoplasmic 
loop connecting TM V and TM VI and TM I and II from the adjacent dimer. Rows 
assemble into paracrystals through extracellular contacts formed by TM I 351. 
However, the dimeric structure seen for rhodopsin may be an artifact of the sample 
preparation for AFM 352. Nevertheless, several reports have suggested similar 
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contact interfaces for aminergic GPCRs (Figure 5.3). The importance of TM I in 
homo-oligomerization of the α1B-AR has been shown convincingly 205,218,245. Carrillo 
and co-workers employed co-immunoprecipitation and tr-FRET to study the 
involvement of specific TM domains. They found that TM I and TM IV could self 
associate, while there was a weaker interaction between TM I/-II with TM V-VI 245. 
No role was observed for TM VII 245. In contrast, Stanasila and co-workers reported 
that TM VII of the α1B-AR is involved in the oligomerization interface, albeit to a 
lesser extent than TM I 218.  
 
 
Figure 5.3.  Schematic representation of an oligomeric complex of aminergic GPCRs. A single row of 
oligomeric GPCRs can be formed by alternating GPCRs interacting with an adjacent GPCR either via 
TM IV or TM I. A second row of oligomeric GPCRs is stabilized via an interaction between TM I and TM 
VI. Figure adapted from 245. 
 
Several reports have shown the importance of TM IV in dopamine D2R homo-
oligomerization 244,298,299. Cross linking experiments convincingly showed the 
involvement of TM IV in the oligomerization interface 244,298. However, TM IV is not 
crucial as oligomers could still be observed when the conformation of TM IV was 
distorted by insertion of a proline residue 299. 5-HT4R homodimers are stabilized by 
disulfide bonds between cysteine residues in TM III and TM IV 353. Earlier studies 
showed cysteine residues located in EL2 and EL3 to play an important, albeit not 
crucial role, in M3 receptor oligomerization 339. These cysteines are highly 
conserved among aminergic receptors, compared to the cysteines residues found 
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in the TM domains of the 5-HT4R, and can undergo either intra- or inter-molecular 
cross-linking. Zeng and Wess suggest that in general non-covalent TM domain 
interactions precedes cross linking 339. Other TM domains that may play a role in 
D2R oligomerization are TM VI and VII. Co-expression of the D2R with either of 
these domains was able to dissociate D2R homo-oligomers 323. While TM VI 
appears not to be important in D1R oligomerization 318, the involvement of TM VI 
was shown for the β2-AR. For the β2-AR the involvement of TM VI was deduced to 
the presence of a glycophorin like motif (GXXXGXXXL) within this domain 354. The 
glycophorin motif is a potential interface for GPCR oligomerization as has been 
shown for the yeast α-factor receptor 355. However, it appears that it is mainly the 
leucine residue that is crucial for the interaction 285. Yet, no involvement of the 
glycophorin motif could be observed for the α1B-AR, suggesting that this motif is not 
a general requirement for GPCR oligomerization 218,245. 
 
In summary, three TM domains in particular are important within the contact 
interface model, namely TM I, TM IV and to a lesser extent TM VI. It is noteworthy 
that these TM domains, especially TM I and TM IV are less involved in ligand 
binding to aminergic GPCRs 34, thus allowing them to fulfill different roles such as 
formation of oligomers. Moreover, amino acids within these TM domains are less 
conserved than in other TM domains 347. This lack of conservation may provide a 
way for receptors to form hetero-oligomers with only a limited amount of other 
GPCRs, thus creating a certain degree of specificity.  
Regarding non TM domain regions, several reports have shown that N-
glycosylation is not a requirement for oligomerization 218,234,299,331. However, 
inhibition of N-glycosylation resulted in a reduction in β2-AR oligomerization 313. In 
contrast, blocking N-glycosylation increased the formation of the β1-AR-α2A-AR 
hetero-oligomers 304. The C-terminal-tail is reported to play no role of importance in 
the formation of α1B-AR and H2R oligomers 107,293, whereas an electrostatic 
interaction between an arginine rich region in the IL3 of the D2R and either a DD 
region or a phosphorylated serine in the C-terminal tail of the A2A receptor is 
involved in the hetero-olgiomerization of these two receptors 300,328. In general, 
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based on data from Western blot analysis, two different types of interaction can be 
appreciated: covalent (dithiothreitol (DTT) sensitive) and strong hydrophobic (SDS 
insensitive) interactions (Table 5.2). Often Western blot experiments reveal both 
monomeric and dimeric reactive species. Whether the monomeric species in these 
blots are SDS sensitive dimers, or native monomers can not be deduced from 
these experiments.  
 
Table 5.2.  Overview of interactions types involved in the formation of oligomers. 
Interaction type Receptor oligomer 
Strong hydrophobic  
(SDS insensitive) 
5-HT1BR 216,  5-HT1DR 299,342, D1R 299,342, D2R 299,322,342, D3R 299, H4R 234, 5-
HT4dR 353, 5-HT4gR 353, 5-HT4dR-5-HT4gR 353, α2A-AR-MOR 241, β2-AR-DOR 
65, β2-AR-KOR 65 
Covalent  
(DTT sensitive) 
5-HT1AR 216, 5-HT1DR 216,299,342,  M2R 336, M3R 339, D1R 299,342 
 
Monomer, dimer or oligomer? 
 
Not only dimers can be identified in Western blots, often immunoreactive species  
running at approximately four times the weight of a monomeric receptor can be 
detected Bands corresponding to these putative tetrameric oligomers have been 
observed for the D1R 289,299,318, D2R 289,299, D3R 230,299,332, M2R 253,268,335, β2-AR 65, 
α1B-AR 205, 5HT1B 342, 5HT1D 299, H1R 205, H2R 107. Only for the H1R 205, H2R 107 and 
α1B-AR 205 immunoreactive species corresponding to putative trimers have been 
observed. However, one has to be very careful in interpreting these results. High 
molecular weight bands can also arise from aggregates between the studied 
receptor and other proteins, with similar molecular weight. Also the procedure of 
sample preparation and SDS-page gelelectrophoresis can introduce or break up 
oligomers. Changes in temperature during sample preparation have been shown to 
induce oligomerization 335 as well as cause dissociation of oligomers 323.  
 
Several studies that address the oligomerization state of GPCRs have been 
performed.   BRET saturation curves of β2-AR 301 and muscarinic M1R, M2R and 
M3R 334 oligomers, fitted a dimer model better than a trimer model as well. 
However, the M2R is not present exclusively as dimeric or higher oligomeric 
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structures, but also as monomers 268. Three-fluorophore FRET showed that the 
α1B-AR is able to form at least trimeric complexes 281.  
 
It is difficult to determine whether observed functional effects arise from a GPCR 
monomer, homo-oligomer or from both. Recent studies show that both rhodopsin 
monomers as well as oligomers can be activated 356. pbFRET and co-
immunoprecipitation have been employed to study the G-protein coupling of an 
inactive 5-HT2C mutant receptor when co-expressed with the wild-type receptor, 
revealing that one dimer interacts with only one G-protein, and that two ligands 
were required to activate this dimer 48. This apparent 2:2:1 stoichiometry is in sharp 
contrast with the traditional belief that GPCRs function in a 1:1:1 stochiometry. Yet, 
it is in agreement with the finding that the leukotriene B4 receptor forms a 
pentameric structure, consisting of a hetero-trimeric G-protein and a dimeric 
receptor 47. Still, several reports have argued that a monomeric receptors can also 
be activated by one hetero-trimeric G-proteins 357-359. Moreover, in several 
instances one ligand has been shown to induce internalization of a hetero-dimeric 
complex, suggesting that one ligand is enough to activate the dimer 289,304,343. More 
studies are required to truly understand the roles and potential differences of 
receptor monomers and oligomers and the effect of ligand occupation on their 
activation. 
 
 
Effect of ligand binding on oligomerization 
 
A relatively controversial issue concerning GPCR oligomerization is the effect of 
ligand binding on the formation of oligomers. The majority of the studies involved in 
determining the effects of ligand, techniques employ either BRET or FRET. These 
methods rely heavily on the orientation and conformation of the fluorescent groups. 
A ligand induced change in conformation, could result in a change in conformation 
and a concomitant increase or decrease in the distance between the donor and 
acceptor. Thus, this would give a false notion of an increase or decrease in the 
amount of oligomers. Similarly, an increase in oligomerization may not be detected 
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if it would coincide with a conformational rearrangement, increasing the distance 
between donor and acceptor. This was nicely demonstrated in a study on 
melatonin receptors. While an agonist induced an increase in BRET signal 
between MT1R-Rluc and MT2R-eYFP, no effect was detected when MT1R-eYFP 
were co-expressed with MT2R-Rluc 310. This observation clearly demonstrates that 
a change in BRET signal is not necessarily due to a ligand induced change in the 
formation of oligomers. In general, for homo-oligomers no ligand effect on oligomer 
formation or dissociation is observed 218,234,244,288,294,301,322,324,339,341. Nevertheless, 
several interesting findings regarding the effect of ligand binding on the formation 
of hetero-oligomers have been reported. For example, an increase in α2A-AR-MOR 
hetero-oligomerization, could be accomplished by activating either receptor, but a 
decrease was detected when both receptors were activated simultaneously 241. In 
contrast, an increase in pbFRET signal was observed for the D2R-SSTR5 hetero-
oligomer, when the receptors were activated individually as well as simultaneously 
272. A possible explanation for such observations came from the study of hetero-
oligomerization between the D2R and D1R mutants 320. Stably formed homo-
oligomers of a D1R mutant, with two mutations in its binding domain (S198A, 
S199A) in TM V were not affected by binding of the inverse agonist (+)-butaclamol. 
However, binding of the same ligand to hetero-oligomers between the mutant D1R 
and the wild-type D1R disrupted the hetero-oligomeric complex 320. In a recent 
study, Damian and co-workers showed that in a ligand bound leukotriene B4 
receptor homodimer, each individual receptor displayed a different conformation, 
which remained even when both receptors were occupied by ligands 360. 
Apparently conformational changes, caused by ligand binding can have a serious 
impact on the stability of the oligomer, even if the two receptors within the complex 
don’t differ much in amino-acid sequence. So even though in most cases ligand 
binding does not influence GPCR oligomerization, certainly, binding of ligand(s) 
affects receptor conformation. Hence, it is plausible that in certain cases, e.g.  
binding of allosteric ligands or binding of two ligands to a hetero-oligomer, may 
stabilize or destabilize receptor-receptor interactions.  
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Why are oligomers formed? 
 
Although, so far hetero-oligomerization is only found vital for receptor function for 
the GABAB 42 and taste receptors 45,46 numerous hetero-oligomers have been 
reported to have a unique pharmacology 304,308,340. Often receptor trafficking, both 
transport from the ER to the cell membrane or from the cell membrane to endocytic 
vesicles by internalization, is altered upon hetero-oligomerization.  As previously 
mentioned, hetero-oligomerization can have a dominant negative 204,285,286 or 
positive effect 217,287 on receptor cell surface expression. Internalization of GPCRs 
can change upon hetero-oligomerization. For example, stimulation of β2-ARs has 
led to co-internalization of MOR 65 and M71 olfactory receptors 287, whereas MOR 
65 or M71 287 stimulation results in β2-AR internalization. In contrast, KOR has a 
dominant negative influence on β2-AR internalization 65. Stimulation of α2A-AR 
receptors results in internalization of β1-AR receptors 304, whereas activation of α1A-
AR leads to α1B-AR internalization 218. Activation of D1R causes internalization of 
D2R and vice versa 289. D2R also co-internalizes with the adenosine A2aR 321. 
Additionally, when co-expressed with M2R, carbachol stimulation resulted in 
increased downregulation of M3R 334  
 
Besides affecting trafficking of receptors, hetero-oligomers may also exhibit altered 
signaling properties.  For instance, the β2-AR-β3-AR hetero-oligomer can only 
signal via Gαs, while the individual receptors can signal via Gαi/o as well 62. 
Additionally, the recruitment of β-arrestins is reduced for the β2-AR -β3-AR hetero-
oligomer, resulting in a decrease of internalization 62. Novi and co-workers showed 
that the M3R-α2A-AR receptor chimera’s need to oligomerize in order to signal via 
ERK1/2 phosphorylation 340 and recruit β-arrestins to be internalized 338.Other 
examples of hetero-oligomers expressing a unique pharmacology are: M2R-M3R 
265, β1-AR-β2-AR 308,309, α1B-AR-α1D-AR 302, D2R-D1R 319, D2LR-SSTR5 272, β1-AR-
α2A-AR 304, D3R- A2aR 333 and D1-A1R 295 It would be reasonable to suggest that 
each hetero-oligomer has a physiological role, either crucial or merely supportive.  
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Future prospects 
The use of chimeric receptors, epitope tagged or fluorescent protein fused 
receptors has been tremendously valuable for studying GPCR oligomerization in 
vitro. However, only a limited number of studies have reported on GPCR 
oligomerization in vivo. Antibodies raised against GPCRs have been an important 
tool in the detection of oligomers in vivo. Using such antibodies, M2R oligomers 
have been detected in porcine atrial sarcolemmal membranes 253, M3R 339 and 
rH3R 204,210 oligomers in rat brain, D3R oligomers in human motor cortical tissue 332, 
and H4R oligomers in human spleen tissue and PHA blasts 234. While these 
antibodies were used in Western blotting experiments, labeling these antibodies 
with europium- or allophycocyanin-conjugates, could potentially allow performing tr-
FRET assays in vivo. Also production of antibodies that specifically recognize a 
hetero-oligomer would be very helpful to study GPCR hetero-oligomerization in 
vivo. The ability to study GPCR oligomerization in vivo using different and more 
advanced techniques would undoubtedly aid in understanding their physiological 
relevance, and potentially linking them to pathological conditions. For example, in 
pre-eclamptic hypertensive women an increase in hetero-dimers between the 
angiotensin AT1 and bradykinin B2 receptors has been shown to result in a 
concomitant increase in responsiveness to angiotensin II 361. Designing ligands that 
target hetero-oligomers may be successful as therapeutics in these cases. 
Recently, a bivalent ligand that is selective for the DOR-KOR heterodimer has 
been developed 197. Although it is very difficult to produce these (specific) bivalent 
ligands, as can be seen from the attempts to produce bivalent ligands for the 5-HT4 
receptor 362, these ligands provide compelling tools to study GPCR oligomerization 
in vivo. Besides bivalent ligands, it may be possible to develop small, monovalent 
hetero-oligomer selective ligands. Ligands that can apparently recognize different 
populations of receptors (monomer vs oligomer) have already been discovered. 
For e.g. the D2Rs [125I]azidophenethylspiperone was shown to detect only 
monomeric receptors while [125I]-4-azido-5-iodonemonapride can also detect 
dimeric receptors 325. Similarly [3H]quinuclidinylbenzilate labeled a different 
population of M2Rs than N-[3H]methylscopolamine or [3H]AF-DX 384 253. For the 
H1Rs [3H]mepyramine has been shown to label a different population of receptors 
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compared to [3H]H2-PAT, that possibly recognized only dimeric receptors 199. 
Recently SKF83959 was identified as a specific agonist for the D1R-D2R hetero-
oligomer 319. Perhaps some orphan ligands, like e.g. CXCL14 (BRAK), do not 
recognize a single GPCR but only a hetero-dimer, explaining why these ligands 
have not been de-orphanized yet. Although increasingly more information on 
GPCR oligomerization is becoming available, still many aspects are not full 
understood (Figure 5.4).  
 
Figure 5.4.  Overview of GPCR oligomerization ontogeny and trafficking. A, GPCR oligomers already 
form in the endoplasmatic reticulum. B, dominant negative GPCRs may block surface trafficking, while 
other GPCRs may facilitate surface expression by hetero-oligomerization. C, GPCR oligomers are 
constitutively present at the cell surface. D, GPCRs can be co-internalized after agonist stimulation, or 
internalization can be inhibited through hetero-oligomerization. Questions remaining: ?, What are the 
specific roles of the monomers and oligomers. ??, can GPCRs within different oligomeric complexes 
exchange partners while on the cell surface. ???, What determines through which G-protein (Gαi, Gαs, 
Gαq or Gα12) will be signaled if an activated hetero-oligomer  binds only one G-protein. 
 
Extensive study on rhodopsin has shown that the receptor can be activated as a 
monomer 356,358 as well as a oligomer 356. Recent papers have also shown that one 
G-protein can be activated by one receptor dimer 47,48. However, only few studies 
have tried to determine the percentage of receptors present as dimers. Western 
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blot and BRET analysis estimated that 45-85% of receptors are interacting as 
dimers 301,334,339. The question arises what the physiological purpose is of having 
populations of monomers and oligomers. Work of Jastrzebska and co-workers 
suggest that oligomers are activated at a higher rate then monomers 356. Are 
receptor monomers primarily created by break up of oligomers, waiting to form new 
oligomeric complexes, or are they transported to the cell surface as monomers, 
having to fulfill different tasks than receptor oligomers (Figure 5.4)? In order to 
more accurately predict pharmacology of dimers it is necessary to understand the 
dynamics of dimerization. Regarding these dynamics of GPCR hetero-
oligomerization, it would be interesting to determine whether oligomers, can 
dissociate while on the cell surface (Figure 5.4). If so, this would allow for the 
exchange of partners within hetero-oligomers complexes. Computer simulation of 
GPCR arrangement predicted that in such a situation homo-dimers or hetero-
dimers would form clusters 363. However, if oligomers are formed solely intracellular 
and do not exchange partner during their lifespan, this would raise new questions. 
For example, in order for the β2-AR to exert the dominant-positive effect on cell 
surface translocation of α1D-AR 217 and M71 287 both receptors would have to be 
transcribed and translated at the same time. It would therefore be interesting to 
investigate if for example expression of β2-ARs coincides with the expression of 
M71 olfactory receptors or α1D-ARs to determine if this effect is indeed 
physiologically relevant. Recently, Law and co-workers used an inducible promoter 
to express δ-opioid receptors in cells endogenously expressing μ-opioid receptors 
364. The use of inducible promoters could be used to specifically address the 
question of oligomer formation at the cell surface. By placing two receptors under 
control of different inducers, the receptors could be expressed consecutively 
instead of simultaneously, excluding that any observed oligomers would have been 
formed during formation and transport. Other techniques, such as eBRET 278 may 
also be used to investigate whether homo-dimers or hetero-dimers break up at the 
cell surface to exchange partners, by using the EnduRen™ substrate on cells 
expressing receptors fused to Renilla luciferase and eGFP, and studying the BRET 
signal over a prolonged amount of time. Finally, if indeed one dimer binds only one 
G-protein, this raises exciting questions from a molecular pharmacological point of 
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view. For example, it would be interesting to determine to which class of G-proteins 
(Gαi, Gαs, Gαq or Gα12) a hetero-dimer, made up of receptors that individually couple 
to different G-proteins, would couple upon activation  and what the driving force is 
behind this coupling (Figure 5.4). 
    
In conclusion, over the last twenty years the study of GPCR oligomerization has 
increased steadily. This has resulted in a definite increase in the understanding of 
the mechanism behind the formation and the cellular role of these oligomers. 
However, still many questions remain unanswered. In order to take the research of 
GPCR oligomerization to the next level, more in vivo studies are required 365. The 
development of new techniques and new tools will be of crucial importance to 
obtain new insights into GPCR oligomerization and elucidate the physiological 
importance and dynamics of this phenomenon. 
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ABSTRACT 
 
The histamine H4 receptor (H4R); a member of the G protein-coupled receptor 
(GPCR) family and is predominantly involved in inflammatory responses, such as 
chemotaxis of leukocytes and the release of chemotactic peptides. Human 
cytomegalovirus (HCMV) is a β-herpesvirus, which is believed to contribute to the 
pathology of chronic inflammation and several other diseases, and is able to infect 
leukocytes. The four GPCRs encoded by the HCMV genome are homologous to 
chemokine receptors. The most well studied of these is US28, which has been 
previously reported is able to interact with the human chemokine receptor CCR1 (J. 
Biol. Chem. 279:5152-5161). As US28 and the H4R are co-expressed on 
leukocytes, and we have previously shown that the H4R can homo-oligomerize 
(Mol. Pharmacol 70:604-615), we set out to investigate if US28 can also interact 
with the H4R. We found that in a heterologous system, in which H4R is co-
expressed with US28, additional signaling pathways for the H4Rs are unmasked. 
Using biochemical and biophysical assays, we were able to show that H4R can 
hetero-oligomerize with US28. Therefore the change in signal transduction may be 
due to hetero-oligomerization between H4R and US28. These data suggest that 
US28 may exert part of its physiological influences by hetero-oligomerization with 
the H4R. 
 
INTRODUCTION 
 
It is now well established that GPCRs can form homo- and hetero-oligomers 366, 
and we have recently shown homo-oligomerization of the human H4R in 
lymphocytes 234. The H4R is an aminergic GPCR that is expressed almost 
exclusively in cells belonging to the hematopoietic lineage 148,150-152. Based on the 
expression pattern and the ability of the H4R to induce chemotaxis of eosinophils 
168 and mast cells 164, this receptor has been linked to inflammatory diseases, such 
as allergy 184 and rheumatoid arthritis 188. Recently, evidence for a role of H4Rs in 
cancer has emerged as well 189-191.  
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Chemokine receptors are renowned for their role in inflammation 367. Several of 
these peptidergic receptors, e.g. CXCR1 368, CXCR2 368,369, CXCR4 370 and CCR5 
269, have been shown to form homo-oligomers as well as hetero-oligomers 
368,371,372. Several viruses encode chemokine receptors, including Epstein-Barr 
virus, Karposi’s sarcoma associate herpesvirus and human cytomegalovirus 
(HCMV) 373. Infection with HCMV has been linked to colon cancer 374 and breast 
cancer 375,376. The best characterized chemokine receptor encoded by the HCMV is 
US28 377. US28 shares highest homology with CCR1 and CX3CR1 378 and is 
capable of binding a broad spectrum of chemokines such as CCL2, CCL3, CCL4, 
CCL5 379 and CX3CL1 380. Recently, we reported that the Gαq/11-coupled US28 
receptor potentiates signaling via the Gαi/o-coupled CCR1 receptor , which might 
be a common feature among GPCRs 381. 
The H4R is not only expressed in the same tissue and cells as chemokine 
receptors and acting as chemotactic receptor, but the H4R also plays a role in 
cytokine and chemokine release 161,181,184. Moreover, Nakayama and co-workers 
reported that CCL16 (LEC) is able to bind and signal via the H4R 166. Hetero-
oligomerization between peptidergic and aminergic receptors has already been 
reported, as both the δ- and κ-opioid receptor could form hetero-oligomers with the 
β2-adrenergic receptor 65. We previously reported on the synergistic effects 
between US28 and CCR1 381, which might possibly occur through 
heterodimerization. As both US28 and H4Rs are preferentially expressed on 
leukocytes, we set out to investigate the effects of co-expression of the H4R and 
US28. 
Herein we report on the homo-oligomerization of US28 as well as on the hetero-
oligomerization of US28 with hH4Rs as determined using both biochemical (co-
immunoprecipitation) and biophysical approaches (BRET, tr-FRET). Co-expression 
of H4Rs with US28 affects the pharmacology of the H4R, causing a reduction in 
H4R Bmax-values. In addition, co-expression of the H4R with US28 reveals H4R 
mediated NF-κB and InsP3 signaling.  
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RESULTS 
 
The viral chemokine US28 receptor forms homo-oligomers and  
hetero-oligomers with the H4R. 
We have previously shown that the H4R can form homo-oligomers 234 and that H4R 
splice variants act as dominant negative by forming hetero-oligomers with the full 
length H4R 382. We have also shown previously that constitutively active Gq/11-
coupled receptors constitute a regulatory switch for signal transduction of Gi/o-
coupled receptors. As both the Gi/o-coupled H4R and the Gq/11-coupled US28 play a 
role in inflammatory responses we were interested to see whether the H4R and 
US28 could form hetero-oligomers and/or interact with each other on the level of 
receptor signaling. To investigate whether hetero-oligomerization occurs between 
the H4R and US28 bioluminescent resonance energy transfer (BRET) 
measurements were performed. To this end, C-terminal tagged eYFP (US28-
eYFP) or Renilla luciferase (US28-Rluc) US28 were constructed. The US28-Rluc 
and US28-eYFP were paired and co-expressed with either H4R-eYFP or H4R-Rluc 
234, respectively. Upon addition of coelenterazine, the substrate for Renilla 
luciferase, BRET measurements were performed. A clear BRET signal was 
observed when US28-Rluc was co-expressed with H4R-eYFP or when US28-eYFP 
was co-expressed with H4R-Rluc (Figure 6.1). Additionally, a BRET signal was 
observed in cells co-expressing US28-Rluc and US28-eYFP (Figure 6.1). Both the 
BRET signals for the US28 homo-oligomer and US28-H4R hetero-oligomer are 
stronger than for the H4R homo-oligomer. 
To further confirm the existence of H4R-US28 hetero-oligomers and to determine 
whether the hetero-oligomer is also present on the cell surface tr-FRET 
measurements were performed. For this purpose COS-7 cells co-expressing N-
terminally FLAG-tagged histamine H4R (FLAG-H4R) and N-terminally HA-tagged 
US28 (HA-US28) were incubated with Europium (Eu3+) labelled anti-FLAG 
antibodies or a combination of the Eu3+ labelled anti-FLAG and allophycocyanin 
(APC) labelled anti-HA antibodies. As a control, cells solely expressing FLAG-H4R 
or HA-US28 were mixed and exposed to the two antibodies. A significant tr-FRET 
signal was observed in COS-7 cells co-expressing  both FLAG-H4R and HA-US28 
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compared to the signal obtained from cells only  expressing either receptor that 
were mixed prior to incubation with the antibodies (Figure 6.2). To determine the 
specificity of the hetero-oligomerization between the H4R and the US28 receptor, 
FLAG-H4R were co-transfected with a N-terminally 3xHA-tagged human 
chemokine receptor CCR2 (3xHA-CCR2). However, no significant tr-FRET signal 
could be obtained for this combination. 
 
 
Figure 6.1. Evaluation of hetero-oligomerization between the H4R-Rluc US28-eYFP receptors by BRET 
using the co-expression of Renilla luciferase (Rluc) and eYFP C-terminal receptor-fusion proteins. 
BRET ratios for transiently transfected COS-7 cells co-expressing the H4R-Rluc and H4R-eYFP, US28-
Rluc and US28-eYFP receptors or H4R-Rluc and US28-eYFP. Cells expressing the indicated receptor-
fusion proteins were exposed to 5 μM coelenterazine after which resonance energy transfer was 
measured. Ratios are expressed as mean ± S.E.M. from at least three experiments each performed in 
triplicate. 
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Figure 6.2. Evaluation of hetero-oligomerization between the FLAG-tagged H4R and HA-tagged US28 
receptors by tr-FRET. Transiently transfected COS-7 cells co-expressing the H4R and US28 receptors 
were incubated for 2 hours with the Eu3+-labelled anti-FLAG and APC-labelled anti-HA antibodies. A, tr-
FRET in COS-7 cells co-expressing FLAG-US28 and HA-US28 compared to COS-7 cells co-expressing 
FLAG-H4R and HA-H4R. B, tr-FRET in COS-7 cells co-expressing FLAG-H4R and HA-US28 or 3xHA-
tagged CCR2. Data are normalized for the tr-FRET signal obtained from a mixture of COS-7 cells that 
individually expressing the indicated constructs. Data shown are average of at least three experiments 
each performed in triplicate. 
 
Both BRET and tr-FRET assays are based on resonance energy transfer. 
Consequently, observed signals may arise from receptors that are in close 
proximity of each other, but do not physically interact to form oligomers. To 
establish whether the H4R physically interacts with US28 co-immunoprecipitation 
assays were performed. Anti-FLAG coupled sepharose beads were used to 
precipitate FLAG-H4R from HEK 293 cells co-expressing HA-US28 and FLAG-H4R. 
Subsequent Western blotting experiments performed with anti-HA antibodies 
revealed the presence of US28 in the precipitate (Figure 6.3, lane 3). No HA-US28 
was immunoprecipitated with control sepharose beads that were not coupled to 
antibodies (Figure 6.3, lane 2).  
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Figure 6.3. Immunoprecipitation evidence for H4R receptor interaction with US28. HEK 293 cells were 
co-transfected with equal amounts of cDNAs encoding FLAG-H4R(390) and HA-US28 , harvested 40h 
post transfection, solubilised with 1% (v/v) Triton-X100 and subjected to immunoprecipitaion with anti-
FLAG sepharose or sepharose control beads for 2h at 4ºC. Following washing, bound material was 
eluted using SDS-PAGE sample buffer and analysed by immunoblotting. Immunoblots were probed with 
anti-HA antibody. A single diffuse species was identified consistent with the US28. Lane 1 solubilized 
cells, Lane 2 cells immunoprecipitated with sepharose beads , Lane 3 cells immunoprecipitated with 
anti-FLAG sepharose beads. 
 
Co-expression of US28 decreases number of H4R binding sites. 
To investigate the effect of hetero-oligomerization between US28 and the H4R on 
their pharmacology [3H]histamine radioligand binding was performed on 
membranes of COS-7 cells transfected with H4R and US28 cDNA in a 1:1 ratio. 
[3H]histamine bound to the COS-7 cells co-expressing the H4R and US28 
according to a one site, saturable model with a dissociation constant (KD) that is 
not significantly different than the value obtained when only the H4R is expressed  
in COS-7 cells (40 ± 13.1 vs 17 ± 2.1 nM). However, the Bmax, the maximal amount 
of H4R labeled by [3H]histamine (0.84 ± 0.2 pmol/mg protein) decreased by 35% 
(65.1% ± 17.7, n=3) upon co-expression with US28 compared to COS-7 cells 
expressing only the H4R. To further investigate the effect of US28 co-expression on 
H4R pharmacology radioligand displacement assays were performed. [3H]histamine 
radioligand binding was performed on membranes of COS-7 cells expressing the 
HA-H4R in the presence or absence of US28. The selective H4R agonist 4-
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methylhistamine 115, partial agonist clobenpropit, neutral antagonist JNJ 7777120 
172 and inverse agonist thioperamide were used to displace [3H]histamine. On 
COS-7 cells expressing US28, no [3H]histamine binding was observed (data not 
shown). The affinity of the H4R ligands for the H4R does not significantly (p>0.05) 
change when US28 receptors are co-expressed (Table 6.1, Figure 6.4B).   
 
Table 6.1. Characterization of the H4R expressed individually or co-expressed with US28 in transiently 
transfected COS-7 cells. The KD values for [3H]histamine, H4R expression (Bmax) and the pKi values of 4-
methylhistamine (4-Me-HA), clobenpropit, JNJ7777120 and thioperamide were determined by 
[3H]histamine saturation and displacement binding assays. COS-7 cells were transfected in a 1:1 ratio 
with cDNA encoding the H4R and US28. The values are expressed as mean ± SEM of at least three 
independent experiments 
[3H]histamine 
pKi Receptor KD (nM) Bmax (%) 4-Me-HA Clobenpropit JNJ7777120 Thioperamide 
H4R 17.1 ± 2 100 ± 3.3 7.1 ± 0.1 7.8 ± 0.1 7.6 ± 0.1 7.3 ± 0.1 
H4R + US28 40.1 ± 13 59.1 ± 4.3 6.9 ± 0.1 7.5 ± 0.2 7.4 ± 0.1 7.0 ± 0.2 
 
Finally, ligand induced dissociation of [3H]histamine from COS-7 cells individually 
or co-expressing H4R and US28 was investigated. In COS-7 cells expressing H4R 
the selective H4R JNJ 7777120, but not CCL5 was able to dissociate [3H]histamine 
(Figure 6.4C). With the exception of a reduction in Bmax similar results were 
obtained in COS-7 cells co-expressing H4R and US28 (Figure 6.4C). No difference 
was observed in dissociation constants (7.0 ± 2.0 vs 5.6 ± 1.6 min).  
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Figure 6.4. Dominant negative effect of US28 receptors on [3H]histamine binding to H4R. A, Saturation 
of binding to H4R receptors expressed individually (z) or co-expressed with the US28 ({) in COS-7 
cells. B, Displacement of [3H]histamine by the selective H4R agonist 4-methylhistamine in COS-7 cells. 
C, Dissociation of [3H]histamine from COS-7 cells individually expressing H4R (closed symbols) or co-
expressing with the US28 (open symbols) induced by the H4R antangonist JNJ 7777120 (circle) or 
US28 selective ligand CCL5 (square) Representative experiments are shown.  
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Surface labeling shows large intracellular population of  
H4R-US28 hetero-oligomers. 
The findings of an apparent reduction in H4R expression when co-expressed with 
US28 together with the ability of these receptors to form hetero-oligomers 
prompted us to further study the localization of the H4R and US28 when co-
expressed. US28 has been reported to be rapidly constitutively internalize 383. 
Surface labeling of HEK 293 cells expressing US28 showed the majority of US28 
receptors to be located intracellular, with only a small percentage present on the 
cell membrane (Figure 6.5A).  
 
 
Figure 6.5. Surface Biotinylation of US28 and H4R. HEK 293 cells were transfected with either cDNAs 
encoding H4R or HA-US28 alone, or contransfected with equal amounts of H4R and HA-US28. Intact 
cells were biotinylated for 15 min at 4ºC with 1mg/ml Sulfo-NHS-SS-Biotin, washed and homogenised. 
Biotinylated surface fractions were isolated by streptavidin chromatography, and analysed by 
immunoblotting. A, HA-US28 transfected alone and immunoblot probed with anti-HA antibody. A single 
diffuse species labelled consitent with the size of HA-US28. B, H4R alone or contransfected with HA-
US28. Immunoblot probed with rabbit anti-hH4R antibody (Two major diffuse protein species labelled 
corresponding to dimeric and monomeric glycoproteins) or mouse anti-beta-actin antibody. The lack of 
beta-actin signal in reprobed surface fractions demonstrates successful fractionation. I = Intracellular 
fraction; S = Surface fraction. 
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The H4R expressed in HEK 293 cells is also present at the cell surface (Figure 
6.5B, lane 2). However co-expression with US28 results in a decrease in surface 
localized H4R to undetectable proportions (Figure 6.5B, lane 4). β-actin controls 
show that this result is not caused by an overall decrease in protein expression 
(Figure 6.5C). Additionally, the β-actin control show that the fractionation was 
successful as β-actin is not expressed on the surface. 
 
Co-expression of H4R and US28 unmasks H4R mediated NF-κB signaling. 
The functional analysis of co-expression of the H4R and US28 receptors was 
performed using a NF-κB-luciferase reporter gene assay in transiently transfected 
HEK 293T cells. In line with earlier findings 384, US28 exhibits constitutive NF-κB 
signaling when expressed in HEK 293T cells (5-fold versus mock) (Figure 6.6). The 
H4R does not signal via NF-κB, as no constitutive activity or ligand induced 
changes in NF-κB signaling are observed versus mock HEK 293T cells (Figure 
6.6). On HEK 293T cells expressing US28 receptors no effect on NF-κB signaling 
is observed after stimulation with 10 μM of the selective H4R agonists 4-
methylhistamine 115 and clobenpropit, the selective H4R antagonist JNJ 7777120 
172 and the H4R inverse agonist thioperamide 115,150 (Figure 6.6). However, in HEK 
293T cells co-expressing both US28 and H4R an increase on top of the constitutive 
US28 signaling is observed compared to HEK 293T cells expressing US28 
receptor alone (100 vs 153%). Stimulation with the H4R agonists 4-methylhistamine 
and clobenpropit resulted in a clear induction of NF-κB signaling (Figure 6.6). 
Surprisingly, the H4R antagonist JN J777120 increased NF-κB signaling (p<0.005), 
behaving like a partial agonist. The H4R inverse agonist thioperamide reduced the 
H4R mediated NF-κB signaling back to the level observed in HEK 293T cells 
expressing US28 alone (Figure 6.6). Co-stimulation of HEK 293T cells co-
expressing US28 and H4R with 4-methylhistamine and JNJ 7777120 resulted in 
signaling comparable to stimulation with JNJ 7777120 alone (Figure 6.6).  
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Figure 6.6. Co-expression with US28 reveals H4R mediated NF-κB signaling in HEK 293T cells. HEK 
293T cells expressing either H4R, US28 or co-expressing H4R and US28 receptors were stimulated with 
10 μM of the selective H4R agonists 4-methylhistamine and clobenpropit, the selective H4R anatagonist 
JNJ 7777120, the H4R inverse agonist thioperamide or a combination of 4-methylhistamine and JNJ 
7777120. NF-κB signaling was measured in a NF-κB-luciferase reportergene assay. Data is normalized 
against signal from non-stimulated HEK 293T cells expressing only US28 receptors. 
 
Activation of the H4R induces InsP3 accumulation  
when co-expressed with US28. 
Since analysis of NF-kB signaling involves a downstream mechanism, we set out 
to investigate the effect of H4R and US28 co-expression in an upstream signaling 
event such as inositol phosphate production. To study the consequence on 
functional effect of co-expression of the H4R and US28 receptors an [3H]inositol 
phosphate (InsP3) assay was employed using transiently transfected COS-7 cells. 
US28 receptors exhibit constitutive InsP3 accumulation when expressed in COS-7 
cells (3-fold vs mock). Although the H4R is not Gαq/11-coupled, the H4R is known to 
induce Ca2+-release via βγ-subunit activation of PLC 164 and may therefore cause 
InsP3 accumulation. No H4R ligand induced InsP3 accumulation was observed in 
COS-7 cells expressing H4R (Figure 6.7). The tested H4R ligands are selective and 
do not produce InsP3 accumulation in COS-7 cells expressing US28 receptors 
alone (Figure 6.7).  In cells co-expressing H4R and US28 receptors, stimulation 
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with 10 μM of the H4R agonist 4-methylhistamine results in a small (105 ± 17 vs 
120 ± 17 %) but significant (p<0.01) increase  in InsP3 accumulation (Figure 6.7). 
This 4-methylhistamine mediated InsP3 production can be effectively inhibited by 
the H4R inverse agonist thioperamide (Figure 6.7). 
 
Figure 6.7. Acivation of H4R induces InsP3 accumulation in COS-7 cells when co-expressed with US28. 
COS-7 cells expressing either H4R, US28 or co-expressing H4R and US28 receptors were stimulated 
with 10 μM of the selective H4R agonists 4-methylhistamine, the H4R inverse agonist thioperamide or 
co-stimulated of 4-methylhistamine with thioperamide. InsP3 accumulation was measured in a [3H]InsP3 
accumulation assay. Data is normalized against signal from non-stimulated COS-7 cells expressing only 
US28 receptors. 
 
DISCUSSION 
HCMV is a species-specific virus belonging to the beta herpesvirus subfamily. 
HCMV is common in all human populations, with a seroprevalence ranging from 50 
to 80% 385. Leukocytes are a major site of HCMV latency 386,387. CMV infection has 
a potential role in atherosclerosis 388 and recently we have shown that the CMV-
encoded chemokine receptor US28 might play a role in tumorigenesis 389. US28 
promiscuously binds several chemokine ligands, including CCL2, CCL3, CCL4, 
CCL5 and CX3CL1 379,380, and US28 is rapidly internalized 383, which has led to the 
suggestion that US28 acts as a chemokine scavenger 390. This chemokine 
sequestration may be a strategy of US28 to evade immune surveillance. In this 
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study we describe another strategy in which US28 takes control of the human 
immune machinery to increase its signaling output and potentially influence 
immune responses, such as by modulating chemotactic responses of leukocytes 
i.e. by removing chemotactic receptors from the cell surface, US28 may prevent 
the HCMV infected cell to migrate to a site of inflammation.  
The latent presence of CMV and US28 mRNA in infected leukocytes 391 brought us 
to investigate the interaction between US28 and H4Rs. The H4R is expressed 
almost exclusively in hematopoietic cells and H4R activation can induce 
chemotaxis of eosinophils and mast cells 150,164,168. The H4R is involved in 
mediating the release of several interleukins and chemokines 161,181,184. Moreover, 
activation of the H4R may also cause modulation of cytokine-induced JAK/STAT 
signaling 162. This clearly demonstrates that the H4R can interact and exert 
influence on the chemokine system. 
One way for GPCRs to interact with each other is by means of hetero-
oligomerization 366. Several chemokine receptors have been shown to form homo-
oligomers as well as hetero-oligomers 368-370. We have recently shown that the H4R 
can form homo-dimers 234. The possible existence of US28 homo-dimers has also 
been predicted by the presence of high molecular weight species in Western blot 
assays 392. By means of BRET and tr-FRET we determined that US28 forms homo-
oligomers that are present at the cell surface of living cells. Interestingly, we could 
detect strong BRET and tr-FRET signals between the H4R and US28, suggesting 
the existence of H4R-US28 hetero-oligomers. This was further supported by the 
fact that HA-US28 could be immuno-precipitated by FLAG-H4R. This data suggest 
the presence of three populations when H4R and US28 are co-expressed; a 
population of H4R monomers/homo-oligomers, a population of US28 
monomers/homo-oligomers and a population of H4R-US28 hetero-oligomers. 
When we recombinantly co-expressed H4Rs with US28 we detected a decrease in 
binding sites for [3H]histamine, an H4R radioligand. However, the remaining H4R 
binding sites retained their H4R pharmacology as determined by radioligand 
displacement and dissociation assays. Recently, we demonstrated that Gαi/o-
coupled signaling may be unmasked when co-expressed with the constitutively 
active Gαq/11 coupled receptors 381. Co-expression of Gαq/11 coupled US28 and 
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Gαi/o -coupled CCR1 results in an robust increase in the Gαi/o-mediated response 
to CCL5 in a NF-κB reporter-gene assay 381. Since the H4R is also coupled to Gαi/o-
proteins, we were interested in the possible effects of co-expression of H4R and 
US28 in a NF-κB reporter gene assay, as well as in an [3H]inositol phosphates 
accumulation assay. We found that co-expression of H4R results in an increase in 
basal US28-mediated NF-κB signaling. This increase is most likely due to the 
constitutive activity of the H4R 115, since it could be completely blocked with the 
H4R inverse agonist thioperamide. Additionally, when co-expressed with US28 
stimulation with selective H4R agonists, such as 4-methylhistamine and 
clobenpropit resulted in a clear increase in NF-κB signaling. Interestingly, the H4R 
partial agonist clobenpropit 115 induced a stronger increase then the H4R full 
agonist 4-methylhistamine. Moreover the antagonist JNJ 7777120 115 behaved as a 
weak partial agonist in this co-expressed system, suggesting that these H4R 
ligands have a different pharmacology when co-expressed with US28. While less 
robust than in the NF-κB-reporter gene assay, activation of H4R with 4-
methylhistamine resulted in InsP3 formation only when co-expressed with US28, 
but not when expressed alone.  
We put forward two possible mechanisms for the observed effects. 1) The H4R 
forms hetero-oligomers with US28 that have an altered pharmacology in signaling. 
Moreover the H4R is rapidly co-internalized by US28, based on the low surface 
expression of H4R when co-expressed with the rapid and constitutive internalizer 
US28 383. 2) Hetero-oligomerization between the H4R and US28 retains the both 
receptors intracellular, however through downstream cross-activation, 
(constitutively) activated H4R influences US28 signal transduction (figure 6.8). 
More experiments are necessary to determine whether one of the mechanisms or a 
combination of both can be fully explain the observed effects. Under both 
circumstances we hypothesize that US28 may hijack the H4R for its own 
advantage. By reducing the H4R binding sites, through hetero-oligomerization and 
ER retention or subsequent rapid internalization, H4R-mediated signaling, e.g. 
chemotaxis, may be reduced. Thereby US28 may evade the immune response of 
the cells upon encountering chemotactic ligands. While the chemotactic properties 
of histamine are debatable 165 167,168 ,through activation of H4R, histamine has been 
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shown to prime leukocytes to potentiate the chemotactic effect of several 
chemokines e.g. CCL7/MCP-3, CCL11/eotaxin and CCL24/eotaxin-2 165,167. 
 
 
Figure 6.8. Schematic representation of NF-κB signal transduction by Gαq/11- and Gαi/o-coupled 
receptors.  
 
Secondly, in cells in which the H4R is co-expressed with the US28, US28 may 
increase its physiological output. Further studies should be performed to 
investigate to what extent US28 is able to interfere with H4R signal transduction 
e.g. by determining EC50 values for histaminergic and chemokine ligands in 
signaling assays and by determining receptor trafficking in more detail via 
fluorescence techniques or e.g. biotin protection assays 393. Also cells 
endogenously expressing H4R which have been infected with HCMV might be 
employed to study the interaction between H4R and US28 under more 
physiologically relevant conditions. Additionally, it will be very interesting to study 
the effects of US28 co-expression on H4R mediated chemotaxis. 
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MATERIALS AND METHODS 
Materials. Reagents for tr-FRET were from Cis Bio international (Bagnols-sur-Cèze Cedex, France). 
Chloroquine diphosphate, DEAE-dextran (chloride form) and histamine (2-[4-imidazolyl]ethylamine 
hydrochloride), was purchased from Sigma (USA). Calf serum was purchased from Integro BV (Dieren, 
The Netherlands). Polyethylenimine (linear, MW~25.000) was from Polysciences, Inc (Warrington, PA, 
USA). D-luciferin was from Duchefa (Haarlem, The Netherlands). Cell culture media, penicillin, and 
streptomycin were obtained from Life technologies (Merelbeke, Belgium). Cell culture plastics were from 
Greiner Bio-one (Wemmel, Belgium). Oligonucleotides were purchased from Isogen Bioscience 
(Maarsen, The Netherlands). PfuTurbo® DNA polymerase was purchased from Stratagene (La Jolla, 
USA). Restriction enzymes were from MBI Fermentas (St. Leon-Rot, Germany). Thioperamide, 
clobenpropit, 4-methylhistamine and JNJ 7777120, were synthesized at the Department of Medicinal 
Chemistry, Vrije Universiteit Amsterdam, Amsterdam. Gifts of expression vector pcDEF3 (Dr. J Langer), 
and are greatly acknowledged. Wild type human H4R in pcDNA3.1 was purchased from Guthrie cDNA 
resource center (Sayre, PA). The vector was subcloned into the pcDEF3 using BamHI/XbaI sites.  
 
Cell culture and transfection. COS-7 African green monkey kidney and HEK 293T human embryonic 
kidney cells were maintained at 37ºC humidified in 5% CO2/95% air atmosphere in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 5% (v/v) fetal calf serum, 50 IU/ml of penicillin and 50 
μg/ml streptomycin and grown in 100 mm dishes. COS-7 Cells were transiently transfected using the 
DEAE-dextran method as previously described 85. HEK 293T cells were transfected using the PEI 
transfection method as described previously 382.  When necessary the total amount of DNA transfected 
was maintained constant by addition of pcDEF3. 
 
BRET assay. Forty-eight hours post-transfection cells were detached with trypsin and washed twice 
with PBS. Approximately 50,000 cells per well were distributed in white bottom 96-wells microplates. 
Coelenterazine was added to a final concentration of 5 μM and readings were collected immediately 
following this addition using a Victor2 1420 Multilabel Counter allowing signal detection at 460 nm and 
530 nm. 
 
Time resolved -FRET assay. tr-FRET assays were performed using a combination of both Eu3+-labeled 
and allophyocyanin-labeled anti-FLAG and anti-HA antibodies as described previously 234 Briefly, tr-
FRET was assessed in 1 x 106 whole COS-7 cells transiently expressing the appropriate HA and FLAG 
tagged receptors. Cells were incubated in PBS containing 50% FCS (v/v), 0.8 nM of Eu3+-labelled 
antibody, and 8 nM of allophycocyanin-labelled antibody for two hours at room temperature on a 
rotating wheel, after which the membranes were washed twice with PBS. The final pellet was 
resuspended in 50 μl PBS and transferred to a 384-microtiter plate. Energy transfer was measured by 
exciting the Eu3+ at 320 nm and monitoring the allophycocyanin emission for 500 μs at 665 nm using a 
Novostar (BMG Labtechnologies) configured for tr-fluorescence after a 100 μs delay. 
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Immunoprecipitation assay. HEK 293 cells were transfected with cDNAs encoding FLAG-H4R(390) with 
or without HA-US28 using a lipofectamine method. Cell samples were solubilised with 1% Triton-X100 
in 50 mM Tris-HCL pH 7.4 and incubated with 50 μl 50% (w/v) slurry of anti-FLAG Sepharose beads 
(Sigma, UK) for 2 hrs at 4ºC. Following incubation, beads were centrifuged at 9000rpm at 4ºC for  5 
min. The supernatant was retained (unbound fraction) and the beads washed in 50 mM Tris-HCL 
pH7.4/Triton X100 and bound fraction isolated by elution in SDS PAGE Sample buffer/50mM DTT at  
50ºC for 30 min. Supernatants following centrifugation at 9000 rpm were retained (bound fraction) for 
analysis.  
 
Immunoblotting. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was carried 
out using 6 % or 7.5 % polyacrylamide slab gels under reducing conditions. Samples of HEK 293 cells 
(20-50 µg protein) were prepared using a chloroform/methanol method of protein precipitation, and 
immunoblotting was performed as previously described 203,204,234. Immunoblots were probed with anti-H4R 
374-390 antibody 234 at a concentration of 0.5 µg /ml. Blots containing FLAG- or HA-tagged receptors 
were probed with primary antibodies, mouse anti-FLAG (1.5 μg/ml) or rat anti-HA (1 μg/ml), respectively. 
Horseradish peroxidase conjugated goat anti-mouse or anti-rat antibodies (1:2000-5000) were used as 
secondary antibodies (Little Chalfont, Buckinghamshire, England). 
 
Surface Biotinylation assay. HEK 293 cells were transfected with individual cDNAs encoding H4R(390) 
or US28 , or co-transfected with H4R(390)  with equal amounts of US28 using lipofectamine method. The 
medium was carefully removed 24-40 hours post transfection and cells were washed with ice-cold 
PBS/4 % (w/v) sucrose (3x1 ml per 35mm dish).  The cells were then incubated for 15 min at 4ºC with 
1mg/ml Sulfo-NHS-SS-Biotin in ice-cold PBS/4 % (w/v) sucrose (0.5 ml/dish) with gentle shaking. 
Subsequently, cells were washed once with ice- cold PBS/4 % (w/v) sucrose (1ml/dish), and incubated 
for 10 min at 4ºC with quenching buffer (192mM glycine, 4%  (w/v) sucrose in 50mM Tris-HCl pH 8.0 ) 
(0.5 ml/dish). Cells were scraped into PBS//4 % (w/v) sucrose and spun at 6000 rpm for 2 min. This 
wash procedure was repeated on a further occasion and the cells were homogenised in 1% (w/v) SDS 
in lysis buffer (50mM Tris-HCl, pH 8.0/ 2 mM EDTA/1% Triton-X100 The samples were then diluted five-
fold in lysis buffer (without SDS), and incubated with 20 μl 50% (w/v) slurry of streptavidin beads for 2 
hrs at 4ºC. Following incubation, beads were centrifuged at 9000rpm at 4ºC for  5 min. The supernatant 
(intracellular fraction) was retained and the beads washed in lysis buffer. The bound fraction was 
isolated by elution in SDS PAGE Sample buffer/50mM DTT at  50ºC for 30 min. Supernatants following 
centrifugation at 9000 rpm were retained (surface fraction) for analysis.                                               
 
Radioligand binding studies. Cells used for radioligand binding studies were harvested 48h post 
transfection and homogenized in ice cold hH4R binding buffer (50 mM Tris, pH 7.4). For saturation 
isotherms cell membrane homogenates were incubated at 37ºC for 60 minutes with 0-150 nM 
[3H]histamine in a total assay volume of 200 μl. For competition binding assays the cell homogenates 
were incubated at 37ºC for 60 minutes with 0.1-10.000 nM ligand in the presence of ~15 nM 
[3H]histamine in a total volume of 200 μl. The incubations were stopped by rapid dilution with ice cold 
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hH4R binding buffer. Bound radioactivity was separated by filtration through GF/C filterplates (Perkin 
Elmer) that had been treated with 0.3% PEI. Filters were washed four times with ice cold hH4R binding 
buffer and radioactivity retained on the filters was measured by liquid scintillation counting. 
 
Radioligand dissociation assay. Cells used for radioligand binding studies were harvested 48h post 
transfection and homogenized in ice cold hH4R binding buffer (50 mM Tris, pH 7.4). Cell membranes 
were incubated for 1 hour with 10-20 nM of [3H]histamine. The [3H]histamine was dissociated by 
addition of 10 μM of the selective H4R antagonist JNJ 7777120 or 1 μM of CCL5 (RANTES). Samples 
were collected at different time intervals. Non dissociated radiolabel was harvested by filtration through 
GF/C filterplates. Filters were washed four times with ice cold hH4R binding buffer and radioactivity 
retained on the filters was measured by liquid scintillation counting. 
 
NF-κB-luciferase reporter gene assay. HEK 293T cells transiently co-transfected with 5 μg pNF-κB-
Luc and 1 μg pcDEF3-H4R and  1 μg pcDEF3-US28 were seeded in 96-well whiteplates (Costar, 
Cambridge, MA) in culture medium and after 24 h incubated with ligands. After 48 h, cells were assayed 
for luminescence by aspiration of the medium and the addition of 25 μl/well luciferase assay reagent 
(0.83 mM ATP, 0.83 mM D-luciferin, 18.7 mM MgCl2, 0.78 μM Na2H2P2O7, 38.9 mM Tris, pH 7.8, 0.39% 
(v/v) glycerol, 0.03% (v/v) Triton X-100, and 2.6 μM dithiothreitol). After 30 min, luminescence was 
measured for 3 s/well in a Victor2 1420 Multilabel Counter (PerkinElmer Life and Analytical Sciences). 
 
[3H]inositol phosphate accumulation assay. Cells were seeded in 24-well plates, and 24 h after 
transfection labelled overnight in inositol-free-medium supplemented with 1μCi/ml myo-[2-3H]inositol. 
Subsequently, the labeling medium was aspirated, cells were washed with PBS and pre-incubated for 
10 min with Dulbecco’s modified Eagle’s medium containing 25 mM HEPES (pH 7,4), 20 mM LiCl2. The 
pre-incubation medium was aspirated and cells were incubated in the same medium in the absence or 
presence of ligands. The incubation was stopped by aspiration of the medium and addition of cold 10 
mM formic acid. After 90 min of incubation of ice, inositol phosphates were isolated by anion exchange 
chromatography (Dowex AG1-X8 columns, Bio-Rad) and counted by liquid scintillation. 
 
Analytical methods. All radioligand binding data were evaluated by a non-lineair least squares curve 
fitting program using Graphpad Prism® (Graphpad Software Inc, San Diego, CA). Protein concentrations 
were determined according to Bradford, using BSA as standard. All data are represented as mean ± 
S.E.M. from at least three independent experiments in triplicate. Statistical significance was determined 
by a ANOVA tuckey test (p<0.05 was considered statistically significant). 
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ABSTRACT 
 
The human histamine H4 receptor (hH4R) is the fourth and latest discovered 
member of the histamine family of G protein coupled receptors (GPCRs). The H4R 
has been suggested to play a role in e.g. inflammatory diseases like allergic rhinitis 
and rheumatoid arthritis. Recently, suggestions have been made for the H4R to be 
involved in certain forms of cancer as well, showing the potential for the H4R as 
interesting drug target. The rational design of new drugs strongly benefits from high 
resolution structural information of the target. However, to obtain this information, 
using biophysical techniques, large and pure amounts of the GPCR are required.  
This study describes our attempts to overexpress the hH4R using several different 
techniques, including viral expression systems and codon optimization of the H4R. 
Both the Semliki Forest virus and the baculovirus expression system were 
employed to overexpress the H4R. While highest H4R expression was obtained 
with the baculovirus system we also found that epitope tagging of the H4R could 
significantly enhance H4R expression levels, especially hemagglutinin and c-myc 
epitope tags gave marked increases in H4R expression. On the other hand codon 
optimization only resulted in a maximal 2-fold increase in H4R expression. 
Combining several of the strategies used, could help to increase H4R expression to 
start purification efforts and subsequently biophysical studies. 
INTRODUCTION 
 
G protein coupled receptors (GPCRs) form one of the largest family of drug targets 
for the pharmaceutical industry 2. The development of new drugs is currently based 
predominantly on high throughput screening of large libraries of drug like 
compounds and the rational design of ligands based on current knowledge of the 
receptor target. The cloning of many GPCRs during the last decades has helped 
tremendously in studying the binding pocket of the receptor. Applying site directed 
mutagenesis, the interaction points of the ligand binding pocket can be determined 
to a certain degree. A key step in rational approach to receptor-ligand interactions 
was the crystallization of rhodopsin in 2000, resulting in the high resolution (2.8 Å) 
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structure of this GPCR 33. Until today rhodopsin remains the only GPCR for which 
such a high resolution structure has been produced. However, for the other 
GPCRs, the use of computer models together with the protein sequence of the 
receptor has resulted in the formation of homology models i.e. computer models of 
GPCRs for which the protein sequence has been overlaid on the rhodopsin 
structure. These models can be improved with the data obtained from mutational 
studies. An additional option is to obtain structural data for the receptor target 
directly.  
Besides the hydrophobic membranous nature of GPCRs, one of the main reasons 
why no other GPCRs have been crystallized so far is the difficulty to obtain large 
and pure enough amounts of receptor protein. Under physiological conditions most 
of the GPCRs are expressed at very low levels. Over the last decade several 
methods have been exploited to overexpress GPCRs. For example, E.coli and 
certain yeast strains like Saccharomyces cerevisiae and P. pastoris have been 
widely employed for this purpose 394,395. However, expression of GPCRs in non-
mammalian cells suffer from the lack of post-translational modifications, which can 
affect the folding and transport of these proteins, and potentially GPCR 
functionality 396. The use of viral expression systems has facilitated large scale 
production of many GPCRs 397,398. The two most commonly used viral expression 
systems are the baculovirus 396 and the Semliki Forest virus 399. Finally epitope 
tagging or codon optimization of GPCRs can also result in significant increases of 
receptor expression 400. 
Six years ago a fourth receptor belonging to the family of histamine receptors was 
cloned 148-153. This histamine H4 receptor (H4R) is suggested to play a role in 
inflammatory diseases 194,401 and might also be involved in  rheumatoid arthritis 188 
and cancer 189,190, making the H4R an interesting new drug target. To facilitate the 
synthesis of high affinity and selective ligands targeting the H4R the availability of 
detailed structural information of the H4R binding pocket would be helpful. Such 
structural information can only be obtained with large quantities of H4R protein. 
Since the H4R is not endogenously expressed at high levels, recombinant methods 
have to be employed to enhance the expression level of the H4R.  
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Herein we report on our attempts to overexpress the human histamine H4 receptor 
using several different strategies. We have employed both baculovirus and Semliki 
Forest virus as well as differentially epitope tagging and codon optimizing the 
hH4R. In our hands higher levels of H4R expression was obtained using the 
baculovirus expression system than by employing the Semliki Forest virus 
expression system. We found that codon optimization resulted only in a minor 
increase of H4R expression, whereas the use of certain epitope tags resulted in a 
10-fold increase in expression over wild-type H4R expression. 
 
RESULTS 
 
Overexpression of the hH4R through codon optimization and epitope tagging. 
In 1999 Mirabekov et al. enhanced the expression of the CCR5 chemokine 
receptor by codon optimizing the coding region of the CCR5 gene. The codon 
optimized CCR5 showed 2-5 times enhanced expression compared to the wild-
type receptor. Incubation with sodium butyrate further increased the expression of 
the CCR5 402. Codon optimization is considered to facilitate the 
transcription/translation machinery by removing rare codons from the gene of 
interest 403. To determine whether codon optimization of the hH4R would help 
increase its expression level we developed a codon optimized hH4R (hH4coR). The 
gene for the H4coR was constructed to predominantly use only the most abundant 
codon for each amino acid (Figure 7S). The following codons were used: alanine 
(GCC), arginine (AGA), asparagine (AAC), aspartate (GAC), cysteine (TGC), 
glutamate (GAG), glutamine (CAG), glycine (GGC), histidine (CAC), isoleucine 
(ATC), methionine (ATG), leucine (CTG), lysine (AAG), phenylalanine (TTC), 
proline (CCC), serine (AGC or TCC), threonine (ACC), tryptophan (TGG), tyrosine 
(TAC), valine (GTG) (Figure 7S). Expression of the hH4coR in HEK293T cells 
(Figure 7.1A) or COS-7 (Figure 7.1B) resulted maximally in a 2-fold increase in the 
expression level of the wild type H4R (0.2 and 1.5 pmol/mg protein in HEK 293T 
and COS-7, respectively).  
Epitope tagging of a receptor can have a significant effect on receptor expression 
levels 400. To determine the effect of N-terminal epitope tags on the expression 
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level of the wild-type H4R, we created several H4R constructs; a hemagglutinin 
tagged H4R (HA-H4R), a FLAG tagged H4R (FLAG-H4R), a c-myc tagged H4R 
(myc-H4R) and an N-terminally c-myc tagged plus C-terminally histidine tagged 
H4R (myc-H4R-His10). When transiently expressed in HEK 293T (Figure 7.1A) or 
COS-7 cells (Figure 7.1B) a 2- and 11-fold increase in expression level was 
observed for the HA- and myc-tagged H4Rs compared to the wild-type H4R in 
COS-7 and HEK 293T cells, respectively.  The introduction of a FLAG epitope tag 
did not show a marked effect on H4R expression level in COS-7 cells, while in HEK 
293T cells a relatively small 3-fold increase was observed. A >10-fold increase was 
observed with the HA- and c-myc-tagged H4Rs.  
 
 
Figure 7.1.  Recombinant expression of a codon optimized H4R and differentially tagged H4Rs in 
mammalian cells. HEK 293T (A) or COS-7 (B) cells were transiently transfected with either wild-type 
H4R, codon optimized H4R (H4coR), FLAG-H4R, HA-H4R, c-myc-H4R, or c-myc-H4R, expression levels 
were determined by [3H]histamine displacement.   
 
Another option to increase receptor expression levels is the addition of sodium 
butyrate in the growth medium. Sodium butyrate is a histone deacetylase inhibitor 
found to arrest growth and to induce differentiation in various cell types by 
modulating gene expression 404. For several GPCRs incubation of the cells with 
sodium butyrate has been shown to enhance receptor expression 402,405. To test 
whether sodium butyrate has a positive effect on H4R expression levels we 
produced a CHO cell line stably expressing the H4coR. However, 48 hour incubation 
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of stably transfected CHO-H4coR cells with 5 mM, 10 mM or 50 mM sodium 
butyrate did not have a positive effect on the expression of the H4R (Figure 7.2).  
Expression levels can be enhanced by increasing the number of receptors that are 
correctly folded on the plasma membrane. Pre-incubation with ligand may stabilize 
the receptor 406,407. Previously we have shown that incubation with the H2R inverse 
agonist ranitidine has a positive effect on H2R expression levels 408. However, 
incubation of stably transfected CHO-H4coR with the H4R inverse agonist 
thioperamide (10 μM) for 24 hours resulted in a significant decrease in the H4R 
expression level (2.5 pmol/mg protein vs 1.6 pmol/mg protein), while longer 
incubation (48 hours) resulted in a even stronger, 2-fold, reduction in H4R 
expression (Figure 7.2). 
 
Figure 7.2.  Effect of sodium butyrate and inverse agonist incubation on H4R expression in CHO cells, 
stably expressing the H4coR. CHO cells stably expressing H4coR were cultured in the presence or 
absence of the H4R inverse agonist thioperamide (10 µM, TP) for 24 and 48 hours or different 
concentrations of sodium butyrate (5, 10 or 20 mM) for 48 hours. Expression levels were determined by 
[3H]histamine displacement. 
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Overexpression of the hH4R using Semliki Forest virus. 
We have previously successfully employed the SFV viral expression system to 
increase rH2R expression levels in infected COS-7 cells 408. One of the main 
advantages of the SFV over the baculovirus expression system (BEVS) is the 
ability to infect a variety of mammalian cells e.g. CHO, COS-7, BHK, HEK 293 409. 
To investigate the ability of the SFV expression system to facilitate high expression 
of the hH4R we constructed an N-terminally FLAG and C-terminally His10 tagged 
H4R (FLAG-H4R-His10) in the pSFVgenB vector. The epitope tags were used for 
eventual detection and purification of the receptor, respectively. To determine what 
the optimal time of infection is to reach maximal H4R expression for SFV infection, 
cells were infected with recombinant SFV and harvested at different time points. 
For H2R expressed in COS-7 cells using recombinant SFV, expression reached a 
plateau after 16 hours, which was sustained for at least 24 hours (Hoffmann et al., 
2001). We infected CHO cells with SFV-H4R and harvested the cells either 24 
hours (1 dpi) or 48 hours (2 dpi) after infection and H4R expression level were 
determined using [3H]histamine binding (Figure 7.3A). Compared to 1 dpi, a drastic 
decrease in H4R expression level was observed at 2 dpi (Figure 7.3A). Therefore, 
to determine expression levels in recombinant SFV-H4R infected in COS-7, BHK, 
HEK 293T or CHO cells were harvested 24 hours after infection. The expression 
level of H4R in BHK, HEK 293T and CHO cells were 2-fold (BHK) and 5-fold (HEK 
293T and CHO) lower than that in SK-N-MC neuroblastoma cells stably expressing 
the H4R (Figure 7.3B). SFV-H4R infection in COS-7 cells resulted in H4R 
expression levels that were slightly higher than the expression in the SK-N-MC-
H4R cell line (2.45 vs 1.8 pmol/mg protein).  
To characterize the pharmacology of the H4R in infected CHO cells radioligand 
displacement assays were performed in which [3H]histamine was displaced by a 
selection of typical H4R ligands: the endogenous agonist histamine, the full agonist 
clobenpropit, the neutral antagonist JNJ7777120 and the inverse agonist 
thioperamide (Figure 7.3C). The obtained pKi-values of these compounds for the 
FLAG-H4R-His10 in infected CHO cells were comparable to the values obtained for 
the H4R in stable transfected SK-N-MC cells (Table 7.1). 
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Figure 7.3.  Expression of FLAG-H4R-His10 in mammalian cell lines infected with recombinant Semliki 
Forest virus. A, Infected CHO cells were harvested one or two days after infection (dpi) with 
recombinant Semliki Forest virus B, COS-7, BHK, HEK 293T and CHO cells were infected with 
recombinant SFV. As control SK-N-MC neuroblastoma cells stably expressing H4Rs were used. H4R 
expression was determined by [3H]histamine displacement. C, Displacement of [3H]histamine by typical 
H4R ligands on Semliki Forest virus infected CHO cells recombinantly expressing FLAG-H4R-His10. 
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Table 7.1. Characterization FLAG-H4R-His10 in Semliki Forest virus infected CHO cells or baculovirus 
infected Spodoptera frugiperda Sf9 cells. As control SK-N-MC neuroblastoma cells stably expressing 
the wild-type H4R were characterized. The KD values for histamine in nM, and the pKi values of 
histamine and thioperamide for the H4R constructs used in the experiments as determined by 
[3H]histamine saturation and displacement binding assays. The values are expressed as mean ± SEM 
of at least three separate experiments performed in triplicate. 
[3H]histamine 
pKi  FLAG-H4R-His10  
KD (nM) 
Histamine Clobenpropit JNJ 7777120 Thioperamide 
CHO (SFV infected) 24 ± 22* 7.7 ± 0.2 7.8 ± 0.1 8.0 ± 0.2 7.6 ± 0.2 
Sf9 (baculovirus infected) 153 ± 17* 
125.9** 
6.8 ± 0.1 7.2 ± 0.1 6.7 ± 0.2 6.7 ± 0.1 
SK-N-MC-H4R 21 ± 2 7.6 ± 0.1 7.9 ± 0.2 7.5 ± 0.1 7.0 ± 0.1 
* determined by homologous displacement 
** determined by saturation binding (n=1) 
 
Overexpression of the hH4R using baculovirus. 
Currently, we are successfully employing the BEVS to produce large amount of the 
hH1R 407. The BEVS is frequently used to study GPCRs, as the baculovirus infects 
insect cells naturally devoid of endogenous mammalian GPCRs 410. Although these 
insect cells do not have the same post translational modification mechanism of 
mammalian cells, it resembles the mammalian system better than yeast or E.coli 
expression sytem 396. However, the generation of recombinant baculovirus can be 
a difficult and tedious job. We have employed the FastBac™ system to obtain 
recombinant baculovirus containing the gene encoding the FLAG-H4R-His10 
relatively quickly. When infecting Spodoptera frugiperda (Sf9) cells expression of 
the hH4R was measured using [3H]histamine radioligand binding. Generally, 
baculovirus infected Sf9 cells reach maximal expression of the recombinant gene 
around 4-6 dpi 396. Baculovirus-H4R infected Sf9 cells were harvest at 3, 4, 5 and 6 
days after infection (3-6 dpi) and H4R expression level were determined using 
[3H]histamine binding (Figure 7.4A). H4R expression was relatively low at 3 and 4 
dpi, but roughly doubled after 5 days, and remained stable at 6 dpi (Figure 7.4A).  
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Figure 7.4.  Expression of FLAG-H4R-His10 in Sf9 insect cells infected with recombinant baculovirus. A, 
Infected Sf9 cells, grown in TNM-FH medium, were harvested at different time points, starting from 3 dpi 
till 6 dpi with recombinant baculovirus. B, Infected Sf9 cells were grown in TNM-FH medium and 
harvested 5 days after infection (dpi) C, Infected Sf9 cells were grown in either TNM-FH medium (black 
bar) or serum free Xpress medium. Infected cells grown in TNM-FH medium were incubated in the 
presence (closed bars) or absence (open bars) of 20 μM thioperamide (TP) and harvested at 4 dpi. H4R 
expression levels were determined by [3H]histamine displacement. D, Displacement of [3H]histamine by 
typical H4R ligands on baculovirus infected Sf9 cells recombinantly expressing FLAG-H4R-His10.  
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Using an M.O.I of 1 and harvesting at 5 dpi expression of the FLAG-H4R-His10 
maximally reached 14 pmol/mg protein (Figure 7.4B). To compare the effect of 
expression medium, Sf9 cells grown in either serum rich TNM-FH medium or 
serum free insect Xpress medium, were infected with baculovirus (M.O.I. = 1) and 
were harvested at 4 dpi. Expression levels were significantly higher in Sf9 cells 
grown in TNM-FH medium than in insect Xpress medium (Figure 7.4C). H4R 
expression did not benefit from incubation with 20 μM of the H4R inverse agonist 
thioperamide during culture, which, by stabilizing the receptor, could have assisted 
in inducing and maintaining proper folding and subsequent transport of the H4R to 
the plasma membrane (figure 7.4C). 
The pharmacology of the H4R in infected Sf9 cells was characterized by 
radioligand displacement assays in which [3H]histamine was displaced by 
histamine, clobenpropit, JNJ7777120 and thioperamide (Figure 7.4D) The 
pharmacology of the FLAG-H4R-His10 in baculovirus infected Sf9 insect cells 
differed from that of H4Rs stably expressed in SK-N-MC neuroblastoma cells as the 
affinity of several tested H4R ligands showed an almost ten fold drop in pKi-values 
compared to the H4R in mammalian cells (Table 7.1). 
 
DISCUSSION 
Over 1% of the human genome is encoded by G protein-coupled receptors 
(GPCRs). These genes give rise to the existence of over 1000 GPCRs 1. Many 
GPCRs are involved in diseases and as such make for interesting targets for the 
pharmaceutical industry. It is estimated that approximately 50 % of available 
therapeutic drugs target GPCRs 2. While more money is spend every year in 
research, development and production of these drugs, fewer and fewer new drugs 
are successfully brought to the market 411. Part of this growing problem lies in the 
difficulty to find more selective and high affinity compounds for existing targets. In 
most cases high throughput screenings are employed to find potential leads for 
new or existing drug targets. In the end these leads still require optimization to 
increase their selectivity and affinity. This step is for the larger part trial and error 
based, as detailed information on the receptor binding pocket is scarce. Up till 
today the only high resolution structure that has been resolved for a GPCR comes 
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from X-ray crystallography of rhodopsin 33. As for other membrane proteins it is 
very difficult to obtain good crystals of GPCRs for X-ray crystallography. 
Considering that under physiological conditions the expression of GPCRs is 
relatively low, an important obstacle is the requirement of large amounts of pure 
protein. Over the last decades several methods have been developed to 
overexpress GPCRs. GPCRs have been expressed in bacteria (E.coli), yeast 
(Saccharomyces cerevisiae, P. pastoris) or in insect cells using baculovirus 
infection 394-396. Another viral expression system which has been broadly used to 
infect mammalian cells is the Semliki Forest virus 399. All of these methods have 
their advantages and disadvantages, but none of these methods have so far 
successfully produced new high resolution structures of GPCRs. To overcome the 
problems encountered when pursuing large scale production and purification of 
GPCRs several national and international networks have been established. 
Examples include Joint Center for Structural Genomics (JCSG), E-Mep and 
Membrane Protein Network (MePNet) 412.  
In recent years we have had success in overexpressing the human histamine H2 
receptor using recombinant Semliki Forest virus 408 and the human histamine H1 
receptor using recombinant baculovirus 407. Six years ago a new member of the 
histamine receptor family was identified and cloned 148-153. The H4R is expressed 
predominantly on leukocytes and mast cells 148,150 and has a potential role in 
inflammatory diseases like allergic rhinitis 160 and rheumatoid arthritis 188. Recently 
the H4R receptor was also linked to a possible role in colon cancer 189,190 making 
this receptor an interesting target for the pharmaceutical industry 194,401.  
To facilitate drug design we attempt to obtain structural information of the H4R 
through biophysical techniques like NMR, MS or FT-IR. The first step in this 
process is the large scale production and subsequent purification of the H4R 
protein. To enable purification of the receptor often a short epitope tag is 
introduced N- or C-terminal of the receptor gene. In some cases the addition of 
such a tag has no influence on receptor expression level. For example the 
introduction of an N-terminal c-myc tag to the serotonin 5-HT1B receptor did not 
result in a significant increase of the expression level using recombinant 
baculovirus 264. On the other hand double tagging (His6-FLAG) of the adenosine A1 
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and in particular the A2A receptors showed marked amplification of receptor 
expression levels compared to wild-type receptors 400. To investigate the influence 
of epitope tagging on H4R expression level a broad range of differentially tagged 
H4Rs were examined. In the case of the H4R the most significant increase (3-10 
fold) in expression levels were obtained using either c-myc- or HA-epitope tags. A 
similar positive influence of the HA-epitope tag was apparent for the H1R 
(unpublished observation).  
Previous studies on the CCR5 chemokine 402 and the human herpesvirus encoded 
U51 413 receptors have shown that codon optimization can enhance receptor 
expression levels from 2-5 fold (CCR5) to 10-100 fold 413. However, codon 
optimization of the H4R gene did not result in a marked increase of H4R expression. 
Maximally a 2-fold increase was observed in transiently transfected HEK 293T 
cells. Apparently the codon usage of the H4R receptor is not the rate limiting step in 
the production of the H4R protein. 
We have previously demonstrated that the use of viral expression systems can be 
a valuable tool in the large scale production of histamine receptors. Infection of 
COS-7 cells with recombinant SFV-rH2R resulted in H2R expression levels up to 50 
pmol/mg protein 408. Also expression levels of other GPCRs have been 
successfully amplified using SFV. Expression levels over 30 pmol/mg protein have 
been obtained for the metabotropic glutamate R1 receptor 414 the adrenergic α2BR 
415 and the human neurokinin receptor NK1R 416. However, infection of recombinant 
SFV-FLAG-H4R-His10 in a set of different mammalian cell lines did not result in 
expression levels exceeding that of the wild-type H4R in stably expressing SK-N-
MC neuroblastoma cells (2.5 pmol/mg protein). The use of different epitope tags 
e.g. c-myc or hemagglutinin could help improve expression levels as was shown in 
transiently transfected cells (this manuscript).  
Besides SFV, the use of baculovirus expression vector system (BEVS) has been 
widely employed to express (human) GPCRs in insect cells. We have successfully 
used the BEVS to produce and purify large amounts of the hH1R 407. Infection of 
Sf9 cells with recombinant baculovirus containing the FLAG-H4R-His10 resulted in 
H4R expression levels maximally ranging from 9-14 pmol/mg protein. However, the 
pharmacology of the H4R differed from the H4R expressed in mammalian cells. A 
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possible explanation for the decreased binding affinity of H4R ligands towards the 
FLAG-H4R-His10 expressed in Sf9 cells could be that the tags have a negative 
effect on the binding pharmacology of the H4R. However, the same double tagged 
receptor did not affect the binding of ligands when expressed in mammalian cells 
using the SFV. Therefore it is more likely that the low abundance of native G-
proteins in insect cells is the reason for the observed decrease in affinity.  The 
effect of G-proteins would be more pronounced when using an agonist radioligand, 
as is the case for the H4R binding ([3H]histamine). In the present experimental set 
up a FLAG-H4R-His10 was used. However, it turned out that the FLAG-epitope tag 
has the least beneficial effect on H4R expression levels. It would therefore be of 
interest to generate a recombinant baculovirus containing c-myc or HA eptiope 
tagged H4R. Also the H4R was placed behind the p10 promoter, whereas high 
expression for e.g. the hH1R 407 and the turkey β-adrenergic receptor 417 were 
obtained when the gene was under control of the polyhedron promoter. Although 
the use of both SFV and BEVS is widely spread, these methods have not yet 
resulted in the production of purified receptors suitable for high resolution structure 
elucidation. Therefore it is important to also consider different approaches. A 
technique that does not require any host cell is the cell free expression system. 
This method has recently been employed to successfully produce milligrams of 
human β2-adrenergic receptor protein 418. While no post-translational modifications 
are applied to the receptor, production of protein is much faster than using viral 
expression systems and also the produced protein is already relatively pure 
compared to proteins produced in cells. Altogether this makes the cell free 
expression system potentially valuable for large scale production of GPCRs. 
In summary, we have investigated several different methods to overexpress the 
human H4R in a various range of different cell lines. We found that epitope tagging 
the H4R with an N-terminal c-myc or a hemagglutinin HA tag resulted in significant 
increase (up to 10-fold) of H4R expression. Codon optimization of the H4R or 
introduction of an N-terminal FLAG tag did not have a marked effect on H4R 
expression. Whereas for the H2R, SFV 408 gave higher expression than the BEVS 
108, for the hH4R highest expression levels (up to 14 pmol/mg protein) were 
obtained using baculovirus. The obtained knowledge can be used to choose and 
Overexpression of H4R 
 
 173
optimize the best technique to increase H4R expression levels high enough to 
facilitate large scale production of H4R protein to continue with GPCR purification 
and potentially structural studies like MS, NMR, FT-IR or X-ray crystallography. 
 
MATERIALS AND METHODS 
Materials. Bovin serum albumin, chloroquine diphosphate, DEAE-dextran (chloride form), histamine(2-
[4-imidazolyl]ethylamine hydrochloride), polyethyleneimine Leupeptin and TNM-FH insect medium was 
purchased from Sigma (USA). Cellfectin, pFastBac_Dual vector and DH10Bac competent cells were 
from Invitrogen (Breda, The Netherlands). Calf serum (Integro BV, Dieren, The Netherlands). Insect-
Xpress medium and Sea plaque agarose was from Cambrex (Walkersville, MD, USA). Cell culture 
media, penicillin, and streptomycin were obtained from Life technologies (Merelbeke, Belgium). Cell 
culture plastics were from Greiner Bio-one (Wemmel, Belgium). Tris was from AppliChem (Darmstadt, 
Germany). [3H]histamine (12.40 and 18.10 Ci/mmol) was from PerkinElmer Life and Analytical Sciences 
(Boston, MA). Geneticin (G418), kanamycin, gentamycin and tetracyclin were purchased from Duchefa 
(The Netherlands). Oligonucleotides were purchased from Isogen Biocience (Maarsen, The 
Netherlands). PfuTurbo® DNA polymerase was purchased from Stratagene (La Jolla, CA). Restriction 
enzymes were from MBI Fermentas (St. Leon-Rot, Germany). Thioperamide fumarate, clobenpropit 
dihydrochloride and JNJ 7777120, were synthesized at the Department of Medicinal Chemistry, Vrije 
Universiteit Amsterdam, Amsterdam, The Netherlands. Gift of the expression vector pcDEF3 (Dr. J 
Langer, 221 is greatly acknowledged.  
Wild type human H4R in pcDNA3.1 was purchased from Guthrie cDNA resource center (Sayre,PA). The 
vector was subcloned into the pcDEF3 using BamHI/XbaI sites. The codon optimized H4R was 
purchased from GENEART GmbH (Regensburg, Germany) and supplied in a pPCR-script AMP vector 
(Figure 7S). The H4coR gene was subclone into the pcDEF3 expression vector using BamHI/XbaI sites. 
 
Cell culture and transfection of mammalian cells. COS-7 African green monkey kidney, Chinese 
hamster  ovarian (CHO) and human embryonic kidney (HEK 293T) cells were maintained at 37ºC 
humidified in 5% CO2/95% air atmosphere in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 5% (v/v) fetal calf serum, 50 IU/ml of penicillin and 50 μg/ml streptomycin and grown 
in 100 mm dishes. Cells were transiently transfected using the DEAE-dextran method as previously 
described 85. The total amount of DNA transfected was maintained constant by addition of pcDEF3. 
 
Cell culture of Spodoptera frugiperda (Sf9) cells. Sf9 cells were cultured as monolayers and 
maintained at 27°C in TNM-FH medium supplemented with 10% (v/v) FCS, 50 IU/ml penicillin and 50 
μg/ml streptomycin or insect Xpress supplemented with 50 IU/ml penicillin and 50 μg/ml streptomycin. 
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[3H]histamine binding studies. Cells used for radioligand binding studies were harvested 48h post 
transfection and homogenized in ice cold H4R binding buffer (50 mM tris, pH 7.4). For saturation 
isotherms cell membrane homogenates were incubated at 37ºC for 60 minutes with 0-125 nM 
[3H]histamine in a total assay volume of 200 μl. Non-specific binding was determined by incubation in 
the presence of 10 μM JNJ 7777120. For competition binding assays the cell homogenates were 
incubated at 37ºC for 60 minutes with 0.1-10.000 nM ligand in the presence of ~15 nM [3H]histamine in 
a total volume of 200 μl. The incubations were stopped by rapid dilution with ice cold H4R binding buffer. 
The bound radioactivity was separated by filtration through Whatman GF/C filterplates that had been 
treated with 0.3% polyethyleneimine. Filters were washed four times with H4R binding buffer and 
radioactivity retained on the filters was measured by liquid scintillation counting. 
 
Construction of epitope-tagged H4Rs. The construction of FLAG-H4R and HA-H4R and c-myc-H4R-
His10 has been described before 234. An N-terminally c-myc (EQKLISEEDL) epitope tagged H4 receptor 
was created by PCR in two steps. The c-myc tag was amplified by PCR using a pcDEF3-Myc-H1 vector 
(kind gift of Steve Hill) as template with a 3’ NheI site using the following sense 5’-
GGGTGGAGACTGAAGTTAGGCC-3’and antisense primer 5’-GTGCTAGCAGGTCCTCCTCGGAG-3’. 
The fragment was directly cloned to the pCRII-Topo vector (pCRII-topo-myc). The H4 gene was 
amplified without start codon and containing a 5’ NheI restriction site using the following sense 5’-
CCGCTAGCCAGATACTAATAGCAC-3’ and anti sense primer 5’-TCTTTAAGAAGATACTGACC-3’. The 
gene was directly cloned to the pcDNA3.1/ V5-His-Topo vector. The H4 gene was subsequently cloned 
in frame using NheI/NotI into the pCRII-topo-myc vector (pCRII-topo-myc-H4). The resulting myc-H4 
gene was subsequently cloned into the pcDEF3 expression vector using the BamHI/XbaI sites. The 
construct was fully sequenced before its expression and analysis. 
 
Generation of stable cell lines. CHO cells were transfected with pcDEF3-H4coR, pcDEF3-H4-eYFP or 
pcDEF3-myc-H4R-His10 using polyfect (Qiagen Benelux, Venlo The Netherlands) as described by the 
manufactures protocol. In short CHO cells were transfected with 4 μg of DNA using polyfect and splitted 
1:100 in culture medium containing 1 mg/ml G418. Single colonies of cells were picked and H4R 
expression was verified through radioligand binding to select clones highly expressing the H4R.   
 
Generation of recombinant Semliki Forest virus particles. A N-terminally tagged FLAG and C-
terminally tagged His10 H4 gene in a suitable vector for creation of Semliki Forest virus was created by 
PCR in two steps. The H4 gene was amplified from the pcDEF3-H4R vector by PCR without start and 
stop codon with a 5’BamHI site and a 3’ SpeI site using the following sense 5’-
CCGGATCCCCAGATACTAATAGCACAATCAA-3’and anti sense primer 5’-CCGCGGCCGC 
ACTAGTAGAAGATACTGACCG AC-3’. The gene was directly cloned into the pCRII-Topo vector. The 
H4 gene was subsequently cloned in frame from the pCRII-topo-vector using BamHI/SpeI sites in the 
pSFV2genB vector. The construct was fully sequenced before its expression and analysis. 
pSFV2genB–FLAG-H4R-His10 and pSFV–helper2 plasmids 409 were linearised with SapI and SpeI, 
respectively, and were purified by phenol/chloroform extraction prior to in vitro transcription. RNA was 
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synthesised in vitro driven from the bacterial SP6 promoter. 2.5 μg of linearised plasmids were 
transcribed with 7 U SP6 RNA polymerase (Amersham Pharmacia Biotech) in a buffer containing 40 
mM HEPES (pH 7.4), 6 mM MgOAc, 2 mM spermidine, 1 mM of ATP, CTP and UTP, 0.5 mM GTP, 1 
mM m7G(5’) ppp(5’)G (CAP; Amersham Pharmacia Biotech), 1.5 U RNAsin (Roche) and 5 mM 
dithiothreitol in a final volume of 50 μl for 1 h at 37 °C. BHK-21 cells from a semiconfluent 168 cm2 flask 
were detached with Versene/Trypsine solution. Cells were collected by centrifugation for 5 min at 1500 
rpm and washed twice with 10 ml PBS. Cells were resuspended in 2.4 ml PBS prior to electroporation 
with the in vitro synthesised RNA. 400 μl of BHK-21 cell suspension was transferred to a Biorad 
Genepulser cuvette (Biorad, 165–2086) together with 50 μl of transcribed pSFV2genB–FLAG-H4R-His10 
RNA and 25 μl of transcribed pSFV–helper2 RNA. Cells were electroporated twice in a Biorad 
Genepulser (settings: 25 μF, 1500 V, ∞Ω). Following electroporation cells were immediately 
resuspended in growth medium and seeded in 25-cm2 flasks. 24 h after electroporation, the medium 
from the cells was collected, passed through a 0.22-μm filter. Viral particles were stored at -80 °C.  
 
Infection of mammalian cell with SFV Prior to infection the recombinant virus was activated by 
chymotrypsin treatment. 500 μg Chymotrypsin (Roche Biochemicals) was added per 10 ml of virus 
suspension and incubated for 15 min at room temperature. Subsequently, the chymotrypsin was 
inactivated by the addition of 250 μl aprotinin (10 mg/ml, Sigma). Infection of mammalian cells with the 
activated viral particles was similar for all used cell lines. Cells were grown to 80% confluency, the 
medium was aspirated and cells were washed once with PBS. Diluted viral suspensions were added in 
a small volume, just enough to cover the cells. In most experiments, the original viral suspension was 
diluted 10-fold. This did not result in a significant loss of expression. Cells were incubated with the virus 
suspension at 37 °C for 1 h, after which appropriate culture medium was added and the cells were 
cultured for 24–48 h. 
 
Construction and generation of recombinant baculovirus. To produced recombinant baculovirus 
containing the H4R an N-terminally tagged FLAG and C-terminally tagged His10 H4 gene was cloned 
from the pSFV2genB-FLAG-H4-His10 behind the p10 promoter of the pFastBac_DUAL vector using 
NcoI/NheI restriction sites. The construct was fully sequenced before its expression and analysis. 
The pFastBac_DUAL-FLAG-H4R-His10 was transformed into DH10BAC cells using heat-shock. To 
identify correctly transformed DH10BAC cells, the cells were plated out on LB plates containing 
ampicillin, kanamycin, tetracyclin and gentamycin resistance together with blue/white screening using X-
gal en IPTG. After isolation of Bacmid DNA, Sf9 cells were transfected with cellfectin and individual 
virus particles were isolated via a plaque assay. The recombinant virus was amplified by infecting Sf9 
cells with the individual selected plaques, which had been dissolved in TNM-FH expression medium for 
7 days. The titer of the virus was determined via plaques assay and a WST-1 colorimetric assay. 
Finally, amplified virus was used to infect Sf9 cells, which could be harvest in general 3-5 days after 
infection (dpi).  
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Analytical methods. Binding data were evaluated by a non-linear least squares curve fitting program 
using Graphpad Prism® (Graphpad Software Inc, San Diego, CA). Protein concentrations were 
determined according to Bradford 227, using BSA as standard. All data are represented as mean ± 
S.E.M. from at least three independent experiments in triplicate. Statistical significance was determined 
by a Students unpaired t-test (p<0.05 was considered statistically significant). 
 
 
Figure 7S: DNA sequence of the codon optimized human histamine H4 receptor 
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Over 1% of the humane genome is encoded by G protein coupled receptors 
(GPCRs) 1. These receptors bind a large array of first messenger resulting in the 
modulation of a large diversity of intracellular signals, and their involvement in 
many physiological processes 419. Histamine, an endogenous amine, acts on a 
subfamily of these GPCRs, the histamine receptors, causing (patho)physiological 
effects such as anaphylaxis and gastric acid release 79. Over the years several 
therapeutics have been developed targeting the histamine H1 and H2 receptors 
(H1R and H2R) 2, while therapeutics targeting the H3R, are on the verge of entering 
clinical trials 127,143.  
The existence of an additional histamine receptor present on eosinophils was 
already predicted in 1975 146. In 1994 Raible and co-workers showed that the 
pharmacology of this receptor differed from the three histamine receptors, known at 
the time 147. Finally, the cloning of the H3R in 1999 123 facilitated the identification of 
this fourth receptor belonging to the histaminergic class of GPCRs at a molecular 
level a year later 148-153. The work described within this thesis focuses on providing 
a more detailed characterization of this H4R. At the time of the start of this Ph.D. 
project in 2002 only a few papers, besides the original cloning papers, had been 
published and little was known about the pharmacology of the H4R. Based on the 
selective expression pattern of the H4R in cells of the hematopoietic lineage, such 
as leukocytes and mast cells 150-152, the receptor was suggested to play a role in 
inflammatory diseases already early on 148,164,168. This idea was supported further 
by the discovery that the activation of the H4R results in chemotaxis of eosinophils 
165,168, mast cells 164, and monocyte-derived dendritic cells 161. Additionally, release 
of several interleukins, which are important mediators in inflammation 367 is 
mediated by the H4R 118,161,181,184. The link between the H4R with allergic reactions 
was established both in mice 179,184,186,187 and human 163. However, additional roles 
for the H4R were also identified. The H4R may play a role in rheumatoid arthritis 188, 
colon cancer 189,190 and breast cancer 191.  
One of the reasons why it has been difficult to determine the physiological role of 
the H4R is the lack of available selective ligands. Since the H4R shares relatively 
high homology with the H3R (58% within the TM domains 149) most of the available 
ligands have comparable affinity for the H4R as for the H3R. Often this problem 
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could be avoided as the expression pattern of the H4R and the H3R, expressed 
predominantly in the brain, hardly overlaps. Another option was the use of the 
partial agonist H4R clobenpropit, which behaves as inverse agonist on the H3R. 
The development of the selective H4R antagonist JNJ 7777120 169 aided many 
researchers in their study of H4R pharmacology 161,165,184,189,190. In our search to try 
and identify analogues of JNJ 7777120, that could possible have even higher 
selectivity, we identified the benzimidazole analog VUF6002, a H4R antagonist 
which showed comparable selectivity as JNJ 7777120 173. Besides a selective H4R 
antagonist, the availability of a selective H4R agonist would be very useful to 
determine the involvement of the H4R in a certain pathway or disease, by 
mimicking the actions of histamine. Therefore we decided to screen a specific set 
of histaminergic compounds. This screen revealed 4-methylhistamine, previously 
characterized as moderate H2R agonist, as high affinity (>100-fold over H1R, H2R 
and H3R) H4R agonist 115. The screen also yielded the identification of VUF 4742, a 
burimamide analogue, as second inverse agonist for the H4R 115, with thioperamide 
being the first one. Synthesis efforts performed by other research groups confirmed 
VUF6002 174 and 4-methylhistamine 420 as H4R agonists. Further screening of 
clozapine and dimaprit analogues within our group have resulted in the discovery 
of other potent H4R agonists such as (E)-7-chloro-11-(4-methylpiperazin-1-
yl)dibenzo[b,f][1,4]oxazepine 175 and VUF 8430 170. A high affinity H4R ligand could 
also potentially be useful as radioligand. We have investigated three different 
radioligands for the H4R: [3H]histamine, [3H]JNJ 7777120 and [125I]iodophenpropit. 
All three ligands have their drawbacks. The most widely used radioligand is tritiated 
histamine. However, histamine does not have a very high affinity (~10 nM) and is 
not selective. While [3H]JNJ 7777120 is more selective, the affinity is not very 
different from histamine, and at the moment it is not commercially available. 
[125I]Iodophenpropit exhibits the highest affinity for the H4R compared to histamine 
and JNJ 7777120. [125I]iodine is an advantage for in situ radioligand binding and 
autoradiography assays. However, iodophenpropit is not selective for the H4R as it 
binds with similar affinity to the H3R. Additionally, [125I]iodophenpropit suffers from 
high levels of aspecific binding. To study in more detail the suggested presence of 
the H4R in brain 421 the availability of a selective high affinity iodinated H4R 
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radioligand, which can be iodinated would be very helpful. Another options would 
be the development of a high affinity, selective fluorescent H4R ligand, as have 
been created for the H3R already 422 and to a lesser extent the H2R 274. 
 
Homo-oligomerization of the human histamine H4R 
The ability of monomeric proteins to form larger multimeric complexes has been 
shown for several classes of proteins, such as enzymes, ion channels and 
transcription factors 258,259. Additionally, several peptidergic ligands targeting 
GPCRs, such as chemokines, are also known to form oligomeric structures 423. 
However, until the early 90’s the general view was that GPCRs act as monomers 
interacting with the G-protein in a 1:1 stoichiometry. From that time more and more 
evidence emerged supporting the hypothesis that GPCRs exist and function as 
oligomers 30,39,198,207. From 2000 and onwards the use of biophysical techniques 
such as fluorescence resonance energy transfer (FRET) and bioluminescence 
resonance energy transfer (BRET) to study GPCR oligomerization  has generated 
compelling evidence 40. Together with the finding that some receptors, such as 
GABAB and taste receptors need to form oligomers in order to function 41-43,45,46, 
this has eventually led to the general acceptation that GPCRs can also exist as 
oligomers.  
In our study on the oligomerization of the H4R we employed both biochemical (co-
immunoprecipitation, cross-linking) as well as biophysical assays (BRET, time-
resolved FRET). The use of a selective H4R antibody allowed for the detection of 
H4R in native tissue (human T-lymphocytes and human spleen lysates). It appears 
that in human T-lymphocytes the H4R is predominantly present as a dimeric entity 
234. The existence of H1R-H4R hetero-oligomers was dismissed, based on the 
finding that at expression levels, considered to be physiologically relevant, no H1R-
H4R hetero-oligomers were detected in both the BRET and tr-FRET assays 234. The 
H1R was chosen as this receptor is co-expressed in several different cells also 
expressing H4R 150,202. Also both receptors have been shown to play a role in 
inflammatory diseases, such as allergy 200,201. 
From a homology point of view it would have been logical to investigate hetero-
oligomerization between the H3R and the H4R. Since the H3R is expressed 
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predominantly in brain, while the H4R is expressed almost exclusively in leukocytes 
and mast cells, the physiological relevance of H3R-H4R would be difficult to prove. 
However, recent studies showed that the H3R is expressed together with the H4R in 
human nasal mucosa 160. Recently, using the H4R antibody, the H4R protein was 
identified in brain as well 421. These findings make the study of H3R-H4R potentially 
interesting. The study of H2R-H4R hetero-oligomers would also be appealing as the 
H4R can be found co-localized with the H2R 424. Additionally H2R and H4R control 
histamine-induced IL16 release from human CD8+ T cells 118. Moreover, histamine 
was shown to exert pro-proliferative and pro-angiogenic effects via H2R/H4R 
receptor activation 190.  
The use of computer models is often applied to assist rational drug design. At the 
moment these computer models are based on the monomeric structure of 
rhodopsin. To evaluate the effect of dimeric GPCRs on the binding pocket and 
ligand binding to dimeric receptors, it would be very helpful and scientifically 
interesting to try and create a computer model, that would represent dimeric 
GPCRs. Very recently a first attempt to model GPCR dimers and trimers was 
published 425. Computer simulation might already predict what effect the binding of 
a ligand to one receptor has on the binding pocket of the other receptor. To make 
good predictions much more detailed information on the dimerization interface is 
however required. A good example of the type of data required is the study 
performed on the dopamine D2 receptors by Guo and co-workers. In these studies 
amino-acids within TM IV were exchanged for cysteine residues and the 
importance of each amino-acid in the dimer interface was determined by cross 
linking 244,298 
 
Identification of differentially spliced H4R isoforms 
Currently twenty splice variants have been identified for the human H3R and ten for 
the rat H3R 124. Since the gene structure of the H3R is very similar to the H4R (both 
genes contain at least three introns 125,126) it was of interest to determine if the 
hH4R gene can also be alternatively spliced. Using an RT-PCR strategy on purified 
eosinophils and mast cells we were able to identify two H4R splice variants 
(H4R(302) and H4R(67)). The existence of other splice variants however, should not 
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be excluded. In March 2003, Merck described two H4R isoforms, the H4bR and the 
H4cR in a patent (WO 03/020907 A2). In both the sequences of the H4bR and H4cR 
one or two additional nucleotides emerge, which can not be explained based on 
the genomic arrangement of the H4R. In the gene of the H4bR splice variant two 
extra cytosines emerge (C197T198C199), instead of T361 in the full length H4R. In the 
gene of H4cR an extra nucleotide (C357) is found. In both cases introduction of these 
additional nucleotides keeps the gene in the “original” reading frame of the full 
length H4R. It is likely that the added nucleotides result from a sequencing error. 
This assumption is strengthened by the fact that the H4bR is identical to the H4R(67) 
isoform if the two additional nucleotides would be omitted. However, the H4cR 
differs from the H4R(302). Removal of the additional nucleotides from the H4cR would 
result in the receptor as depicted in Figure 8.1 (from here on referred to as putative 
H4CR . This would suggest that at least one more H4R splice variant would exist. In 
contrast with the H4R(302) and H4R(67) this H4cR would retain the aspartate residue, 
D94 (3.32), presumed to be crucial for histamine binding, as well as for the high 
affinity binding of other known orthosteric H4R ligands 34. Moreover, unlike the 
H4R(302) and H4R(67) the H4cR retains a topology in which the C-terminal tail is 
intracellular. The presence of a fourth exon located behind the putative stop codon 
of the full length H3R(445) resulted in the existence of additional H3R isoforms 426. In 
our search we did not investigate the occurrence of alternative splicing in the 
3’UTR of the full length H4R Therefore, it is of interest to continue cloning efforts to 
identify other H4R splice variants. Furthermore it can be interesting to construct the 
putative H4cR and characterize this potential H4R splice variant. The presence of 
the aspartate residue D94 (3.32) and an intracellular C-tail, could potentially mean 
that unlike the H4R(302) and H4R(67) the H4CR is able to bind ligands and signal by 
itself, although the fact that the receptor consists of only 3 TM domains may 
decrease the likeliness for this to be true. 
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Figure 8.1: Sequence alignment hydrophobicity plot of putative H4CR. A, Amino acid sequence 
alignment between the hH4R(390) and putative H4CR. The putative H4CR has a deletion between TMIII and 
TMV and reaches a premature stop codon due to a frame shift after being alternatively spliced. B, 
Predicted topology of the putative H4CR as determined by a hydrophobicity plot 
(http://www.cbs.dtu.dk/services/TMHMM/). The putative H4CR is predicted to consist of three TM 
domains and retains its intracellular C-terminal tail. 
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Functionality of H4R splice variants 
It has been shown for many splice variants including the rH3RDEF isoforms 204 that 
non-7TM receptor isoforms can influence full length receptor trafficking and/or 
signalling. In our study, we discovered that both the H4R(302) and H4R(67) are non-
functional, and expressed predominantly intracellular. However, when either of the 
H4R splice variants was co-expressed with the full length H4R(390) an apparent 
reduction in Bmax could be observed. The reduction could be explained through the 
observation that co-expression of either splice variant retained the H4R(390) 
intracellular, by forming hetero-oligomers. However, the hetero-oligomers were 
also present at the cell surface as determined by tr-FRET. It is possible that the 
H4R-H4R splice variant hetero-oligomers create some sort of H4R receptor reserve; 
keeping the H4R(390) inactive when little H4R activity is required.  
 
Oligomerization of aminergic GPCRs 
Oligomerization occurs for receptors within each of the three major families of 
GPCRs. However, only for members of family C has oligomerization shown to be 
vital for receptor function 41-43,45,46. While in the last two decades over 300 articles 
have dealt with GPCR hetero-oligomerization, still many questions remain 
unanswered or have only been partially answered. For example, is there a general 
motif which is responsible for the GPCRs to form oligomers? At which stage do the 
GPCRs within the oligomers dissociate from each other and what is the percentage 
of receptors that are present within oligomeric complexes? Within the family A of 
rhodospin-like GPCRs, the oligomerization of the aminergic GPCRs has been 
extensively studied. Studies on the α- and β-adrenergic receptors have revealed 
that TMI and TMVI are of importance in the interaction between the receptors 
within the oligomeric complex 205,218,245. Studies on the dopamine D2 receptors also 
indicated a role for TMIV 244,298. The discovery that the truncated H4R(67), consisting 
only of TMI and part of TM II, was still able to hetero-oligomerize with the full length 
H4R, emphasized the importance of this region in the oligomerization interface 
(chapter 4). Whereas the TM domains are involved in the direct interaction within in 
the oligomerization interface, the oligomeric complex may be stabilized via the 
glycosylated N-terminus. We indeed found evidence for a decrease in the amount 
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H4R oligomers after deglycosylation of the receptors (chapter 3). This stabilizing 
role of N-glycosylation has been reported also for the bradykinin receptors 212. 
However, this is not necessarily a general feature as for dopamine D3 receptors no 
decrease in the amount of receptor dimers was observed after deglycosylation 331.   
 
Hetero-oligomerization between the H4R and human chemokine receptors 
The H4R is involved in mediating the release of several cytokines 118,161,184 and 
shows substantial overlap in cellular expression with the family of chemokine 
receptors 427. Chemokine receptors are well known for their role in inflammation 
192,193 and several cases of chemokine receptor oligomerization have been reported 
269,368-372. To investigate if the H4R is able to form hetero-oligomers with chemokine 
receptors, we screened all CC chemokine receptors, with the exception of CCR7 
and CCR11, for their ability to hetero-oligomerize with the H4R in a tr-FRET assay. 
Distinct tr-FRET signals were observed only for H4R-CCR1, H4R-CCR4 and H4R-
CCR8 hetero-oligomers (Figure 8.2). The physiological relevance of these 
apparent H4R-CC chemokine receptor interactions is not yet clear. However, 
Buckland and co-workers already reported that histamine induced activation of the 
H4R can potentiate the chemotactic effect of CCL11 167, CCL27 and CCL24 165. 
CCL11 (eotaxin) and CCL24 (eotaxin-2) are chemokines known to bind CCR3 427, 
whereas CCL7 (MCP-3) binds both CCR1 and CCR2 with high affinity 427. 
Therefore it is possible that the effect of potentiation of CCL7 chemotaxis may 
(partially) be attributed to H4R-chemokine hetero-oligomerization. Further studies 
are required to obtain a better understanding of the physiological role of the H4R-
chemokine receptor interaction. 
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Figure 8.2: Hetero-oligomerization between the human histamine H4R and human CCR chemokine 
receptors as determined by a time-resolved FRET assay in COS-7 cells transiently expressing FLAG-
tagged H4R and 3xHA-tagged CCR receptors. Data are normalized for the tr-FRET signal obtained from 
a mixture of COS-7 cells that individually expressing the indicated constructs. Data shown are average 
of at least three experiments performed in triplicate. 
 
Liver expressed chemokine (CCL16), a ligand for H4R? 
In 2004 Nakayama and co-workers reported on a liver expressed chemokine (LEC, 
CCL16), which was able to bind with high affinity to the H4R and able to induce 
Ca2+-mobilization and chemotaxis in murine L1.2 cells expressing the H4R 166. 
CCL16 is an interesting chemokine, because so far no receptor has been identified 
for which CCL16 has high affinity. Only moderate affinity towards CCR1, CCR2, 
CCR5 and CCR8 has been shown 428,429. In our attempts to reproduce these 
results of Nakayama and co-workers, we were unable to show displacement of 
[125I]CCL16 using high dosage (10 μM) of unlabeled histamine both in COS-7 and 
L1.2 cells expressing recombinant H4R (Figure 8.3A). It should be noted that 
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Nakayama and co-workers used the Bolton-Hunter method 166 to label CCL16, 
whereas we employed the iodogen method. The methods differ in the amino-acid 
to which the 125I is attached. However, we were also unable to show displacement 
of [3H]histamine by CCL16 (Figure 8.3B. Moreover at concentrations of CCL16, 
which showed clear  effects in both Ca2+-mobilization as well as chemotaxis assays 
166 we were unable to induce a strong inhibition in CRE-driven luciferase production 
(Figure 8.3C). It is possible that CCL16 does not target the H4R directly but that it 
binds for example the potential H4R-CCR1 or H4R-CCR8 hetero-oligomer. Further 
experiments will need to be performed to investigate this hypothesis. 
 
 
Figure 8.3: Lack of effect of [125I]CCL16 on H4R. A, [125I]CCL16 displacement by 10 μM histamine on 
COS-7 cells transiently expressing H4R or murine L1.2 cells stably expressing H4R. B, No displacement 
of [3H]histamine by CCL16.  C, Marginal effect of CCL16 on 1 μM forskolin induced inhibition of cAMP, 
measured using a CRE-luciferase reporter gene assay in COS-7 cells transiently expressing H4R and a 
CRE-luciferase reporter gene. * = P<0.05, **** = P<0.0001. (HA, histamine; TP, thioperamide) 
 
Hetero-oligomerization between the H4R and US28 
Several viruses carry genes encoding GCPRs, sharing high homology with 
chemokine receptors, within their genome 373. The genome of the human 
cytomegalovirus encodes four viral chemokine receptors, US28, US27, UL33 and 
UL78 377. Out of these four, US28 has been the most studied GPCR. So far, US28 
has been shown to induce migration of smooth muscle cells, potentially linking it to 
atherosclerosis 430. Additionally, US28 may serve as co-receptor for HIV-1 entry 431. 
Morever, recently US28 was identified as a potential oncogen, inducing a 
proangiogenic and transformed phenotype by up-regulating the expression of 
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vascular endothelial growth factor and enhancing cell growth and cell cycle 
progression 389. US28 shares highest homology with CX3CR1 378. US28 may act as 
a chemokine scavenger, potentially preventing chemotaxis of leukocytes 390,432. In 
addition, co-expression of US28 with the Gi/o-coupled CCR1 chemokine receptor, 
potentiated a marked increase in Gi/o-sensitive CCL5 activation of NF-κB signalling 
381. Moreover, US28 is also transcribed in latently infected monocytes 391. The Gi/o-
coupled H4R has been shown to induce chemotaxis of eosinophils 165,168 and is 
also expressed in monocytes 150,152,382. Therefore it was of interest to investigate 
the interaction between the H4R and US28. Using biophysical and biochemical 
approaches we determined that the hetero-oligomerization occurs between the 
H4R and the US28. A reduction in H4R binding was observed when co-expressed 
with the US28. Moreover, the co-expression increased US28 mediated NF-κB-
signalling. The transcription factor NF-κB promotes expression of >100 genes, 
predominantely involved in the immune response 433,434. It appears that US28 tries 
to escape the immune system, by scavenging chemokines as well as altering 
immune related gene transcription and by blocking activation of chemotactic 
receptors through hetero-oligomerization. To further support this hypothesis, 
chemotaxis assays should be performed. In order to study this in a physiological 
setting, these experiments would preferentially be carried out in HCMV infected 
cells endogenously expressing the H4R. 
Many chemokine receptors signal via the JAK-STAT pathway 435,436.  Activation of 
the H4R may also cause modulation of the cytokine induced JAK/STAT 163. So far, 
no information is available whether US28 can activate JAK-STAT. Therefore, it will 
be interesting to study US28 mediated JAK-STAT signalling and the effect of 
hetero-oligomerization between the H4R and US28 on this particular pathway.  
 
Overexpression of the H4R for structural studies 
Currently, we are successful in producing large amounts of H1R protein. Employing 
baculovirus expression system 407, heterologous expression in mammalian cells, as 
well as cell free expression using E.coli extracts, milligram amount of purified H1R 
could be obtained 437. This purified H1R will be used to study the structure of the 
receptor and binding pocket in more detail using spectrometric techniques such as 
General discussion 
 
 189
NMR (nuclear magnetic resonance), MS (mass spectrometry) and FT-IR (fourier-
transformed infrared). In a more distant past we were also successful in 
overexpressing the H2R using the Semliki forest virus 408. 
The H4R receptor is a potential drug target to treat diseases like rheumatoid 
arthritis, inflammatory bowel disease and allergic rhinitis. Therefore, to assist in the 
development of H4R lead compounds specific structural information of the H4R 
would be useful. In order to attain such information using spectrometric techniques, 
large amounts of pure H4R protein need to be produced. Several methods to 
overexpress the H4R have been evaluated and described in chapter 7. Each of the 
methods (baculovirus, Semliki Forest virus, codon optimization and epitope 
tagging) by itself did not result in expression levels (maximally 14 pmol/mg protein) 
that were comparable to the Bmax obtained for the H1R (>50 pmol/mg protein). 
However, it is plausible that combination of some of the methods will be able to 
increase the H4R expression level. One of the options that could be investigated is 
to construct an N-terminally hemagluttinin (HA) codon optimized H4R under a 
polyhedron promoter to use in the baculovirus expression system. Another option 
is the use of cell free expression, which has been successfully employed to 
produce mg amounts of the human β2-adrenergic receptor 418 and the hH1R 437. 
The use of the H4coR, as described in chapter 7, would not be advised in this 
strategy as the H4R was codon optimized for human, not for E.coli.  
 
Concluding remarks 
Since the original six papers, describing the cloning of the H4R published in 
2000/2001 148-153, the scientific output regarding the H4R has increased almost ten 
fold in six year time, to over 50 articles. In these six years the involvement of the 
H4R in inflammation, initially suggested based on its expression in hematopoietic 
cells, has been established 184. Potential involvements in other diseases such as 
colon cancer 172,189, breast cancer 191 and rheumatoid arthritis 188 have been put 
forward, making the H4R an interesting potential drug target. Several selective 
agonists and antagonists have been identified, including 4-methylhistamine and 
VUF 6002 described within this thesis. Yet, besides these compounds the only 
other true selective compound is JNJ 7777120. H4R ligands with subnanomolar 
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affinities and/or potencies, as are available for the H3R, are not (yet) available. The 
search for these ligands will benefit from more structural information on the H4R. In 
general this can be obtained using spectroscopical analysis techniques such as 
MS, NMR or FT-IR. However, this requires a relatively large and pure amount of 
H4R protein. We have shown that it is possible to obtain reasonable expression 
levels of the H4R in recombinant systems, to continue with further purification and 
analysis steps. Current work on the H1R shows that MS analysis is able to provide 
information on the receptors ligand binding pocket 437. 
So far two and perhaps three (putative H4cR) H4R splice variants have been 
identified. Considering that the genomic arrangement of the H4R gene is similar to 
that of the H3R for which already twenty splice variants have been discovered 
124,130, several more H4R isoforms may exist. The currently known H4R splice 
variants are able to interact and regulate functional H4R expression through hetero-
oligomerization. However, other roles for these H4R isoforms may exist. The viral 
chemokine receptor US28 appears to interact with the H4R through hetero-
oligomerization to potentially use (abuse) this receptor for its own benefit e.g. 
increased signalling and perhaps evading host defence mechanisms. It is possible 
that the US28 receptor mimics native H4R hetero-oligomeric partners. The H4R 
may form hetero-oligomers with other chemokine receptors including CCR1, which 
shares high homology with the US28 receptor. The interaction between the H4R 
and the chemokine system has been subject of several studies 163,165,167,184. 
However, many more studies are required to try and truly understand the 
physiological role and actions of the H4R herein.  
All in all, much progress has been made in the understanding of the 
molecular pharmacology of the H4R, but still many questions remain unanswered, 
while new findings, often add more questions. Therefore, the H4R deserves to 
receive the same (if not more) attention and continuous research efforts it has 
received so far, for many more years to go. 
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De moleculaire farmacologie van de histamine H4 receptor 
De aandacht in dit proefschrift is gericht om een beter inzicht te krijgen in hoe de 
histamine H4 receptor functioneert. De focus ligt hierbij op moleculair niveau. De 
histamine H4 receptor is een G-eiwit gekoppelde receptor (GPCR). Dit type 
receptor speelt een belangrijke rol in ons lichaam, en vormen de bindingsplaats 
voor verschillende stimuli zoals licht, geur, endorfine, adrenaline en histamine. 
Naar schatting 50% van alle medicijnen op de markt binden aan deze GPCRs. De 
GPCRs zijn onder te verdelen in kleinere subpopulaties/families. Een subpopulatie 
van GPCRs vormen de histamine receptoren. De histamine receptor familie 
bestaat uit 4 leden. De histamine H1 receptor is het langst bekend en speelt een rol 
in allergie. De histamine H2 receptor is onder meer belangrijk in de secretie van 
maagzuur. De histamine H3 receptor komt voornamelijk voor in de hersenen en is 
mogelijk betrokken bij verscheidene processen, zoals, voedsel inname, slaap/waak 
cyclus. De histamine H4 receptor is het jongste lid van de histamine receptor 
familie en het DNA dat codeert voor het eiwit dat de H4 receptor opmaakt is rond 
het jaar 2000 ontdekt en gekloneerd. 
 
Tijdens de start van dit promotie onderzoek was er slechts weinig bekend over de 
rol van de histamine H4 receptor. Om een idee te krijgen wat voor stoffen/liganden 
goed kunnen binden aan deze receptor zijn verschillende liganden, waarvan 
bekend is dat ze een interactie vertonen met tenminste een van de drie andere 
histamine receptoren,  getest op de sterkte van hun affiniteit voor de histamine H4 
receptor. De ontdekking dat 4-methylhistamine, een ligand met middelmatige 
affiniteit voor de histamine H2 receptor, een goede affiniteit heeft voor de H4R is 
beschreven in hoofdstuk 2. 
 
Verscheidene eiwitten in de natuur hebben de neiging om aan elkaar te plakken. 
Dit fenomeen staat bekend als oligomerizatie. Wanneer de eiwitten indentiek zijn 
spreekt men over homo-oligomerizatie en wanneer de eiwitten van elkaar 
verschillen wordt dit aangeduid als hetero-oligomerizatie. Hoewel oligomerizatie 
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van eiwitten al langer bekend was, werd over het algemeen aangenomen dat 
GPCRs als enkele units functioneerden.  
Pas sinds het eind van de 20ste eeuw is er sterk bewijs dat oligomerizatie echter 
ook voorkomt bij GPCRs. Hoofdstuk 3 beschrijft hoe met behulp van verschillende 
technieken is bepaald dat de H4R hoogstwaarschijnlijk ook kan oligomerizeren. 
 
Eiwitten worden gecodeerd door genen in ons lichaam. Elk gen is een stuk DNA 
met een specifiek begin en einde. Voor sommige eiwitten, waaronder de H3R en 
H4R is het gen dat codeert voor het receptor eiwit niet een onafgebroken stuk DNA, 
maar is het verspreid in stukjes over een grotere afstand. Normaal gesproken 
verwijdert ons lichaam het DNA dat niet codeert voor het receptor eiwit en plakt alle 
stukken van het gen vervolgens aan elkaar. Echter, soms maakt het lichaam een 
fout en verwijdert het teveel of te weing DNA, wat vervolgens een gen oplevert dat 
een iets anders receptor eiwit oplevert dan “normaal”. Het is bekend dat dit voor de 
H3R gebeurt. Hierdoor bestaan er in ieder geval 20 vormen van de H3R, die of 
langer of korter zijn dan de “normale” H3R. 
Hoofdstuk 4 beschrijft de identificatie van kleinere vormen van de H4R. Deze 
kleinere H4Rs kunnen hetero-oligomers vormen met de “normale” H4R en hebben 
zodanig een negatieve invloed op het functioneren van de “normale” H4R. 
 
De histamine receptoren behoren tot de speciale klasse van aminerge GPCRs. De 
GPCRs in deze klasse binden kleine liganden, die van aminozuren zijn afgeleid.In 
hoofdstuk 5 wordt een overzicht gegeven van alle gepubliceerde data, die de 
oligomerizatie van deze aminerge GPCRs betreft. 
 
De chemokine receptoren zijn een klasse van GPCRs die een grote rol spelen in 
inflammatie. Recent onderzoek heeft uitgewezen dat de histamine H4 receptor een 
rol speelt in inflammatie. Bepaalde herpesvirussen zoals karposi’s sarcoma virus 
en humaan cytomegalovirus bevatten genen, die coderen voor chemokine 
receptoren. Een veel bestudeerde virale chemokine receptor is US28. Hoofdstuk 6 
beschrijft hoe de H4R en US28 receptor hetero-oligomeren kunnen vormen en hoe 
dit de signaal transductie beïnvloedt.  
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Voor de ontwikkeling van nieuwe geneesmiddelen is het erg informatief om in 
detail de structuur van de GPCR te kennen. Om gedetailleerde informatie te krijgen 
is het noodzakelijk om relatief grote en zuivere hoeveelheden van het receptor 
eiwit te verkrijgen. Hoofdstuk 7 beschrijft hoe met onder andere gemodificeerde 
virussen geprobeerd is grote hoeveelheden H4R the produceren. 
 
 Tenslotte word in hoofdstuk 8 getracht de bevindingen gedaan in dit promotie 
onderzoek in een breder perspectief te plaatsen. Verder worden suggesties 
gegeven voor mogelijke experimenten om het onderzoek naar de H4R voor te 
zetten. 
 
Hoewel er sinds de ontdekking van de H4R vooruitgang is geboekt in het begrip 
van de rol van de H4R blijven er voldoende vragen nog onbeantwoord. Tot dusver 
is nog niet bekend of de H4R een cruciale rol speelt in een bepaald ziektebeeld, 
hoewel suggesties voor een rol in artritis en borstkanker zijn onlangs zijn gemaakt. 
Als de H4R een belangrijk doelwit blijkt te zijn, zal dit de ontwikkeling van nieuwe 
liganden met hoge affiniteit voor de H4R zeker doen bespoedigen. Met het oog op 
hetero-oligomerizatie is het misschien noodzakelijk of therapeutisch effectiever om 
liganden te ontwikkelen, die selectief binden aan de hetero-oligomeer.
References 
 
 194
References 
1. Perez, D. M. The evolutionarily triumphant 
g-protein-coupled receptor. Mol Pharmacol 
63, 1202-5 (2003). 
2. Ma, P. & Zemmel, R. Value of novelty? 
Nat Rev Drug Discov 1, 571-2 (2002). 
3. Patel, T. B. Single transmembrane 
spanning heterotrimeric g protein-coupled 
receptors and their signaling cascades. 
Pharmacol Rev 56, 371-85 (2004). 
4. Holinstat, M., Oldham, W. M. & Hamm, H. 
E. G-protein-coupled receptors: evolving 
views on physiological signalling: 
symposium on G-protein-coupled 
receptors: evolving concepts and new 
techniques. EMBO Rep 7, 866-9 (2006). 
5. Gether, U. Uncovering molecular 
mechanisms involved in activation of G 
protein-coupled receptors. Endocr Rev 21, 
90-113 (2000). 
6. Klabunde, T. & Hessler, G. Drug design 
strategies for targeting G-protein-coupled 
receptors. Chembiochem 3, 928-44 
(2002). 
7. Gether, U. & Kobilka, B. K. G protein-
coupled receptors. II. Mechanism of 
agonist activation. J Biol Chem 273, 
17979-82 (1998). 
8. Swillens, S. Interpretation of binding 
curves obtained with high receptor 
concentrations: practical aid for computer 
analysis. Mol Pharmacol 47, 1197-203 
(1995). 
9. Deng, H. et al. Identification of a major co-
receptor for primary isolates of HIV-1. 
Nature 381, 661-6 (1996). 
10. Pierce, K. L., Premont, R. T. & Lefkowitz, 
R. J. Signalling: Seven-transmembrane 
receptors. Nat Rev Mol Cell Biol 3, 639-50 
(2002). 
11. Howard, A. D. et al. Orphan G-protein-
coupled receptors and natural ligand 
discovery. Trends Pharmacol Sci 22, 132-
40 (2001). 
12. Kilpatrick, G. J., Dautzenberg, F. M., 
Martin, G. R. & Eglen, R. M. 7TM 
receptors: the splicing on the cake. Trends 
Pharmacol Sci 20, 294-301 (1999). 
13. Higashijima, T., Ferguson, K. M., 
Sternweis, P. C., Smigel, M. D. & Gilman, 
A. G. Effects of Mg2+ and the beta 
gamma-subunit complex on the 
interactions of guanine nucleotides with G 
proteins. J Biol Chem 262, 762-6 (1987). 
14. Brandt, D. R. & Ross, E. M. GTPase 
activity of the stimulatory GTP-binding 
regulatory protein of adenylate cyclase, 
Gs. Accumulation and turnover of enzyme-
nucleotide intermediates. J Biol Chem 260, 
266-72 (1985). 
15. Hamm, H. E. The many faces of G protein 
signaling. J Biol Chem 273, 669-72 (1998). 
16. Neves, S. R., Ram, P. T. & Iyengar, R. G 
protein pathways. Science 296, 1636-9 
(2002). 
17. Marinissen, M. J. & Gutkind, J. S. G-
protein-coupled receptors and signaling 
networks: emerging paradigms. Trends 
Pharmacol Sci 22, 368-76 (2001). 
18. Kenakin, T. Inverse, protean, and ligand-
selective agonism: matters of receptor 
conformation. Faseb J 15, 598-611 (2001). 
19. Takai, Y., Sasaki, T. & Matozaki, T. Small 
GTP-binding proteins. Physiol Rev 81, 
153-208 (2001). 
20. Milligan, G. & Kostenis, E. Heterotrimeric 
G-proteins: a short history. Br J Pharmacol 
147 Suppl 1, S46-55 (2006). 
21. Lefkowitz, R. J. & Shenoy, S. K. 
Transduction of receptor signals by beta-
arrestins. Science 308, 512-7 (2005). 
22. Reiter, E. & Lefkowitz, R. J. GRKs and 
beta-arrestins: roles in receptor silencing, 
trafficking and signaling. Trends 
Endocrinol Metab 17, 159-65 (2006). 
23. Costa, T. & Herz, A. Antagonists with 
negative intrinsic activity at delta opioid 
receptors coupled to GTP-binding 
proteins. Proc Natl Acad Sci U S A 86, 
7321-5 (1989). 
24. Kjelsberg, M. A., Cotecchia, S., Ostrowski, 
J., Caron, M. G. & Lefkowitz, R. J. 
Constitutive activation of the alpha 1B-
adrenergic receptor by all amino acid 
substitutions at a single site. Evidence for 
a region which constrains receptor 
activation. J Biol Chem 267, 1430-3 
(1992). 
25. Seifert, R. & Wenzel-Seifert, K. 
Constitutive activity of G-protein-coupled 
receptors: cause of disease and common 
property of wild-type receptors. Naunyn 
Schmiedebergs Arch Pharmacol 366, 381-
416 (2002). 
26. Samama, P., Cotecchia, S., Costa, T. & 
Lefkowitz, R. J. A mutation-induced 
activated state of the beta 2-adrenergic 
receptor. Extending the ternary complex 
model. J Biol Chem 268, 4625-36 (1993). 
27. Kenakin, T. Drug efficacy at G protein-
coupled receptors. Annu Rev Pharmacol 
Toxicol 42, 349-79 (2002). 
28. Kenakin, T. Efficacy at G-protein-coupled 
receptors. Nat Rev Drug Discov 1, 103-10 
(2002). 
References 
 
 195
29. Monczor, F. et al. Tiotidine, a histamine h2 
receptor inverse agonist that binds with 
high affinity to an inactive g-protein--
coupled form of the receptor. Experimental 
support for the cubic ternary complex 
model. Mol Pharmacol 64, 512-20 (2003). 
30. Bouvier, M. Oligomerization of G-protein-
coupled transmitter receptors. Nat Rev 
Neurosci 2, 274-86 (2001). 
31. George, S. R. et al. Oligomerization of mu- 
and delta-opioid receptors. Generation of 
novel functional properties. J Biol Chem 
275, 26128-35 (2000). 
32. Durroux, T. Principles: A model for the 
allosteric interactions between ligand 
binding sites within a dimeric GPCR. 
Trends Pharmacol Sci 26, 376-84 (2005). 
33. Palczewski, K. et al. Crystal structure of 
rhodopsin: A G protein-coupled receptor. 
Science 289, 739-45 (2000). 
34. Bywater, R. P. Location and nature of the 
residues important for ligand recognition in 
G-protein coupled receptors. J Mol 
Recognit 18, 60-72 (2005). 
35. Ballesteros, J. & Palczewski, K. G protein-
coupled receptor drug discovery: 
implications from the crystal structure of 
rhodopsin. Curr Opin Drug Discov Devel 4, 
561-74 (2001). 
36. Ballesteros, J. et al. Functional 
microdomains in G-protein-coupled 
receptors. The conserved arginine-cage 
motif in the gonadotropin-releasing 
hormone receptor. J Biol Chem 273, 
10445-53 (1998). 
37. Ballesteros, J. & Weinstein, H. Integrated 
methods for the construction of three-
dimensional models of structure-function 
relations in G protein-coupled receptors. 
Methods Neurosci. 25, 336-428 (1995). 
38. Jongejan, A. et al. Linking agonist binding 
to histamine H1 receptor activation. Nat 
Chem Biol 1, 98-103 (2005). 
39. Angers, S., Salahpour, A. & Bouvier, M. 
Dimerization: an emerging concept for G 
protein-coupled receptor ontogeny and 
function. Annu Rev Pharmacol Toxicol 42, 
409-35 (2002). 
40. Milligan, G. Applications of 
bioluminescence- and fluorescence 
resonance energy transfer to drug 
discovery at G protein-coupled receptors. 
Eur J Pharm Sci 21, 397-405 (2004). 
41. Kaupmann, K. et al. GABA(B)-receptor 
subtypes assemble into functional 
heteromeric complexes. Nature 396, 683-7 
(1998). 
42. Jones, K. A. et al. GABAB receptors 
function as a heteromeric assembly of the 
subunits GABABR1 and GABABR2. Nature 
396, 674-9 (1998). 
43. White, J. H. et al. Heterodimerization is 
required for the formation of a functional 
GABA(B) receptor. Nature 396, 679-82 
(1998). 
44. Kuner, R. et al. Role of heteromer 
formation in GABAB receptor function. 
Science 283, 74-7 (1999). 
45. Nelson, G. et al. An amino-acid taste 
receptor. Nature 416, 199-202 (2002). 
46. Nelson, G. et al. Mammalian sweet taste 
receptors. Cell 106, 381-90 (2001). 
47. Baneres, J. L. & Parello, J. Structure-
based analysis of GPCR function: 
evidence for a novel pentameric assembly 
between the dimeric leukotriene B4 
receptor BLT1 and the G-protein. J Mol 
Biol 329, 815-29 (2003). 
48. Herrick-Davis, K., Grinde, E., Harrigan, T. 
J. & Mazurkiewicz, J. E. Inhibition of 
serotonin 5-hydroxytryptamine2c receptor 
function through heterodimerization: 
receptor dimers bind two molecules of 
ligand and one G-protein. J Biol Chem 
280, 40144-51 (2005). 
49. Goodman, O. B., Jr., Krupnick, J. G., 
Gurevich, V. V., Benovic, J. L. & Keen, J. 
H. Arrestin/clathrin interaction. Localization 
of the arrestin binding locus to the clathrin 
terminal domain. J Biol Chem 272, 15017-
22 (1997). 
50. Benovic, J. L. et al. Phosphorylation of the 
mammalian beta-adrenergic receptor by 
cyclic AMP-dependent protein kinase. 
Regulation of the rate of receptor 
phosphorylation and dephosphorylation by 
agonist occupancy and effects on coupling 
of the receptor to the stimulatory guanine 
nucleotide regulatory protein. J Biol Chem 
260, 7094-101 (1985). 
51. Roth, N. S., Campbell, P. T., Caron, M. G., 
Lefkowitz, R. J. & Lohse, M. J. 
Comparative rates of desensitization of 
beta-adrenergic receptors by the beta-
adrenergic receptor kinase and the cyclic 
AMP-dependent protein kinase. Proc Natl 
Acad Sci U S A 88, 6201-4 (1991). 
52. Pitcher, J., Lohse, M. J., Codina, J., 
Caron, M. G. & Lefkowitz, R. J. 
Desensitization of the isolated beta 2-
adrenergic receptor by beta-adrenergic 
receptor kinase, cAMP-dependent protein 
kinase, and protein kinase C occurs via 
distinct molecular mechanisms. 
Biochemistry 31, 3193-7 (1992). 
53. Winstel, R., Freund, S., Krasel, C., Hoppe, 
E. & Lohse, M. J. Protein kinase cross-
talk: membrane targeting of the beta-
adrenergic receptor kinase by protein 
References 
 
 196
kinase C. Proc Natl Acad Sci U S A 93, 
2105-9 (1996). 
54. Cong, M. et al. Regulation of membrane 
targeting of the G protein-coupled receptor 
kinase 2 by protein kinase A and its 
anchoring protein AKAP79. J Biol Chem 
276, 15192-9 (2001). 
55. Attramadal, H. et al. Beta-arrestin2, a 
novel member of the arrestin/beta-arrestin 
gene family. J Biol Chem 267, 17882-90 
(1992). 
56. Lohse, M. J. et al. Receptor-specific 
desensitization with purified proteins. 
Kinase dependence and receptor 
specificity of beta-arrestin and arrestin in 
the beta 2-adrenergic receptor and 
rhodopsin systems. J Biol Chem 267, 
8558-64 (1992). 
57. Pizard, A., Blaukat, A., Muller-Esterl, W., 
Alhenc-Gelas, F. & Rajerison, R. M. 
Bradykinin-induced internalization of the 
human B2 receptor requires 
phosphorylation of three serine and two 
threonine residues at its carboxyl tail. J 
Biol Chem 274, 12738-47 (1999). 
58. Lee, K. B., Ptasienski, J. A., Bunemann, 
M. & Hosey, M. M. Acidic amino acids 
flanking phosphorylation sites in the M2 
muscarinic receptor regulate receptor 
phosphorylation, internalization, and 
interaction with arrestins. J Biol Chem 275, 
35767-77 (2000). 
59. Fukushima, Y. et al. Role of the C 
terminus in histamine H2 receptor 
signaling, desensitization, and agonist-
induced internalization. J Biol Chem 272, 
19464-70 (1997). 
60. Pan, L., Gurevich, E. V. & Gurevich, V. V. 
The nature of the arrestin-receptor 
complex determines the ultimate fate of 
the internalized receptor. J Biol Chem 
(2003). 
61. Pula, G., Mundell, S. J., Roberts, P. J. & 
Kelly, E. Analysis of mGluR1a constitutive 
internalization using a pulse-chase 
enzyme-linked immuno-sorbant assay 
(ELISA). J Biochem Biophys Methods 64, 
167-81 (2005). 
62. Breit, A., Lagace, M. & Bouvier, M. Hetero-
oligomerization between beta2- and beta3-
adrenergic receptors generates a beta-
adrenergic signaling unit with distinct 
functional properties. J Biol Chem 279, 
28756-65 (2004). 
63. Jordan, B. A. & Devi, L. A. G-protein-
coupled receptor heterodimerization 
modulates receptor function. Nature 399, 
697-700 (1999). 
64. Pfeiffer, M. et al. Heterodimerization of 
somatostatin and opioid receptors cross-
modulates phosphorylation, internalization, 
and desensitization. J Biol Chem 277, 
19762-72 (2002). 
65. Jordan, B. A., Trapaidze, N., Gomes, I., 
Nivarthi, R. & Devi, L. A. Oligomerization 
of opioid receptors with beta 2-adrenergic 
receptors: a role in trafficking and mitogen-
activated protein kinase activation. Proc 
Natl Acad Sci U S A 98, 343-8 (2001). 
66. Barger, G. & Dale, H. H. Chemical 
structure and sympathomimetic action 
of amines. J. Physiol. (Lond.) 41, 19–59 (1910). 
67. Bodmer, S., Imark, C. & Kneubuhl, M. 
Biogenic amines in foods: histamine and 
food processing. Inflamm Res 48, 296-300 
(1999). 
68. Szeberenyi, J. B. et al. Intracellular 
histamine content increases during in vitro 
dendritic cell differentiation. Inflamm Res 
50 Suppl 2, S112-3 (2001). 
69. Parsons, M. E. & Ganellin, C. R. Histamine 
and its receptors. Br J Pharmacol 147 
Suppl 1, S127-35 (2006). 
70. Schneider, E., Rolli-Derkinderen, M., 
Arock, M. & Dy, M. Trends in histamine 
research: new functions during immune 
responses and hematopoiesis. Trends 
Immunol 23, 255-63 (2002). 
71. Dy, M. & Schneider, E. Histamine-cytokine 
connection in immunity and 
hematopoiesis. Cytokine Growth Factor 
Rev 15, 393-410 (2004). 
72. Bovet, D. & Staub, A. Action protectrice 
des éthers phénoliques au cours 
de l’intoxication histaminique. C. R. Seances 
Soc. Biol. Fil. 124, 547–549 (1936). 
73. Ash, A. S. & Schild, H. O. Receptors 
mediating some actions of histamine. Br J 
Pharmacol Chemother 27, 427-39 (1966). 
74. Black, J. W., Duncan, W. A., Durant, C. J., 
Ganellin, C. R. & Parsons, E. M. Definition 
and antagonism of histamine H 2 -
receptors. Nature 236, 385-90 (1972). 
75. De Backer, M. D. et al. Genomic cloning, 
heterologous expression and 
pharmacological characterization of a 
human histamine H1 receptor. Biochem 
Biophys Res Commun 197, 1601-8 (1993). 
76. Fukui, H. et al. Molecular cloning of the 
human histamine H1 receptor gene. 
Biochem Biophys Res Commun 201, 894-
901 (1994). 
77. Le Coniat, M., Traiffort, E., Ruat, M., 
Arrang, J. M. & Berger, R. Chromosomal 
localization of the human histamine H1-
receptor gene. Hum Genet 94, 186-8 
(1994). 
78. De Backer, M. D., Loonen, I., Verhasselt, 
P., Neefs, J. M. & Luyten, W. H. Structure 
References 
 
 197
of the human histamine H1 receptor gene. 
Biochem J 335 ( Pt 3), 663-70 (1998). 
79. Hill, S. J. et al. International Union of 
Pharmacology. XIII. Classification of 
histamine receptors. Pharmacol Rev 49, 
253-78 (1997). 
80. Dees, G., Bakker, R. A. & Leurs, R. 
Characterisation of human H1-receptor 
polymorphisms. 32nd Ann. EHRS meeting 
Poster 9 (2003). 
81. Leopoldt, D., Harteneck, C. & Nurnberg, B. 
G proteins endogenously expressed in Sf 
9 cells: interactions with mammalian 
histamine receptors. Naunyn 
Schmiedebergs Arch Pharmacol 356, 216-
24 (1997). 
82. Smit, M. J., Hoffmann, M., Timmerman, H. 
& Leurs, R. Molecular properties and 
signalling pathways of the histamine H1 
receptor. Clin Exp Allergy 29 Suppl 3, 19-
28 (1999). 
83. Smit, M. J. et al. Short-term 
desensitization of the histamine H1 
receptor in human HeLa cells: involvement 
of protein kinase C dependent and 
independent pathways. Br J Pharmacol 
107, 448-55 (1992). 
84. Fujimoto, K. et al. Identification of protein 
kinase C phosphorylation sites involved in 
phorbol ester-induced desensitization of 
the histamine H1 receptor. Mol Pharmacol 
55, 735-42 (1999). 
85. Bakker, R. A., Schoonus, S. B., Smit, M. 
J., Timmerman, H. & Leurs, R. Histamine 
H1-receptor activation of nuclear factor-κB: 
roles for Gβγ- and Gαq/11-subunits in 
constitutive and agonist-mediated 
signaling. Mol Pharmacol 60, 1133-42 
(2001). 
86. Bakker, R. A., Wieland, K., Timmerman, H. 
& Leurs, R. Constitutive activity of the 
histamine H(1) receptor reveals inverse 
agonism of histamine H(1) receptor 
antagonists. Eur J Pharmacol 387, R5-7 
(2000). 
87. Yang, Q. Z. & Hatton, G. I. Histamine H1-
receptor modulation of inter-neuronal 
coupling among vasopressinergic neurons 
depends on nitric oxide synthase 
activation. Brain Res 955, 115-22 (2002). 
88. Leurs, R. et al. Guinea pig histamine H1 
receptor. II. Stable expression in Chinese 
hamster ovary cells reveals the interaction 
with three major signal transduction 
pathways. J Neurochem 62, 519-27 
(1994). 
89. Resink, T. J., Grigorian, G., Moldabaeva, 
A. K., Danilov, S. M. & Buhler, F. R. 
Histamine-induced phosphoinositide 
metabolism in cultured human umbilical 
vein endothelial cells. Association with 
thromboxane and prostacyclin release. 
Biochem Biophys Res Commun 144, 438-
46 (1987). 
90. Baenziger, N. L., Force, L. E. & Becherer, 
P. R. Histamine stimulate prostacyclin 
synthesis in cultured human umbilical vein 
endothelial cells. Biochem Biophys Res 
Commun 92, 1435-40 (1980). 
91. Mitchell, R. et al. Rhodopsin-family 
receptors associate with small G proteins 
to activate phospholipase D. Nature 392, 
411-4 (1998). 
92. Seifert, R., Grunbaum, L. & Schultz, G. 
Histamine H1-receptors in HL-60 
monocytes are coupled to Gi-proteins and 
pertussis toxin-insensitive G-proteins and 
mediate activation of Ca2+ influx without 
concomitant Ca2+ mobilization from 
intracellular stores. Naunyn 
Schmiedebergs Arch Pharmacol 349, 355-
61 (1994). 
93. Leurs, R., Smit, M. J. & Timmerman, H. 
Molecular pharmacological aspects of 
histamine receptors. Pharmacol Ther 66, 
413-63 (1995). 
94. Leschke, C., Elz, S., Garbarg, M. & 
Schunack, W. Synthesis and histamine H1 
receptor agonist activity of a series of 2-
phenylhistamines, 2-heteroarylhistamines, 
and analogues. J Med Chem 38, 1287-94 
(1995). 
95. Donaldson, J. & Hill, S. J. Selective 
enhancement of histamine H1-receptor 
responses in guinea-pig ileal smooth 
muscle by 1,4-dithiothreitol. Br J 
Pharmacol 87, 191-9 (1986). 
96. Elz, S. et al. Histaprodifens: synthesis, 
pharmacological in vitro evaluation, and 
molecular modeling of a new class of 
highly active and selective histamine H(1)-
receptor agonists. J Med Chem 43, 1071-
84 (2000). 
97. Bakker, R. A. et al. 8R-lisuride is a potent 
stereospecific histamine H1-receptor 
partial agonist. Mol Pharmacol 65, 538-49 
(2004). 
98. Mantegani, S., Brambilla, E. & Varasi, M. 
Ergoline derivatives: receptor affinity and 
selectivity. Farmaco 54, 288-96 (1999). 
99. Simons, F. E. Advances in H1-
antihistamines. N Engl J Med 351, 2203-
17 (2004). 
100. Golightly, L. K. & Greos, L. S. Second-
generation antihistamines: actions and 
efficacy in the management of allergic 
disorders. Drugs 65, 341-84 (2005). 
101. Govoni, M. et al. Synthesis and 
pharmacological identification of neutral 
References 
 
 198
histamine H1-receptor antagonists. J Med 
Chem 46, 5812-24 (2003). 
102. Genovese, A., Gross, S. S., Sakuma, I. & 
Levi, R. Adenosine promotes histamine 
H1-mediated negative chronotropic and 
inotropic effects on human atrial 
myocardium. J Pharmacol Exp Ther 247, 
844-9 (1988). 
103. Gantz, I. et al. Molecular cloning of a gene 
encoding the histamine H2 receptor. Proc 
Natl Acad Sci U S A 88, 429-33 (1991). 
104. Sasaki, Y. et al. Lack of association 
between atopic asthma and 
polymorphisms of the histamine H1 
receptor, histamine H2 receptor, and 
histamine N-methyltransferase genes. 
Immunogenetics 51, 238-40 (2000). 
105. Mancama, D. et al. Investigation of 
promoter variants of the histamine 1 and 2 
receptors in schizophrenia and clozapine 
response. Neurosci Lett 333, 207-11 
(2002). 
106. Fukushima, Y. et al. Palmitoylation of the 
canine histamine H2 receptor occurs at 
Cys(305) and is important for cell surface 
targeting. Biochim Biophys Acta 1539, 
181-91 (2001). 
107. Fukushima, Y. et al. Oligomer formation of 
histamine H2 receptors expressed in Sf9 
and COS7 cells. FEBS Lett 409, 283-6 
(1997). 
108. Beukers, M. W. et al. Heterologous 
expression of rat epitope-tagged histamine 
H2 receptors in insect Sf9 cells. Br J 
Pharmacol 122, 867-74 (1997). 
109. Delvalle, J., Wang, L., Gantz, I. & Yamada, 
T. Characterization of H2 histamine 
receptor: linkage to both adenylate cyclase 
and [Ca2+]i signaling systems. Am J 
Physiol 263, G967-72 (1992). 
110. Wang, L., Gantz, I. & DelValle, J. 
Histamine H2 receptor activates adenylate 
cyclase and PLC via separate GTP-
dependent pathways. Am J Physiol 271, 
G613-20 (1996). 
111. Kuhn, B., Schmid, A., Harteneck, C., 
Gudermann, T. & Schultz, G. G proteins of 
the Gq family couple the H2 histamine 
receptor to phospholipase C. Mol 
Endocrinol 10, 1697-707 (1996). 
112. Traiffort, E. et al. Expression of a cloned 
rat histamine H2 receptor mediating 
inhibition of arachidonate release and 
activation of cAMP accumulation. Proc 
Natl Acad Sci U S A 89, 2649-53 (1992). 
113. Smit, M. J. et al. Inverse agonism of 
histamine H2 antagonist accounts for 
upregulation of spontaneously active 
histamine H2 receptors. Proc Natl Acad 
Sci U S A 93, 6802-7 (1996). 
114. Smit, M. J., Timmerman, H., Alewijnse, A. 
E. & Leurs, R. From histamine H2 receptor 
regulation to reclassification of H2 
antagonists; inverse agonism as the basis 
for H2 receptor upregulation. Receptors 
Channels 5, 99-102 (1998). 
115. Lim, H. D. et al. Evaluation of histamine 
H1-, H2-, and H3-receptor ligands at the 
human histamine H4 receptor: identification 
of 4-methylhistamine as the first potent 
and selective H4 receptor agonist. J 
Pharmacol Exp Ther 314, 1310-21 (2005). 
116. Ellis, C. The state of GPCR research in 
2004. Nat Rev Drug Discov 3, 575, 577-
626 (2004). 
117. Savarino, V. & Dulbecco, P. Optimizing 
symptom relief and preventing 
complications in adults with gastro-
oesophageal reflux disease. Digestion 69 
Suppl 1, 9-16 (2004). 
118. Gantner, F. et al. Histamine H4 and H2 
receptors control histamine-induced 
interleukin-16 release from human CD8+ T 
cells. J Pharmacol Exp Ther 303, 300-7 
(2002). 
119. Del Valle, J. & Gantz, I. Novel insights into 
histamine H2 receptor biology. Am J 
Physiol 273, G987-96 (1997). 
120. Sander, L. E. et al. Selective expression of 
histamine receptors H1R, H2R, and H4R, 
but not H3R, in the human intestinal tract. 
Gut 55, 498-504 (2006). 
121. Bissonnette, E. Y. Histamine inhibits tumor 
necrosis factor alpha release by mast cells 
through H2 and H3 receptors. Am J Respir 
Cell Mol Biol 14, 620-6 (1996). 
122. Arrang, J. M., Garbarg, M. & Schwartz, J. 
C. Auto-inhibition of brain histamine 
release mediated by a novel class (H3) of 
histamine receptor. Nature 302, 832-7 
(1983). 
123. Lovenberg, T. W. et al. Cloning and 
functional expression of the human 
histamine H3 receptor. Mol Pharmacol 55, 
1101-7 (1999). 
124. Hancock, A. A., Esbenshade, T. A., 
Krueger, K. M. & Yao, B. B. Genetic and 
pharmacological aspects of histamine H3 
receptor heterogeneity. Life Sci 73, 3043-
72 (2003). 
125. Wiedemann, P., Bonisch, H., Oerters, F. & 
Bruss, M. Structure of the human 
histamine H3 receptor gene (HRH3) and 
identification of naturally occurring 
variations. J Neural Transm 109, 443-53 
(2002). 
126. Coge, F. et al. Genomic organization and 
characterization of splice variants of the 
human histamine H3 receptor. Biochem J 
355, 279-88 (2001). 
References 
 
 199
127. Leurs, R., Bakker, R. A., Timmerman, H. & 
de Esch, I. J. The histamine H3 receptor: 
from gene cloning to H3 receptor drugs. 
Nat Rev Drug Discov 4, 107-20 (2005). 
128. Molderings, G. J., Weissenborn, G., 
Schlicker, E., Likungu, J. & Gothert, M. 
Inhibition of noradrenaline release from the 
sympathetic nerves of the human 
saphenous vein by presynaptic histamine 
H3 receptors. Naunyn Schmiedebergs 
Arch Pharmacol 346, 46-50 (1992). 
129. Imamura, M., Seyedi, N., Lander, H. M. & 
Levi, R. Functional identification of 
histamine H3-receptors in the human 
heart. Circ Res 77, 206-10 (1995). 
130. Leurs, R., Blandina, P., Tedford, C. & 
Timmerman, H. Therapeutic potential of 
histamine H3 receptor agonists and 
antagonists. Trends Pharmacol Sci 19, 
177-83 (1998). 
131. Clark, E. A. & Hill, S. J. Sensitivity of 
histamine H3 receptor agonist-stimulated 
[35S]GTP gamma[S] binding to pertussis 
toxin. Eur J Pharmacol 296, 223-5 (1996). 
132. Morisset, S. et al. High constitutive activity 
of native H3 receptors regulates histamine 
neurons in brain. Nature 408, 860-4 
(2000). 
133. Giovannini, M. G. et al. Improvement in 
fear memory by histamine-elicited ERK2 
activation in hippocampal CA3 cells. J 
Neurosci 23, 9016-23 (2003). 
134. Silver, R. B. et al. Decreased intracellular 
calcium mediates the histamine H3-
receptor-induced attenuation of 
norepinephrine exocytosis from cardiac 
sympathetic nerve endings. Proc Natl 
Acad Sci U S A 99, 501-6 (2002). 
135. Silver, R. B. et al. Coupling of histamine 
H3 receptors to neuronal Na+/H+ 
exchange: a novel protective mechanism 
in myocardial ischemia. Proc Natl Acad Sci 
U S A 98, 2855-9 (2001). 
136. Drutel, G. et al. Identification of rat H3 
receptor isoforms with different brain 
expression and signaling properties. Mol 
Pharmacol 59, 1-8 (2001). 
137. Wieland, K. et al. Constitutive activity of 
histamine h(3) receptors stably expressed 
in SK-N-MC cells: display of agonism and 
inverse agonism by H(3) antagonists. J 
Pharmacol Exp Ther 299, 908-14 (2001). 
138. Kitbunnadaj, R. et al. Identification of 4-
(1H-imidazol-4(5)-ylmethyl)pyridine 
(immethridine) as a novel, potent, and 
highly selective histamine H(3) receptor 
agonist. J Med Chem 47, 2414-7 (2004). 
139. Kitbunnadaj, R. et al. N-substituted 
piperidinyl alkyl imidazoles: discovery of 
methimepip as a potent and selective 
histamine H3 receptor agonist. J Med 
Chem 48, 2100-7 (2005). 
140. Esbenshade, T. A. et al. Pharmacological 
properties of ABT-239 [4-(2-{2-[(2R)-2-
Methylpyrrolidinyl]ethyl}-benzofuran-5-
yl)benzonitrile]: I. Potent and selective 
histamine H3 receptor antagonist with 
drug-like properties. J Pharmacol Exp Ther 
313, 165-75 (2005). 
141. Apodaca, R. et al. A new class of diamine-
based human histamine H3 receptor 
antagonists: 4-
(aminoalkoxy)benzylamines. J Med Chem 
46, 3938-44 (2003). 
142. Esbenshade, T. A. et al. Pharmacological 
and behavioral properties of A-349821, a 
selective and potent human histamine H3 
receptor antagonist. Biochem Pharmacol 
68, 933-45 (2004). 
143. Passani, M. B., Lin, J. S., Hancock, A., 
Crochet, S. & Blandina, P. The histamine 
H3 receptor as a novel therapeutic target 
for cognitive and sleep disorders. Trends 
Pharmacol Sci 25, 618-25 (2004). 
144. Cannon, K. E. et al. Activation of spinal 
histamine H3 receptors inhibits mechanical 
nociception. Eur J Pharmacol 470, 139-47 
(2003). 
145. Hancock, A. A. H3 receptor 
antagonists/inverse agonists as anti-
obesity agents. Curr Opin Investig Drugs 
4, 1190-7 (2003). 
146. Clark, R. A., Gallin, J. I. & Kaplan, A. P. 
The selective eosinophil chemotactic 
activity of histamine. J Exp Med 142, 
1462-76 (1975). 
147. Raible, D. G., Lenahan, T., Fayvilevich, Y., 
Kosinski, R. & Schulman, E. S. 
Pharmacologic characterization of a novel 
histamine receptor on human eosinophils. 
Am J Respir Crit Care Med 149, 1506-11 
(1994). 
148. Liu, C. et al. Cloning and pharmacological 
characterization of a fourth histamine 
receptor (H4) expressed in bone marrow. 
Mol Pharmacol 59, 420-6 (2001). 
149. Nguyen, T. et al. Discovery of a novel 
member of the histamine receptor family. 
Mol Pharmacol 59, 427-33 (2001). 
150. Morse, K. L. et al. Cloning and 
characterization of a novel human 
histamine receptor. J Pharmacol Exp Ther 
296, 1058-66 (2001). 
151. Zhu, Y. et al. Cloning, expression, and 
pharmacological characterization of a 
novel human histamine receptor. Mol 
Pharmacol 59, 434-41 (2001). 
152. Oda, T., Morikawa, N., Saito, Y., Masuho, 
Y. & Matsumoto, S. Molecular cloning and 
characterization of a novel type of 
References 
 
 200
histamine receptor preferentially 
expressed in leukocytes. J Biol Chem 275, 
36781-6 (2000). 
153. Nakamura, T., Itadani, H., Hidaka, Y., 
Ohta, M. & Tanaka, K. Molecular cloning 
and characterization of a new human 
histamine receptor, HH4R. Biochem 
Biophys Res Commun 279, 615-20 (2000). 
154. Coge, F., Guenin, S. P., Rique, H., Boutin, 
J. A. & Galizzi, J. P. Structure and 
expression of the human histamine H4-
receptor gene. Biochem Biophys Res 
Commun 284, 301-9 (2001). 
155. Oda, T. et al. cDNA cloning and 
characterization of porcine histamine H4 
receptor. Biochim Biophys Acta 1575, 135-
8 (2002). 
156. Liu, C., Wilson, S. J., Kuei, C. & 
Lovenberg, T. W. Comparison of human, 
mouse, rat, and guinea pig histamine H4 
receptors reveals substantial 
pharmacological species variation. J 
Pharmacol Exp Ther 299, 121-30 (2001). 
157. Oda, T. et al. Molecular cloning of monkey 
histamine H4 receptor. J Pharmacol Sci 
98, 319-22 (2005). 
158. Shin, N. et al. Molecular modeling and 
site-specific mutagenesis of the histamine-
binding site of the histamine h(4) receptor. 
Mol Pharmacol 62, 38-47 (2002). 
159. Stark, H., Schlegel, B. & Sippl, W. [News 
of the old histamine. I. A widening of the 
receptor family]. Pharm Unserer Zeit 32, 
92-3 (2003). 
160. Nakaya, M., Takeuchi, N. & Kondo, K. 
Immunohistochemical localization of 
histamine receptor subtypes in human 
inferior turbinates. Ann Otol Rhinol 
Laryngol 113, 552-7 (2004). 
161. Gutzmer, R. et al. Histamine H4 Receptor 
Stimulation Suppresses IL-12p70 
Production and Mediates Chemotaxis in 
Human Monocyte-Derived Dendritic Cells. 
J Immunol 174, 5224-32 (2005). 
162. Horr, B., Borck, H., Thurmond, R., Grosch, 
S. & Diel, F. STAT1 phosphorylation and 
cleavage is regulated by the histamine 
(H4) receptor in human atopic and non-
atopic lymphocytes. Int Immunopharmacol 
6, 1577-85 (2006). 
163. Horr, B. et al. The role of the histamine H4 
receptor in signal transduction of atopic 
and non-atopic human lymphocytes ex 
vivo. Inflamm Res 55, S53-S54 (2006). 
164. Hofstra, C. L., Desai, P. J., Thurmond, R. 
L. & Fung-Leung, W. P. Histamine H4 
receptor mediates chemotaxis and calcium 
mobilization of mast cells. J Pharmacol 
Exp Ther 305, 1212-21 (2003). 
165. Ling, P. et al. Histamine H4 receptor 
mediates eosinophil chemotaxis with cell 
shape change and adhesion molecule 
upregulation. Br J Pharmacol 142, 161-71 
(2004). 
166. Nakayama, T. et al. Liver-Expressed 
Chemokine/CC Chemokine Ligand 16 
Attracts Eosinophils by Interacting with 
Histamine H4 Receptor. J Immunol 173, 
2078-83 (2004). 
167. Buckland, K. F., Williams, T. J. & Conroy, 
D. M. Histamine induces cytoskeletal 
changes in human eosinophils via the H4 
receptor. Br J Pharmacol 140, 1117-27 
(2003). 
168. O'Reilly, M. et al. Identification of a 
histamine H4 receptor on human 
eosinophils--role in eosinophil chemotaxis. 
J Recept Signal Transduct Res 22, 431-48 
(2002). 
169. Jablonowski, J. A. et al. The first potent 
and selective non-imidazole human 
histamine H4 receptor antagonists. J Med 
Chem 46, 3957-60 (2003). 
170. Lim, H. D. et al. Discovery of S-(2-
guanidylethyl)-isothiourea (VUF 8430) as a 
potent nonimidazole histamine H4 receptor 
agonist. J Med Chem 49, 6650-1 (2006). 
171. Hashimoto, T. et al. A Selective Human 
H(4)-Receptor Agonist: (-)-2-Cyano-1-
methyl-3-{(2R,5R)-5- [1H-imidazol-4(5)-
yl]tetrahydrofuran-2-yl}methylguanidine. J 
Med Chem 46, 3162-3165 (2003). 
172. Thurmond, R. L. et al. A potent and 
selective histamine H4 receptor antagonist 
with anti-inflammatory properties. J 
Pharmacol Exp Ther 309, 404-13 (2004). 
173. Terzioglu, N., Van Rijn, R. M., Bakker, R. 
A., De Esch, I. J. & Leurs, R. Synthesis 
and structure-activity relationships of 
indole and benzimidazole piperazines as 
histamine H(4) receptor antagonists. 
Bioorg Med Chem Lett 14, 5251-5256 
(2004). 
174. Venable, J. D. et al. Preparation and 
biological evaluation of indole, 
benzimidazole, and thienopyrrole 
piperazine carboxamides: potent human 
histamine h(4) antagonists. J Med Chem 
48, 8289-98 (2005). 
175. Smits, R. A. et al. Characterization of the 
histamine H4 receptor binding site. Part 1. 
Synthesis and pharmacological evaluation 
of dibenzodiazepine derivatives. J Med 
Chem 49, 4512-6 (2006). 
176. Crimi, E., Chiaramondia, M., Milanese, M., 
Rossi, G. A. & Brusasco, V. Increased 
numbers of mast cells in bronchial mucosa 
after the late-phase asthmatic response to 
References 
 
 201
allergen. Am Rev Respir Dis 144, 1282-6 
(1991). 
177. Gauvreau, G. M. et al. Increased numbers 
of both airway basophils and mast cells in 
sputum after allergen inhalation challenge 
of atopic asthmatics. Am J Respir Crit 
Care Med 161, 1473-8 (2000). 
178. Takeshita, K., Bacon, K. B. & Gantner, F. 
Critical role of L-selectin and histamine H4 
receptor in zymosan-induced neutrophil 
recruitment from the bone marrow: 
comparison with carrageenan. J 
Pharmacol Exp Ther 310, 272-80 (2004). 
179. Takeshita, K., Sakai, K., Bacon, K. B. & 
Gantner, F. Critical role of histamine H4 
receptor in leukotriene B4 production and 
mast cell-dependent neutrophil recruitment 
induced by zymosan in vivo. J Pharmacol 
Exp Ther 307, 1072-8 (2003). 
180. Griffiths, R. J. et al. Leukotriene B4 plays a 
critical role in the progression of collagen-
induced arthritis. Proc Natl Acad Sci U S A 
92, 517-21 (1995). 
181. Dijkstra, D. et al. Histamine downregulates 
monocyte CCL2 production through the 
histamine H4 receptor. J Allergy Clin 
Immunol 120, 300-7 (2007). 
182. Laberge, S., Cruikshank, W. W., Kornfeld, 
H. & Center, D. M. Histamine-induced 
secretion of lymphocyte chemoattractant 
factor from CD8+ T cells is independent of 
transcription and translation. Evidence for 
constitutive protein synthesis and storage. 
J Immunol 155, 2902-10 (1995). 
183. Cruikshank, W. W. et al. Early 
identification of interleukin-16 (lymphocyte 
chemoattractant factor) and macrophage 
inflammatory protein 1 alpha (MIP1 alpha) 
in bronchoalveolar lavage fluid of antigen-
challenged asthmatics. Am J Respir Cell 
Mol Biol 13, 738-47 (1995). 
184. Dunford, P. J. et al. The histamine H4 
receptor mediates allergic airway 
inflammation by regulating the activation of 
CD4+ T cells. J Immunol 176, 7062-70 
(2006). 
185. Kalinski, P., Hilkens, C. M., Wierenga, E. 
A. & Kapsenberg, M. L. T-cell priming by 
type-1 and type-2 polarized dendritic cells: 
the concept of a third signal. Immunol 
Today 20, 561-7 (1999). 
186. Bell, J. K., McQueen, D. S. & Rees, J. L. 
Involvement of histamine H4 and H1 
receptors in scratching induced by 
histamine receptor agonists in BalbC mice. 
Br J Pharmacol 142, 374-80 (2004). 
187. Dunford, P. J. et al. Histamine H4 receptor 
antagonists are superior to traditional 
antihistamines in the attenuation of 
experimental pruritus. J Allergy Clin 
Immunol 119, 176-83 (2007). 
188. Ikawa, Y. et al. Histamine H4 receptor 
expression in human synovial cells 
obtained from patients suffering from 
rheumatoid arthritis. Biol Pharm Bull 28, 
2016-8 (2005). 
189. Varga, C. et al. Inhibitory effects of 
histamine H4 receptor antagonists on 
experimental colitis in the rat. Eur J 
Pharmacol 522, 130-8 (2005). 
190. Cianchi, F. et al. The role of 
cyclooxygenase-2 in mediating the effects 
of histamine on cell proliferation and 
vascular endothelial growth factor 
production in colorectal cancer. Clin 
Cancer Res 11, 6807-15 (2005). 
191. Maslinska, D. et al. Histamine H4 receptors 
on mammary epithelial cells of the human 
breast with different types of carcinoma. 
Inflamm Res 55, S77-S78 (2006). 
192. Danese, S. & Gasbarrini, A. Chemokines 
in inflammatory bowel disease. J Clin 
Pathol 58, 1025-7 (2005). 
193. Szekanecz, Z., Szucs, G., Szanto, S. & 
Koch, A. E. Chemokines in rheumatic 
diseases. Curr Drug Targets 7, 91-102 
(2006). 
194. de Esch, I. J., Thurmond, R. L., Jongejan, 
A. & Leurs, R. The histamine H4 receptor 
as a new therapeutic target for 
inflammation. Trends Pharmacol Sci 26, 
462-9 (2005). 
195. Lambright, D. G. et al. The 2.0 Å crystal 
structure of a heterotrimeric G protein. 
Nature 379, 311-9 (1996). 
196. Terrillon, S. & Bouvier, M. Roles of G-
protein-coupled receptor dimerization. 
EMBO Rep 5, 30-4 (2004). 
197. Waldhoer, M. et al. From the Cover: A 
heterodimer-selective agonist shows in 
vivo relevance of G protein-coupled 
receptor dimers. Proc Natl Acad Sci U S A 
102, 9050-5 (2005). 
198. Devi, L. A. Heterodimerization of G-
protein-coupled receptors: pharmacology, 
signaling and trafficking. Trends 
Pharmacol Sci 22, 532-7 (2001). 
199. Bakker, R. A. et al. Domain Swapping in 
the Human Histamine H1 Receptor. J 
Pharmacol Exp Ther 311, 131-138 (2004). 
200. Matsubara, M., Tamura, T., Ohmori, K. & 
Hasegawa, K. Histamine H1 receptor 
antagonist blocks histamine-induced 
proinflammatory cytokine production 
through inhibition of Ca2+-dependent 
protein kinase C, Raf/MEK/ERK and IKK/I 
κB/NF-κB signal cascades. Biochem 
Pharmacol 69, 433-49 (2005). 
References 
 
 202
201. Giustizieri, M. L. et al. H1 histamine 
receptor mediates inflammatory responses 
in human keratinocytes. J Allergy Clin 
Immunol 114, 1176-82 (2004). 
202. Cameron, W., Doyle, K. & Rocklin, R. E. 
Histamine type I (H1) receptor radioligand 
binding studies on normal T cell subsets, B 
cells, and monocytes. J Immunol 136, 
2116-20 (1986). 
203. Chazot, P. L., Hann, V., Wilson, C., Lees, 
G. & Thompson, C. L. Immunological 
identification of the mammalian H3 
histamine receptor in the mouse brain. 
Neuroreport 12, 259-62 (2001). 
204. Bakker, R. A. et al. Discovery of naturally 
occurring splice variants of the rat 
histamine H3 receptor that act as 
dominant-negative isoforms. Mol 
Pharmacol 69, 1194-206 (2006). 
205. Carrillo, J. J., Pediani, J. & Milligan, G. 
Dimers of Class A G Protein-coupled 
Receptors Function via Agonist-mediated 
Trans-activation of Associated G Proteins. 
J Biol Chem 278, 42578-87 (2003). 
206. Patel, R. C., Lange, D. C. & Patel, Y. C. 
Photobleaching fluorescence resonance 
energy transfer reveals ligand-induced 
oligomer formation of human somatostatin 
receptor subtypes. Methods 27, 340-8 
(2002). 
207. George, S. R., O'Dowd, B. F. & Lee, S. P. 
G-protein-coupled receptor oligomerization 
and its potential for drug discovery. Nat 
Rev Drug Discov 1, 808-20 (2002). 
208. Fotiadis, D. et al. Atomic-force microscopy: 
Rhodopsin dimers in native disc 
membranes. Nature 421, 127-8 (2003). 
209. Suda, K., Filipek, S., Palczewski, K., 
Engel, A. & Fotiadis, D. The 
supramolecular structure of the GPCR 
rhodopsin in solution and native disc 
membranes. Mol Membr Biol 21, 435-46 
(2004). 
210. Shenton, F. C., Hann, V. & Chazot, P. L. 
Evidence for native and cloned H3 
Histamine receptor higher oligomers. 
Inflamm Res 54 Suppl 1, S48-9 (2005). 
211. Boute, N., Jockers, R. & Issad, T. The use 
of resonance energy transfer in high-
throughput screening: BRET versus FRET. 
Trends Pharmacol Sci 23, 351 (2002). 
212. Michineau, S., Alhenc-Gelas, F. & 
Rajerison, R. M. Human bradykinin B2 
receptor sialylation and N-glycosylation 
participate with disulfide bonding in 
surface receptor dimerization. 
Biochemistry 45, 2699-707 (2006). 
213. Pfleger, K. D. & Eidne, K. A. Monitoring 
the formation of dynamic G-protein-
coupled receptor-protein complexes in 
living cells. Biochem J 385, 625-37 (2005). 
214. Angers, S. et al. Detection of β2-adrenergic 
receptor dimerization in living cells using 
bioluminescence resonance energy 
transfer (BRET). Proc Natl Acad Sci U S A 
97, 3684-9 (2000). 
215. Franco, R. et al. Regulation of 
heptaspanning-membrane-receptor 
function by dimerization and clustering. 
Trends Biochem Sci 28, 238-43 (2003). 
216. Salim, K. et al. Oligomerization of G-
protein-coupled receptors shown by 
selective co-immunoprecipitation. J Biol 
Chem 277, 15482-5 (2002). 
217. Uberti, M. A., Hague, C., Oller, H., 
Minneman, K. P. & Hall, R. A. 
Heterodimerization with beta2-adrenergic 
receptors promotes surface expression 
and functional activity of alpha1D-
adrenergic receptors. J Pharmacol Exp 
Ther 313, 16-23 (2005). 
218. Stanasila, L., Perez, J. B., Vogel, H. & 
Cotecchia, S. Oligomerization of the alpha 
1a- and alpha 1b-adrenergic receptor 
subtypes. Potential implications in receptor 
internalization. J Biol Chem 278, 40239-51 
(2003). 
219. Kroeger, K. M., Hanyaloglu, A. C., Seeber, 
R. M., Miles, L. E. & Eidne, K. A. 
Constitutive and agonist-dependent homo-
oligomerization of the thyrotropin-releasing 
hormone receptor. Detection in living cells 
using bioluminescence resonance energy 
transfer. J Biol Chem 276, 12736-43 
(2001). 
220. Ferre, S. et al. Synergistic interaction 
between adenosine A2A and glutamate 
mGlu5 receptors: implications for striatal 
neuronal function. Proc Natl Acad Sci U S 
A 99, 11940-5 (2002). 
221. Goldman, L. A., Cutrone, E. C., Kotenko, 
S. V., Krause, C. D. & Langer, J. A. 
Modifications of vectors pEF-BOS, 
pcDNA1 and pcDNA3 result in improved 
convenience and expression. 
Biotechniques 21, 1013-5 (1996). 
222. Chazot, P. L., Pollard, S. & Stephenson, F. 
A. in General Neurochemical Techniques: 
Techniques in Vitro, Molecular (eds. 
Boulton, A., Baker, G. & Bateson, A.) 257-
286 (Humana Press Inc, Totowa, 1998). 
223. Bradford, A., Barlow, A. & Chazot, P. L. 
Probing the differential effects of infrared 
light sources IR1072 and IR880 on human 
lymphocytes: Evidence of selective 
cytoprotection by IR1072. J Photochem 
Photobiol B 81, 9-14 (2005). 
224. Chazot, P. L., Coleman, S. K., Cik, M. & 
Stephenson, F. A. Molecular 
References 
 
 203
characterization of N-methyl-D-aspartate 
receptors expressed in mammalian cells 
yields evidence for the coexistence of 
three subunit types within a discrete 
receptor molecule. J Biol Chem 269, 
24403-9 (1994). 
225. Chazot, P. L., Cik, M. & Stephenson, F. A. 
An investigation into the role of N-
glycosylation in the functional expression 
of a recombinant heteromeric NMDA 
receptor. Mol Membr Biol 12, 331-7 
(1995). 
226. Chazot, P. L., Cik, M. & Stephenson, F. A. 
Immunological detection of the NMDAR1 
glutamate receptor subunit expressed in 
embryonic kidney 293 cells and in rat 
brain. J Neurochem 59, 1176-8 (1992). 
227. Bradford, M. M. A rapid and sensitive 
method for the quantitation of microgram 
quantities of protein utilizing the principle 
of protein-dye binding. Anal Biochem 72, 
248-54 (1976). 
228. Brattelid, T. et al. Cloning, 
pharmacological characterisation and 
tissue distribution of a novel 5-HT4 
receptor splice variant, 5-HT4i. Naunyn 
Schmiedebergs Arch Pharmacol 369, 616-
28 (2004). 
229. Coge, F. et al. Truncated isoforms inhibit 
[3H]prazosin binding and cellular trafficking 
of native human alpha1A-adrenoceptors. 
Biochem J 343 Pt 1, 231-9 (1999). 
230. Elmhurst, J. L., Xie, Z., O'Dowd, B. F. & 
George, S. R. The splice variant D3nf 
reduces ligand binding to the D3 dopamine 
receptor: evidence for 
heterooligomerization. Brain Res Mol Brain 
Res 80, 63-74 (2000). 
231. Lai, J. P. et al. Full-length and truncated 
neurokinin-1 receptor expression and 
function during monocyte/macrophage 
differentiation. Proc Natl Acad Sci U S A 
103, 7771-6 (2006). 
232. Sarmiento, J. M. et al. Novel down-
regulatory mechanism of the surface 
expression of the vasopressin V2 receptor 
by an alternative splice receptor variant. J 
Biol Chem 279, 47017-23 (2004). 
233. Seck, T., Baron, R. & Horne, W. C. The 
alternatively spliced deltae13 transcript of 
the rabbit calcitonin receptor dimerizes 
with the C1a isoform and inhibits its 
surface expression. J Biol Chem 278, 
23085-93 (2003). 
234. van Rijn, R. M. et al. Oligomerization of 
recombinant and endogenously expressed 
human histamine H4 receptors. Mol 
Pharmacol 70, 604-15 (2006). 
235. Goetzl, E. J., Wang, W., McGiffert, C., 
Huang, M. C. & Graler, M. H. Sphingosine 
1-phosphate and its G protein-coupled 
receptors constitute a multifunctional 
immunoregulatory system. J Cell Biochem 
92, 1104-14 (2004). 
236. Van Brocklyn, J. R., Behbahani, B. & Lee, 
N. H. Homodimerization and 
heterodimerization of S1P/EDG 
sphingosine-1-phosphate receptors. 
Biochim Biophys Acta 1582, 89-93 (2002). 
237. Ryberg, E. et al. Identification and 
characterisation of a novel splice variant of 
the human CB1 receptor. FEBS Lett 579, 
259-64 (2005). 
238. Ehlert, J. E., Addison, C. A., Burdick, M. 
D., Kunkel, S. L. & Strieter, R. M. 
Identification and partial characterization of 
a variant of human CXCR3 generated by 
posttranscriptional exon skipping. J 
Immunol 173, 6234-40 (2004). 
239. Grosse, R., Schoneberg, T., Schultz, G. & 
Gudermann, T. Inhibition of gonadotropin-
releasing hormone receptor signaling by 
expression of a splice variant of the human 
receptor. Mol Endocrinol 11, 1305-18 
(1997). 
240. Ross, R. J. et al. A short isoform of the 
human growth hormone receptor functions 
as a dominant negative inhibitor of the full-
length receptor and generates large 
amounts of binding protein. Mol Endocrinol 
11, 265-73 (1997). 
241. Jordan, B. A., Gomes, I., Rios, C., 
Filipovska, J. & Devi, L. A. Functional 
interactions between mu opioid and alpha 
2A-adrenergic receptors. Mol Pharmacol 
64, 1317-24 (2003). 
242. Hu, C. D. & Kerppola, T. K. Simultaneous 
visualization of multiple protein interactions 
in living cells using multicolor fluorescence 
complementation analysis. Nat Biotechnol 
21, 539-45 (2003). 
243. Javitch, J. A. The ants go marching two by 
two: oligomeric structure of G-protein-
coupled receptors. Mol Pharmacol 66, 
1077-82 (2004). 
244. Guo, W., Shi, L. & Javitch, J. A. The fourth 
transmembrane segment forms the 
interface of the dopamine D2 receptor 
homodimer. J Biol Chem 278, 4385-8 
(2003). 
245. Carrillo, J. J., Lopez-Gimenez, J. F. & 
Milligan, G. Multiple Interactions between 
Transmembrane Helices Generate the 
Oligomeric {alpha}1b-Adrenoceptor. Mol 
Pharmacol 66, 1123-1137 (2004). 
246. Arock, M., Schneider, E., Boissan, M., 
Tricottet, V. & Dy, M. Differentiation of 
human basophils: an overview of recent 
advances and pending questions. J 
Leukoc Biol 71, 557-64 (2002). 
References 
 
 204
247. Kirshenbaum, A. S. et al. Effect of IL-3 and 
stem cell factor on the appearance of 
human basophils and mast cells from 
CD34+ pluripotent progenitor cells. J 
Immunol 148, 772-7 (1992). 
248. Al-Rabia, M. W., Blaylock, M. G., Sexton, 
D. W., Thomson, L. & Walsh, G. M. 
Granule protein changes and membrane 
receptor phenotype in maturing human 
eosinophils cultured from CD34+ 
progenitors. Clin Exp Allergy 33, 640-8 
(2003). 
249. Geissmann, F. et al. Retinoids regulate 
survival and antigen presentation by 
immature dendritic cells. J Exp Med 198, 
623-34 (2003). 
250. Durocher, Y., Perret, S. & Kamen, A. High-
level and high-throughput recombinant 
protein production by transient transfection 
of suspension-growing human 293-EBNA1 
cells. Nucleic Acids Res 30, E9 (2002). 
251. Casarosa, P. et al. CC and CX3C 
chemokines differentially interact with the 
N terminus of the human cytomegalovirus-
encoded US28 receptor. J Biol Chem 280, 
3275-85 (2005). 
252. Livak, K. J. & Schmittgen, T. D. Analysis of 
relative gene expression data using real-
time quantitative PCR and the 2(-Delta 
Delta C(T)) Method. Methods 25, 402-8 
(2001). 
253. Wreggett, K. A. & Wells, J. W. 
Cooperativity manifest in the binding 
properties of purified cardiac muscarinic 
receptors. J Biol Chem 270, 22488-99 
(1995). 
254. Limbird, L. E. & Lefkowitz, R. J. Negative 
cooperativity among beta-adrenergic 
receptors in frog erythrocyte membranes. 
J Biol Chem 251, 5007-14 (1976). 
255. Salahpour, A., Angers, S. & Bouvier, M. 
Functional significance of oligomerization 
of G-protein-coupled receptors. Trends 
Endocrinol Metab 11, 163-8 (2000). 
256. Gomes, I. et al. G protein coupled receptor 
dimerization: implications in modulating 
receptor function. J Mol Med 79, 226-42 
(2001). 
257. Park, P. S., Filipek, S., Wells, J. W. & 
Palczewski, K. Oligomerization of G 
Protein-Coupled Receptors: Past, Present, 
and Future. Biochemistry 43, 15643-15656 
(2004). 
258. Marianayagam, N. J., Sunde, M. & 
Matthews, J. M. The power of two: protein 
dimerization in biology. Trends Biochem 
Sci 29, 618-25 (2004). 
259. Ali, M. H. & Imperiali, B. Protein 
oligomerization: how and why. Bioorg Med 
Chem 13, 5013-20 (2005). 
260. Bai, M. Dimerization of G-protein-coupled 
receptors: roles in signal transduction. Cell 
Signal 16, 175-86 (2004). 
261. Kammerer, R. A. et al. Heterodimerization 
of a functional GABAB receptor is 
mediated by parallel coiled-coil alpha-
helices. Biochemistry 38, 13263-9 (1999). 
262. Romano, C., Yang, W. L. & O'Malley, K. L. 
Metabotropic glutamate receptor 5 is a 
disulfide-linked dimer. J Biol Chem 271, 
28612-6 (1996). 
263. Kunishima, N. et al. Structural basis of 
glutamate recognition by a dimeric 
metabotropic glutamate receptor. Nature 
407, 971-7 (2000). 
264. Ng, G. Y. et al. Human serotonin1B 
receptor expression in Sf9 cells: 
phosphorylation, palmitoylation, and 
adenylyl cyclase inhibition. Biochemistry 
32, 11727-33 (1993). 
265. Maggio, R. et al. G protein-linked 
receptors: pharmacological evidence for 
the formation of heterodimers. J 
Pharmacol Exp Ther 291, 251-7 (1999). 
266. Maggio, R., Barbier, P., Fornai, F. & 
Corsini, G. U. Functional role of the third 
cytoplasmic loop in muscarinic receptor 
dimerization. J Biol Chem 271, 31055-60 
(1996). 
267. Cvejic, S. & Devi, L. A. Dimerization of the 
delta opioid receptor: implication for a role 
in receptor internalization. J Biol Chem 
272, 26959-64 (1997). 
268. Park, P. S. & Wells, J. W. Oligomeric 
potential of the M2 muscarinic cholinergic 
receptor. J Neurochem 90, 537-48 (2004). 
269. Benkirane, M., Jin, D. Y., Chun, R. F., 
Koup, R. A. & Jeang, K. T. Mechanism of 
transdominant inhibition of CCR5-
mediated HIV-1 infection by ccr5delta32. J 
Biol Chem 272, 30603-6 (1997). 
270. White, J. H., Wise, A. & Marshall, F. H. 
Heterodimerization of gamma-
aminobutyric acid B receptor subunits as 
revealed by the yeast two-hybrid system. 
Methods 27, 301-10 (2002). 
271. Pfleger, K. D. & Eidne, K. A. Illuminating 
insights into protein-protein interactions 
using bioluminescence resonance energy 
transfer (BRET). Nat Methods 3, 165-74 
(2006). 
272. Rocheville, M. et al. Receptors for 
dopamine and somatostatin: formation of 
hetero-oligomers with enhanced functional 
activity. Science 288, 154-7 (2000). 
273. Amon, M., Ligneau, X., Schwartz, J. C. & 
Stark, H. Fluorescent non-imidazole 
histamine H3 receptor ligands with 
nanomolar affinities. Bioorg Med Chem 
Lett 16, 1938-40 (2006). 
References 
 
 205
274. Malan, S. F. et al. Fluorescent ligands for 
the histamine H2 receptor: synthesis and 
preliminary characterization. Bioorg Med 
Chem 12, 6495-503 (2004). 
275. Ramsay, D., Kellett, E., McVey, M., Rees, 
S. & Milligan, G. Homo- and hetero-
oligomeric interactions between G-protein-
coupled receptors in living cells monitored 
by two variants of bioluminescence 
resonance energy transfer (BRET): hetero-
oligomers between receptor subtypes form 
more efficiently than between less closely 
related sequences. Biochem J 365, 429-40 
(2002). 
276. Gadella, T. W., Jr. & Jovin, T. M. 
Oligomerization of epidermal growth factor 
receptors on A431 cells studied by time-
resolved fluorescence imaging 
microscopy. A stereochemical model for 
tyrosine kinase receptor activation. J Cell 
Biol 129, 1543-58 (1995). 
277. Latif, R., Graves, P. & Davies, T. F. 
Ligand-dependent inhibition of 
oligomerization at the human thyrotropin 
receptor. J Biol Chem 277, 45059-67 
(2002). 
278. Pfleger, K. D. et al. Extended 
bioluminescence resonance energy 
transfer (eBRET) for monitoring prolonged 
protein-protein interactions in live cells. 
Cell Signal 18, 1664-70 (2006). 
279. Hu, C. D., Chinenov, Y. & Kerppola, T. K. 
Visualization of interactions among bZIP 
and Rel family proteins in living cells using 
bimolecular fluorescence 
complementation. Mol Cell 9, 789-98 
(2002). 
280. Piehler, J. New methodologies for 
measuring protein interactions in vivo and 
in vitro. Curr Opin Struct Biol 15, 4-14 
(2005). 
281. Lopez-Gimenez, J. F., Canals, M., 
Pediani, J. D. & Milligan, G. The {alpha}1b-
Adrenoceptor Exists as a Higher-Order 
Oligomer: Effective Oligomerization Is 
Required for Receptor Maturation, Surface 
Delivery, and Function. Mol Pharmacol 71, 
1015-29 (2007). 
282. Hoffmann, C. et al. A FlAsH-based FRET 
approach to determine G protein-coupled 
receptor activation in living cells. Nat 
Methods 2, 171-6 (2005). 
283. Adams, S. R. et al. New biarsenical 
ligands and tetracysteine motifs for protein 
labeling in vitro and in vivo: synthesis and 
biological applications. J Am Chem Soc 
124, 6063-76 (2002). 
284. Ng, G. Y. et al. Identification of a GABAB 
receptor subunit, gb2, required for 
functional GABAB receptor activity. J Biol 
Chem 274, 7607-10 (1999). 
285. Salahpour, A. et al. Homodimerization of 
the {beta}2-Adrenergic Receptor as a 
Prerequisite for Cell Surface Targeting. J 
Biol Chem 279, 33390-33397 (2004). 
286. Zhou, F., Filipeanu, C. M., Duvernay, M. T. 
& Wu, G. Cell-surface targeting of 
alpha(2)-adrenergic receptors - Inhibition 
by a transport deficient mutant through 
dimerization. Cell Signal 18, 318-27 
(2006). 
287. Hague, C. et al. Olfactory receptor surface 
expression is driven by association with 
the {beta}2-adrenergic receptor. Proc Natl 
Acad Sci U S A 101, 13672-13676 (2004). 
288. Ramsay, D. et al. High-affinity interactions 
between human alpha1A-adrenoceptor C-
terminal splice variants produce homo- 
and heterodimers but do not generate the 
alpha1L-adrenoceptor. Mol Pharmacol 66, 
228-39 (2004). 
289. So, C. H. et al. D1 and D2 dopamine 
receptors form heterooligomers and 
cointernalize after selective activation of 
either receptor. Mol Pharmacol 68, 568-78 
(2005). 
290. Herrick-Davis, K., Weaver, B. A., Grinde, 
E. & Mazurkiewicz, J. E. Serotonin 5-
HT2C receptor homodimer biogenesis in 
the endoplasmic reticulum: real-time 
visualization with confocal fluorescence 
resonance energy transfer. J Biol Chem 
281, 27109-16 (2006). 
291. Gripentrog, J. M., Kantele, K. P., Jesaitis, 
A. J. & Miettinen, H. M. Experimental 
evidence for lack of homodimerization of 
the G protein-coupled human N-formyl 
peptide receptor. J Immunol 171, 3187-93 
(2003). 
292. Xie, Z., Lee, S. P., O'Dowd, B. F. & 
George, S. R. Serotonin 5-HT1B and 5-
HT1D receptors form homodimers when 
expressed alone and heterodimers when 
co-expressed. FEBS Lett 456, 63-7 
(1999). 
293. Hague, C., Uberti, M. A., Chen, Z., Hall, R. 
A. & Minneman, K. P. Cell surface 
expression of alpha1D-adrenergic 
receptors is controlled by 
heterodimerization with alpha1B-
adrenergic receptors. J Biol Chem 279, 
15541-9 (2004). 
294. Berthouze, M. et al. Constitutive 
dimerization of human serotonin 5-HT4 
receptors in living cells. FEBS Lett 579, 
2973-80 (2005). 
295. Gines, S. et al. Dopamine D1 and 
adenosine A1 receptors form functionally 
References 
 
 206
interacting heteromeric complexes. Proc 
Natl Acad Sci U S A 97, 8606-11 (2000). 
296. Fiorentini, C., Gardoni, F., Spano, P., Di 
Luca, M. & Missale, C. Regulation of 
dopamine D1 receptor trafficking and 
desensitization by oligomerization with 
glutamate N-methyl-D-aspartate receptors. 
J Biol Chem 278, 20196-202 (2003). 
297. Liu, F. et al. Direct protein-protein coupling 
enables cross-talk between dopamine D5 
and gamma-aminobutyric acid A 
receptors. Nature 403, 274-80 (2000). 
298. Guo, W., Shi, L., Filizola, M., Weinstein, H. 
& Javitch, J. A. Crosstalk in G protein-
coupled receptors: changes at the 
transmembrane homodimer interface 
determine activation. Proc Natl Acad Sci U 
S A 102, 17495-500 (2005). 
299. Lee, S. P., O'Dowd, B. F., Rajaram, R. D., 
Nguyen, T. & George, S. R. D2 dopamine 
receptor homodimerization is mediated by 
multiple sites of interaction, including an 
intermolecular interaction involving 
transmembrane domain 4. Biochemistry 
42, 11023-31 (2003). 
300. Ciruela, F. et al. Combining mass 
spectrometry and pull-down techniques for 
the study of receptor heteromerization. 
Direct epitope-epitope electrostatic 
interactions between adenosine A2A and 
dopamine D2 receptors. Anal Chem 76, 
5354-63 (2004). 
301. Mercier, J. F., Salahpour, A., Angers, S., 
Breit, A. & Bouvier, M. Quantitative 
assessment of beta 1- and beta 2-
adrenergic receptor homo- and 
heterodimerization by bioluminescence 
resonance energy transfer. J Biol Chem 
277, 44925-31 (2002). 
302. Hague, C. et al. Heterodimers of alpha1B- 
and alpha1D-adrenergic receptors form a 
single functional entity. Mol Pharmacol 69, 
45-55 (2006). 
303. Nobles, M., Benians, A. & Tinker, A. 
Heterotrimeric G proteins precouple with G 
protein-coupled receptors in living cells. 
Proc Natl Acad Sci U S A 102, 18706-11 
(2005). 
304. Xu, J. et al. Heterodimerization of alpha 
2A- and beta 1-adrenergic receptors. J 
Biol Chem 278, 10770-7 (2003). 
305. Maggio, R., Vogel, Z. & Wess, J. 
Coexpression studies with mutant 
muscarinic/adrenergic receptors provide 
evidence for intermolecular "cross-talk" 
between G-protein-linked receptors. Proc 
Natl Acad Sci U S A 90, 3103-7 (1993). 
306. Lavoie, C. et al. Beta 1/beta 2-adrenergic 
receptor heterodimerization regulates beta 
2-adrenergic receptor internalization and 
ERK signaling efficacy. J Biol Chem 277, 
35402-10 (2002). 
307. McVey, M. et al. Monitoring receptor 
oligomerization using time-resolved 
fluorescence resonance energy transfer 
and bioluminescence resonance energy 
transfer. The human δ-opioid receptor 
displays constitutive oligomerization at the 
cell surface, which is not regulated by 
receptor occupancy. J Biol Chem 276, 
14092-9 (2001). 
308. Zhu, W. Z. et al. Heterodimerization of 
beta1- and beta2-adrenergic receptor 
subtypes optimizes beta-adrenergic 
modulation of cardiac contractility. Circ 
Res 97, 244-51 (2005). 
309. Lavoie, C. & Hebert, T. E. 
Pharmacological characterization of 
putative beta1-beta2-adrenergic receptor 
heterodimers. Can J Physiol Pharmacol 
81, 186-95 (2003). 
310. Ayoub, M. A. et al. Monitoring of ligand-
independent dimerization and ligand-
induced conformational changes of 
melatonin receptors in living cells by 
bioluminescence resonance energy 
transfer. J Biol Chem 277, 21522-8 (2002). 
311. Cheng, Z. J. & Miller, L. J. Agonist-
dependent dissociation of oligomeric 
complexes of G protein-coupled 
cholecystokinin receptors demonstrated in 
living cells using bioluminescence 
resonance energy transfer. J Biol Chem 
276, 48040-7 (2001). 
312. Lavine, N. et al. G protein-coupled 
receptors form stable complexes with 
inwardly rectifying potassium channels and 
adenylyl cyclase. J Biol Chem 277, 46010-
9 (2002). 
313. He, J., Xu, J., Castleberry, A., Lau, A. & 
Hall, R. Glycosylation of beta(1)-
adrenergic receptors regulates receptor 
surface expression and dimerization. 
Biochem Biophys Res Commun 297, 565 
(2002). 
314. Hebert, T. E. et al. Functional rescue of a 
constitutively desensitized beta2AR 
through receptor dimerization. Biochem J 
330 ( Pt 1), 287-93 (1998). 
315. Cao, T. T., Brelot, A. & von Zastrow, M. 
The Composition of the {beta}-2 
Adrenergic Receptor Oligomer Affects Its 
Membrane Trafficking after Ligand-
Induced Endocytosis. Mol Pharmacol 67, 
288-297 (2005). 
316. Salahpour, A., Bonin, H., Bhalla, S., 
Petaja-Repo, U. & Bouvier, M. 
Biochemical characterization of beta2-
adrenergic receptor dimers and oligomers. 
Biol Chem 384, 117-23 (2003). 
References 
 
 207
317. Wurch, T., Matsumoto, A. & Pauwels, P. J. 
Agonist-independent and -dependent 
oligomerization of dopamine D(2) 
receptors by fusion to fluorescent proteins. 
FEBS Lett 507, 109-13 (2001). 
318. George, S. R. et al. A transmembrane 
domain-derived peptide inhibits D1 
dopamine receptor function without 
affecting receptor oligomerization. J Biol 
Chem 273, 30244-8 (1998). 
319. Rashid, A. J. et al. D1-D2 dopamine 
receptor heterooligomers with unique 
pharmacology are coupled to rapid 
activation of Gq/11 in the striatum. Proc 
Natl Acad Sci U S A 104, 654-9 (2007). 
320. O'Dowd, B. F. et al. Dopamine receptor 
oligomerization visualized in living cells. J 
Biol Chem 280, 37225-35 (2005). 
321. Hillion, J. et al. Coaggregation, 
cointernalization, and codesensitization of 
adenosine A2A receptors and dopamine 
D2 receptors. J Biol Chem 277, 18091-7 
(2002). 
322. Gazi, L., Lopez-Gimenez, J. F., Rudiger, 
M. P. & Strange, P. G. Constitutive 
oligomerization of human D2 dopamine 
receptors expressed in Spodoptera 
frugiperda 9 (Sf9) and in HEK293 cells. 
Eur J Biochem 270, 3928-38 (2003). 
323. Ng, G. Y. et al. Dopamine D2 receptor 
dimers and receptor-blocking peptides. 
Biochem Biophys Res Commun 227, 200-
4 (1996). 
324. Lee, S. P. et al. Inhibition of cell surface 
expression by mutant receptors 
demonstrates that D2 dopamine receptors 
exist as oligomers in the cell. Mol 
Pharmacol 58, 120-8 (2000). 
325. Zawarynski, P. et al. Dopamine D2 
receptor dimers in human and rat brain. 
FEBS Lett 441, 383-6 (1998). 
326. Canals, M. et al. Homodimerization of 
adenosine A2A receptors: qualitative and 
quantitative assessment by fluorescence 
and bioluminescence energy transfer. J 
Neurochem 88, 726-34 (2004). 
327. Kamiya, T., Saitoh, O., Yoshioka, K. & 
Nakata, H. Oligomerization of adenosine 
A2A and dopamine D2 receptors in living 
cells. Biochem Biophys Res Commun 306, 
544-9 (2003). 
328. Canals, M. et al. Adenosine A2A-
Dopamine D2 Receptor-Receptor 
Heteromerization: QUALITATIVE AND 
QUANTITATIVE ASSESSMENT BY 
FLUORESCENCE AND 
BIOLUMINESCENCE ENERGY 
TRANSFER. J Biol Chem 278, 46741-9 
(2003). 
329. Scarselli, M. et al. D2/D3 dopamine 
receptor heterodimers exhibit unique 
functional properties. J Biol Chem 276, 
30308-14 (2001). 
330. Yoshioka, K., Saitoh, O. & Nakata, H. 
Heteromeric association creates a P2Y-
like adenosine receptor. Proc Natl Acad 
Sci U S A 98, 7617-22 (2001). 
331. Karpa, K. D., Lin, R., Kabbani, N. & 
Levenson, R. The dopamine D3 receptor 
interacts with itself and the truncated D3 
splice variant d3nf: D3-D3nf interaction 
causes mislocalization of D3 receptors. 
Mol Pharmacol 58, 677-83 (2000). 
332. Nimchinsky, E. A., Hof, P. R., Janssen, W. 
G., Morrison, J. H. & Schmauss, C. 
Expression of dopamine D3 receptor 
dimers and tetramers in brain and in 
transfected cells. J Biol Chem 272, 29229-
37 (1997). 
333. Torvinen, M. et al. Adenosine A2A 
receptor and dopamine D3 receptor 
interactions: evidence of functional 
A2A/D3 heteromeric complexes. Mol 
Pharmacol 67, 400-7 (2005). 
334. Goin, J. C. & Nathanson, N. M. 
Quantitative analysis of muscarinic 
acetylcholine receptor homo- and 
heterodimerization in live cells: regulation 
of receptor down-regulation by 
heterodimerization. J Biol Chem 281, 
5416-25 (2006). 
335. Park, P. S. & Wells, J. W. Monomers and 
oligomers of the m(2) muscarinic 
cholinergic receptor purified from sf9 cells. 
Biochemistry 42, 12960-71 (2003). 
336. Park, P., Sum, C. S., Hampson, D. R., Van 
Tol, H. H. & Wells, J. W. Nature of the 
oligomers formed by muscarinic m2 
acetylcholine receptors in Sf9 cells. Eur J 
Pharmacol 421, 11-22 (2001). 
337. Wang, D., Sun, X., Bohn, L. M. & Sadee, 
W. Opioid receptor homo- and 
heterodimerization in living cells by 
quantitative bioluminescence resonance 
energy transfer. Mol Pharmacol 67, 2173-
84 (2005). 
338. Novi, F. et al. Paired activation of two 
components within muscarinic M3 receptor 
dimers is required for recruitment of beta-
arrestin-1 to the plasma membrane. J Biol 
Chem 280, 19768-76 (2005). 
339. Zeng, F. Y. & Wess, J. Identification and 
molecular characterization of m3 
muscarinic receptor dimers. J Biol Chem 
274, 19487-97 (1999). 
340. Novi, F., Scarselli, M., Corsini, G. U. & 
Maggio, R. The paired activation of the two 
components of the muscarinic M3 receptor 
dimer is required for induction of ERK1/2 
References 
 
 208
phosphorylation. J Biol Chem 279, 7476-
86 (2004). 
341. Herrick-Davis, K., Grinde, E. & 
Mazurkiewicz, J. E. Biochemical and 
biophysical characterization of serotonin 5-
HT2C receptor homodimers on the plasma 
membrane of living cells. Biochemistry 43, 
13963-71 (2004). 
342. Lee, S. P. et al. Oligomerization of 
dopamine and serotonin receptors. 
Neuropsychopharmacology 23, S32-40 
(2000). 
343. Janoshazi, A. et al. Modified receptor 
internalization upon coexpression of 5-
HT1B receptor and 5-HT2B receptors. Mol 
Pharmacol 71, 1463-74 (2007). 
344. Fotiadis, D. et al. The G protein-coupled 
receptor rhodopsin in the native 
membrane. FEBS Lett 564, 281-8 (2004). 
345. Pagano, A. et al. C-terminal interaction is 
essential for surface trafficking but not for 
heteromeric assembly of GABA(b) 
receptors. J Neurosci 21, 1189-202 
(2001). 
346. Gouldson, P. R. et al. Dimerization and 
domain swapping in G-protein-coupled 
receptors: a computational study. 
Neuropsychopharmacology 23, S60-77 
(2000). 
347. Soyer, O. S., Dimmic, M. W., Neubig, R. 
R. & Goldstein, R. A. Dimerization in 
Aminergic G-Protein-Coupled Receptors: 
Application of a Hidden-Site Class Model 
of Evolution. Biochemistry 42, 14522-
14531 (2003). 
348. Gouldson, P. R., Snell, C. R. & Reynolds, 
C. A. A new approach to docking in the 
beta 2-adrenergic receptor that exploits 
the domain structure of G-protein-coupled 
receptors. J Med Chem 40, 3871-86 
(1997). 
349. Gouldson, P. R., Snell, C. R., Bywater, R. 
P., Higgs, C. & Reynolds, C. A. Domain 
swapping in G-protein coupled receptor 
dimers. Protein Eng 11, 1181-93 (1998). 
350. Gouldson, P. R. et al. Lipid-facing 
correlated mutations and dimerization in 
G-protein coupled receptors. Protein Eng 
14, 759-67 (2001). 
351. Liang, Y. et al. Organization of the G 
protein-coupled receptors rhodopsin and 
opsin in native membranes. J Biol Chem 
278, 21655-62 (2003). 
352. Chabre, M., Cone, R. & Saibil, H. 
Biophysics: is rhodopsin dimeric in native 
retinal rods? Nature 426, 30-1; discussion 
31 (2003). 
353. Berthouze, M. et al. Two transmembrane 
Cys residues are involved in 5-HT4 
receptor dimerization. Biochem Biophys 
Res Commun 356, 642-7 (2007). 
354. Hebert, T. E. et al. A peptide derived from 
a beta2-adrenergic receptor 
transmembrane domain inhibits both 
receptor dimerization and activation. J Biol 
Chem 271, 16384-92 (1996). 
355. Overton, M. C., Chinault, S. L. & Blumer, 
K. J. Oligomerization, Biogenesis, and 
Signaling Is Promoted by a Glycophorin A-
like Dimerization Motif in Transmembrane 
Domain 1 of a Yeast G Protein-coupled 
Receptor. J Biol Chem 278, 49369-77 
(2003). 
356. Jastrzebska, B. et al. Functional and 
structural characterization of rhodopsin 
oligomers. J Biol Chem 281, 11917-22 
(2006). 
357. Whorton, M. R. et al. A monomeric G 
protein-coupled receptor isolated in a high-
density lipoprotein particle efficiently 
activates its G protein. Proc Natl Acad Sci 
U S A 104, 7682-7 (2007). 
358. Chabre, M. & le Maire, M. Monomeric g-
protein-coupled receptor as a functional 
unit. Biochemistry 44, 9395-403 (2005). 
359. Jastrzebska, B. et al. Functional 
characterization of rhodopsin monomers 
and dimers in detergents. J Biol Chem 
279, 54663-75 (2004). 
360. Damian, M., Martin, A., Mesnier, D., Pin, J. 
P. & Baneres, J. L. Asymmetric 
conformational changes in a GPCR dimer 
controlled by G-proteins. Embo J 25, 
5693-702 (2006). 
361. AbdAlla, S., Lother, H., el Massiery, A. & 
Quitterer, U. Increased AT(1) receptor 
heterodimers in preeclampsia mediate 
enhanced angiotensin II responsiveness. 
Nat Med 7, 1003-9 (2001). 
362. Soulier, J. L. et al. Design and synthesis of 
specific probes for human 5-HT4 receptor 
dimerization studies. J Med Chem 48, 
6220-8 (2005). 
363. Woolf, P. J. & Linderman, J. J. An algebra 
of dimerization and its implications for G-
protein coupled receptor signaling. J Theor 
Biol 229, 157-68 (2004). 
364. Law, P. Y. et al. Heterodimerization of mu- 
and delta-opioid receptors occurs at the 
cell surface only and requires receptor-G 
protein interactions. J Biol Chem 280, 
11152-64 (2005). 
365. Pin, J. P. et al. International Union of Basic 
and Clinical Pharmacology. LXVII. 
Recommendations for the Recognition and 
Nomenclature of G Protein-Coupled 
Receptor Heteromultimers. Pharmacol 
Rev 59, 5-13 (2007). 
References 
 
 209
366. Bulenger, S., Marullo, S. & Bouvier, M. 
Emerging role of homo- and 
heterodimerization in G-protein-coupled 
receptor biosynthesis and maturation. 
Trends Pharmacol Sci 26, 131-7 (2005). 
367. Charo, I. F. & Ransohoff, R. M. The many 
roles of chemokines and chemokine 
receptors in inflammation. N Engl J Med 
354, 610-21 (2006). 
368. Wilson, S., Wilkinson, G. & Milligan, G. 
The CXCR1 and CXCR2 receptors form 
constitutive homo- and heterodimers 
selectively and with equal apparent 
affinities. J Biol Chem 280, 28663-74 
(2005). 
369. Trettel, F. et al. Ligand-independent 
CXCR2 Dimerization. J Biol Chem 278, 
40980-8 (2003). 
370. Babcock, G. J., Farzan, M. & Sodroski, J. 
Ligand-independent dimerization of 
CXCR4, a principal HIV-1 coreceptor. J 
Biol Chem 278, 3378-85 (2003). 
371. Percherancier, Y. et al. Bioluminescence 
resonance energy transfer reveals ligand-
induced conformational changes in 
CXCR4 homo- and heterodimers. J Biol 
Chem 280, 9895-903 (2005). 
372. El-Asmar, L. et al. Evidence for negative 
binding cooperativity within CCR5-CCR2b 
heterodimers. Mol Pharmacol 67, 460-9 
(2005). 
373. Vischer, H. F., Vink, C. & Smit, M. J. A 
viral conspiracy: hijacking the chemokine 
system through virally encoded pirated 
chemokine receptors. Curr Top Microbiol 
Immunol 303, 121-54 (2006). 
374. Harkins, L. et al. Specific localisation of 
human cytomegalovirus nucleic acids and 
proteins in human colorectal cancer. 
Lancet 360, 1557-63 (2002). 
375. Schleicher, E. M. Cytomegalovirus 
inclusion bodies in breast cancer. Minn 
Med 67, 21-3 (1984). 
376. Richardson, A. Is breast cancer caused by 
late exposure to a common virus? Med 
Hypotheses 48, 491-7 (1997). 
377. Chee, M. S., Satchwell, S. C., Preddie, E., 
Weston, K. M. & Barrell, B. G. Human 
cytomegalovirus encodes three G protein-
coupled receptor homologues. Nature 344, 
774-7 (1990). 
378. Vischer, H. F., Leurs, R. & Smit, M. J. 
HCMV-encoded G-protein-coupled 
receptors as constitutively active 
modulators of cellular signaling networks. 
Trends Pharmacol Sci 27, 56-63 (2006). 
379. Kuhn, D. E., Beall, C. J. & Kolattukudy, P. 
E. The cytomegalovirus US28 protein 
binds multiple CC chemokines with high 
affinity. Biochem Biophys Res Commun 
211, 325-30 (1995). 
380. Kledal, T. N., Rosenkilde, M. M. & 
Schwartz, T. W. Selective recognition of 
the membrane-bound CX3C chemokine, 
fractalkine, by the human cytomegalovirus-
encoded broad-spectrum receptor US28. 
FEBS Lett 441, 209-14 (1998). 
381. Bakker, R. A., Casarosa, P., Timmerman, 
H., Smit, M. J. & Leurs, R. Constitutively 
active Gq/11-coupled receptors enable 
signaling by co-expressed G(i/o)-coupled 
receptors. J Biol Chem 279, 5152-61 
(2004). 
382. van Rijn, R. M. et al. Cloning and 
characterization of dominant negative 
splice variants of the human histamine H4 
receptor. J Biol Chem (Submitted). 
383. Fraile-Ramos, A. et al. The human 
cytomegalovirus US28 protein is located in 
endocytic vesicles and undergoes 
constitutive endocytosis and recycling. Mol 
Biol Cell 12, 1737-49 (2001). 
384. Casarosa, P. et al. Constitutive signaling 
of the human cytomegalovirus-encoded 
chemokine receptor US28. J Biol Chem 
276, 1133-7 (2001). 
385. Staras, S. A. et al. Seroprevalence of 
cytomegalovirus infection in the United 
States, 1988-1994. Clin Infect Dis 43, 
1143-51 (2006). 
386. Kondo, K., Kaneshima, H. & Mocarski, E. 
S. Human cytomegalovirus latent infection 
of granulocyte-macrophage progenitors. 
Proc Natl Acad Sci U S A 91, 11879-83 
(1994). 
387. Kahl, M., Siegel-Axel, D., Stenglein, S., 
Jahn, G. & Sinzger, C. Efficient lytic 
infection of human arterial endothelial cells 
by human cytomegalovirus strains. J Virol 
74, 7628-35 (2000). 
388. Nerheim, P. L. et al. Enhanced 
cytomegalovirus infection in 
atherosclerotic human blood vessels. Am J 
Pathol 164, 589-600 (2004). 
389. Maussang, D. et al. Human 
cytomegalovirus-encoded chemokine 
receptor US28 promotes tumorigenesis. 
Proc Natl Acad Sci U S A 103, 13068-73 
(2006). 
390. Bodaghi, B. et al. Chemokine 
sequestration by viral chemoreceptors as 
a novel viral escape strategy: withdrawal 
of chemokines from the environment of 
cytomegalovirus-infected cells. J Exp Med 
188, 855-66 (1998). 
391. Beisser, P. S., Laurent, L., Virelizier, J. L. 
& Michelson, S. Human cytomegalovirus 
chemokine receptor gene US28 is 
References 
 
 210
transcribed in latently infected THP-1 
monocytes. J Virol 75, 5949-57 (2001). 
392. Ohagen, A., Li, L., Rosenzweig, A. & 
Gabuzda, D. Cell-dependent mechanisms 
restrict the HIV type 1 coreceptor activity 
of US28, a chemokine receptor homolog 
encoded by human cytomegalovirus. AIDS 
Res Hum Retroviruses 16, 27-35 (2000). 
393. Whistler, J. L. et al. Modulation of 
postendocytic sorting of G protein-coupled 
receptors. Science 297, 615-20 (2002). 
394. Reilander, H. & Weiss, H. M. Production of 
G-protein-coupled receptors in yeast. Curr 
Opin Biotechnol 9, 510-7 (1998). 
395. Sarramegna, V., Talmont, F., Demange, P. 
& Milon, A. Heterologous expression of G-
protein-coupled receptors: comparison of 
expression systems fron the standpoint of 
large-scale production and purification. 
Cell Mol Life Sci 60, 1529-46 (2003). 
396. Massotte, D. G protein-coupled receptor 
overexpression with the baculovirus-insect 
cell system: a tool for structural and 
functional studies. Biochim Biophys Acta 
1610, 77-89 (2003). 
397. Hassaine, G. et al. Semliki Forest virus 
vectors for overexpression of 101 G 
protein-coupled receptors in mammalian 
host cells. Protein Expr Purif 45, 343-51 
(2006). 
398. Akermoun, M. et al. Characterization of 16 
human G protein-coupled receptors 
expressed in baculovirus-infected insect 
cells. Protein Expr Purif 44, 65-74 (2005). 
399. Lundstrom, K. Semliki Forest virus vectors 
for rapid and high-level expression of 
integral membrane proteins. Biochim 
Biophys Acta 1610, 90-6 (2003). 
400. Robeva, A. S., Woodard, R., Luthin, D. R., 
Taylor, H. E. & Linden, J. Double tagging 
recombinant A1- and A2A-adenosine 
receptors with hexahistidine and the FLAG 
epitope. Development of an efficient 
generic protein purification procedure. 
Biochem Pharmacol 51, 545-55 (1996). 
401. Fung-Leung, W. P., Thurmond, R. L., Ling, 
P. & Karlsson, L. Histamine H4 receptor 
antagonists: the new antihistamines? Curr 
Opin Investig Drugs 5, 1174-83 (2004). 
402. Mirzabekov, T. et al. Enhanced 
expression, native purification, and 
characterization of CCR5, a principal HIV-
1 coreceptor. J Biol Chem 274, 28745-50 
(1999). 
403. Gustafsson, C., Govindarajan, S. & 
Minshull, J. Codon bias and heterologous 
protein expression. Trends Biotechnol 22, 
346-53 (2004). 
404. Archer, S. et al. Butyrate inhibits colon 
carcinoma cell growth through two distinct 
pathways. Surgery 124, 248-53 (1998). 
405. Krief, S. et al. Transcriptional modulation 
by n-butyric acid of beta 1-, beta 2-, and 
beta 3-adrenergic receptor balance in 3T3-
F442A adipocytes. J Biol Chem 269, 6664-
70 (1994). 
406. Klaassen, C. H. & DeGrip, W. J. 
Baculovirus expression system for 
expression and characterization of 
functional recombinant visual pigments. 
Methods Enzymol 315, 12-29 (2000). 
407. Ratnala, V. R. et al. Large-scale 
overproduction, functional purification and 
ligand affinities of the His-tagged human 
histamine H1 receptor. Eur J Biochem 271, 
2636-2646 (2004). 
408. Hoffmann, M. et al. Recombinant Semliki 
Forest virus for over-expression and 
pharmacological characterisation of the 
histamine H(2) receptor in mammalian 
cells. Eur J Pharmacol 427, 105-14 (2001). 
409. Lundstrom, K. et al. Expression of ligand-
gated ion channels with the Semliki Forest 
virus expression system. J Recept Signal 
Transduct Res 17, 115-26 (1997). 
410. Butkerait, P. et al. Expression of the 
human 5-hydroxytryptamine1A receptor in 
Sf9 cells. Reconstitution of a coupled 
phenotype by co-expression of 
mammalian G protein subunits. J Biol 
Chem 270, 18691-9 (1995). 
411. DeLamarter, J. Biotechnology 
partnerships--medicine for an ailing 
industry? Nat Biotechnol 21, 847-8 (2003). 
412. Lundstrom, K. Structural biology of G 
protein-coupled receptors. Bioorg Med 
Chem Lett 15, 3654-7 (2005). 
413. Bradel-Tretheway, B. G., Zhen, Z. & 
Dewhurst, S. Effects of codon-optimization 
on protein expression by the human 
herpesvirus 6 and 7 U51 open reading 
frame. J Virol Methods 111, 145-56 
(2003). 
414. Lundstrom, K. Semliki forest virus-based 
expression for versatile use in receptor 
research. J Recept Signal Transduct Res 
22, 229-40 (2002). 
415. Sen, S. et al. Functional expression and 
direct visualization of the human alpha 2B 
-adrenergic receptor and alpha 2B -AR-
green fluorescent fusion protein in 
mammalian cell using Semliki Forest virus 
vectors. Protein Expr Purif 32, 265-75 
(2003). 
416. Lundstrom, K. et al. High-level expression 
of the human neurokinin-1 receptor in 
mammalian cell lines using the Semliki 
References 
 
 211
Forest virus expression system. Eur J 
Biochem 224, 917-21 (1994). 
417. Warne, T., Chirnside, J. & Schertler, G. F. 
Expression and purification of truncated, 
non-glycosylated turkey beta-adrenergic 
receptors for crystallization. Biochim 
Biophys Acta 1610, 133-40 (2003). 
418. Ishihara, G. et al. Expression of G protein 
coupled receptors in a cell-free 
translational system using detergents and 
thioredoxin-fusion vectors. Protein Expr 
Purif 41, 27-37 (2005). 
419. Lefkowitz, R. J. The superfamily of 
heptahelical receptors. Nat Cell Biol 2, 
E133-6 (2000). 
420. Gbahou, F. et al. Compared pharmacology 
of human histamine H(3) and H(4) 
receptors: structure-activity relationships of 
histamine derivatives. Br J Pharmacol 
(2006). 
421. Chazot, P. L., Shenton, F. C., Van Rijn, R. 
M., Bakker, R. A. & Leurs, R. Generation 
of the First Anti-hH4 Receptor Antibody: 
Identification of the H4R in Human 
Lymphocytes and Brain. 35th Ann. EHRS 
meeting oral communication 14 (2006). 
422. Amon, M., Ligneau, X., Schwartz, J. C. & 
Stark, H. Fluorophore-Tagged Non-
Imidazole Histamine H3 Receptor Ligands 
with Subnanomolar Affinities. 35th Ann. 
EHRS meeting oral communication 34 
(2006). 
423. Baggiolini, M., Dewald, B. & Moser, B. 
Human chemokines: an update. Annu Rev 
Immunol 15, 675-705 (1997). 
424. Lippert, U. et al. Human Skin Mast Cells 
Express H2 and H4, but not H3 Receptors. 
J Invest Dermatol 123, 116-23 (2004). 
425. Reggio, P. H. Computational methods in 
drug design: modeling G protein-coupled 
receptor monomers, dimers, and 
oligomers. Aaps J 8, E322-36 (2006). 
426. Wellendorph, P. et al. Molecular cloning 
and pharmacology of functionally distinct 
isoforms of the human histamine H(3) 
receptor. Neuropharmacology 42, 929-40 
(2002). 
427. Murphy, P. M. et al. International union of 
pharmacology. XXII. Nomenclature for 
chemokine receptors. Pharmacol Rev 52, 
145-76 (2000). 
428. Howard, O. M., Dong, H. F., Shirakawa, A. 
K. & Oppenheim, J. J. LEC induces 
chemotaxis and adhesion by interacting 
with CCR1 and CCR8. Blood 96, 840-5 
(2000). 
429. Nomiyama, H. et al. Human CC 
chemokine liver-expressed 
chemokine/CCL16 is a functional ligand for 
CCR1, CCR2 and CCR5, and 
constitutively expressed by hepatocytes. 
Int Immunol 13, 1021-9 (2001). 
430. Streblow, D. N. et al. The human 
cytomegalovirus chemokine receptor 
US28 mediates vascular smooth muscle 
cell migration. Cell 99, 511-20 (1999). 
431. Pleskoff, O. et al. Identification of a 
chemokine receptor encoded by human 
cytomegalovirus as a cofactor for HIV-1 
entry. Science 276, 1874-8 (1997). 
432. Billstrom, M. A., Lehman, L. A. & Scott 
Worthen, G. Depletion of extracellular 
RANTES during human cytomegalovirus 
infection of endothelial cells. Am J Respir 
Cell Mol Biol 21, 163-7 (1999). 
433. Chen, F., Castranova, V., Shi, X. & 
Demers, L. M. New insights into the role of 
nuclear factor-kappaB, a ubiquitous 
transcription factor in the initiation of 
diseases. Clin Chem 45, 7-17 (1999). 
434. Ghosh, S., May, M. J. & Kopp, E. B. NF-
kappa B and Rel proteins: evolutionarily 
conserved mediators of immune 
responses. Annu Rev Immunol 16, 225-60 
(1998). 
435. Mueller, A. & Strange, P. G. CCL3, acting 
via the chemokine receptor CCR5, leads 
to independent activation of Janus kinase 
2 (JAK2) and Gi proteins. FEBS Lett 570, 
126-32 (2004). 
436. Mellado, M., Rodriguez-Frade, J. M., 
Manes, S. & Martinez, A. C. Chemokine 
signaling and functional responses: the 
role of receptor dimerization and TK 
pathway activation. Annu Rev Immunol 19, 
397-421 (2001). 
437. Sansuk, K., Hensbergen, P., Balog, C., 
Bakker, R. A. & Leurs, R. MS analysis of 
human histamine H1 receptors. 36th Ann. 
EHRS meeting (2007). 
 
Abbreviations 
 
 212
Abbrevations 
5-HT    serotonin 
A1-3R    adenosine A1-3 receptor 
APC   allophycocyanin 
BEVS   Baculovirus expression vector system 
BRET   Bioluminescence Resonance Energy Transfer 
BSA   Bovine serum albumine 
COS-7   African green monkey cells 
CHO   Chinese hamster ovarian cell 
CRE   cAMP responsive element 
D1-5R    dopamine D1-5 receptor  
DAG   Diacylglycerol 
DMEM   Dulbecco’s modified Eagle’s medium 
DOR    δ opioid receptor  
Dpi   days post infection 
DTT   dithiothreitol 
E.coli   Escherichia coli 
EL   extracellular loop 
ER   endoplasmatic reticulum 
eYFP   enhanced yellow fluorescent protein 
FT-IR   Fourier-transformed infrared spectroscopy 
GFP   green fluorescent protein 
GPCR   g protein-coupled receptor 
H1-4R   histamine H1-4 receptor 
HA   Hemaggluttinin 
HEK 293  human embryonic kidney cells 
HEK 293T  T-antigen activated HEK 293 cells 
His   histidine 
IL   interleukin 
IL   intracellular loop 
Insp3   Inositol-1,4,5-triphosphate 
JNJ7777120  1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine 
KOR    κ opioid receptor  
M1-5R    muscarinic M1-5 receptor  
MT1-2R    melatonin MT1-2 receptor 
MOR    μ opioid receptor  
MS   Mass spectrometry 
NF-κB   Nuclear factor κB 
NMR   Nuclear Magnetic Resonance spectroscopy  
PBS   phosphate buffered saline 
PHA    phytohaemagglutinin 
Q-PCR   quantitative polymerase chain reaction  
RLuc   Renilla luciferase 
Sf9   Spodoptera frugiperda 9 cells 
SFV   Semliki Forest virus 
TM   transmembrane domain 
tr-FRET  time-resolved Fluorescence Resonance Energy Transfer 
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